{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.13114"}, {"@name": "filename", "#text": "18961_Tese_TatianeTeixeiradeMelo.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "Minist\u00e9rio da Sa\u00fade \n\nFunda\u00e7\u00e3o Oswaldo Cruz \n\nCentro de Pesquisas Ren\u00e9 Rachou \n\nPrograma de P\u00f3s-gradua\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade \n\n \n\n \n\nAvalia\u00e7\u00e3o da resposta imunol\u00f3gica e mecanismos efetores associados \u00e0 prote\u00e7\u00e3o \n\ninduzida pela prepara\u00e7\u00e3o antig\u00eanica do tegumento do esquistoss\u00f4mulo do Schistosoma \n\nmansoni \n\n \n\npor \n\n \n\n \n\nTatiane Teixeira de Melo \n\n \n\n \n\n \n\n \n\n \n\n \n\nBelo Horizonte \n\n           Fevereiro/2014 \n\n                                  TESE   DBCM-CPqRR   T.T. MELO       2014 \n\n\n\n\u00a0\n\n\u00a0\n\nii\u00a0\n\n\u00a0\n\nMinist\u00e9rio da Sa\u00fade \n\nFunda\u00e7\u00e3o Oswaldo Cruz \n\nCentro de Pesquisas Ren\u00e9 Rachou \n\nPrograma de P\u00f3s-gradua\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade \n\n \n\nAvalia\u00e7\u00e3o da resposta imunol\u00f3gica e mecanismos efetores associados \u00e0 prote\u00e7\u00e3o \n\ninduzida pela prepara\u00e7\u00e3o antig\u00eanica do tegumento do esquistoss\u00f4mulo do Schistosoma \n\nmansoni \n\npor \n\nTatiane Teixeira de Melo \n\n \n\n                                                                                 Tese apresentada com vistas \u00e0 obten\u00e7\u00e3o do \n\nT\u00edtulo de Doutor em Ci\u00eancias na \u00e1rea de \n\nconcentra\u00e7\u00e3o Biologia Celular e Molecular \n\nOrienta\u00e7\u00e3o \n\nDra. Cristina Toscano Fonseca \n\nCo-orienta\u00e7\u00e3o \n\nDra. Rosiane Aparecida da Silva Pereira \n\nDr. Paulo Marcos Zech Coelho \n\n \n\nBelo Horizonte \n\nFevereiro/2014 \n\n\n\n\u00a0\n\n\u00a0\n\niii\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n\u00a0\n\n\u00a0\n\n\u00a0\n\nCataloga\u00e7\u00e3o-na-fonte \nRede de Bibliotecas da FIOCRUZ \nBiblioteca do CPqRR \nSegemar Oliveira Magalh\u00e3es CRB/6 1975 \nM528a \n2014 \n\nMelo, Tatiane Teixeira. \n \n\n     Avalia\u00e7\u00e3o da resposta imunol\u00f3gica e mecanismos \nefetores associados \u00e0 prote\u00e7\u00e3o induzida pela prepara\u00e7\u00e3o \nantig\u00eanica do tegumento do esquistoss\u00f4mulo do \nSchistosoma mansoni / Tatiane Teixeira de Melo. \u2013 Belo \nHorizonte, 2014. \n\n \nXIX, 165 f: il.: 210 x 297 mm. \n \nBibliografia: 157 \u2013 184 \nTese (doutorado) \u2013 Tese para obten\u00e7\u00e3o do t\u00edtulo de \n\nDoutor em Ci\u00eancias pelo Programa de P\u00f3s-Gradua\u00e7\u00e3o em \nCi\u00eancias da Sa\u00fade do Centro de Pesquisas Ren\u00e9 Rachou. \n\u00c1rea de concentra\u00e7\u00e3o: Biologia Celular e Molecular. \n\n \n1. Esquistossomose mansoni/imunologia 2. Schistosoma \nmansoni/parasitologia 3. Vacinas/imunologia I. T\u00edtulo. II. \nFonseca, Cristina Toscano (Orienta\u00e7\u00e3o) III. Pereira, Rosiane \nAparecida da Silva (Co-orienta\u00e7\u00e3o) IV. Coelho, Paulo \nMarcos Zech (Co-orienta\u00e7\u00e3o). \n\n \nCDD \u2013 22. ed. \u2013 616.963  \n\n\u00a0\n\n\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\niv\u00a0\n\n\u00a0\n\nMinist\u00e9rio da Sa\u00fade \n\nFunda\u00e7\u00e3o Oswaldo Cruz \n\nCentro de Pesquisas Ren\u00e9 Rachou \n\nPrograma de P\u00f3s-gradua\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade \n\n \n\n \n\nAvalia\u00e7\u00e3o da resposta imunol\u00f3gica e mecanismos efetores associados \u00e0 prote\u00e7\u00e3o \n\ninduzida pela prepara\u00e7\u00e3o antig\u00eanica do tegumento do esquistoss\u00f4mulo do Schistosoma \n\nmansoni \n\npor \n\nTatiane Teixeira de Melo \n\n \n\nFoi avaliada pela banca examinadora composta pelos seguintes membros: \n\nDra. Cristina Toscano Fonseca (Orientadora- Presidente) \n\nDra. Rosiane Aparecida da Silva Pereira  \n\nDr. Paulo Marcos Zech Coelho  \n\nDra. Lis Ribeiro do Valle Antonelli  \n\nDra. Soraya Torres Gaze Jangola  \n\nDr. S\u00e9rgio Costa Oliveira  \n\nDr. Ricardo Toshio Fujiwara  \n\nSuplente: Dra. Caroline Junqueira Giusta  \n\n \n\nTese defendida e aprovada em: 19/02/2014 \n\n\n\n\u00a0\n\n\u00a0\n\nv\u00a0\n\n\u00a0\n\n \n\n \n\n \n\nQuantas vezes chorei?  \n\nQuantas vezes clamei? \n\nQuantas vezes me desesperei? \n\n(...) \n\nDeus veio acalentar \n\nDa maneira mais sublime \n\nSoube dar \n\nAquilo que precisei \n\nPara continuar seguindo em frente \n\nAnjos vieram em forma de gente \n\nFizeram acreditar, que, seguir em frente \n\nEra a melhor sa\u00edda, e assim, fui \n\nSem mais chorar \n\nE quando vi \n\nEstava l\u00e1 \n\n(...) \n\n \n\n \n\nAutor desconhecido \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nvi\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDedico este trabalho aos meus \n\nqueridos pais, um exemplo de for\u00e7a e \n\ndetermina\u00e7\u00e3o que carrego comigo \n\ndiariamente. \n\n\n\n\u00a0\n\n\u00a0\n\nvii\u00a0\n\n\u00a0\n\nAGRADECIMENTOS \n\n \n\nAgrade\u00e7o primeiramente a Deus, se n\u00e3o fossem suas b\u00ean\u00e7\u00e3os sobre mim nunca \n\nconseguiria seguir em frente e alcan\u00e7ar uma vit\u00f3ria t\u00e3o desejada, a ELE devo tudo que j\u00e1 \n\nconquistei at\u00e9 o momento e agrade\u00e7o sempre por tudo. \n\nAgrade\u00e7o imensamente a minha orientadora e amiga Kika, voc\u00ea contribuiu demais na \n\nforma\u00e7\u00e3o do meu conhecimento cient\u00edfico e pessoal tamb\u00e9m. Se hoje sou uma doutora \u00e9 \n\nporque voc\u00ea acreditou em mim, depositou sua confian\u00e7a em uma pessoa que logo no primeiro \n\nano de doutorado n\u00e3o estava mais sob o cuidado de seus olhos. Acreditou que eu era capaz e \n\nque conseguiria mesmo com tantos obst\u00e1culos pela frente. Nunca vou esquecer seu exemplo, \n\no levarei comigo sempre!!!! A voc\u00ea dedico esta tese. \n\nAgrade\u00e7o ao Doutor Paulo pela pessoa maravilhosa que \u00e9, pelo exemplo de \n\npesquisador e ser humano. Muito obrigada por ter me deixado fazer parte de sua equipe. \n\nAgrade\u00e7o a Dra. Rosiane (Rosi) pelo cuidado e imensa contribui\u00e7\u00e3o dada aos meus \n\nexperimentos e a escrita da tese e do artigo. Aprendi demais com voc\u00ea... \n\nAgrade\u00e7o a todos da EMBRAPA pela torcida, principalmente ao Laudares e Carol que \n\nn\u00e3o mediram esfor\u00e7os para me apoiar neste caminho me ajudando sempre que precisei. \n\n\u00c0 equipe do LESQ o meu muito obrigada a cada um de voc\u00eas, nunca vou esquecer a \n\najuda preciosa. Absolutamente todos contribu\u00edram enormemente para esta vit\u00f3ria, voc\u00eas s\u00e3o \n\nminha fam\u00edlia... \n\nAgrade\u00e7o \u00e0 Ma\u00edra, Paola, Dra. Sophie e Janete pela amizade e por me ajudarem nos \n\nexperimentos. Ao Dr. Marcelo Caliari pela ajuda na an\u00e1lise dos granulomas e pela boa \n\nvontade em disponibilizar o laborat\u00f3rio de patologia.  \n\n\n\n\u00a0\n\n\u00a0\n\nviii\u00a0\n\n\u00a0\n\nAos funcion\u00e1rios do Ren\u00e9 Rachou que, de alguma forma, contribu\u00edram para realiza\u00e7\u00e3o \n\ndo meu trabalho. \u00c0 biblioteca pela disponibiliza\u00e7\u00e3o do acervo que me ajudou na forma\u00e7\u00e3o do \n\nconhecimento. \n\nPor \u00faltimo, mas n\u00e3o menos importante agrade\u00e7o minha fam\u00edlia: meus pais pelo \n\ncarinho e por me permitirem estudar e ser hoje a pessoa que sou; a Ju pelo apoio \n\nincondicional, por acreditar em mim, obrigada irm\u00e3; ao David pelo amor, companheirismo, \n\npaci\u00eancia, compreens\u00e3o e apoio principalmente nos momentos que me pareciam n\u00e3o mais \n\nconseguir seguir em frente, voc\u00ea foi fundamental; e a todos os meus familiares pela torcida e \n\ncompreens\u00e3o da aus\u00eancia nos finais de semana... \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nix\u00a0\n\n\u00a0\n\nAGRADECIMENTO \u00c0S INSTITUI\u00c7\u00d5ES FINANCIADORAS \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAgrade\u00e7o ao apoio financeiro concedido pelas Institui\u00e7\u00f5es financiadoras: CPqRR-FIOCRUZ, \n\nINCT-DT, CNPq, FAPEMIG, Papes-VI, Proep-CPqRR e Ripag. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nx\u00a0\n\n\u00a0\n\nSUM\u00c1RIO \n\nLISTA DE FIGURAS______________________________________________ xii \nLISTA DE TABELAS_____________________________________________ xiii \nLISTA DE ABREVIATURAS E S\u00cdMBOLOS__________________________ xiv \nRESUMO________________________________________________________ xvii \nABSTRACT______________________________________________________ xix \n1 INTRODU\u00c7\u00c3O_________________________________________________ 20 \n1.1 A esquistossomose______________________________________________ 20 \n1.2 Ciclo de vida do Schistosoma mansoni_____________________________ 21 \n1.3 Controle da esquistossomose_____________________________________ 25 \n1.4 Imunobiologia da esquistossomose________________________________ 27 \n1.5 Patologia da esquistossomose_____________________________________ 32 \n1.5.1 Patologia aguda______________________________________________ 32 \n1.5.2 Patologia cr\u00f4nica_____________________________________________ 33 \n1.6 Vacinas_______________________________________________________ 34 \n1.6.1 Vacinas de Primeira Gera\u00e7\u00e3o___________________________________ 35 \n1.6.2 Vacinas Recombinantes________________________________________ 35 \n1.6.3 Vacinas de DNA______________________________________________ 36 \n1.6.4 Vacinas para esquistossomose__________________________________ 41 \n1.7 Tegumento do Schistosoma mansoni como alvo vacinal_______________ 47 \n1.8 Adjuvantes____________________________________________________ 50 \n2 OBJETIVOS___________________________________________________ 54 \n2.1 Objetivo Geral________________________________________________ 54 \n2.2 Objetivos espec\u00edficos____________________________________________ 54 \n3  METODOLOGIA_______________________________________________ 55 \n3.1 Obten\u00e7\u00e3o de ant\u00edgeno Smteg_____________________________________ 55 \n3.2 Protocolo de imuniza\u00e7\u00e3o com diferentes formula\u00e7\u00f5es vacinais_________ 55 \n3.3 Protocolo de imuniza\u00e7\u00e3o g\u00eanica__________________________________ 57 \n3.4 Dosagens de anticorpos_________________________________________ 58 \n3.5 Exame Parasitol\u00f3gico HPJ (Hoffman, Pons e Janner)________________ 59 \n3.6 Recupera\u00e7\u00e3o de vermes adultos__________________________________ 59 \n3.7 Oograma_____________________________________________________ 60 \n3.8 \u00c1rea e n\u00famero de granulomas hep\u00e1ticos___________________________ 60 \n3.9 Contagem do n\u00famero de ovos do intestino e f\u00edgado__________________ 60 \n3.10 Avalia\u00e7\u00e3o da imunidade celular induzida pelas formula\u00e7\u00f5es vacinais_ 61 \n3.11 Detec\u00e7\u00e3o de anticorpos espec\u00edficos na superf\u00edcie de esquistoss\u00f4mulos_ 62 \n3.12 Ensaio de citotoxicidade________________________________________ 63 \n3.13 Transfer\u00eancia passiva de anticorpos______________________________ 64 \n3.14 Eletroforese Bidimensional (2-DE)_______________________________ 65 \n\n\n\n\u00a0\n\n\u00a0\n\nxi\u00a0\n\n\u00a0\n\n3.14.1 Primeira dimens\u00e3o - Focaliza\u00e7\u00e3o Isoel\u00e9trica______________________ 65 \n3.14.2 Segunda dimens\u00e3o- SDS-PAGE________________________________ 66 \n3.15 Western-blotting bidimensional__________________________________ 67 \n3.16 Digest\u00e3o tr\u00edptica in gel de prote\u00ednas______________________________ 68 \n3.17 Espectrometria de massas______________________________________ 69 \n3.18 Identifica\u00e7\u00e3o das prote\u00ednas_____________________________________ 69 \n3.19 An\u00e1lise in silico das prote\u00ednas___________________________________ 69 \n3.19.1 Predi\u00e7\u00e3o de localiza\u00e7\u00e3o celular_________________________________ 69 \n3.19.2 Similaridade com prote\u00ednas humanas e de outros helmintos________ 70 \n3.19.3 Predi\u00e7\u00e3o de epitopos de c\u00e9lulas B e T___________________________ 70 \n3.19.4 Predi\u00e7\u00e3o de s\u00edtios de glicosila\u00e7\u00e3o e de adi\u00e7\u00e3o de \u00e2ncora de \nGPI_____________________________________________________________ 71 \n3.20 Clonagem____________________________________________________ 71 \n3.21 Transforma\u00e7\u00e3o de E. coli DH5-alpha eletrocompetentes_____________ 72 \n3.22 PCR________________________________________________________ 73 \n3.23 Digest\u00e3o do DNA plasmidiano com BamHI e AgeI__________________ 74 \n3.24 Sequenciamento do DNA plasmidiano____________________________ 74 \n3.25 Express\u00e3o e an\u00e1lise de prote\u00ednas recombinantes em c\u00e9lulas HEK293T 75 \n3.25.1Transfec\u00e7\u00e3o transiente de c\u00e9lulas HEK293T por lipossomos_________ 75 \n3.25.2 Extra\u00e7\u00e3o de prote\u00ednas a partir da lise das c\u00e9lulas HEK293T \ntransfectadas_____________________________________________________ 76 \n3.25.3 An\u00e1lise dos extratos prot\u00e9icos por SDS-PAGE____________________ 77 \n3.25.4 An\u00e1lise das prote\u00ednas por Western blotting unidimensional_________ 77 \n3.26 An\u00e1lises estat\u00edsticas____________________________________________ 78 \n4  RESULTADOS_________________________________________________ 79 \n5 CONSIDERA\u00c7\u00d5ES FINAIS______________________________________ 140 \n6 ANEXOS_______________________________________________________ 148 \n6.1 Aceite CEUA _________________________________________________ 148 \n6.2 Artigo Revis\u00e3o \u201cSchistosoma tegument protein in vaccine and Diagnosis \ndevelopment: an Update\u201d___________________________________________ 149 \n7 REFER\u00caNCIAS BIBLIOGR\u00c1FICAS______________________________ 157 \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nxii\u00a0\n\n\u00a0\n\nLISTA DE FIGURAS \n\nFigura 1: Mapa de distribui\u00e7\u00e3o mundial da esquistossomose___________ 20 \nFigura 2: Morfologia dos Schistosomas adultos_______________________ 23 \nFigura 3: Ciclo de vida do Schistosoma mansoni______________________ 25 \nFigura 4: Controle da esquistossomose no campo_____________________ 27 \nFigura 5: Representa\u00e7\u00e3o esquem\u00e1tica de um plasm\u00eddeo para uso como \nvacina de DNA__________________________________________________ 37 \nFigura 6: Representa\u00e7\u00e3o esquem\u00e1tica da indu\u00e7\u00e3o da imunidade celular e \nhumoral por vacinas de DNA_____________________________________ 40 \nFigura 7. Representa\u00e7\u00e3o do tegumento do Schistosoma mansoni com \nant\u00edgenos do parasito identificados por estudos prote\u00f4micos____________ 49 \nFigura 8: Protocolo de imuniza\u00e7\u00e3o_________________________________ 57 \nFigura 09: Protocolo de imuniza\u00e7\u00e3o g\u00eanica__________________________ 58 \nFigura 10: Transfer\u00eancia passiva de anticorpos______________________ 65 \nFigura 11: Perfil eletrofor\u00e9tico unidimensional de extrato prot\u00e9ico do \ntegumento (Smteg) de esquistoss\u00f4mulos de S. mansoni________________ 103 \nFigura 12: Perfil eletrofor\u00e9tico bidimensional do extrato prot\u00e9ico do \ntegumento de esquistoss\u00f4mulos de Schistosoma mansoni (Smteg)________ 104 \nFigura 13: 2D-PAGE e respectivos 2D-WB de extrato prot\u00e9ico do \ntegumento de esquistoss\u00f4mulos do Schistosoma mansoni_______________ 106 \nFigura 14: Amplifica\u00e7\u00e3o da regi\u00e3o codificadora do gene correspondente a \nSmCyp_______________________________________________________ 110 \nFigura 15: Digest\u00e3o do DNA plasmidiano  pcDNA3.1/V5-His A vazio e \ncontendo o gene codificador da prote\u00edna SmCyp_____________________ 111 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nxiii\u00a0\n\n\u00a0\n\nLISTA DE TABELAS \n\nTabela 1: Candidatos vacinais para esquistossomose__________________ 42 \nTabela 2: Grupos de camundongos imunizados com PBS e/ou Smteg na \npresen\u00e7a e na aus\u00eancia de adjuvante_______________________________ 56 \nTabela 3: An\u00e1lise in silico das prote\u00ednas do tegumento do esquistoss\u00f4mulo \ndo Schistosoma mansoni identificadas por espectrometria de massas_____ 108 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nxiv\u00a0\n\n\u00a0\n\nLISTA DE ABREVIATURAS E S\u00cdMBOLOS \n\n \n\n2D-WB: Western blotting bidimensional \n\nADCC: Citotoxidade celular dependente de anticorpo (do ingl\u00eas: antibody-dependent cell \n\ncitotoxicity) \n\nAPC: C\u00e9lula apresentadora de ant\u00edgeno (do ingl\u00eas: Antigen presenting cell) \n\nBCG: Bacillus Calmette-Gu\u00e9rin \n\nCD40: mol\u00e9cula co-estimuladora, ligante de CD154, expresso em linf\u00f3citos B, macr\u00f3fagos, \n\nc\u00e9lulas dendr\u00edticas, c\u00e9lulas endoteliais. \n\nCD86: mol\u00e9cula co-estimuladora , ligante de CD28 e CTLA-4, expresso em mon\u00f3citos, \n\nc\u00e9lulas B ativadas e c\u00e9lulas dendr\u00edticas \n\nCFA: Adjuvante Completo de Freund (do ingl\u00eas: Complete Freund Adjuvant) \n\nCHAPS: Tamp\u00e3o (3-colamidopropil)-imetilamonio]-1-propanosulfonato \n\nDNA: \u00c1cido desoxirribonucl\u00e9ico (do ingl\u00eas: Deoxyribonucleic acid) \n\nDTT: Tamp\u00e3o DITHIOTHREITOL \n\nELAC: meio de cultura contendo sais de Earl's mais hidrolisado de lactoalbumina (do ingl\u00eas: \n\nEarl\u00b4s salts plus lactoalbumin hydrolysate) \n\nELISA: Ensaio de absor\u00e7\u00e3o imunoenzim\u00e1tico (do ingl\u00eas: Enzyme Linked Immuno Sorbent \n\nAssay) \n\nFoxp3: fator de transcri\u00e7\u00e3o, (do ingl\u00eas \u201c Forhead box protein 3\u201d) \n\nGPI: glicosilfosfatidilinositol \n\nGST: Glutationa S-transferase  \n\nHE: Hematoxilina- Eosina \n\nHPJ: Hoffman - Pons e Janer \n\nIEF: Isoeletrofocaliza\u00e7\u00e3o \n\nIFA: Adjuvante Incompleto de Freund (do ingl\u00eas: Incomplet Freund Adjuvant) \n\nIFN-?: Interferon gama \n\nIg: Imunoglobulina \n\nIL: Interleucina \n\nIPG: Gradiente de pH imobilizado \n\nKOH: Hidr\u00f3xido de Pot\u00e1ssio \n\n\n\n\u00a0\n\n\u00a0\n\nxv\u00a0\n\n\u00a0\n\nLPS: Lipopolissacar\u00eddeo \n\nMALDI: do ingl\u00eas: Matrix-assisted laser desorption/ionization \n\nMHC: Complexo principal de Histocompatibilidade (do ingl\u00eas: major histocompatibility \n\ncomplex) \n\nmRNA: RNA mensageiro \n\nMS: espectrometria de massas ( do ingl\u00eas: mass spectometry) \n\nNK: c\u00e9lulas natural killer (do ingl\u00eas: \u201cnatural killer cells) \n\nPAMPs: Padr\u00f5es de reconhecimento de pat\u00f3geno (do ingl\u00eas: pathogen associated molecular \n\npatterns) \n\nPBMC: C\u00e9lulas Mononucleares do sangue Perif\u00e9rico (do ingl\u00eas: Peripheral Blood \n\nMononuclear Cell) \n\nPBS: Tamp\u00e3o de Fosfato Salina (do ingl\u00eas: Phosphate-buffered saline) \n\nPBST20: Tamp\u00e3o de Fosfato Saline e Tween 20 (do ingl\u00eas: Phosphate-buffered saline e Tween \n\n20) \n\nPCR: Rea\u00e7\u00e3o da cadeia de polimerase (do ingl\u00eas: polymerase chain reaction) \n\nPVDF: Fluoreto Polivinidileno \n\nPZQ: praziquantel \n\nRNA: \u00c1cido ribonucleico (do ingl\u00eas: Ribonucleic acid) \n\nRpm: Rota\u00e7\u00e3o por minuto \n\nRPMI: Meio de cultura RPMI (do ingl\u00eas: Roswell Park Memorial Institute) \n\nSDS-PAGE: Eletroforese do gel de poliacrilamida do sulfato dodecil de s\u00f3dio (do ingl\u00eas: \n\nSodium dodecyl sulfate polyacrylamide gel electrophoresis) \n\nSGTP4: Prote\u00edna transportadora de Gglicose 4 (do ingl\u00eas: Glucose Transport Protein 4) \n\nSEA: Extrato sol\u00favel do ovo do S. mansoni (do ingl\u00eas: soluble egg antigen) \n\nSFB: Soro fetal bovino \n\nSmteg: Tegumento do esquistoss\u00f4mulo do Schistosoma mansoni \n\nSWAP: Extrato sol\u00favel de ant\u00edgenos do verme adulto do Schistosoma mansoni (do ingl\u00eas: \n\nSoluble adult worm ant\u00edgens) \n\nTBST: Tamp\u00e3o Tris salinico e tween 20 (do ingl\u00eas: Tris buffered saline and Tween 20) \n\nTEMED: N, N, N', N'-tetra metiletileNODiamina \n\nTGF-?: Fator de crescimento tumoral (do ingl\u00eas: Transforming growth factor\u2013?) \n\n\n\n\u00a0\n\n\u00a0\n\nxvi\u00a0\n\n\u00a0\n\nTh1: C\u00e9lulas T auxiliares do tipo 1 (do ingl\u00eas:T helper cells type 1) \n\nTh2: C\u00e9lulas T auxiliares do tipo 2 (do ingl\u00eas:T helper cells type 2) \n\nTMB: Tetrametilbenzidina (do ingl\u00eas: Tetramethylbenzidine) \n\nTNF-?: Fator de necrose tumoral ? (do ingl\u00eas:Tumor necrosis factor ?) \n\nTOF: Time-Of-Flight \n\nTSP: Tetraspanina \n\nTreg: C\u00e9lulas T reguladoras (do ingl\u00eas: T regulatory cells) \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nxvii\u00a0\n\n\u00a0\n\nRESUMO \n\nSegundo a Organiza\u00e7\u00e3o Mundial da Sa\u00fade (WHO), atualmente 200 milh\u00f5es de pessoas est\u00e3o \n\ninfectadas por esp\u00e9cies do g\u00eanero Schistosoma, uma vacina, administrada sozinha ou em \n\ncombina\u00e7\u00e3o com drogas anti-helm\u00ednticas, seria importante para o controle da \n\nesquistossomose. Recentemente, nosso grupo demonstrou que uma prepara\u00e7\u00e3o do tegumento \n\nde esquistoss\u00f4mulo do S. mansoni (Smteg) \u00e9 capaz de elicitar uma diminui\u00e7\u00e3o \n\nestatisticamente significativa na carga parasit\u00e1ria quando formulado com adjuvante de \n\nFreund. Neste trabalho n\u00f3s avaliamos a imunoprote\u00e7\u00e3o induzida em camundongos pelo Smteg \n\nsem adjuvante ou Smteg associado ao Alum ou Alum + CpG. Na aus\u00eancia de adjuvante n\u00e3o \n\nhouve diminui\u00e7\u00e3o estatisticamente significativa da carga parasit\u00e1ria. Apesar disso, o Smteg \n\nfoi capaz de ativar a resposta imune produzindo n\u00edveis significativos de anticorpos \n\nespec\u00edficos, aumentando a porcentagem de c\u00e9lulas TCD4+IFN-?+ e de c\u00e9lulas TCD4+IL-10+ \n\nno ba\u00e7o e aumentando a produ\u00e7\u00e3o das citocinas IFN-? e IL-10 pelas c\u00e9lulas espl\u00eanicas e IL-10 \n\npor c\u00e9lulas dendr\u00edticas,. Ao contr\u00e1rio, a associa\u00e7\u00e3o Smteg/alum/CpG-ODN foi capaz de \n\ninduzir uma redu\u00e7\u00e3o parcial na carga parasit\u00e1ria (43,1%) al\u00e9m de uma reduzir \n\nsignificativamente o n\u00famero de ovos eliminados nas fezes. Esta resposta protetora foi \n\nassociada com um perfil predominantemente do tipo Th1, com o aumento na produ\u00e7\u00e3o de \n\nIgG2c, IFN-?  e TNF-?. O papel dos anticorpos na elimina\u00e7\u00e3o do parasito em animais \n\nimunizados com o Smteg tamb\u00e9m foi avaliado, e demonstramos que anticorpos espec\u00edficos \n\nest\u00e3o envolvidos na elimina\u00e7\u00e3o do parasito. Uma vez observada a import\u00e2ncia dos anticorpos \n\nna imunidade protetora, realizamos an\u00e1lises prote\u00f4micas e sorol\u00f3gicas pela t\u00e9cnica de \n\nWestern-blotting bidimensional (2D-WB) para identificar candidatos vacinais. Uma das \n\nprote\u00ednas identificadas, a ciclofilina do S. mansoni (SmCyp), foi utilizada como ant\u00edgeno em \n\num protocolo de imuniza\u00e7\u00e3o g\u00eanica, por\u00e9m  n\u00e3o  observamos redu\u00e7\u00e3o significativa da carga \n\nparasit\u00e1ria e do n\u00famero de ovos nas fezes e no intestino e f\u00edgado de camundongos \n\nimunizados, apesar da  imuniza\u00e7\u00e3o diminuir significativamente a \u00e1rea dos granulomas \n\nhep\u00e1ticos em animais imunizados. Nossos resultados demonstram a import\u00e2ncia do \n\ntegumento do esquistoss\u00f4mulo do S. mansoni como fonte de ant\u00edgenos vacinais para a \n\nesquistossomose mansoni; a import\u00e2ncia dos anticorpos na elimina\u00e7\u00e3o do parasito e identifica \n\nprote\u00ednas candidatas a serem utilizadas em formula\u00e7\u00f5es vacinais, abrindo novas possibilidades \n\n\n\n\u00a0\n\n\u00a0\n\nxviii\u00a0\n\n\u00a0\n\nde estudos avaliando as mesmas em diferentes formula\u00e7\u00f5es e estrat\u00e9gias vacinais em ensaios \n\npr\u00e9-clinicos. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\nxix\u00a0\n\n\u00a0\n\nABSTRACT \n\nAccording to the World Health Organization (WHO), currently 200 million people are \n\ninfected by Schistosoma species, the vaccine, administered alone or in association with anti-\n\nhelminthic drugs, would be important to control schistosomiasis. Recently, our group \n\ndemonstrated that the schistosomula tegument preparation from S. mansoni (Smteg) is able to \n\ninduce a significant reduction in worm burden when formulated to Freund adjuvant. In this \n\nwork we evaluated the protection induced by Smteg without adjuvant or Smteg with Alum or \n\nAlum + CpG. Without adjuvant any significant reduction in parasite burden was observed. \n\nHowever, Smteg immunization activate immune response inducing significant production of \n\nspecific antibody; increased percentage of TCD4+IFN-?+ and TCD4+IL-10+ cells in spleen \n\nand increased production of IFN-? and IL-10 cytokines by spleen cell and IL-10 by dendritic \n\ncells.  On the other hand Smteg/alum/CpG-ODN formulation was able to induce partial \n\nreduction in worm burden (43.1%) and also a significant reduction in the number of eggs \n\neliminated in the feces. This protective response was associated with a predominant Th1 type \n\nof immune response, with increased production of specific IgG2c, IFN-? and TNF-?. The role \n\nof antibodies in the elimination of parasites in animals immunized with Smteg was also \n\nevaluated and we have demonstrated that specific antibodies are involved in the elimination of \n\nthe parasite. Once we have observed the importance of antibodies in protective immunity, we \n\nperformed proteomic and serological analyzes by two-dimensional Western blotting (WB 2D) \n\ntechnique to identify vaccine candidates. One of the identified proteins, the S. mansoni \n\ncyclophilin (SmCyp), was used as antigen in a genetic immunization protocol, although no \n\nsignificant reduction in parasite burden and the number of eggs in the feces and intestine and \n\nliver of immunized mice was observed, immunization significantly decrease the area of \n\nhepatic granulomas in immunized animals. Our results demonstrate the importance of S. \n\nmansoni schistosomula tegument as a source of vaccine targets for  schistosomiasis; the \n\nimportance of antibodies in parasite elimination  and also identify proteins to be used in \n\nvaccine formulations, opening new studies possibilities in the evaluation of these candidates \n\nin different formulations and vaccination strategies in preclinical trials.\n\n\n\n\u00a0\n\n\u00a0\n\n20\u00a0\n\n\u00a0\n\n1  INTRODU\u00c7\u00c3O \n\n1.1 A esquistossomose \n\nA esquistossomose \u00e9 uma das principais doen\u00e7as tropicais negligenciadas em termos \n\nde import\u00e2ncia na sa\u00fade p\u00fablica. Estima-se que 200 milh\u00f5es de pessoas estejam \n\nconstantemente infectadas, sendo que 779 milh\u00f5es de indiv\u00edduos est\u00e3o sob o risco de infec\u00e7\u00e3o \n\nem aproximadamente 78 pa\u00edses (WHO, 2013). Esta doen\u00e7a parasit\u00e1ria humana \u00e9 causada por \n\ntrematodos digen\u00e9ticos do g\u00eanero Schistosoma.  O ser humano \u00e9 o hospedeiro definitivo das \n\nseis esp\u00e9cies de Schistosoma as quais s\u00e3o morfologicamente muito similares. Tr\u00eas destas \n\nesp\u00e9cies s\u00e3o de import\u00e2ncia global ou regional: S. japonicum (China e sudeste da \u00c1sia), S. \n\nmansoni (\u00c1frica, Ar\u00e1bia e Am\u00e9rica do Sul) as quais vivem nas v\u00eanulas peri-intestinais \n\ncausando esquistossomose intestinal e hepatoespl\u00eanica e o S. haematobium (\u00c1frica e Ar\u00e1bia), \n\nesp\u00e9cie esta que vive no plexo perivesical que causa esquistossomose urin\u00e1ria. S. intercalatum \n\n(oeste e regi\u00e3o central da \u00c1frica), S. mekongi (Mekong Delta) e S. malayensis (Mal\u00e1sia) est\u00e3o \n\nlimitados a poucos focos locais e possuem menor import\u00e2ncia epidemiol\u00f3gica (Jordan  et al., \n\n1993; Ross  et al., 2002; Gryssel  et al., 2006; Chitsulo  et al., 2000; WHO, 2002) (Fig. 1).  \n\n \n\nFigura 1: Mapa de distribui\u00e7\u00e3o mundial da esquistossomose. (Gryssel et al., 2006) \n\n\n\n\u00a0\n\n\u00a0\n\n21\u00a0\n\n\u00a0\n\nO Brasil \u00e9 o pa\u00eds mais afetado pela esquistossomose nas Am\u00e9ricas com \n\naproximadamente 2 milh\u00f5es de pessoas infectadas e mais de 36 milh\u00f5es sob o risco de \n\nadquirir a Infec\u00e7\u00e3o (Steinmann et al., 2006; Lambertucci et al., 2010). As \u00e1reas end\u00eamicas \n\npara a esquistossomose de maior preval\u00eancia da doen\u00e7a est\u00e3o nos estados de Minas Gerais e \n\nBahia. H\u00e1 ainda focos isolados nos estados do Piau\u00ed, Amazonas, Amap\u00e1, Tocantins, Santa \n\nCatarina, Rio Grande do Sul, Goi\u00e1s e Mato Grosso do Sul (DATA SUS, 2013). \n\n Neglig\u00eancia sanit\u00e1ria e migra\u00e7\u00e3o humana t\u00eam contribu\u00eddo enormemente para espalhar \n\na esquistossomose tanto nas \u00e1reas rurais como em aglomerados urbanos (Jordan et al., 1993; \n\nGryssel et al., 2006). Embora haja esfor\u00e7os globais para reduzir a doen\u00e7a atrav\u00e9s da \n\nquimioterapia via praziquantel (droga desenvolvida em 1970), as taxas de Infec\u00e7\u00f5es \n\ncontinuam altas nas regi\u00f5es end\u00eamicas (Hotez et al., 2006; Hotez et al., 2010). O praziquantel \n\nn\u00e3o elimina os esquistoss\u00f4mulos ou ovos, al\u00e9m disso, algumas preocupa\u00e7\u00f5es em rela\u00e7\u00e3o a \n\nessa droga t\u00eam sido relatadas uma vez que toler\u00e2ncia ao praziquantel foi facilmente induzida \n\nem modelo animal (Gryssels et al., 2001). Assim, torna-se importante a busca de \n\nmetodologias alternativas de controle e cura dessa doen\u00e7a como, por exemplo, a vacina\u00e7\u00e3o. \n\n1.2 Ciclo de vida do Schistosoma mansoni \n\nO ciclo de vida do S. mansoni envolve duas gera\u00e7\u00f5es: a primeira no hospedeiro \n\nvertebrado em que ocorre a reprodu\u00e7\u00e3o sexuada e matura\u00e7\u00e3o; e a segunda no hospedeiro \n\nintermedi\u00e1rio invertebrado em que somente ocorre a reprodu\u00e7\u00e3o assexuada. O hospedeiro \n\nintermedi\u00e1rio para o S. mansoni \u00e9 o caramujo do g\u00eanero Biomphalaria (Davis et al., 1985). \n\nMilhares de cerc\u00e1rias s\u00e3o produzidas por um \u00fanico esporocisto durante a reprodu\u00e7\u00e3o \n\nassexuada no hospedeiro intermedi\u00e1rio. As cerc\u00e1rias saem atrav\u00e9s da forma\u00e7\u00e3o de ves\u00edculas \n\nno tegumento do molusco, que se rompem e liberam de forma intermitente nas horas mais \n\nclaras do dia. (Gryssel, 2012; Souza et al., 2011). Na \u00e1gua, as cerc\u00e1rias possuem geotropismo \n\nnegativo, fototropismo positivo e tendem a acumular-se sob a superf\u00edcie l\u00edquida por at\u00e9 72 \n\nhoras (Rollinson &amp; Simpsom, 1987; Gryssel et al., 2012). Quando a cerc\u00e1ria encontra o \n\nhospedeiro definitivo, penetra pela sua pele ou mucosa por ingest\u00e3o de \u00e1gua contaminada, \n\n\u00e0quelas que chegam ao est\u00f4mago s\u00e3o destru\u00eddas, e as que penetram na mucosa oral \n\ndesenvolvem-se normalmente perdendo a cauda (Souza et al., 2011). A capacidade invasora \n\n\n\n\u00a0\n\n\u00a0\n\n22\u00a0\n\n\u00a0\n\ndas larvas depende de um esfor\u00e7o mec\u00e2nico e da a\u00e7\u00e3o qu\u00edmica exercida pelas secre\u00e7\u00f5es \n\nhistol\u00edticas das gl\u00e2ndulas cef\u00e1licas de penetra\u00e7\u00e3o. A a\u00e7\u00e3o mec\u00e2nica ocorre por aux\u00edlio de uma \n\nventosa oral. A a\u00e7\u00e3o qu\u00edmica ocorre por proteases do tipo colagenase e elastase, ou por \n\nenzimas que s\u00e3o ativas contra as glicoprote\u00ednas da pele. Ap\u00f3s penetrar, a cerc\u00e1ria passa por \n\nmudan\u00e7as na conforma\u00e7\u00e3o da membrana, que se torna pentalaminada e no metabolismo, que \n\nse torna principalmente anaer\u00f3bico (Rollinson &amp; Simpsom, 1987; Gordon &amp; Griffiths, 1951). \n\nInicia-se ent\u00e3o o processo de transforma\u00e7\u00e3o em esquistoss\u00f4mulos (Silva et al., 2008; Stirewalt \n\net al., 1983). Ap\u00f3s permanecer na pele por tempo vari\u00e1vel, de minutos a 72 horas, os \n\nesquistoss\u00f4mulos, caso n\u00e3o sejam destru\u00eddos pelos mecanismos de defesa, iniciam a migra\u00e7\u00e3o \n\natrav\u00e9s do corpo do seu hospedeiro. Os esquistoss\u00f4mulos utilizam as secre\u00e7\u00f5es l\u00edticas das \n\ngl\u00e2ndulas cef\u00e1licas posteriores para penetrar nos vasos cut\u00e2neos. Atrav\u00e9s da circula\u00e7\u00e3o, eles \n\nchegam direto ao cora\u00e7\u00e3o e aos pulm\u00f5es em aproximadamente 4 dias, tornando-se mais \n\nlongos e delgados, o que facilita a sua migra\u00e7\u00e3o atrav\u00e9s da rede vascular pulmonar (Miller &amp; \n\nWilson, 1980). Do pulm\u00e3o, os esquistoss\u00f4mulos voltam ao cora\u00e7\u00e3o e s\u00e3o enviados atrav\u00e9s da \n\ncircula\u00e7\u00e3o geral a todas as partes do corpo do hospedeiro. Somente quando alcan\u00e7am o \n\nsistema porta intra-hep\u00e1tico podem completar seu desenvolvimento (Rollinson &amp; Simpsom, \n\n1987; Miller et al., 1980). Quatro semanas ap\u00f3s a infec\u00e7\u00e3o, a maioria dos vermes encontra-se \n\nmaduros e prontos para se acasalarem. Os vermes acasalados deslocam-se ativamente contra a \n\ncorrente circulat\u00f3ria do sistema porta e migram para as veias mesent\u00e9ricas inferiores p\u00e9lvicas. \n\nAs localiza\u00e7\u00f5es habituais s\u00e3o as v\u00eanulas da parede do reto, sigm\u00f3ide e intestino grosso \n\n(Rollinson &amp; Simpsom, 1987; Bloch, 1980). O casal est\u00e1 em constante associa\u00e7\u00e3o, \n\nencontrando-se a f\u00eamea alojada no canal ginec\u00f3foro do macho (Fig. 2). O macho mede cerca \n\nde 1 cm de comprimento, apresenta forma foli\u00e1cea e cor esbranqui\u00e7ada e a f\u00eamea possui \n\nforma cil\u00edndrica, com 1,2 a 1,6 cm de comprimento e colora\u00e7\u00e3o mais escura. \n\n\n\n\u00a0\n\n\u00a0\n\n23\u00a0\n\n\u00a0\n\n \n\nFigura 2: Morfologia dos Schistosomas adultos. (Museu hist\u00f3rico natural de \n\nLondres) \n\nAs f\u00eameas fecundadas, isoladas ou acopladas ao macho, migram contra a corrente \n\nsangu\u00ednea e iniciam a postura dos ovos na submucosa dos vasos de menor calibre da parede \n\nintestinal. A maior parte da energia das f\u00eameas \u00e9 gasta na produ\u00e7\u00e3o de ovos. Cerca de 300 a \n\n400 ovos de S. mansoni s\u00e3o liberados por f\u00eamea em camundongos infectados a cada dia, \n\nsendo que este n\u00famero aumenta em primatas (Juberg et al., 2009; Cheever et al., 1994). A \n\nprodu\u00e7\u00e3o de ovos come\u00e7a 30 a 40 dias ap\u00f3s a infec\u00e7\u00e3o. Os ovos s\u00e3o eliminados para o \n\nambiente atrav\u00e9s das fezes dos indiv\u00edduos infectados (Valadares et al., 1981). Muitos dos \n\novos n\u00e3o ultrapassam a parede intestinal e s\u00e3o levados a \u00f3rg\u00e3os e tecidos do hospedeiro pela \n\ncorrente sangu\u00ednea. A presen\u00e7a destes ovos nos tecidos resulta na forma\u00e7\u00e3o de granulomas, \n\nproveniente da resposta do sistema imune do hospedeiro. No momento da ovoposi\u00e7\u00e3o, o \n\ndesenvolvimento embrion\u00e1rio \u00e9 ainda incompleto, requerendo mais seis ou sete dias para \n\ncompletar-se. Os mirac\u00eddios morrem caso a expuls\u00e3o n\u00e3o se complete dentro de tr\u00eas a quatro \n\nsemanas ap\u00f3s a ovoposi\u00e7\u00e3o. Os ovos eliminados pelo hospedeiro atrav\u00e9s das fezes, se \n\nencontrarem condi\u00e7\u00f5es adequadas, como por exemplo: \u00e1gua natural com temperatura morna, \n\nbaixa hipotonicidade e ilumina\u00e7\u00e3o adequada, liberar\u00e3o o mirac\u00eddio de dentro da casca do ovo \n\n(Juberg etal., 2009). Uma vez que o ovo \u00e9 rompido em \u00e1gua natural, o mirac\u00eddio eclode e \n\ncome\u00e7a a nadar ativamente. O mirac\u00eddio possui geotropismo negativo e fototropismo positivo, \n\nque o auxilia na localiza\u00e7\u00e3o do hospedeiro intermedi\u00e1rio, al\u00e9m de ser atra\u00eddo por subst\u00e2ncias \n\nqu\u00edmicas eliminadas pelo caramujo. O encontro deve ocorrer em um per\u00edodo de 8 horas e o \n\n\n\n\u00a0\n\n\u00a0\n\n24\u00a0\n\n\u00a0\n\ntempo total de penetra\u00e7\u00e3o \u00e9 de 10 a 15 minutos. O mirac\u00eddio penetra no hospedeiro \n\nintermedi\u00e1rio espec\u00edfico por movimentos rotat\u00f3rios e a\u00e7\u00e3o l\u00edtica. Ap\u00f3s a penetra\u00e7\u00e3o, o \n\nmirac\u00eddio perde seu revestimento epitelial e seus \u00f3rg\u00e3os de penetra\u00e7\u00e3o, atrofiando sua \n\nmusculatura (Rollinson &amp; Simpsom., 1987). Por volta do oitavo dia, o mirac\u00eddio apresenta-se \n\ncomo um tubo enovelado, im\u00f3vel, repleto de c\u00e9lulas germinativas em multiplica\u00e7\u00e3o, se \n\ntransformando em esporocisto prim\u00e1rio. O esporocisto prim\u00e1rio apresenta grandes c\u00e9lulas \n\ngerminativas isoladas ou agrupadas. Por volta da segunda semana de exist\u00eancia, as c\u00e9lulas \n\ngerminativas rompem-se para liberar esporocistos filhos, em n\u00famero de 20 a 40 por \n\npoliembrionia. Os esporocistos secund\u00e1rios apresentam c\u00e9lulas germinativas, em constante \n\nmultiplica\u00e7\u00e3o. Estes migram para as gl\u00e2ndulas digestivas e ovotestis do planorb\u00eddeo. Pouco a \n\npouco, aglomerados celulares v\u00e3o se diferenciando para formar cerc\u00e1rias. Os esporocistos \n\npodem formar v\u00e1rias gera\u00e7\u00f5es de cerc\u00e1rias. A transforma\u00e7\u00e3o dos esporocistos em cerc\u00e1rias \n\nocorre apenas quando atingem sua localiza\u00e7\u00e3o permanente, nas gl\u00e2ndulas digestivas do \n\ncaramujo. A cerc\u00e1ria deixa o hospedeiro intermedi\u00e1rio caindo em \u00e1gua fresca, completando o \n\nciclo do parasito (Rollinson &amp; Simpsom, 1987) (Fig. 3). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n25\u00a0\n\n\u00a0\n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 3: Ciclo de vida do Schistosoma mansoni. As cerc\u00e1rias penetram pela pele no \n\nhospedeiro definitivo perdendo a cauda e iniciando-se o processo de transforma\u00e7\u00e3o em \n\nesquistoss\u00f4mulos. Os esquistoss\u00f4mulos migram at\u00e9 o sistema porta-hep\u00e1tico, onde \n\ncompletam o desenvolvimento transformando-se em vermes adultos. O casal copula e as \n\nf\u00eameas depositam seus ovos que podem se alojar em \u00f3rg\u00e3os ou serem eliminados com as \n\nfezes. Em \u00e1gua fresca os ovos eclodem e liberam os mirac\u00eddios que nadam e penetram no \n\nhospedeiro intermedi\u00e1rio e transformando em cerc\u00e1rias.  \n\n1.3 Controle da esquistossomose \n\nA estrat\u00e9gia de controle e preven\u00e7\u00e3o da esquistossomose utilizada atualmente \u00e9 \n\nbaseada principalmente na quimioterapia, saneamento b\u00e1sico e educa\u00e7\u00e3o ambiental (Jordan et \n\nal., 1993; Gryssel et al., 2006; Jordan et al., 2000). Em alguns pa\u00edses, mais notadamente no \n\nJap\u00e3o em 1950, conseguiu-se eliminar a esquistossomose combinando abastecimento de \u00e1gua, \n\nsaneamento b\u00e1sico e interven\u00e7\u00f5es ambientais (Minai et al., 2003). Hoje em dia, o uso da \n\n\n\n\u00a0\n\n\u00a0\n\n26\u00a0\n\n\u00a0\n\nquimioterapia nas comunidades e grupos de riscos \u00e9 comumente realizado (Molyneux, 2005; \n\nWHO, 2013). Dependendo dos recursos e epidemiologia local, comunidades em \u00e1reas \n\nend\u00eamicas ou s\u00e3o examinadas e tratadas, caso o exame encontra-se positivo, ou toda a \n\npopula\u00e7\u00e3o \u00e9 tratada independentemente do estado de infec\u00e7\u00e3o individual. Esta estrat\u00e9gia \u00e9 \n\nespecialmente aplicada com crian\u00e7as em idade escolar, pois est\u00e3o em maior risco de infec\u00e7\u00e3o \n\ne s\u00e3o facilmente acess\u00edveis nas escolas. Os medicamentos s\u00e3o distribu\u00eddos por equipes \n\nespeciais: os agentes de sa\u00fade local ou pelos professores da escola. Embora o objetivo \n\nprim\u00e1rio de quimioterapia seja controlar e prevenir a morbidade, tamb\u00e9m \u00e9 esperado que, \n\neventualmente, a transmiss\u00e3o seja afetada e at\u00e9 mesmo interrompida (Fig. 4). \n\nDevido ao fato de n\u00e3o ser f\u00e1cil modificar as condi\u00e7\u00f5es sanit\u00e1rias e socioecon\u00f4micas, \n\nseja por causa do alto investimento necess\u00e1rio inicialmente, seja pela falta de vontade ou \n\nconsci\u00eancia pol\u00edtica, tradicionalmente, o controle da esquistossomose tem sido feito atrav\u00e9s \n\ndo tratamento com uma \u00fanica droga, o praziquantel (PZQ). O desenvolvimento de resist\u00eancia \n\n\u00e0 droga pelos parasitos \u00e9, al\u00e9m disso, uma preocupa\u00e7\u00e3o a ser considerada (Coles et al., 1986). \n\nO uso de tratamentos repetidos em intervalos curtos de dois a tr\u00eas anos, com custos \n\noperacionais importantes, justifica o desenvolvimento de estrat\u00e9gias de controle adicionais \n\nque possam ter um efeito mais duradouro. Assim, eliminar a esquistossomose apenas com o \n\nuso de drogas, sem a utiliza\u00e7\u00e3o de medidas adicionais como saneamento, abastecimento de \n\n\u00e1gua, controle do caramujo e educa\u00e7\u00e3o \u00e9 praticamente imposs\u00edvel.  \n\n\n\n\u00a0\n\n\u00a0\n\n27\u00a0\n\n\u00a0\n\n \n\nFigura 4: Controle da esquistossomose no campo. (A) Tratamento em massa com \n\npraziquantel na comunidade. (B) Cuidados no suplemento de \u00e1gua. (C) Controle do caramujo \n\ncom moluscicida. (Fonte: Gryssel, 2012).  \n\n1.4 Imunobiologia da esquistossomose \n\nDevido ao seu complexo ciclo de vida, o S. mansoni representa um desafio para o \n\nsistema imune do hospedeiro, principalmente porque o parasito apresenta diferentes est\u00e1gios \n\nevolutivos e habita distintos nichos durante seu desenvolvimento no hospedeiro definitivo. \n\nUm aspecto fundamental da rela\u00e7\u00e3o parasito-hospedeiro \u00e9 o desenvolvimento de mecanismos \n\neficientes de escape pelo S. mansoni, que permite a este evadir-se da resposta imune e \n\nsobreviver por d\u00e9cadas no hospedeiro utilizando-se de suas biomol\u00e9culas para completar o \n\n\n\n\u00a0\n\n\u00a0\n\n28\u00a0\n\n\u00a0\n\nciclo, e tamb\u00e9m para desenvolver uma infec\u00e7\u00e3o cr\u00f4nica (Pearce et al., 2002). No curso da \n\ninfec\u00e7\u00e3o, a resposta imune progride por, pelo menos, tr\u00eas fases, em todas as fases \n\ncomponentes do sistema imunol\u00f3gico do hospedeiro s\u00e3o importantes tanto para o \n\ndesenvolvimento do parasito, quanto para sua elimina\u00e7\u00e3o ou regula\u00e7\u00e3o da resposta \n\ninflamat\u00f3ria desencadeada em resposta a seus ant\u00edgenos. Produtos de c\u00e9lulas TCD4+ \n\nmodulam o desenvolvimento do parasito (Davies et al., 2001) visto que em hospedeiros \n\nimunodeprimidos, o desenvolvimento do parasito \u00e9 retardado. J\u00e1 foi demonstrado que o \n\nparasito utiliza TNF-? produzido pelo hospedeiro como sinal estimulat\u00f3rio para a produ\u00e7\u00e3o de \n\novos (Amiri et al., 1992). A participa\u00e7\u00e3o de IL-7 j\u00e1 foi demonstrada no crescimento e \n\nfecundidade do verme (Wolowczuk et al., 1989). A presen\u00e7a do receptor de TGF- ? expresso \n\nna superf\u00edcie do tegumento sincicial indica a utiliza\u00e7\u00e3o deste fator pelo verme (Davies et al., \n\n1998). Fatores de crescimento epitelial humano estimulam a express\u00e3o do fator de \n\ncrescimento epitelial no parasito (Vicogne et al., 2004). A primeira fase da resposta \n\nimunol\u00f3gica do hospedeiro \u00e0 Infec\u00e7\u00e3o pelo Schistosoma acontece ap\u00f3s infec\u00e7\u00e3o por cerc\u00e1rias \n\nno hospedeiro, que, posteriormente, se transformam em esquistoss\u00f4mulos e vermes adultos \n\njovens os quais migram pelos tecidos (Cheever et al., 2001), nesta fase, a resposta \n\nimunol\u00f3gica predominante \u00e9 a do tipo Th1 (Pearce et al., 2002). Em indiv\u00edduos que j\u00e1 \n\nestiveram expostos ao parasito, e que, portanto, j\u00e1 desenvolveram uma sensibiliza\u00e7\u00e3o pr\u00e9via, a \n\npartir das primeiras 12 horas ap\u00f3s a penetra\u00e7\u00e3o das cerc\u00e1rias, observa-se importante rea\u00e7\u00e3o \n\ninflamat\u00f3ria d\u00e9rmica e subd\u00e9rmica, originando a dermatite cercariana, a qual \u00e9 capaz de \n\ndestruir um importante quantitativo de cerc\u00e1rias e esquistoss\u00f4mulos ainda na pele sendo a \n\nprimeira linha de defesa contra a infec\u00e7\u00e3o (Lichtenbergova et al., 2008). Nesta rea\u00e7\u00e3o \n\npredomina principalmente c\u00e9lulas mononucleares e polimorfonucleares e apresenta-se \n\nclinicamente como um exantema maculopapular pruriginoso (Mahmoud et al., 2009). Durante \n\na passagem pela epiderme e derme, ocorre rea\u00e7\u00e3o de hipersensibilidade do tipo imediata com \n\nativa\u00e7\u00e3o de v\u00e1rios componentes da resposta imune inata. Em dois dias organiza-se um \n\ninfiltrado de polimorfonucleares, mononucleares e c\u00e9lulas de Langerhans, al\u00e9m de produ\u00e7\u00e3o \n\nlocal de quimiocinas- CCL3/MIP-1? \u2013 e citocinas- IL-1?, IL-6, IL12 p40, IL-10. Depois de \n\nquatro a cinco dias, este cen\u00e1rio ainda \u00e9 predominante, podendo se observar o influxo de \n\nlinf\u00f3citos T CD4+e produ\u00e7\u00e3o de IL12 p40, IFN- ? e IL-4, os quais se reduzem na segunda \n\nsemana (Hogg et al., 2003; Kourilov\u00e1 et al., 2004). \n\n\n\n\u00a0\n\n\u00a0\n\n29\u00a0\n\n\u00a0\n\n\u00c0 medida que essas formas do parasito imaturas se desenvolvem, copulam e produzem \n\novos, ap\u00f3s cinco ou seis semanas de infec\u00e7\u00e3o, ocorre uma altera\u00e7\u00e3o consider\u00e1vel na resposta \n\nimunol\u00f3gica. A resposta imunol\u00f3gica que era predominantemente Th1 \u00e9 substitu\u00edda pelo \n\npredom\u00ednio da resposta Th2, induzida principalmente por ant\u00edgenos do ovo do Schistosoma \n\nmansoni.  Acredita-se que a resposta imune do tipo Th1 seja respons\u00e1vel pelas les\u00f5es \n\nteciduais e manifesta\u00e7\u00f5es cl\u00ednicas da fase aguda. Al\u00e9m disso, outro aspecto importante \u00e9 a \n\ncitotoxidade celular dependente de anticorpos (ADCC), com a\u00e7\u00e3o efetora sobre \n\nesquistoss\u00f4mulos, mas aparentemente in\u00f3cua para os helmintos adultos (Souza et al., \n\n2011).Tem-se evidenciado que as classes e subclasses de anticorpos anti-Schistosoma variam \n\ncom a idade, a intensidade da infec\u00e7\u00e3o, e, provavelmente, com a dura\u00e7\u00e3o da infec\u00e7\u00e3o. Alguns \n\nestudos t\u00eam demonstrado que a composi\u00e7\u00e3o de isotipos de anticorpos anti-Schistosoma pode \n\ndesempenhar uma influ\u00eancia marcante na efici\u00eancia de mecanismos efetores de citotoxidade \n\ncelular dependente de anticorpo (A.D.C.C.) e, consequentemente, na express\u00e3o da imunidade \n\nprotetora ou na patologia (Dunne et al., 1993). V\u00e1rias c\u00e9lulas efetoras, em presen\u00e7a de \n\nanticorpos anti-esquistoss\u00f4mulo, participam do mecanismo de A.D.C.C., dentre elas \n\nmon\u00f3citos, eosin\u00f3filos, e plaquetas (Joseph et al., 1983). \u00c9 sabido que, ao contr\u00e1rio de IgG1, \n\no isotipo IgG4 \u00e9 ineficiente na ativa\u00e7\u00e3o de complemento e na liga\u00e7\u00e3o a receptores de \n\nimunoglobulinas presentes em mon\u00f3citos e macr\u00f3fagos. Al\u00e9m disso, compete com IgE \n\nespec\u00edfica na liga\u00e7\u00e3o a ant\u00edgenos do verme nos s\u00edtios de liga\u00e7\u00e3o de mast\u00f3citos, bloqueando \n\nsua degranula\u00e7\u00e3o (Stanworth &amp; Smith, 1973). Neste contexto, os anticorpos anafil\u00e1ticos t\u00eam \n\nsido associados com a imunidade. Al\u00e9m disso, estes anticorpos induzem alto n\u00edvel de \n\nprote\u00e7\u00e3o contra novas exposi\u00e7\u00f5es \u00e0s cerc\u00e1rias quando transferidos passivamente para ratos \n\nn\u00e3o infeectados (Joseph et al., 1983) \n\nDurante a terceira fase da resposta, entre a 16\u00ba e 17\u00ba semanas ap\u00f3s a infec\u00e7\u00e3o, um \n\naumento significativo na produ\u00e7\u00e3o de IL-10 \u00e9 respons\u00e1vel pela modula\u00e7\u00e3o da produ\u00e7\u00e3o e das \n\nfun\u00e7\u00f5es efetoras dos mediadores pr\u00f3-inflamat\u00f3rios (Ara\u00fajo et al., 1996; Malaquias et al., \n\n1997; Montenegro et al., 1999, Cheever et al., 2001). A aus\u00eancia dessa modula\u00e7\u00e3o mant\u00e9m \n\naltos os n\u00edveis de mediadores inflamat\u00f3rios, o que pode ocasionar o desenvolvimento das \n\nformas graves da esquistossomose, com fibrose hep\u00e1tica e hipertens\u00e3o portal podendo resultar \n\nem morte do hospedeiro (Hoffmann et al., 2000; Rutzky et al., 2001). Estudos em \n\n\n\n\u00a0\n\n\u00a0\n\n30\u00a0\n\n\u00a0\n\ncamundongos deficientes das citocinas IL-10 e IL-12 demonstraram que estes animais \n\ndesenvolveram uma vigorosa resposta do tipo Th2 com significativa mortalidade entre a 12\u00ba e \n\n15\u00ba semanas ap\u00f3s a infec\u00e7\u00e3o. Ainda neste trabalho, camundongos deficientes das citocinas IL-\n\n10 e IL-4 desenvolveram forte resposta Th1 com 100% de mortalidade 9 semanas ap\u00f3s \n\ninfec\u00e7\u00e3o. Isso indica que as citocinas caracter\u00edsticas dos perfis Th1 e Th2 s\u00e3o ambas \n\npotencialmente patog\u00eanicas e tamb\u00e9m demonstra o papel regulador da IL-10 tanto no perfil \n\nTh1 como Th2 promovendo um granuloma capaz de reter os est\u00edmulos inflamat\u00f3rios \n\nliberados pelo ovo os quais poderiam levar a destrui\u00e7\u00e3o hep\u00e1tica (Hoffman et al., 2000). Por \n\noutro lado, a contribui\u00e7\u00e3o do IFN-? produzido por c\u00e9lulas Th1 e IL-4, IL-5 e IL-13 produzidas \n\npor c\u00e9lulas Th2 na resposta granulomatosa tem sido discutida sendo que a fibrose e os outros \n\nsintomas da patologia s\u00e3o mediados principalmente por citocinas do tipo Th2 (Cheever et al., \n\n1994, Remain et al., 2006). Camundongos deficientes na sinaliza\u00e7\u00e3o de IFN-? apresentam \n\nredu\u00e7\u00e3o no tamanho do granuloma e parecem transitar para fase cr\u00f4nica mais rapidamente. \n\nUma forte atividade antifibr\u00f3tica tem sido associada \u00e0 presen\u00e7a de IFN-? (Mukai et al., 2006), \n\npor\u00e9m, n\u00edveis excessivos de IFN-? podem causar graves consequ\u00eancias patol\u00f3gicas para o \n\nhospedeiro, como, por exemplo, efeito hepatot\u00f3xico (Hoffmann et al., 2000). \n\nA polariza\u00e7\u00e3o da resposta imune na dire\u00e7\u00e3o de um perfil Th1, Th2 ou Th17 \u00e9 \n\nprejudicial se n\u00e3o letal para o hospedeiro (Hoffmann et al., 2000; Stadecker et al., 2004; \n\nWilson et al., 2007). Similar ao paradigma Th1-Th2, o antagonismo se estende \u00e0s c\u00e9lulas \n\nsecretoras de IL-17, com ambas as citocinas IFN-? e IL-4 suprimindo a sua secre\u00e7\u00e3o (Cruz  et \n\nal., 2006; Lubberts et al., 2000).  Dado aos elevados n\u00edveis de IFN-? e IL-4 durante v\u00e1rios \n\nmomentos da Infec\u00e7\u00e3o pelo S. mansoni, \u00e9 prov\u00e1vel que a produ\u00e7\u00e3o de IL-17 seja rigidamente \n\ncontrolada. Em um trabalho desenvolvido por Rutitzky et al. (2005), camundongos CBA \n\napresentavam uma vigorosa resposta com alta produ\u00e7\u00e3o de IL-17 durante o curso da Infec\u00e7\u00e3o \n\npor S. mansoni induzindo uma patologia severa do f\u00edgado. A neutraliza\u00e7\u00e3o com anti-IL-17 \n\nmAb levou a uma regulariza\u00e7\u00e3o do tamanho do granuloma sendo este comparado aos \n\ntamanhos dos granulomas presentes no f\u00edgado dos camundongos controles. Apesar de se \n\nobservar tamb\u00e9m um aumento das c\u00e9lulas T CD8+e uma redu\u00e7\u00e3o da raz\u00e3o CD4+/CD8+ \n\ndurante o curso da Infec\u00e7\u00e3o, o papel destas c\u00e9lulas na imunidade celular anti-Schistosoma \n\nainda n\u00e3o est\u00e1 totalmente elucidado (Yanget al., 2000). Embora o recrutamento de c\u00e9lulas T \n\n\n\n\u00a0\n\n\u00a0\n\n31\u00a0\n\n\u00a0\n\nCD8+ por ant\u00edgenos ex\u00f3genos seja primeiramente n\u00e3o esperado, estudos recentes t\u00eam \n\ndemonstrado que estas c\u00e9lulas s\u00e3o propensas a responder a esses ant\u00edgenos em doen\u00e7as \n\ninfecciosas via ativa\u00e7\u00e3o dirigida por estimula\u00e7\u00e3o antig\u00eanica persistente (Manfras et al., 2002); \n\ncitocinas (Martins-Filho et al., 1999) ou por apresenta\u00e7\u00e3o cruzada via MHC de classe I (Grant \n\n&amp; Rock, 1992; Rock et al., 1990; Lipscomb &amp; Masten, 2002). \n\nUm poss\u00edvel papel para as c\u00e9lulas CD8+ na elimina\u00e7\u00e3o do Schistosoma pode estar \n\nrelacionado \u00e0 sua fun\u00e7\u00e3o citot\u00f3xica sobre esquistoss\u00f4mulos. Em um ensaio de imuniza\u00e7\u00e3o \n\nrealizado por Zhou et al. (2012) foram utilizados dois ant\u00edgenos presentes na superf\u00edcie do \n\nesquistoss\u00f4mulo: Sj22.6/ 26GTS os quais foram ligados em esferas magn\u00e9ticas de Sepharose \n\n4B a fim de mimetizar o esquistoss\u00f4mulo do Schistosoma japonicum. Neste trabalho \n\nobservou-se uma apresenta\u00e7\u00e3o cruzada pelas c\u00e9lulas dendr\u00edticas \u00e0s c\u00e9lulas T CD8+ com um \n\naumento da express\u00e3o de MHC I pelas c\u00e9lulas dendr\u00edticas e estimula\u00e7\u00e3o e prolifera\u00e7\u00e3o de \n\nc\u00e9lulas T CD8+. Estas exerceram fun\u00e7\u00e3o citot\u00f3xica matando os esquistoss\u00f4mulos em um \n\nensaio in vitro e, in vivo foi observada uma diminui\u00e7\u00e3o significativa da carga parasit\u00e1ria e \n\nredu\u00e7\u00e3o do n\u00famero de ovos no f\u00edgado. \n\nOutra popula\u00e7\u00e3o de c\u00e9lulas, as c\u00e9lulas T CD4+ reguladoras (Treg) tamb\u00e9m contribuem \n\npara manter a homeostase imunol\u00f3gica suprimindo a ativa\u00e7\u00e3o de c\u00e9lulas autoreativas, bem \n\ncomo controlando a magnitude da resposta imune aos pat\u00f3genos invasores (Sakagucchi et al., \n\n2006; Belkaid &amp; Rouse, 2005). A descoberta do \u201cForkhead box protein 3\u201d (Foxp3) como um \n\nfator de transcri\u00e7\u00e3o natural das c\u00e9lulas Treg foi importante para diferenciar as c\u00e9lulas Treg \n\nnatural das c\u00e9lulas Treg induz\u00edveis mas que apresentam propriedades regulat\u00f3rias similares. \n\nC\u00e9lulas Treg naturais expressam Foxp3 e desenvolvem-se no timo sendo componentes \n\nessenciais do repert\u00f3rio de c\u00e9lulas T perif\u00e9ricas. A express\u00e3o constitutiva da cadeia ? do \n\nreceptor de IL-2 (CD25), Foxp3, o requerimento de IL-2, juntamente com a express\u00e3o do co-\n\nreceptor inibit\u00f3rio, CTLA-4, e o receptor de TNF-? induzido por glicocortic\u00f3ides, GITR, \n\nservem como marcadores de Tregs naturais. J\u00e1 as c\u00e9lulas T reguladoras induz\u00edveis \n\nfrequentemente se espelham nas respostas das c\u00e9lulas T efetoras e se originam das c\u00e9lulas \n\nCD4+ convencionais, a nomenclaturas para as essas c\u00e9lulas Tregs induz\u00edveis incluem: caso \n\nsecretam IL-10 s\u00e3o consideradas c\u00e9lulas Tr1, se secretam TGF-? s\u00e3o c\u00e9lulas Th3 e c\u00e9lulas \n\nCD4+CD25+Foxp3-. Durante a infec\u00e7\u00e3o pelo S. mansoni, ambas as c\u00e9lulas reguladoras \n\n\n\n\u00a0\n\n\u00a0\n\n32\u00a0\n\n\u00a0\n\nnatural e induz\u00edvel tem sido descritas com pap\u00e9is variados incluindo a supress\u00e3o ou ativa\u00e7\u00e3o \n\ndas c\u00e9lulas dendr\u00edticas, a orquestra\u00e7\u00e3o da resposta Th2 e a regula\u00e7\u00e3o dessa resposta no \n\ndesenvolvimento do granuloma e fibrose (Wilson et al., 2007). Quatro semanas ap\u00f3s a \n\ninfec\u00e7\u00e3o com S. mansoni, h\u00e1 uma significativa expans\u00e3o de c\u00e9lulas Treg natural \n\nCD4+CD25+Foxp3+ que se desenvolvem no linfonodo mesent\u00e9rico e com grande expans\u00e3o e \n\nacumula\u00e7\u00e3o de Treg no f\u00edgado e ba\u00e7o (Baumgart et al., 2006; Taylor et al., 2006; Singh et al., \n\n2005). Assim, uma \u00fanica imuniza\u00e7\u00e3o com ovos do S. mansoni ocorre uma significativa \n\nresposta de c\u00e9lulas Treg Foxp3+, sugerindo que ant\u00edgenos imunog\u00eanicos do ovo podem ser \n\num potente indutor de ambas as c\u00e9lulas efetoras e Treg durante a Infec\u00e7\u00e3o (Baumgart et al., \n\n2006; Taylor et al., 2006; Singh et al., 2005).  \n\n1.5 Patologia da esquistossomose \n\n1.5.1 Patologia aguda \n\nMinutos ap\u00f3s a infec\u00e7\u00e3o por cerc\u00e1rias pode aparecer urtic\u00e1ria local que, usualmente, \n\ndiminui em poucas horas. Em casos mais raros, pode persistir por dias. O substrato \n\nfisiopatol\u00f3gico \u00e9 a morte na pele de cerca de at\u00e9 a metade das cerc\u00e1rias que a penetram \n\ncaracterizando-se por erup\u00e7\u00e3o micropapular eritematosa e discretamente edemaciada \n\n(Lambertucci et al., 2005). De uma a quatro semanas ap\u00f3s a Infec\u00e7\u00e3o, a migra\u00e7\u00e3o e matura\u00e7\u00e3o \n\ndo esquistoss\u00f4mulo podem causar uma rea\u00e7\u00e3o de hipersensibilidade sist\u00eamica (Gryssels, \n\n2012). Esta forma aguda da esquistossomose \u00e9 tamb\u00e9m conhecida como febre de Katayama \n\n(distrito do Jap\u00e3o onde foi primeiramente descrita). Possui como sintomas febre, prostra\u00e7\u00e3o, \n\nfadiga, mialgia, dor de cabe\u00e7a e tosse seca (Jordan et al., 1993; Ross et al., 2002; Gryssels et \n\nal., 2006; Jelinek  et al., 1996; Ross et al., 2007; Clerinx &amp; Van Gompel, 2011). Os exames de \n\nfezes ou urina ainda s\u00e3o negativos, mas eosinofilia, sorologia positiva, e um hist\u00f3rico de \n\ncontato com a \u00e1gua tropical geralmente indicam o diagn\u00f3stico. O f\u00edgado ou ba\u00e7o pode estar \n\naumentado e a radiografia de t\u00f3rax pode revelar infiltrados irregulares. Mais tarde, a migra\u00e7\u00e3o \n\ne o posicionamento dos vermes adultos para as veias mesent\u00e9ricas podem levar aos mais \n\npronunciados sintomas abdominais, incluindo c\u00f3licas intestinais e diarr\u00e9ia (Gazzinelli et al. \n\n1987). \n\n\n\n\u00a0\n\n\u00a0\n\n33\u00a0\n\n\u00a0\n\n1.5.2 Patologia cr\u00f4nica \n\nDurante a fase cr\u00f4nica, que pode durar a vida do hospedeiro, os vermes continuam a \n\nprodu\u00e7\u00e3o de ovos (aproximadamente 300 ovos/dia/f\u00eamea), e os granulomas que se formam ao \n\nredor dos ovos ficam menores se comparados ao per\u00edodo inicial da Infec\u00e7\u00e3o (Pearce et al., \n\n2002). Nesta fase surge, abruptamente, febre elevada acompanhada de calafriose, significativa \n\nsudorese, mal-estar geral, eventualmente com crise asmatiforme, anorexia, n\u00e1useas e v\u00f4mitos, \n\nos quais podem ser intensos, com mialgias e cefal\u00e9ia (Coura et al., 1970). \u00c9 poss\u00edvel observar \n\ntamb\u00e9m diarr\u00e9ia com numerosas evacua\u00e7\u00f5es. Ao exame f\u00edsico, \u00e9 poss\u00edvel detectar \n\nemagrecimento, desidrata\u00e7\u00e3o, hepatoesplenomegalia, microadenomegalia, taquicardia e \n\nhipotens\u00e3o arterial sist\u00eamica (Milan &amp; Keim, 2007). Nesta fase, os indiv\u00edduos exibem uma \n\nbaixa resposta de IgG1, IgG2 e IgG3 e alta produ\u00e7\u00e3o de IgG4 e IgE a ant\u00edgenos de \n\nesquistoss\u00f4mulos e de verme adulto (Jassim et al., 1987). Indiv\u00edduos da forma cl\u00ednica \n\nintestinal apresentam menor produ\u00e7\u00e3o de IFN-? e maior produ\u00e7\u00e3o de IL-10 em resposta a \n\nestimula\u00e7\u00e3o de PBMC com ant\u00edgeno sol\u00favel do ovo (SEA) ou do verme adulto (SWAP) \n\n(Correa-Oliveira et al., 1998). O papel da IL-10 nesta fase \u00e9 fundamental para o controle da \n\nmorbidade contribuindo para a sobreviv\u00eancia do hospedeiro (Sadler et al., 2003; Teixeira-\n\nCarvalho et al., 2008; Malaquias et al., 1997; Falc\u00e3o et al., 1998). \n\nOs granulomas, que est\u00e3o associados \u00e0 patologia da doen\u00e7a, se desenvolvem quando \n\nparte dos ovos produzidos pela f\u00eamea fica retida em v\u00e1rios \u00f3rg\u00e3os como: intestino, f\u00edgado, \n\np\u00e2ncreas, pulm\u00f5es e outros provocando uma rea\u00e7\u00e3o inflamat\u00f3ria peculiar, chamada de rea\u00e7\u00e3o \n\ninflamat\u00f3ria granulomatosa. Essa inflama\u00e7\u00e3o granulomatosa provoca microulcera\u00e7\u00f5es, \n\npseudop\u00f3lipos, irrita\u00e7\u00e3o muscular, dentre outros sintomas. A frequ\u00eancia e a severidade dos \n\nsintomas dependem da intensidade da Infec\u00e7\u00e3o (King et al., 2005). A forma\u00e7\u00e3o dos \n\ngranulomas em d\u00edspares \u00f3rg\u00e3os e tecidos explica as manifesta\u00e7\u00f5es da doen\u00e7a tais como: \n\nhipertens\u00e3o portal (granulomas hep\u00e1ticos com a desorganiza\u00e7\u00e3o da arquitetura sinusoidal \n\nhep\u00e1tica); forma\u00e7\u00e3o de pseudotumores (granulomas na parede intestinal); disfun\u00e7\u00f5es \n\nneurol\u00f3gicas (granuloma no sistema nervoso central, principalmente na medula); les\u00f5es \n\nvasculares pulmonares (granuloma nos vasos pulmonares) (Carvalhoet al., 2008). \n\n\n\n\u00a0\n\n\u00a0\n\n34\u00a0\n\n\u00a0\n\n O processo de forma\u00e7\u00e3o dos granulomas hep\u00e1ticos se inicia quando ant\u00edgenos \n\nprovenientes do envelope periovular (Von Lichtenberg`s) s\u00e3o liberados atrav\u00e9s de microporos \n\nlocalizados na casca dos ovos estimulando a resposta inflamat\u00f3ria (Boros et al., 1989). Esses \n\nant\u00edgenos s\u00e3o transportados para \u00f3rg\u00e3os linf\u00f3ides atrav\u00e9s de vasos sangu\u00edneos e linf\u00e1ticos. \n\nNestes \u00f3rg\u00e3os, os ant\u00edgenos s\u00e3o capturados e processados por c\u00e9lulas apresentadoras de \n\nant\u00edgenos que incluem linf\u00f3citos B, c\u00e9lulas dendr\u00edticas e macr\u00f3fagos. Posteriormente, os \n\nant\u00edgenos s\u00e3o apresentados aos linf\u00f3citos pelas mol\u00e9culas do complexo principal de \n\nhistocompatibilidade MHC de classe II presente nas c\u00e9lulas apresentadoras de ant\u00edgenos \n\n(Phillips et al., 1986). Esta intera\u00e7\u00e3o leva \u00e0 ativa\u00e7\u00e3o de c\u00e9lulas T, expans\u00e3o clonal, secre\u00e7\u00e3o \n\nde citocinas e recrutamento de leuc\u00f3citos adicionais. Desta resposta participam linf\u00f3citos, \n\nmacr\u00f3fagos, c\u00e9lulas gigantes multinucleadas, c\u00e9lulas epiteli\u00f3ides, eosin\u00f3filos, neutr\u00f3filos, \n\nmast\u00f3citos e fibroblastos (Von Lichtenberg et al., 1964; Moore et al., 1977; Silva-Teixeira et \n\nal., 1996). As c\u00e9lulas recrutadas acumulam-se em torno dos ovos dando origem ao granuloma \n\npropriamente dito, que pode apresentar um volume at\u00e9 100 vezes maior do que os ovos. A \n\ndestrui\u00e7\u00e3o local dos tecidos \u00e9 seguida de fibrose, um processo de cicatriza\u00e7\u00e3o no qual os \n\nfibroblastos s\u00e3o conduzidos para a les\u00e3o e a consequente produ\u00e7\u00e3o de col\u00e1geno resulta em \n\ncicatriz que pode ocasionar a obstru\u00e7\u00e3o de vasos sangu\u00edneos ou linf\u00e1ticos (Von Lichtenberg et \n\nal., 1964; Domingo &amp; Warren, 1969; Cheever et al. 1972; Warren et al., 1973). A fibrose \u00e9 \n\nmediada pela IL-13, o principal produto de c\u00e9lulas polarizadas Th2 (Barrie et al., 2012). \n\n1.6 Vacinas \n\n As vacinas est\u00e3o entre as interven\u00e7\u00f5es mais efetivas na era atual. Desde a primeira \n\nutiliza\u00e7\u00e3o por Edward Jenners, o uso da vacina tem-se tornado indispens\u00e1vel na erradica\u00e7\u00e3o \n\nde doen\u00e7as. Atualmente mais de 70 vacinas foram licenciadas para uso contra cerca de 30 \n\nmicroorganismos poupando muitas vidas (Nabel, 2013). \n\n O progresso no entendimento de diferentes \u00e1reas como imunologia, virologia, \n\ngen\u00e9tica, biologia molecular, gen\u00f4mica e prote\u00f4mica proporcionou o desenvolvimento de um \n\nconjunto de ferramentas para a abordagem atual da vacinologia, n\u00e3o apenas para doen\u00e7as \n\ninfecciosas agudas, mas tamb\u00e9m infec\u00e7\u00f5es cr\u00f4nicas, alergias, doen\u00e7as auto-imune e c\u00e2ncer \n\n(Nabel, 2013; Andre, 2003).  \n\n\n\n\u00a0\n\n\u00a0\n\n35\u00a0\n\n\u00a0\n\nAo longo destes dois s\u00e9culos, tr\u00eas gera\u00e7\u00f5es de vacinas foram desenvolvidas. As \n\nvacinas de primeira gera\u00e7\u00e3o constitu\u00eddas de microorganismos inativados ou mortos, as de \n\nsegunda gera\u00e7\u00e3o que s\u00e3o vacinas de subunidades constitu\u00eddas de ant\u00edgenos purificados ou \n\nrecombinantes. As vacinas de terceira gera\u00e7\u00e3o s\u00e3o as vacinas de DNA, nas quais os genes ou \n\nfragmentos de genes que codificam ant\u00edgenos imunog\u00eanicos s\u00e3o carreados por DNA \n\nplasmidiano e s\u00e3o inoculados nesta forma (Mir, 2004). \n\n1.6.1 Vacinas de Primeira Gera\u00e7\u00e3o \n\n As vacinas de primeira gera\u00e7\u00e3o s\u00e3o produzidas a partir de microorganismos vivos e \n\natenuados (vacina de BCG) ou mortos inativados (vacinas contra Bordetella pertussis) \n\n(Bloom, 1989). Consequentemente, n\u00e3o h\u00e1 a possibilidade de replica\u00e7\u00e3o de tais \n\nmicroorganismos no hospedeiro. Sendo assim existe a necessidade de administra\u00e7\u00e3o de doses \n\nmaiores e m\u00faltiplas al\u00e9m da limita\u00e7\u00e3o da produ\u00e7\u00e3o da vacina (Palatnick, 2008). \n\n1.6.2 Vacinas Recombinantes \n\n A t\u00e9cnica de express\u00e3o de prote\u00edna recombinante consiste em isolar, clonar e expressar \n\nos genes que codificam uma prote\u00edna de interesse (Mir, 2004). As prote\u00ednas heter\u00f3logas s\u00e3o \n\nproduzidas tanto em organismos procariotos como em eucariotos e, uma vez expressas, \n\npodem ser rapidamente purificadas e administradas aos animais em altas concentra\u00e7\u00f5es. Isto, \n\nsomado \u00e0s novas estrat\u00e9gias de apresenta\u00e7\u00e3o de ant\u00edgenos e uma nova gera\u00e7\u00e3o de adjuvantes, \n\naumenta significativamente o potencial destas subunidades antig\u00eanicas de induzirem uma \n\nimunidade celular e humoral (Clark et al., 2005). \n\n A bact\u00e9ria E. coli \u00e9 um importante microorganismo utilizado na express\u00e3o de \n\nprote\u00ednas recombinantes (Makrides et al., 1996). No entanto, em alguns casos, esta \n\nmetodologia de produ\u00e7\u00e3o pode apresentar alguns problemas como, por exemplo, a n\u00e3o \n\nrealiza\u00e7\u00e3o de modifica\u00e7\u00f5es p\u00f3s-transducionais, como a glicosila\u00e7\u00e3o (Mir, 2004). Al\u00e9m disso, \n\na estimula\u00e7\u00e3o do sistema imune pelas prote\u00ednas recombinantes pode ser vari\u00e1vel j\u00e1 que uma \n\ns\u00e9rie de fatores pode interferir, tais como, caracter\u00edsticas peculiares do ant\u00edgeno, formas de \n\napresenta\u00e7\u00e3o do mesmo ao sistema imune e via de imuniza\u00e7\u00e3o utilizada. Sistemas de \n\nexpress\u00e3o de prote\u00ednas baseados em  E. coli ou em leveduras podem gerar uma conforma\u00e7\u00e3o \n\n\n\n\u00a0\n\n\u00a0\n\n36\u00a0\n\n\u00a0\n\nincorreta da prote\u00edna, acarretando aus\u00eancia de epitopos conformacionais requeridos na \n\nprodu\u00e7\u00e3o de anticorpos neutralizantes protetores em algumas Infec\u00e7\u00f5es (Swartz, 2001). \n\nSimilarmente, a forma\u00e7\u00e3o de agregados prot\u00e9icos (corp\u00fasculos de inclus\u00e3o), comumente \n\nformados devido a n\u00edveis muito elevados de express\u00e3o, compromete a estrutura tridimensional \n\nnativa das prote\u00ednas (Swartz, 2001). Por outro lado, n\u00edveis baixos de express\u00e3o podem estar \n\nrelacionados com a degrada\u00e7\u00e3o das prote\u00ednas por proteases do hospedeiro, a utiliza\u00e7\u00e3o de \n\nc\u00f3dons n\u00e3o preferenciais, toxicidade da prote\u00edna recombinante para a c\u00e9lula hospedeira e a \n\naus\u00eancia de modifica\u00e7\u00f5es p\u00f3s-traducionais (Segatori et al., 2005). \n\n1.6.3 Vacinas de DNA \n\nDentre as atuais formula\u00e7\u00f5es vacinais, as \u201cvacinas de DNA\u201d s\u00e3o as mais recentes e \n\nrepresentam uma interessante alternativa para a apresenta\u00e7\u00e3o de mol\u00e9culas antig\u00eanicas ao \n\nsistema imune. As vacinas de DNA consistem na administra\u00e7\u00e3o de vetores plasmidianos \n\ncontendo o gene de interesse, respons\u00e1vel por codificar o ant\u00edgeno no hospedeiro (Gurunathan \n\net al., 2000a). \n\nOs primeiros estudos que sugeriram que a inje\u00e7\u00e3o de uma vacina de DNA, in vivo, \n\npoderia levar \u00e0 express\u00e3o do ant\u00edgeno e \u00e0 produ\u00e7\u00e3o da prote\u00edna foram realizados por Ito \n\n(1960), o qual demonstrou que a inje\u00e7\u00e3o de DNA de papilomav\u00edrus induzia tumores em \n\ncoelhos. Resultados semelhantes foram observados por Atanasiu e colaboradores (1962) ap\u00f3s \n\na inocula\u00e7\u00e3o do DNA de papilomav\u00edrus em hamster. No entanto, a primeira evid\u00eancia na \n\nliteratura do uso imunol\u00f3gico da mol\u00e9cula de DNA foi publicada em 1992 por Tang e \n\ncolaboradores. Seus estudos mostraram que a inje\u00e7\u00e3o da sequ\u00eancia codificadora do horm\u00f4nio \n\ndo crescimento humano na pele de camundongos utilizando a t\u00e9cnica de gene gun, foi capaz \n\nde aumentar o n\u00edvel de anticorpos espec\u00edficos contra este horm\u00f4nio, sugerindo que o DNA \n\npoderia ser utilizado para induzir resposta imune contra Infec\u00e7\u00f5es patog\u00eanicas. Naquele ano, \n\ndurante a Reuni\u00e3o Anual de Vacinas no \u201cCold Spring Harbor Laboratory\u201d, pesquisadores \n\nderam origem a uma nova era da vacina, com a apresenta\u00e7\u00e3o de trabalhos reportando o uso de \n\nvacinas de DNA para estimula\u00e7\u00e3o da resposta imune humoral e celular. Dois trabalhos \n\ndemonstraram a gera\u00e7\u00e3o de resposta imune contra o v\u00edrus influenza e o v\u00edrus da \n\nimunodefici\u00eancia humana 1 (HIV1) (Ulmer et al., 1993; Wang et al., 1993). Posteriormente, \n\n\n\n\u00a0\n\n\u00a0\n\n37\u00a0\n\n\u00a0\n\nresultados semelhantes foram obtidos ap\u00f3s imuniza\u00e7\u00e3o com DNA contra o v\u00edrus herpes \n\nbovino (Cox et al., 1993) e contra o v\u00edrus da raiva (Xiang et al., 1994). As vacinas de DNA \n\ns\u00e3o compostas de vetores plasmidianos que codificam ant\u00edgenos vacinais. Tais vetores cont\u00eam \n\num gene de resist\u00eancia ao antibi\u00f3tico controlado por um promotor procarioto, e uma origem \n\nprocari\u00f3tica de replica\u00e7\u00e3o, permitindo a sele\u00e7\u00e3o e a replica\u00e7\u00e3o dos plasm\u00eddeos em bact\u00e9rias \n\ntransformadas, respectivamente. A unidade de transcri\u00e7\u00e3o \u00e9 geralmente composta por um \n\npromotor viral forte e constitutivo, que confere um alto n\u00edvel de express\u00e3o do gene de \n\ninteresse em c\u00e9lulas eucari\u00f3ticas pela sequ\u00eancia Kozak e por uma sequ\u00eancia sinal de \n\npoliadenila\u00e7\u00e3o (Fig. 5). \n\n \n\nFigura 5: Representa\u00e7\u00e3o esquem\u00e1tica de um plasm\u00eddeo para uso como vacina de DNA. \n\nNa parte superior da figura encontra-se a Regi\u00e3o de Express\u00e3o Eucari\u00f3tica, respons\u00e1vel pela \n\nexpress\u00e3o do ant\u00edgeno em c\u00e9lulas eucari\u00f3ticas, contendo o promotor que promove a express\u00e3o \n\nda Open Read Frame (ORF) de interesse, a seq\u00fc\u00eancia de Kozak e o c\u00f3don de parada de \n\ntradu\u00e7\u00e3o, e a seq\u00fc\u00eancia sinal de poliadenila\u00e7\u00e3o (Poli-A) para estabiliza\u00e7\u00e3o do transcrito \n\nprim\u00e1rio. Na parte inferior encontra-se a Regi\u00e3o de Propaga\u00e7\u00e3o Procari\u00f3tica, respons\u00e1vel pela \n\n\n\n\u00a0\n\n\u00a0\n\n38\u00a0\n\n\u00a0\n\npropaga\u00e7\u00e3o e manuten\u00e7\u00e3o do plasm\u00eddeo vacinal na c\u00e9lula bacteriana, contendo assim uma \n\norigem de replica\u00e7\u00e3o procari\u00f3tica e um marcador de sele\u00e7\u00e3o, respectivamente (Adaptado de \n\nKutzler &amp; Weiner, 2008). \n\nAtualmente todos os vetores utilizados para vacina g\u00eanica ou terap\u00eautica utilizam \n\norigens de replica\u00e7\u00e3o teta e a grande maioria destes plasm\u00eddeos s\u00e3o derivados de pBR322 ou \n\npUC, com a origem de replica\u00e7\u00e3o ColE1 de Escherichia coli (Williams et al., 2009). ColE1 \u00e9 \n\no sistema melhor caracterizado, sendo capaz de manter mais de 20 plasm\u00eddeos por c\u00e9lula de \n\nE. coli, o que resulta em alta produ\u00e7\u00e3o de DNA plasmidiano em um per\u00edodo relativamente \n\ncurto (Ingolotti et al., 2010). \n\nOs marcadores de sele\u00e7\u00e3o mais utilizados s\u00e3o genes que conferem resist\u00eancia a \n\nantibi\u00f3ticos, sendo tamb\u00e9m respons\u00e1veis pela estabilidade/manuten\u00e7\u00e3o do plasm\u00eddeo na \n\nc\u00e9lula bacteriana (Ingolotti et al., 2010). \n\nNo cassete de express\u00e3o eucari\u00f3tica, os promotores virais, tais como o do \n\nCitomegalov\u00edrus (pCMV), Rous v\u00edrus (pRSV), S\u00edmio v\u00edrus (pSV40), Baculov\u00edrus (promotor \n\nda polihedrina) e Herpes simplex v\u00edrus tipo 1 (promotor da timidina quinase) s\u00e3o \n\nfrequentemente utilizados para a express\u00e3o do transgene ou ant\u00edgeno de interesse em uma \n\ngrande variedade de c\u00e9lulas dos mam\u00edferos (Becker et al., 2008) \n\nA inser\u00e7\u00e3o de uma sequ\u00eancia consenso espec\u00edfica presente no mRNA eucarioto, \n\nsinalizando o start codon, denominada sequ\u00eancia Kozak, \u00e9 necess\u00e1ria para inicia\u00e7\u00e3o da \n\ns\u00edntese prot\u00e9ica em c\u00e9lulas eucariotas. Para garantir a termina\u00e7\u00e3o correta da prote\u00edna, tamb\u00e9m \n\n\u00e9 importante a inser\u00e7\u00e3o de um ou mais stop codons, impedindo a leitura incorreta do mRNA, \n\ncomo produtos de alto peso molecular  e com conforma\u00e7\u00e3o incorreta (Kutzler e Weiner, \n\n2008). \n\nA inclus\u00e3o de uma sequ\u00eancia sinal de poliadenila\u00e7\u00e3o (AAUAAA) junto \u00e0 extremidade \n\n3\u2019 da sequ\u00eancia de interesse \u00e9 essencial para express\u00e3o eucari\u00f3tica. O sinal de poliadenila\u00e7\u00e3o \n\n\u00e9 necess\u00e1rio para correta finaliza\u00e7\u00e3o da transcri\u00e7\u00e3o da janela aberta de leitura de interesse, \n\nadi\u00e7\u00e3o da cauda poli-A e exporta\u00e7\u00e3o do mRNA do n\u00facleo para o citoplasma, desempenhando \n\num papel importante na estabilidade do mRNA (Kutzler e Weiner et al., 2008). A maioria dos \n\n\n\n\u00a0\n\n\u00a0\n\n39\u00a0\n\n\u00a0\n\nvetores cont\u00e9m o sinal de poliadenila\u00e7\u00e3o de SV40 ou do Horm\u00f4nio Bovino de Crescimento \n\n(BGH). Estudos t\u00eam revelado que a sequ\u00eancia sinal de poliadenila\u00e7\u00e3o do BGH \u00e9 at\u00e9 duas \n\nvezes mais eficiente que as demais, sendo, por isso, mais utilizada (Xu et al. 2002). \n\n Embora o mecanismo de indu\u00e7\u00e3o da imunidade por vacinas de DNA ainda permane\u00e7a \n\nincerto, o lento aumento da resposta imune ap\u00f3s a vacina\u00e7\u00e3o com DNA sugere que esta siga \n\num caminho complexo que pode mimetizar a infec\u00e7\u00e3o natural. Acredita-se que uma vez que o \n\nDNA plasmidiano \u00e9 administrado e internalizado pela c\u00e9lula, estes utilizam a rede de \n\nmicrot\u00fabulos e suas prote\u00ednas motoras associadas para o tr\u00e1fego atrav\u00e9s do citoplasma para o \n\nn\u00facleo (Vaughan &amp; DeGiulio, 2006), e a transcri\u00e7\u00e3o do imunogene \u00e9 iniciada utilizando o \n\nmaquin\u00e1rio celular do hospedeiro (Kutzler e Weiner, 2008). \n\nDiferentemente das vacinas inativadas ou de subunidade, as vacinas de DNA resultam \n\nem uma exibi\u00e7\u00e3o antig\u00eanica via mol\u00e9culas de MHC I e MHC II, como a infec\u00e7\u00e3o natural, \n\nativando linf\u00f3citos T CD4+, TCD8+ e a produ\u00e7\u00e3o de anticorpos. Logo ap\u00f3s a imuniza\u00e7\u00e3o, \n\nAPCs carregadas com o ant\u00edgeno podem migrar para o linfonodo, ativando linf\u00f3citos T via \n\nMHC e receptores de c\u00e9lulas T (TCR), ativando tamb\u00e9m linf\u00f3citos B via receptores de c\u00e9lulas \n\nB (BCRs), induzindo assim a produ\u00e7\u00e3o de anticorpos (Kutzler e Weiner, 2008)(Figura 6). \n\n Assim, os diferentes tipos de resposta imune induzida pela imuniza\u00e7\u00e3o g\u00eanica \n\njustificam sua aplica\u00e7\u00e3o nos campos das doen\u00e7as infecciosas, das alergias e dos tumores. \n\nTanto uma resposta tipo Th1 quanto Th2 s\u00e3o induzidas, dependendo da via de entrega da \n\nvacina de DNA, podendo ser empregada para controle de infec\u00e7\u00f5es intracelulares, como \n\nleishmaniose, tuberculose, toxoplasmose, brucelose e listeriose assim como direcionado ao \n\ncontrole de infec\u00e7\u00f5es extracelulares, como esquistossomose e outras doen\u00e7as (Azevedo &amp; \n\nOliveira, 2003). \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n40\u00a0\n\n\u00a0\n\n \n\nFigura 6: Representa\u00e7\u00e3o esquem\u00e1tica da indu\u00e7\u00e3o da imunidade celular e humoral por \n\nvacinas de DNA. Ap\u00f3s a imuniza\u00e7\u00e3o intramuscular com a vacina de DNA, (1) mi\u00f3citos e (2) \n\nAPCs s\u00e3o transfectados. Ap\u00f3s a express\u00e3o do ant\u00edgeno de interesse, estes s\u00e3o apresentados ao \n\nsistema imune via MHC I. O ant\u00edgeno pode ainda ser secretado pelos mi\u00f3citos ou h\u00e1 a \n\nforma\u00e7\u00e3o de corpos apopt\u00f3ticos/necr\u00f3ticos que ir\u00e3o levar a apresenta\u00e7\u00e3o antig\u00eanica por APCs \n\nvia MHC II. As APCs migram para o linfonodo e ativam linf\u00f3citos T CD4+ e T CD8+. TCR: \n\nReceptor de C\u00e9lula T; BCR: Receptor de C\u00e9lula B, (Adaptado de Kutzler e Weiner, 2008). \n\n\n\n\u00a0\n\n\u00a0\n\n41\u00a0\n\n\u00a0\n\n1.6.4 Vacinas para esquistossomose \n\n Nos \u00faltimos tempos, tentativas de desenvolvimento de vacinas para esquistossomose \n\nt\u00eam-se revelado uma tarefa dif\u00edcil por in\u00fameras raz\u00f5es. Um dos obst\u00e1culos para esta \n\ndificuldade \u00e9 a necessidade de compreender os mecanismos da imunidade protetora em \n\nhumanos. Ainda h\u00e1 um entendimento insuficiente dessa complexa intera\u00e7\u00e3o entre o \n\nhospedeiro humano e o parasito (Siddiqui et al., 2011). \n\n Entretanto, algumas observa\u00e7\u00f5es d\u00e3o suporte \u00e0 ideia de que uma efetiva vacina para \n\neste complexo parasito multicelular pode ser desenvolvida, entre elas:  \n\n1: A imuniza\u00e7\u00e3o de camundongos com uma dose de cerc\u00e1ria irradiada resultou em 50%-70% \n\nna redu\u00e7\u00e3o da carga parasit\u00e1ria, sendo que esta redu\u00e7\u00e3o pode ser aumentada para acima de \n\n80% caso sejam feitas duas ou tr\u00eas doses da imuniza\u00e7\u00e3o (Smythies et al., 1996); \n\n2: Em modelos de animais n\u00e3o permissivos, tais como ratos e macaco Reshus, por exemplo, a \n\nelimina\u00e7\u00e3o dos vermes est\u00e1 associada a ativa\u00e7\u00e3o da resposta imune do hospedeiro (Cutts &amp; \n\nWilson, 1997; Wilson et al., 2008); \n\n3: A popula\u00e7\u00e3o humana submetida a exposi\u00e7\u00f5es seguidas, como os habitantes das \u00e1reas \n\nend\u00eamicas, invariavelmente, desenvolve algum grau de prote\u00e7\u00e3o natural contra o parasito \n\n(Hagan  et al., 1991; Hagan et al., 1992). \n\nAssim, o desenvolvimento de uma vacina que limita a penetra\u00e7\u00e3o de cerc\u00e1rias ou a \n\nmatura\u00e7\u00e3o em vermes adultos, que seja capaz de reduzir o n\u00famero de ovos, de controlar a \n\npatologia, e, consequentemente a morbidade da doen\u00e7a, \u00e9 de extrema import\u00e2ncia. Mais de \n\n100 ant\u00edgenos candidatos \u00e0 vacina j\u00e1 foram identificados, devido principalmente, ao avan\u00e7o \n\ndo entendimento da imunidade protetora do hospedeiro, al\u00e9m de uma melhor compreens\u00e3o da \n\nbiologia do parasito possibilitada pelos estudos de transcriptoma, genoma e proteoma. Mais \n\nde um quarto dos mesmos tem mostrado algum n\u00edvel de prote\u00e7\u00e3o em modelo murino \n\n(Siddiqui, 2011). A tabela 1 apresenta alguns dos candidatos \u00e0 vacina incluindo o(s) est\u00e1gio(s) \n\nde express\u00e3o durante o desenvolvimento do Schistosoma, n\u00edvel de prote\u00e7\u00e3o e t\u00e9cnica utilizada \n\npara sua descoberta.  \n\n\n\n\u00a0\n\n\u00a0\n\n42\u00a0\n\n\u00a0\n\nTabela 1: Canditados vacinais para esquistossomose. \n\nAnt\u00edgeno Est\u00e1gio de express\u00e3o N\u00edvel de prote\u00e7\u00e3o M\u00e9todo de descoberta \n\nSm TSP-2 * Esquistoss\u00f4mulo, vermes adultos 57% Busca de pept\u00eddeo sinal \n\nSm14/SJ14/ FABP Todos os est\u00e1gios > 40% Soro contra extrato de vermes adultos usado em \n\nscreening de biblioteca de cDNA \n\nSm28GST/Sh28GST/SJ28GST * Todos os est\u00e1gios 30-50% Soro contra extrato de vermes adultos usado em \n\nscreening de biblioteca de cDNA \n\nSm TSP 1 Esquistoss\u00f4mulos, vermes adultos 34% Busca de pept\u00eddeo sinal \n\nSm 23 Todos os est\u00e1gios 30-50% Anticorpo monoclonal contra extrato de \n\nesquistoss\u00f4mulos usados em screening de \n\nbiblioteca de cDNA \n\nSm 21.7 * Esquistoss\u00f4mulos, vermes adultos 41-70% N\u00e3o determinado  \n\nSm 28-TPI Todos os est\u00e1gios 70% Anticorpo monoclonal contra extrato de \n\nesquistoss\u00f4mulos, pept\u00eddeo sequencia \n\nSm-p80 Tegumento verme adulto, esquistoss\u00f4mulos 39% (administrada sozinha) ou 57% quando \n\nadministrada com IL-12. \n\nSoro contra extrato de vermes adultos usado em \n\nscreening de biblioteca de cDNA \n\nSm29 * Esquistoss\u00f4mulos, vermes adultos 51% InterProScan; BLAST; SignalIP 3.0; Signal IP \n\nneural; WolfpSORT, SOSUI, Compute pI/Mw \n\ntool, vacinologia reversa. \n\nCu/Zn superoxide dismutase * Vermes adultos 44-60% N\u00e3o determinado \n\nECL (200 kDa protein) * Vermes adultos 38.1 % N\u00e3o determinado  \n\nSm22.6 * \n\nCiclofilina (Cyp) *                           \n\nEsquistoss\u00f4mulos, vermes adultos \n\nTodos os est\u00e1gios                            \n\n34.5% \n\n17.2% \n\nScreening de biblioteca de cDNA \n\nScreening de biblioteca de cDNA \n\n* ant\u00edgenos do tegumento do Schistosoma mansoni \n\n\n\n\u00a0\n\n\u00a0\n\n43\u00a0\n\n\u00a0\n\nUma subfam\u00edlia de prote\u00ednas que s\u00e3o localizadas predominante no tegumento externo \n\ndo S. mansoni s\u00e3o as tetraspaninas, que possuem quatro dom\u00ednios transmembrana expressos \n\nna superf\u00edcie de c\u00e9lulas eucari\u00f3ticas incluindo c\u00e9lulas T e B (Levy &amp; Shohan, 2005) e s\u00e3o \n\npromissoras como candidatas a vacinas. Uma dessas tetraspaninas, a Sm23, expressa no \n\ntegumento do S. mansoni (Reynolds et al., 1992) \u00e9 uma das candidatas \u00e0 vacina selecionada \n\npela WHO para compor uma vacina de subunidade contra a esquistossomose.  A Sm23 \u00e9 a \n\nmais eficiente quando apresentada na forma de DNA e n\u00e3o confere prote\u00e7\u00e3o na forma de \n\nprote\u00edna recombinante quando formulada com alum (Da\u2019Dara et al., 2006). Mais \n\nrecentemente, o rastreamento de pept\u00eddeo sinal em c\u00e9lulas de mam\u00edferos foi usado como \n\nestrat\u00e9gia para a identifica\u00e7\u00e3o de duas novas tetraspaninas de S. mansoni: SmTSP1 e SmTSP2 \n\ntamb\u00e9m expressas no tegumento do S. mansoni (Tran et al., 2006). A TPS2 em particular, \n\ninduz altos n\u00edveis de prote\u00e7\u00e3o quando usada como vacina recombinante em modelo murino, e \n\nambas as prote\u00ednas s\u00e3o reconhecidas por IgG1 e IgG3 de indiv\u00edduos resistentes a Infec\u00e7\u00e3o \n\npelo S. mansoni, mas n\u00e3o pelo soro de indiv\u00edduos cronicamente Infectados (Tran MH et al., \n\n2006). \n\nA literatura sobre as tetraspaninas de mam\u00edferos sugere que tais prote\u00ednas t\u00eam um \n\nimportante papel na forma\u00e7\u00e3o de uma rede estrutural para manuten\u00e7\u00e3o da integridade da \n\nmembrana do tegumento do parasito (Levy &amp; Shohan, 2005). Uma vez que foram descritas \n\nprote\u00ednas do hospedeiro na superf\u00edcie do parasito, alternativamente, as tetraspaninas poderiam \n\nfuncionar como receptores para mol\u00e9culas do hospedeiro (Tran et al., 2006). Em um trabalho \n\nrealizado por Tran e colaboradores (2010), que utilizou a t\u00e9cnica de RNA de interfer\u00eancia \n\npara explorar os pap\u00e9is da SmTSP-1 e TSP-2 em esquistoss\u00f4mulos e vermes adultos foram \n\nobservadas mal-forma\u00e7\u00e3o do tegumento dos vermes adultos quando realizado experimento de \n\ncultura in vitro. Al\u00e9m disso, o silenciamento de TSP-1 e TSP2 em esquistoss\u00f4mulos os quais \n\nforam, posteriormente, injetados via intramuscular em camundongos, resultou na diminui\u00e7\u00e3o \n\nde at\u00e9 90% na matura\u00e7\u00e3o das larvas em vermes adultos comparado ao grupo controle. Tal \n\ntrabalho destaca a import\u00e2ncia das tetraspaninas na biog\u00eaneso do tegumento. \n\nRecentemente uma nova prote\u00edna do tegumento selecionada a partir de uma biblioteca \n\nde cDNA de verme adulto de S. mansoni foi identificada por Cardoso e colaboradores (2006) \n\ne denominada Sm29. A reatividade de soros de indiv\u00edduos de \u00e1reas end\u00eamicas para a \n\n\n\n\u00a0\n\n\u00a0\n\n44\u00a0\n\n\u00a0\n\nesquistossomose \u00e0 Sm29 recombinante foi avaliada. Anticorpos IgG1 e IgG3 anti-Sm29r \n\nforam os isotipos predominantemente identificados no soro de indiv\u00edduos naturalmente \n\nresistentes \u00e0 infec\u00e7\u00e3o e reinfec\u00e7\u00e3o (Cardoso et al., 2006).  \n\n Entre as prote\u00ednas que est\u00e3o em fase de testes cl\u00ednicos encontram-se a Sm14 e \n\nSm28/Sh28 GST. A Sm14 \u00e9 uma prote\u00edna de 14 kDa do S. mansoni pertencente \u00e0 fam\u00edlia de \n\nprote\u00ednas ligadoras de \u00e1cido graxos que foi identificada em uma biblioteca de cDNA de verme \n\nadulto do S. mansoni por soro de camundongos imunizados com extrato salino de vermes \n\nadultos (SE) (Moser et al., 1991). Esta prote\u00edna \u00e9 expressa em todos os est\u00e1gios do parasito \n\npresentes no hospedeiro vertebrado (Brito et al., 2002). A forma recombinante desta prote\u00edna \n\nfoi utilizada com sucesso em protocolos de imuniza\u00e7\u00e3o no modelo murino, sendo capaz de \n\ninduzir uma redu\u00e7\u00e3o parcial no n\u00famero de vermes adultos variando de acordo com o \n\nadjuvante utilizado, por\u00e9m, sem nenhum efeito sobre a \u00e1rea do granuloma hep\u00e1tico (Tendler \n\net al., 1996; Ribeiro et al., 2002; Fonseca et al., 2004).Recentemente, a utiliza\u00e7\u00e3o da Sm14 \n\ncomo ant\u00edgeno vacinal foi aprovada em testes cl\u00ednicos de fase 1, em volunt\u00e1rios humanos, \n\npela Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) e patenteado pelo Instituto \n\nOswaldo Cruz (IOC-Fiocruz). Como tem potencial multivalente, a vacina j\u00e1 mostrou ser \n\neficaz para fasciolose. A prote\u00edna foi constru\u00edda de forma recombinante e escalonada \n\nmantendo sua capacidade de produ\u00e7\u00e3o em volume industrial comprovada chegando-se a \n\nprodu\u00e7\u00e3o do chamado lote semente da vacina para testes cl\u00ednicos aprovado pela ANVISA \n\n(Comunica\u00e7\u00e3o/ Instituto Oswaldo Cruz - www.fiocruz.br/ioc).  \n\nA Sm28 ou Glutationa S-transferase (GST) \u00e9 uma enzima que exerce um importante \n\npapel na detoxifica\u00e7\u00e3o de xenobi\u00f3ticos e funciona como uma prote\u00edna ligadora intracelular, \n\nligando-se a uma s\u00e9rie de anti-helminticos, protegendo o parasito do ataque das c\u00e9lulas \n\nimunes do hospedeiro (Mannervik et al., 1985; Brophy &amp; Barret, 1990). A Sm28 foi a \n\nprinc\u00edpio isolada de vermes adultos do S. mansoni, mas \u00e9 expressa tamb\u00e9m na superf\u00edcie de \n\nesquistoss\u00f4mulos, al\u00e9m de ser secretada pelo mirac\u00eddio dentro do ovo (Balloul et al., 1987; \n\nPorchet et al., 1994). A Sm28 demonstrou ser eficiente quando utilizada em protocolos de \n\nimuniza\u00e7\u00e3o, reduzindo a carga parasit\u00e1ria, a fecundidade da f\u00eamea e a viabilidade do ovo do \n\nparasito (Balloul et al., 1987; Boulanger et al., 1991). A forma nativa da Sm28 \u00e9 capaz de \n\ninduzir uma redu\u00e7\u00e3o de 70% na carga parasit\u00e1ria de camundongos e ratos, e a resposta a esta \n\n\n\n\u00a0\n\n\u00a0\n\n45\u00a0\n\n\u00a0\n\nprote\u00edna em ratos est\u00e1 associada a uma grande produ\u00e7\u00e3o de IgG2a, capaz de induzir \n\ncitotoxicidade in vitro mediada por eosin\u00f3filos (Balloul et al., 1987). No modelo murino, a \n\nimunidade protetora induzida pela Sm28 envolve um mecanismo celular no qual a produ\u00e7\u00e3o \n\nde citocinas como o IFN-?, o TNF-? e a IL-6 est\u00e3o envolvidas nos mecanismos citot\u00f3xicos \n\ncontra o esquistoss\u00f4mulo (Damonneville et al., 1988; Pancre et al., 1990). O efeito anti-\n\nfecundidade da Sm28 parece estar associado \u00e0 indu\u00e7\u00e3o de anticorpos capazes de inibir a \n\natividade enzim\u00e1tica da prote\u00edna (Xu et al., 1991). Estudos pr\u00e9-cl\u00ednicos tem sido realizados \n\nutilizando a Sm28 proveniente de Schistosoma haematobium. A forma recombinante da \n\nprote\u00edna (rSh28GST) foi produzida em leveduras sob boas condi\u00e7\u00f5es de fabrica\u00e7\u00e3o.O \n\nprincipal objetivo dos primeiros passos dos ensaios cl\u00ednicos foi avaliar a seguran\u00e7a de tal \n\nprote\u00edna em volunt\u00e1rios adultos saud\u00e1veis, crian\u00e7as saud\u00e1veis e adultos e crian\u00e7as \n\npreviamente infectados com Schistosoma. Resultados semelhantes de citotoxidade em ratos e \n\ncoelhos foram apresentados: nenhuma rea\u00e7\u00e3o local ou sist\u00eamica foi observada bem como \n\nnenhuma rea\u00e7\u00e3o cruzada com GST de ratos e humanos (Capron et al., 2005). \n\n ECL ou Sm200 \u00e9 uma prote\u00edna ancorada por GPI (glicosilfosfatidilinositol) e tem sido \n\nassociada com a efic\u00e1cia do praziquantel, uma vez que os anticorpos contra a mesma podem \n\nrestaurar a efic\u00e1cia da droga em camundongos nocautes para c\u00e9lulas B (Sauma &amp; Strand, \n\n1990; Brindley et al., 1989).Em camundongos, a vacina de DNA da Sm200 elicitou uma \n\nprote\u00e7\u00e3o de 38,1%, al\u00e9m disso, a imuniza\u00e7\u00e3o de camundongos com prote\u00ednas ancoradas por \n\nGPI provenientes do tegumento resultou em uma redu\u00e7\u00e3o de 43% da carga parasit\u00e1ria \n\n(Nascimento et al., 2007; Martins et al., 2012). \n\nA Sm 21.7 \u00e9 uma prote\u00edna do tegumento e foi isolada utilizando biblioteca de cDNA \n\nde vermes da cepa eg\u00edpcia de Schistosoma mansoni presentes no f\u00edgado. Utilizou-se a t\u00e9cnica \n\nde \u201cimmunoscreening\u201d com soro de coelhos infectados para a identifica\u00e7\u00e3o. A prote\u00edna \n\nSm21.7 foi testada como vacina recombinante e vacina de DNA. A imuniza\u00e7\u00e3o de \n\ncamundongos utilizando a prote\u00edna recombinante rSm21.7 resultou em uma diminui\u00e7\u00e3o de \n\n41% - 70% da carga parasit\u00e1ria, enquanto a vacina\u00e7\u00e3o utilizando o DNA reduziu em 41,5% \n\n(Ahmed &amp; Romeiih, 2001; Romeih et al., 2008). \n\n\n\n\u00a0\n\n\u00a0\n\n46\u00a0\n\n\u00a0\n\n A express\u00e3o da enzima antioxidante Cu/Zn super\u00f3xido dismutase \u00e9 regulada durante o \n\ndesenvolvimento do parasito. Os maiores n\u00edveis de express\u00e3o foram encontrados no est\u00e1gio de \n\nverme adulto, sugerindo que as enzimas antioxidantes s\u00e3o importantes na evas\u00e3o imune dos \n\nvermes adultos (Mei H &amp; Lo Verde, 1997). Al\u00e9m disso, ensaios utilizando RNAi \n\ndemonstraram que a diminui\u00e7\u00e3o da express\u00e3o dessas enzimas, resultou numa dram\u00e1tica \n\ndiminui\u00e7\u00e3o da sobreviv\u00eancia do esporocisto (Mour\u00e3o et al., 2012). Camundongos imunizados \n\ncom a enzima antoxidante Cu/Zn super\u00f3xido dismutase na forma de vacina de DNA \n\napresentaram redu\u00e7\u00e3o de 44-60% na carga parasit\u00e1ria (Shalaby et al., 2003). \n\n A Smp80 ou Calpaina \u00e9 expressa no tegumento dos vermes adultos, mais \n\nespecificamente na membrana interna do tegumento (Braschi &amp; Wilson, 2006) e est\u00e1 \n\nenvolvida com a renova\u00e7\u00e3o da membrana (Siddiqui et al., 1993). Essa prote\u00edna tem sido \n\nreportada como alvo de linf\u00f3citos TCD4+, induzindo morte de esquistoss\u00f4mulos, in vitro, por \n\nmacr\u00f3fagos peritoneais (Jankovic et al., 1996). Subsequentes esfor\u00e7os para aumentar a \n\nefic\u00e1cia da vacina t\u00eam sido feitos com foco na constru\u00e7\u00e3o de vacina de DNA para \n\ncamundongos e babu\u00ednos (Siddiqui et al., 2003). Em um experimento com camundongos, a \n\nutiliza\u00e7\u00e3o da Sm-p80 na forma de DNA induziu uma redu\u00e7\u00e3o de 59% da carga parasit\u00e1ria \n\nal\u00e9m de uma diminui\u00e7\u00e3o de 84% na produ\u00e7\u00e3o de ovos (Ahmad et al., 2009). Em baboons, a \n\nvacina de DNA induziu uma redu\u00e7\u00e3o de 38% da carga parasit\u00e1ria e 32% de diminui\u00e7\u00e3o do \n\nn\u00famero de ovos (Ahmada et al., 2009). Al\u00e9m disso, a transfer\u00eancia passiva de soro de \n\nbabu\u00ednos previamente imunizado com Sm-p80 conferiu uma diminui\u00e7\u00e3o da carga parasit\u00e1ria \n\nde 31-45%nos animais receptores do soro (Torben et al., 2011). \n\nAs ciclofilinas (Cyps) s\u00e3o prote\u00ednas extremamente conservadas da fam\u00edlia das \n\nubiquinonas. Conhecidas por possuir o dom\u00ednio peptidil-prolil cis-trans isomerases (PPIase) \u00e9 \n\nalvo da droga imunosupressora ciclosporina A (Galat et al., 1993; Walsh et al., 1992). \n\nEstudos sugerem que a ciclosporina A \u00e9 uma importante droga anti-parasit\u00e1ria. No caso da \n\nesquistossomose, a ciclosporina A \u00e9 capaz de reduzir a carga parasit\u00e1ria, fecundidade da \n\nf\u00eamea e a atividade de hemoglobinase (Bueding et al., 1981). Uma vez que as ciclofilinas s\u00e3o \n\ncapazes de se ligar \u00e0s ciclosporina, as ciclofilinas possuem importante papel nos efeitos \n\ndanosos ao Schistosoma provocado pela ciclosporina. Imuniza\u00e7\u00f5es de camundongos \n\nutilizando ciclofilina recombinante de Schistosoma japonicum (rSJCyPA) resultou em uma \n\n\n\n\u00a0\n\n\u00a0\n\n47\u00a0\n\n\u00a0\n\ndiminui\u00e7\u00e3o estat\u00edsticamente significativa da carga parasit\u00e1ria (17,2%) e em 52,7% na redu\u00e7\u00e3o \n\nde ovos presos no f\u00edgado (Hongxiao et al., 2012). \n\nComo apresentado na tabela 1, v\u00e1rios n\u00edveis de prote\u00e7\u00e3o foram observados em \n\nmodelos animais ap\u00f3s utiliza\u00e7\u00e3o de diferentes formula\u00e7\u00f5es vacinais. Entretanto, ainda n\u00e3o se \n\nconseguiu alcan\u00e7ar o elevado n\u00edvel de prote\u00e7\u00e3o obtido com os modelos de parasitos atenuados \n\npela radia\u00e7\u00e3o. Assim, novos candidatos e formula\u00e7\u00f5es vacinais ainda precisam ser \n\ndescobertos. \n\n1.7 Tegumento do Schistosoma mansoni como alvo vacinal \n\nMuitos estudos t\u00eam revelado que o tegumento do Schistosoma mansoni possui papel \n\nfundamental na rela\u00e7\u00e3o parasito-hospedeiro (Fonseca et al., 2012; Abath &amp; Werkhauser, \n\n1996; Han et al., 2009). A cerc\u00e1ria \u00e9 revestida por um tegumento sincicial com uma regi\u00e3o \n\ncitoplasm\u00e1tica anucleada, diretamente subjacente \u00e0 membrana superficial cont\u00ednua, com \n\ncorpos celulares situados mais profundamente no par\u00eanquima. Uma membrana plasm\u00e1tica \n\ntrilaminada sob uma membrana basal tamb\u00e9m trilaminada formam a superf\u00edcie externa do \n\ntegumento, que \u00e9 coberta por numerosas fibrilas (glicoc\u00e1lice). O glicoc\u00e1lice \u00e9 uma mol\u00e9cula \n\ncomplexa formada por oligossacar\u00eddeos que atuam, entre outras fun\u00e7\u00f5es, protegendo a \n\npermeabilidade da cerc\u00e1ria (Dorsey, 2002). \n\nA transforma\u00e7\u00e3o de cerc\u00e1rias para esquistoss\u00f4mulos \u00e9 representada por elimina\u00e7\u00e3o \n\nprogressiva do glicoc\u00e1lice, esvaziamento das gl\u00e2ndulas secretoras e reorganiza\u00e7\u00e3o do \n\ntegumento, com ac\u00famulo de uma prote\u00edna transportadora de glicose (SGTP4) na rede de \n\nc\u00edtons (corpos membranosos) subtegumentares (Skelly &amp; Shoemaker, 2000). Uma \n\nconsequ\u00eancia da aus\u00eancia do glicoc\u00e1lice \u00e9 o aumento da permeabilidade do esquistoss\u00f4mulo \u00e0 \n\n\u00e1gua. \n\nA partir da penetra\u00e7\u00e3o no hospedeiro vertebrado, o tegumento se torna especializado \n\nna absor\u00e7\u00e3o e secre\u00e7\u00e3o e representa o principal s\u00edtio das a\u00e7\u00f5es imunol\u00f3gicas do hospedeiro \n\n(Joneset al., 2004). Os estudos ultraestruturais dos esquistoss\u00f4mulos recuperados 30 minutos \n\nap\u00f3s a passagem pela pele ou mantidos in vitro ainda apresentam membrana externa \n\ntrilaminada, por\u00e9m menos espessa. As c\u00e9lulas subtegumentares cont\u00eam pequenos corpos \n\n\n\n\u00a0\n\n\u00a0\n\n48\u00a0\n\n\u00a0\n\nlaminares que s\u00e3o transportados para o tegumento por conex\u00f5es citoplasm\u00e1ticas. Nos \n\nesp\u00e9cimes com 60 minutos, os corpos membranosos se fundem para formar grandes vac\u00faolos \n\ncom a membrana externa heptalaminada. Com tr\u00eas horas, a maior parte da membrana externa \n\n\u00e9 heptalaminada e o tegumento cont\u00e9m grandes vac\u00faolos, corpos alongados e pequenos \n\ncorpos membranosos. No esquistoss\u00f4mulo de 24 horas, a principal modifica\u00e7\u00e3o \u00e9 a forma\u00e7\u00e3o \n\nde pregas e cavidades na superf\u00edcie (Mc Laren, 1980; Hockley, 1973). A transi\u00e7\u00e3o do \n\nesquistoss\u00f4mulo pulmonar para o sistema hep\u00e1tico envolve significativas mudan\u00e7as na \n\ntopografia da superf\u00edcie do parasito, al\u00e9m de mudan\u00e7as fisiol\u00f3gicas. Os esquistoss\u00f4mulos \n\napresentam superf\u00edcie estriada e pregueada, sem evid\u00eancias de depress\u00f5es como nas formas \n\npulmonares. O tegumento tem uma espessura de cerca de 2 \u00b5m, sem diferen\u00e7as entre as \n\nformas com duas ou tr\u00eas semanas de idades (Mc Laren, 1980). \n\nO tegumento do verme adulto consiste em um sinc\u00edcio citoplasm\u00e1tico (Mc Laren, \n\n1980, Mc Laren, 1977). O tegumento \u00e9 ligado na sua superf\u00edcie basal por uma membrana \n\nplasm\u00e1tica convencional invaginada e possui em sua superf\u00edcie apical uma apar\u00eancia \n\nheptalaminada pouco usual. Esta \u00faltima estrutura foi interpretada como sendo uma membrana \n\nplasm\u00e1tica normal, sobreposta por uma bicamada secretada denominada membranoc\u00e1lice, por \n\nanalogia com glicoc\u00e1lice das c\u00e9lulas eucariotas (Braschi &amp; Wilson, 2006). Corpos celulares \n\nnucleados est\u00e3o situados abaixo das camadas musculares, conectados ao tegumento por canais \n\ncitoplasm\u00e1ticos alinhados a microt\u00fabulos. A maquinaria de s\u00edntese prot\u00e9ica, constitu\u00edda por \n\nribossomos, ret\u00edculo endoplasm\u00e1tico e pelo Complexo de Golgi est\u00e1 situada nos corpos \n\ncelulares. Duas formas de inclus\u00f5es secret\u00f3rias, corpos disc\u00f3ides e ves\u00edculas multilaminadas, \n\ns\u00e3o produzidos nos corpos celulares e se direcionam ao tegumento atrav\u00e9s das conex\u00f5es \n\ncitoplasm\u00e1ticas. Esp\u00edculas, pequenas mitoc\u00f4ndrias e uma variedade de outras inclus\u00f5es est\u00e3o \n\npresentes no citoplasma do tegumento (Fig. 7) (Wilson &amp; Barnes, 1974). \n\n\n\n\u00a0\n\n\u00a0\n\n49\u00a0\n\n\u00a0\n\n \n\nFigura 7. Representa\u00e7\u00e3o do tegumento do Schistosoma mansoni com ant\u00edgenos do \n\nparasito identificados por estudos prote\u00f4micos. (Braschi &amp; Wilson, 2006) \n\nOs mecanismos de evas\u00e3o como mimetismo antig\u00eanico, modifica\u00e7\u00f5es da membrana, \n\nprodu\u00e7\u00e3o de mol\u00e9culas imunomodulat\u00f3rias e modula\u00e7\u00e3o da express\u00e3o de ant\u00edgenos de \n\nsuperf\u00edcie contribuem para a sobreviv\u00eancia do parasito no hospedeiro. Por esta raz\u00e3o, os \n\ncomponentes do tegumento s\u00e3o importantes alvos de vacina\u00e7\u00e3o. Na tabela 1 os ant\u00edgenos do \n\ntegumento est\u00e3o representados por um asterisco.  \n\nEstudos revelam que o est\u00e1gio mais suscept\u00edvel \u00e0 resposta do sistema imune \u00e9 o \n\nesquistoss\u00f4mulo. Al\u00e9m dos ant\u00edgenos do tegumento de vermes adultos, o tegumento do \n\nesquistoss\u00f4mulo \u00e9 um alvo importante, j\u00e1 que esse est\u00e1gio \u00e9 o primeiro que interage com o \n\nsistema imune do hospedeiro ativando as c\u00e9lulas apresentadoras de ant\u00edgenos e promovendo a \n\nativa\u00e7\u00e3o e diferencia\u00e7\u00e3o de linf\u00f3citos B e T (Teixeira de Melo et al., 2010). Em experimento \n\nrealizado por Dur\u00e3es e colaboradores (2009) foi demonstrado que o tegumento do \n\nesquistoss\u00f4mulo do Schistosoma mansoni (Smteg) foi capaz de ativar as c\u00e9lulas dendr\u00edticas a \n\nexpressar marcadores de ativa\u00e7\u00e3o CD80 e CD86, al\u00e9m disso, aumentou de forma significativa \n\na produ\u00e7\u00e3o de citocinas inflamat\u00f3rias tais como IL-12 e IFN-?. Ao se utilizar o Smteg como \n\n\n\n\u00a0\n\n\u00a0\n\n50\u00a0\n\n\u00a0\n\nant\u00edgeno vacinal acrescentado de adjuvantes, o mesmo foi capaz de reduzir de forma \n\nsignificativa a carga parasit\u00e1ria em 43-48% quando administrado com adjuvante de Freund \n\n(Teixeira de Melo, 2010) e reduzir de forma significativa a carga parasit\u00e1ria em 43,1% \n\nquando administrado com CpG-ODN (Teixeira de Melo 2012). Essa resposta protetora est\u00e1 \n\nassociada a um perfil de resposta imunol\u00f3gica Th1 com o aumento da produ\u00e7\u00e3o de anticorpos \n\nespec\u00edficos. Estudos demonstram que os anticorpos est\u00e3o associados \u00e0 elimina\u00e7\u00e3o do \n\nSchistosoma pelo hospedeiro (Torben et al., 2011; Dunne et al., 1993). Melo et al. e \n\ncolaboradores (2014) demonstraram que os anticorpos espec\u00edficos contra o tegumento do \n\nesquistoss\u00f4mulo do Schistosoma mansoni (Smteg) foram capazes de se ligar \u00e0 superf\u00edcie do \n\nparasito aumentando consideravelmente a morte dos esquistoss\u00f4mulos pela ativa\u00e7\u00e3o do \n\ncomplemento. Al\u00e9m disso, nos camundongos que receberam o soro por transfer\u00eancia passiva, \n\nhouve diminui\u00e7\u00e3o estatisticamente significativa da carga parasit\u00e1ria e do n\u00famero de ovos \n\npresos no intestino e f\u00edgado.  \n\n1.8 Adjuvantes \n\nAdjuvantes s\u00e3o mol\u00e9culas, componentes ou macromol\u00e9culas complexas que \n\naumentam a pot\u00eancia e a longevidade de uma resposta imune espec\u00edfica a um ant\u00edgeno (Wack \n\n&amp; Rappuoli, 2005). A adi\u00e7\u00e3o de adjuvantes \u00e0s formula\u00e7\u00f5es vacinais aumenta, sustenta e \n\ndireciona a resposta imunol\u00f3gica reduzindo, assim, a quantidade de ant\u00edgeno ou o n\u00famero de \n\nimuniza\u00e7\u00f5es necess\u00e1rias (Kenney et al., 2004). Adjuvantes possuem efic\u00e1cia dependente de \n\numa formula\u00e7\u00e3o apropriada. Contudo, tanto os componentes quanto a formula\u00e7\u00e3o do \n\nadjuvante (ex: \u00f3leo e \u00e1gua, tamanho da part\u00edcula, etc) s\u00e3o cruciais para o aumento da \n\nefici\u00eancia de uma vacina (Reed et al., 2009). \n\nAdjuvantes podem promover uma resposta imune atrav\u00e9s do recrutamento de c\u00e9lulas \n\napresentadoras de ant\u00edgenos (APCs) ao local de vacina\u00e7\u00e3o liberando os ant\u00edgenos para as \n\nmesmas as quais, ativadas, al\u00e9m de apresentarem o ant\u00edgeno, produzem citocinas o que \n\npromove a ativa\u00e7\u00e3o de c\u00e9lulas T (Mckee et al., 2010). Os adjuvantes podem induzir \n\ninflama\u00e7\u00e3o local aumentando o contato do ant\u00edgeno com c\u00e9lulas adicionais que s\u00e3o atra\u00eddas \n\npara o local da inocula\u00e7\u00e3o, al\u00e9m de promover a libera\u00e7\u00e3o lenta de ant\u00edgeno, prolongando \n\nassim sua intera\u00e7\u00e3o com as c\u00e9lulas apresentadoras de ant\u00edgeno (Rush &amp; Flaminio, 2000). \n\n\n\n\u00a0\n\n\u00a0\n\n51\u00a0\n\n\u00a0\n\nAl\u00e9m disso, podem induzir imunidade de mucosas e aumentar a resposta imunol\u00f3gica em \n\nindiv\u00edduos imunologicamente imaturos ou senis (Singh et al., 1999). O in\u00edcio da resposta \n\nimune \u00e9 controlado pelas c\u00e9lulas da imunidade inata juntamente com um grande grupo de \n\nreceptores intra e extracelulares chamados receptotes de reconhecimento padr\u00e3o. A melhor \n\nclasse descrita de tais receptores s\u00e3o os denominados Tolls (TLR) respons\u00e1veis pelo \n\nreconhecimento de v\u00e1rias vias de padr\u00f5es de reconhecimento de pat\u00f3genos (PAMPs) \n\nexpressas por um amplo espectro de agentes infecciosos, adicionalmente existem outros \n\nreceptores tais como NOD- Like (NLRs que est\u00e3o relacionados \u00e0 est\u00edmulos microbianos e \n\nNALP3, um membro da fam\u00edlia NLR e que est\u00e1 relacionado \u00e0 forma\u00e7\u00e3o de IFNlamossomas \n\nque regula a libera\u00e7\u00e3o de citocinas pr\u00f3-IFNlamat\u00f3rias tais como IL-1b, IL-18 e IL-33 \n\n(Sutterwala et al., 2006; Rimaniol et al., 2004; Li et al., 2007). Avan\u00e7os nos estudos do \n\nsistema imune inato t\u00eam revelado que muitos adjuvantes agem atrav\u00e9s de receptores tais como \n\nToll-Like, NOD-Like, RIG-I-Like, C-Type Lectinas ativando as c\u00e9lulas dendr\u00edticas a \n\napresentarem os ant\u00edgenos para as c\u00e9lulas T (Kim et al., 2011; Van Duim et al., 2006). \n\nO hidr\u00f3xido de alum\u00ednio (Alum) tem sido comumente utilizado como adjuvante \n\napesar de sua forma de a\u00e7\u00e3o s\u00f3 agora estar sendo esclarecida (Marrack et al., 1996; Spreacific \n\net al., 2010; McKee et al., 2010). Dentre os adjuvantes, esta formula\u00e7\u00e3o tem sido utilizada em \n\nv\u00e1rios tipos de vacinas humanas como: t\u00e9tano, difteria, hepatite B, dentre outras e vacinas \n\nveterin\u00e1rias como: vacinas para febre ef\u00eamera, Haemophilus e encefalite japonesa. Muitos \n\nestudos t\u00eam evidenciado a neurotoxicidade de compostos de alum\u00ednio e relacionam os \n\nmesmos \u00e0s doen\u00e7as como Alzheimer e encefalopatias (Goto et al., 1993). Este adjuvante \n\ninduz o aumento na migra\u00e7\u00e3o macrof\u00e1gica e neutrof\u00edlica para o s\u00edtio de inocula\u00e7\u00e3o, o que \n\npode explicar o eritema, n\u00f3dulos subcut\u00e2neos, hipersensibilidade de contato e Inflama\u00e7\u00e3o \n\ngranulomatosa, efeitos colaterais, associados ao uso do hidr\u00f3xido de alum\u00ednio.  Estudos \n\nrevelam que, o Alum direciona a resposta imunol\u00f3gica para um perfil Th2. Em rela\u00e7\u00e3o \u00e0 \n\nresposta humoral, o Alum induz uma maior produ\u00e7\u00e3o de IgG1 e IgE. (El-Ridi et al., 2009; \n\nMosmann &amp; Sad, 1996). \n\nO MF59 \u00e9 um adjuvante licenciado para humanos desde 2000 na Europa. Este foi o \n\nprimeiro adjuvante a ser utilizado em uso humano depois do Alum. O MF59 \u00e9 uma emuls\u00e3o \n\nde \u00f3leo em \u00e1gua contendo esqualeno, Tween-80 e outros componentes. Embora os \n\n\n\n\u00a0\n\n\u00a0\n\n52\u00a0\n\n\u00a0\n\nmecanismos de a\u00e7\u00e3o exatos desse adjuvante n\u00e3o sejam conhecidos, parece que ele atua na \n\nativa\u00e7\u00e3o de c\u00e9lulas apresentadoras de ant\u00edgenos. Extensos dados cl\u00ednicos demonstram que o \n\nMF59 aumenta fortemente a resposta imunol\u00f3gica induzida pela vacina contra a gripe em \n\nindiv\u00edduos idosos (OMS, 2001). \n\nMonofosfolip\u00eddeo A (MPL), derivado do LPS de salmonela, \u00e9 um promissor \n\nadjuvante estimulante de uma resposta imunol\u00f3gica tipo Th1. MPL \u00e9 formulado como uma \n\nemuls\u00e3o est\u00e1vel para inje\u00e7\u00e3o chamada MPL-SE, capaz de interagir com o TLR-4 (OMS, \n\n2001). O MPL foi aprovado para o uso na vacina contra o papilomav\u00edrus juntamente com o \n\nAlum (Mckee et al., 2010). \n\nO adjuvante completo de Freund (CFA) \u00e9 uma suspens\u00e3o de componentes da parede \n\ncelular deMycobacterium tuberculosis em \u00f3leo mineral e um agente emulsionante. \u00c9 \n\npreparado de acordo com a t\u00e9cnica de Freund que utiliza M. tuberculosis H37 Ra ao inv\u00e9s de \n\nM. butyricum. O adjuvante incompleto de Freund (IFA) \u00e9 similar ao adjuvante completo, sem \n\na adi\u00e7\u00e3o do M. tuberculosis (Billiau &amp; Matthys, 2001). A adi\u00e7\u00e3o de micobact\u00e9ria a este \n\nadjuvante provoca o aumento da resposta imune aos ant\u00edgenos, particularmente aos ant\u00edgenos \n\nsol\u00faveis. Um componente essencial desta resposta \u00e9 a rea\u00e7\u00e3o inflamat\u00f3ria intensa no local de \n\ndeposi\u00e7\u00e3o do ant\u00edgeno resultando em um IFNluxo de leuc\u00f3citos e sua intera\u00e7\u00e3o com o \n\nant\u00edgeno. O CFA pode resultar em rea\u00e7\u00f5es granulomatosas no local da inje\u00e7\u00e3o quando usado \n\nde forma abusiva e tamb\u00e9m pode causar efeitos colaterais, como inflama\u00e7\u00e3o cr\u00f4nica, \n\nulcera\u00e7\u00e3o da pele, abscesso local, febre e dor (Broderson et al., 1989). A administra\u00e7\u00e3o de \n\nCFA/ IFA como adjuvante associada a v\u00e1rios ant\u00edgeno do S. mansoni induz uma resposta \n\nprotetora contra a esquistossomose com perfil Th1 associada com alta produ\u00e7\u00e3o de citocinas \n\nIFNlamat\u00f3rias como IFN-gama e TNF-alfa, bem como de anticorpos do isotipo IgG e IgG2c \n\n(Cardoso, et al., 2008, Fonseca et al., 2004, Pac\u00edfico et al., 2006b; Teixeira de Melo et al., \n\n2010). Entretanto, pelo seu exacerbado efeito inflamat\u00f3rio, o adjuvante de Freund n\u00e3o \u00e9 \n\nlicenciado para utiliza\u00e7\u00e3o em humanos (Chu et al., 1997). \n\nRecentes descobertas demonstraram que certas prepara\u00e7\u00f5es de DNA possuem efeito \n\nna produ\u00e7\u00e3o de citocinas pelas c\u00e9lulas do sistema imune. In vitro, DNA bacteriano induz a \n\nexpress\u00e3o de IL-12 e TNF-? por macr\u00f3fagos que n\u00e3o s\u00e3o induzidas por DNA de mam\u00edferos \n\n\n\n\u00a0\n\n\u00a0\n\n53\u00a0\n\n\u00a0\n\n(Chace et al., 1997; Stacey et al., 1996). Al\u00e9m disso, o DNA bacteriano induz a ativa\u00e7\u00e3o de \n\nc\u00e9lulas NK com expressiva produ\u00e7\u00e3o de IFN-?, esta produ\u00e7\u00e3o \u00e9 dirigida pela IL-12 \n\nanteriormente produzida por macr\u00f3fagos em resposta ao DNA bacteriano (Chace et al., 1997; \n\nHalperet al., 1996, Yamamoto et al., 1992; Ballas et al., 1996). A fim de definir os \n\ncomponentes do DNA bacteriano que possuem efeito imunomodulat\u00f3rio, um painel de \n\nOligodeoxinucleot\u00eddeos (ODN) sint\u00e9ticos foi usado para a posterior identifica\u00e7\u00e3o das \n\nsequ\u00eancias de pares de seis bases espec\u00edficas as quais conferiam esta atividade (Krieg et al., \n\n1995). Estas sequ\u00eanciaschamadas de motivos de CpG, contendo um dinucleot\u00eddeo central n\u00e3o \n\nmetilado preferenciamente flanqueado por 5`purinas e 3`pirimidinas. Os dinucleot\u00eddeos CpG \n\nest\u00e3o presentes no DNA bacteriano na propor\u00e7\u00e3o 1/16 bases, estando presente em uma \n\npropor\u00e7\u00e3o 3 a 4 vezes menor em DNA de mam\u00edferos, fen\u00f4meno conhecido como supress\u00e3o de \n\nCpG (Bird et al., 1986). Al\u00e9m disso, a citosina do CpG de mam\u00edferos \u00e9 altamente metilada, \n\nsendo que essa metila\u00e7\u00e3o n\u00e3o \u00e9 encontrada no DNA bacteriano (Bird et al., 1986). \n\nAo se utilizar CpG-ODN em cultura de esplen\u00f3citos, observou-se um perfil de \n\nresposta Th1 associada \u00e0 produ\u00e7\u00e3o de citocinas IFN-? e IL-12 e nenhuma produ\u00e7\u00e3o de IL-4, \n\nIL-5 e IL-10. Isto sugere que a administra\u00e7\u00e3o de CpG-ODN, in vivo, induz uma resposta \n\nimune do tipo Th1. Adicionalmente, vacina com DNA plasmidiano bacteriano, o qual \n\ncontinha motivos de CpG, levou a ativa\u00e7\u00e3o de c\u00e9lulas CD4+  IFN-?+, mas n\u00e3o IL-4+ ou IL-\n\n5+ (Sato et al., 1996; Raz et al. 1996).  Devido a atividade imunoestimulat\u00f3ria do CpG-ODN \n\nenvolvendo receptores do tipo Toll, mais especificamente o TLR-9, o mesmo vem sendo \n\nutilizado como adjuvante em formula\u00e7\u00f5es vacinais (Kim et al., 2011).Uma vez observado este \n\nperfil de resposta imune Th1 induzido pelo CpG-ODN, este composto vem sendo utilizado \n\nem vacinas para pat\u00f3genos intracelulares (Krieg et al., 1998) bem como para testes de vacinas \n\ncontra o Schistosoma mansoni, uma vez que \u00e9 bem demonstrado pela literatura que o perfil \n\nTh1 \u00e9 protetor levando a redu\u00e7\u00e3o da carga parasit\u00e1ria em modelo murino (Teixeira de Melo et \n\nal., 2012; Sparwasser et al., 1998, Yamamoto et al., 1992) \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n54\u00a0\n\n\u00a0\n\n2 OBJETIVOS \n\n2.1 Objetivo Geral \n\nDeterminar o perfil imunol\u00f3gico e mecanismos protetores induzido pela imuniza\u00e7\u00e3o \n\ncom uma prepara\u00e7\u00e3o antig\u00eanica do tegumento do esquistoss\u00f4mulo do Schistosoma mansoni \n\n(Smteg) em um ant\u00edgeno recombinante identificado nesta prepara\u00e7\u00e3o. \n\n2.2 Objetivos espec\u00edficos \n\n1.  Identificar padr\u00f5es imunol\u00f3gicos associados \u00e0 redu\u00e7\u00e3o da carga parasit\u00e1ria induzida pela \n\nimuniza\u00e7\u00e3o com ant\u00edgenos do tegumento de esquistoss\u00f4mulo do S. mansoni, atrav\u00e9s da \n\navalia\u00e7\u00e3o da resposta protetora induzida pelo Smteg na presen\u00e7a de diferentes formula\u00e7\u00f5es \n\nadjuvantes.  \n\n2.  Avaliar o papel dos anticorpos espec\u00edficos contra os ant\u00edgenos do Smteg na elimina\u00e7\u00e3o do \n\nparasito por ensaios de citotoxicidade in vitro e transfer\u00eancia de anticorpos in vivo. \n\n3.  Identificar ant\u00edgenos imunog\u00eanicos do tegumento de esquistoss\u00f4mulos do S. mansoni por \n\nWestern-blotting bidimensional seguido por espectrometria de massas; \n\n4.  Avaliar a capacidade do ant\u00edgeno SmCyp, identificado por imunoprote\u00f4mica, de induzir \n\nimunidade protetora contra o S. mansoni em protocolo de imuniza\u00e7\u00e3o g\u00eanica em \n\ncamundongos atrav\u00e9s da determina\u00e7\u00e3o do n\u00famero de vermes recuperados por perfus\u00e3o do \n\nsistema porta, n\u00famero de ovos nas fezes, f\u00edgado e intestino. \n\n5.  Avaliar o perfil de resposta imune humoral e celular induzida pelas imuniza\u00e7\u00f5es atrav\u00e9s da \n\ndetec\u00e7\u00e3o de anticorpos IgG, IgG1, IgG2c espec\u00edficos, avalia\u00e7\u00e3o do perfil celular e  \n\nquantifica\u00e7\u00e3o de citocinas IFN-?, IL-4, IL-10 e TNF-?, IL-6, IL-2e IL-17 no sobrenadante de \n\ncultura de esplen\u00f3citos e por marca\u00e7\u00e3o intracitoplasm\u00e1tica de linf\u00f3citos. \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n55\u00a0\n\n\u00a0\n\n3  METODOLOGIA \n\n3.1 Obten\u00e7\u00e3o de ant\u00edgeno Smteg \n\n O ciclo de vida da cepa LE (Belo Horizonte, Brasil) do S. mansoni tem sido mantido \n\npela passagem em caramujos Biomphalaria glabrata, hamsters e camundongos Swiss ou \n\nBalb/c. As cerc\u00e1rias foram obtidas no molusc\u00e1rio do Centro de Pesquisa Ren\u00e9 Rachou e \n\ntransformadas mecanicamente em esquistoss\u00f4mulos atrav\u00e9s da t\u00e9cnica descrita por Ramalho-\n\nPinto e colaboradores (1974). Resumidamente, as cerc\u00e1rias foram deixadas no gelo durante 30 \n\nminutos, acondicionadas em tubos c\u00f4nicos, para reduzir a sua movimenta\u00e7\u00e3o. Em seguida, as \n\nmesmas foram centrifugadas a 1800 x g por 3 minutos. O \u201cpellet\u201d ent\u00e3o foi ressuspendido em \n\n1mL de meio Earl\u00b4s salts plus lactoalbumin hydrolysate (ELAC) gelado. As caudas foram \n\nquebradas utilizando-se o v\u00f3rtex na velocidade m\u00e1xima (Genie 2- Scientific industries-USA) \n\npor um per\u00edodo de dois minutos. Posteriormente as caudas foram retiradas do meio atrav\u00e9s de \n\nrepetidas lavagens com ELAC \u00e0 37\u00b0C restando, ent\u00e3o, os esquistoss\u00f4mulos. Estes foram \n\nincubados por 90 minutos no banho-maria a 37\u00ba C. \n\n           Ap\u00f3s a incuba\u00e7\u00e3o, os esquistoss\u00f4mulos foram lavados com 5 mL de salina apirog\u00eanica \n\ne centrifugados a 200 x g por 1 minuto. Para a remo\u00e7\u00e3o do tegumento dos esquistoss\u00f4mulos \n\n(Smteg), foram acrescentados 2mL de CaCl20,3M, e as larvas foram agitadas no v\u00f3rtex no \n\ncanal 3 por um per\u00edodo de 7 minutos e centrifugados a 200 x g por 1 minuto por duas vezes. \n\nO sobrenadante, contendo o tegumento, foi coletado e posteriormente, centrifugado a 50000 x \n\ng durante uma hora a 4\u00baC. O pellet enriquecido com membranas foi submetido \u00e0 di\u00e1lise contra \n\n6 litros de salina 1,7% com duas trocas sendo que na \u00faltima troca foi utilizada salina 0,9%. A \n\nconcentra\u00e7\u00e3o prot\u00e9ica foi determinada pelo m\u00e9todo de Bradford (Bradford , 1976). \n\n3.2 Protocolo de imuniza\u00e7\u00e3o com diferentes formula\u00e7\u00f5es vacinais  \n\n Camundongos C57BL/6 f\u00eameas foram separados para a vacina\u00e7\u00e3o, sendo que os \n\nmesmos foram divididos em grupos de 10 camundongos cada. Um grupo controle da Infec\u00e7\u00e3o \n\nfoi utilizado para avaliar a qualidade da Infec\u00e7\u00e3o, os grupos n\u00e3o vacinados inoculados apenas \n\ncom salina sem adjuvante (Salina), ou Salina + alum (Salina+ alum) ou salina + alum + 50ug \n\nde CpG-ODN 1826 (Salina + alum + CpG-ODN).  Os grupos experimentais consistiram de \n\n\n\n\u00a0\n\n\u00a0\n\n56\u00a0\n\n\u00a0\n\ncamundongos imunizados com 25\u00b5g Smteg dilu\u00eddo em salina na aus\u00eancia de adjuvantes \n\n(Smteg), na presen\u00e7a de alum (Smteg + alum) ou na presen\u00e7a de alum + 50ug de CpG-ODN \n\n(Smteg + alum +CpG-ODN). As formula\u00e7\u00f5es vacinais est\u00e3o representadas na tabela 2. \n\nTabela 2: Grupos de camundongos imunizados com PBS e/ou Smteg na presen\u00e7a e na \n\naus\u00eancia de adjuvante \n\n \n\n A imuniza\u00e7\u00e3o foi realizada por via subcut\u00e2nea, em tr\u00eas doses com intervalos de 15 \n\ndias entre elas. Trinta dias ap\u00f3s a terceira dose, os camundongos foram Infectados com 100 \n\ncerc\u00e1rias por via percut\u00e2nea. Ap\u00f3s 50 dias, os animais foram eutanasiados e perfundidos pela \n\nveia porta (Pellegrino &amp; Siqueira, 1956). O f\u00edgado e o intestino de cada animal foram \n\nretirados para determina\u00e7\u00e3o do n\u00famero de ovos do parasito. Amostras de sangue foram \n\ncoletadas pelo plexo retro-orbital dos camundongos para obten\u00e7\u00e3o do soro de 15 em 15 dias a \n\npartir de 15 dias ap\u00f3s a primeira dose da vacina. A figura 8 abaixo ilustra o esquema de \n\nimuniza\u00e7\u00e3o (Figura 8). Foram realizados 3 ensaios de imuniza\u00e7\u00e3o independentes para cada \n\nformula\u00e7\u00e3o vacinal. \n\n \n\n \n\n \n\nGrupos Salina Smteg Alum CpG-ODN\nSalina 200\u00b5L/cdg \u2013 \u2013 \u2013\nSmteg \u2013 25\u00b5g/cdg \u2013 \u2013\n\nSalina + alum 100\u00b5L/cdg \u2013 100\u00b5L/cdg \u2013\nSmteg + alum \u2013 25\u00b5g/cdg 100\u00b5L/cdg \u2013\n\nSalina + alum + CpG-ODN 100\u00b5L/cdg \u2013 100\u00b5L/cdg 50\u00b5g/cdg\nSmteg + alum + CpG-ODN \u2013 25\u00b5g/cdg 100\u00b5L/cdg 50\u00b5g/cdg\n\nControle da infe\u00e7\u00e3o \u2013 \u2013 \u2013 \u2013\n\n\n\n\u00a0\n\n\u00a0\n\n57\u00a0\n\n\u00a0\n\n \n\nFigura 8: Protocolo de imuniza\u00e7\u00e3o. A primeira dose da imuniza\u00e7\u00e3o foi realizada no dia 0, a \n\nsegunda e a terceira doses foram realizadas com um intervalo de quinze dias. Trinta dias ap\u00f3s \n\na terceira dose, a Infec\u00e7\u00e3o percut\u00e2nea foi realizada utilizando 100 cerc\u00e1rias da cepa LE por \n\ncamundongo e, cinq\u00fcenta dias ap\u00f3s a Infec\u00e7\u00e3o a perfus\u00e3o do sistema porta hep\u00e1tico foi \n\nrealizada. \n\n3.3 Protocolo de imuniza\u00e7\u00e3o g\u00eanica \n\n Trinta camundongos C57BL/6 f\u00eameas foram separados para a vacina\u00e7\u00e3o, sendo que os \n\nmesmos foram divididos em tr\u00eas grupos de 10 camundongos cada. Um grupo controle da \n\nInfec\u00e7\u00e3o, outro inoculado com plasm\u00eddeo pcDNA 3.1V5/HIS.A vazio, e um grupo vacinado \n\ncom o pcDNA3.1.V5/HIS.A contendo o inserto do gene SmCyp. Cinco dias antes da primeira \n\ndose da vacina\u00e7\u00e3o aplicou-se 100\u00b5L/camundongo de cadiotoxina 1X (0,06mg/mL), sendo \n\n50\u00b5L no m\u00fasculo da coxa de cada pata traseira do animal. O protocolo de imuniza\u00e7\u00e3o g\u00eanica \n\nconsistiu de 4 doses de 100\u00b5g de DNA/camundongo por via intramuscular, sendo 50 \u00b5g no \n\nm\u00fasculo da coxa de cada perna, com intervalo de 15 dias entre as doses. Quinze dias ap\u00f3s a \n\nquarta dose, os camundongos foram Infectados com 100 cerc\u00e1rias por via percut\u00e2nea. \n\nCinquenta dias ap\u00f3s a Infec\u00e7\u00e3o, os animais foram sacrificados e perfundidos pela veia porta \n\n(Pellegrino &amp; Siqueira, 1956). Fragmentos do f\u00edgado foram retirados para an\u00e1lise \n\nhistopatol\u00f3gica, f\u00edgado e intestino foram retirados para contagem do n\u00famero de ovos. \n\nAmostras de sangue foram coletadas pelo plexo retro-orbital dos camundongos para obten\u00e7\u00e3o \n\ndo soro de 15 em 15 dias a partir de 15 dias ap\u00f3s a primeira dose da vacina. A figura 09 \n\nabaixo ilustra o esquema de imuniza\u00e7\u00e3o. \n\n \n\nDias\n\n0 15 30 60 \n\nImuniza\u00e7\u00f5es Perfus\u00e3o\n\n110 \nIFNec\u00e7\u00e3o\u00a0\n\npercut\u00e2nea\u00a0\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n58\u00a0\n\n\u00a0\n\n \n\nFigura 09: Protocolo de imuniza\u00e7\u00e3o g\u00eanica. Realizou-se a inje\u00e7\u00e3o de cardiotoxina cinco \n\ndias antes da primeira dose de imuniza\u00e7\u00e3o. A primeira dose da imuniza\u00e7\u00e3o foi realizada no \n\ndia 5, no qual camundongos foram imunizados com DNA 100?g contendo o inserto ou \n\nplasm\u00eddeo vazio. A segunda, a terceira e a quarta doses foram realizadas com um intervalo de \n\nquinze dias utilizando as mesmas formula\u00e7\u00f5es anteriores. Quinze dias ap\u00f3s a quarta dose, a \n\nInfec\u00e7\u00e3o percut\u00e2nea foi realizada utilizando 100 cerc\u00e1rias da cepa LE por camundongo e, \n\ncinq\u00fcenta dias ap\u00f3s a Infec\u00e7\u00e3o foi realizada a perfus\u00e3o do sistema porta hep\u00e1tico. \n\n3.4 Dosagens de anticorpos \n\n An\u00e1lise de anticorpos espec\u00edficos IgG, IgG1, IgG2c foi realizada pelo m\u00e9todo de \n\nELISA. Placas de microensaio de 96 po\u00e7os (Nunc) foram sensibilizadas com 1 \u00b5g/mL de \n\nSmteg ou 1\u00b5g/mL de pept\u00eddeo sint\u00e9tico (imuniza\u00e7\u00e3o g\u00eanica) em tamp\u00e3o carbonato-\n\nbicarbonato, pH 9.6 por 12 a 16 horas \u00e0 4\u00baC. As placas foram ent\u00e3o bloqueadas por 20 horas \u00e0 \n\n4\u00baC com 300\u00b5L por po\u00e7o de PBST20 (phosphate-buffered saline e0,05% de Tween 20) \n\nacrescentado a 10% de SFB (soro fetal bovino). Cem microlitros de soros dilu\u00eddos em PBST20 \n\nnas seguintes concentra\u00e7\u00f5es: 1:100 (para IgG e IgG1) e 1:200 (para IgG2c) e 1:50 (para IgG-\n\nimuniza\u00e7\u00e3o g\u00eanica),foram adicionados por po\u00e7o em duplicata nas placas e incubados por 1 \n\nhora \u00e0 temperatura ambiente. Cem microlitros por po\u00e7o de anti-IgG (Southern Biotech), anti-\n\nIgG1 (Southern Biotech),anti-IgG2c (Southern Biotech) conjugados \u00e0 peroxidase foram \n\nColeta de sangue \n\n0 20 35 50 \n\nImuniza\u00e7\u00e3o com \npcDNA 3.1V5/HIS A-\n\nSmCyp  ou \nplasm\u00eddeo \n\nvazio(100?g) \n\n \n\nPerfus\u00e3o \n65 115 \n\nIFNec\u00e7\u00e3o \n\npercut\u00e2nea \n(100 cerc\u00e1rias) \n\nELISA \n\nIgG, IgG1 e IgG2c \n\n5 \n\nInje\u00e7\u00e3o de \n\ncardiotoxina \n\n\n\n\u00a0\n\n\u00a0\n\n59\u00a0\n\n\u00a0\n\ndilu\u00eddos em PBST20, respectivamente, a 1: 5000, 1:20000, 1:4000, 1:10000 (anti-IgG \n\nImuniza\u00e7\u00e3o G\u00eanica) e adicionados \u00e0 placa. A rea\u00e7\u00e3o de cor foi desencadeada pela adi\u00e7\u00e3o de \n\n100\u00b5L/ po\u00e7o do substrato (TMB- Tetramethylbenzidine) e parada com 50\u00b5L/ po\u00e7o de 5% de \n\n\u00e1cido sulf\u00farico. As placas foram lidas a 450 nm em um leitor de microplacas. \n\n3.5 Exame Parasitol\u00f3gico HPJ (Hoffman, Pons e Janner) \n\n Tr\u00eas amostras de fezes frescas colhidas nos dias 48, 49 e 50 ap\u00f3s a Infec\u00e7\u00e3o (0,5g de \n\nfezes por grupo) foram colocadas em um c\u00e1lice contendo \u00e1gua desclorada e formol 10%. As \n\nfezes foram trituradas com o aux\u00edlio de um bastonete de alum\u00ednio e filtradas em uma gaze \n\ndobrada 4 vezes. A suspens\u00e3o de fezes foi deixada no c\u00e1lice com \u00e1gua desclorada e formol \n\n10% por uma hora para sedimenta\u00e7\u00e3o espont\u00e2nea dos ovos. Ap\u00f3s este per\u00edodo, o sobrenadante \n\nfoi descartado e uma nova etapa de sedimenta\u00e7\u00e3o espont\u00e2nea foi realizada. Todo o sedimento \n\ncontendo os ovos foi avaliado em microsc\u00f3pio de luz para determina\u00e7\u00e3o do n\u00famero de ovos \n\npor grama de fezes. \n\n3.6 Recupera\u00e7\u00e3o de vermes adultos \n\n Camundongos C57BL/6 foram desafiados 30 dias ap\u00f3s a terceira imuniza\u00e7\u00e3o para as \n\nformula\u00e7\u00f5es vacinais contendo salina/Smteg/CpG-ODN e 15 dias ap\u00f3s a quarta imuniza\u00e7\u00e3o \n\ncom DNApela exposi\u00e7\u00e3o percut\u00e2nea da pele do abd\u00f4men com 100 cerc\u00e1rias da cepa LE.  \n\nCinq\u00fcenta dias ap\u00f3s o desafio, vermes adultos foram recuperados do sistema porta-hep\u00e1tico \n\npor perfus\u00e3o das veias mesent\u00e9ricas (Pellegrino &amp; Siqueira, 1956). Os n\u00edveis de prote\u00e7\u00e3o \n\nforam calculados comparando o n\u00famero de vermes recuperados no grupo imunizado com o \n\ngrupo n\u00e3o imunizado, atrav\u00e9s da seguinte f\u00f3rmula: \n\nNP= CRGNI \u2013 CRGI x 100 \n\n               CRGNI \n\nOnde: NP: n\u00edvel de prote\u00e7\u00e3o;CRGNI: carga recuperada do grupo n\u00e3o imunizado e CRGI: \n\ncarga recuperada do grupo imunizado \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n60\u00a0\n\n\u00a0\n\n3.7 Oograma \n\n Ap\u00f3s a perfus\u00e3o para recupera\u00e7\u00e3o dos vermes adultos, um fragmento do intestino (\u00edleo \n\nterminal) de cada animal foi removido para an\u00e1lise dos est\u00e1dios de desenvolvimento dos ovos. \n\nEsses fragmentos foram colocados entre l\u00e2mina de vidro e uma lam\u00ednula de pl\u00e1stico. A \n\nprepara\u00e7\u00e3o foi pressionada em uma prensa de ferro. As l\u00e2minas ent\u00e3o foram levadas ao \n\nmicrosc\u00f3pio a fim de se verificar a presen\u00e7a e determinar os est\u00e1dios de desenvolvimento dos \n\novos em cada grupo. Os est\u00e1dios foram divididos em: primeiro, segundo, terceiro e quarto \n\nest\u00e1dios, ovos maduros e ovos mortos. \n\n3.8 \u00c1rea e n\u00famero de granulomas hep\u00e1ticos \n\n Se\u00e7\u00f5es do f\u00edgado de cada camundongo dos grupos controle e experimental foram \n\ncoletados 50 dias ap\u00f3s a Infec\u00e7\u00e3o para avaliar os efeitos da imuniza\u00e7\u00e3o na forma\u00e7\u00e3o do \n\ngranuloma. Esses fragmentos do f\u00edgado foram fixados em formol 10%. Cortes histol\u00f3gicos \n\nforam feitos com o aux\u00edlio de um micr\u00f3tomo e corados com Hematoxilina e Eosina (HE). \n\nImagens dos granulomas foram capturadas atrav\u00e9s de uma c\u00e2mera acoplada em um \n\nmicrosc\u00f3pio e analisadas no software KS300 do Laborat\u00f3rio de Patologia do ICB -\n\nUFMG.Para realizar as medidas da \u00e1rea dos granulomas, imagens de 100 granulomas/ grupo \n\nque se encontravam no est\u00e1gio exudativo-produtivo e que continham apenas um ovo com \n\nmirac\u00eddio vivo foram capturadas utilizando o microsc\u00f3pio na objetiva de 10X atrav\u00e9s da \n\nmicroc\u00e2mera JVC TK-1270/RGB. Utilizando um cursor digital, a circunfer\u00eancia total do \n\ngranuloma foi delimitada e, posteriormente, analisada no software KS300. Os resultados \n\nforam expressos em \u00b5m2.Para determinar o n\u00famero de granulomas por \u00e1rea, o n\u00famero total de \n\ngranulomas por l\u00e2mina foi contado em um microsc\u00f3pio na objetiva de 10X.  Todas as l\u00e2minas \n\nforam escaneadas e a \u00e1rea de corte foi determinada utilizando o software KS300. Os \n\nresultados foram expressos em ovos/mm2. \n\n3.9 Contagem do n\u00famero de ovos do intestino e f\u00edgado  \n\n Durante a perfus\u00e3o, o f\u00edgado e o intestino de cada camundongo foram retirados. Esses \n\n\u00f3rg\u00e3os foram pesados, acondicionados em b\u00e9queres com KOH10% onde foram mantidos por \n\ncerca de 16 horas. Em seguida a solu\u00e7\u00e3o foi incubada \u00e0 37\u00ba por 30 min a em banho-maria. Os \n\n\n\n\u00a0\n\n\u00a0\n\n61\u00a0\n\n\u00a0\n\n\u00f3rg\u00e3os digeridos foram centrifugados por cinco minutos a 900 x g e o sobrenadante foi \n\ndescartado. O sedimento foi ressuspendido com salina 0,85%. Esta etapa foi repetida por duas \n\nvezes. Depois da \u00faltima centrifuga\u00e7\u00e3o, o sedimento foi ressuspendido em 1mL de salina \n\n0,85% e o n\u00famero de ovos presentes em uma amostra de 10 \u00b5L da solu\u00e7\u00e3o foi contado em \n\nmicrosc\u00f3pio de luz. Foram realizadas 3 contagens para cada amostra. \n\n3.10 Avalia\u00e7\u00e3o da imunidade celular induzida pelas formula\u00e7\u00f5es vacinais \n\n Camundongos (5 por grupo) foram submetidos aos protocolos de imuniza\u00e7\u00f5es \n\ndescritos anteriormente e uma semana ap\u00f3s a \u00faltima dose, os animais foram eutanasiados para \n\nretirada do ba\u00e7o. Este \u00f3rg\u00e3o foi macerado, as hem\u00e1cias foram lisadas e os esplen\u00f3citos foram \n\nlavados com salina e ajustados para 1 X 106 c\u00e9lulas por po\u00e7o. Para a an\u00e1lise de citocinas, os \n\nesplen\u00f3citos foram mantidos em cultura \u00e0 37\u00baC 5% CO2 em meio (RPMI); na presen\u00e7a de \n\nmeio, mit\u00f3geno Concanavalina A (5\u00b5g/mL), Smteg (25\u00b5g/mL), SmCyp (94-108), SmCyp \n\n(107-121), estes dois \u00faltimos est\u00edmulos foram utilizados para cultura de esplen\u00f3citos \n\nprovenientes de camundongos submetidos \u00e0 imuniza\u00e7\u00e3o g\u00eanica. A detec\u00e7\u00e3o de citocinas no \n\nsobrenadante de de cultura foi realizada por ELISA sandu\u00edche utilizando os Kits duoset (R&amp;D \n\nsystem) ou Ready set GO (e-bioscience) ou por Cytometric Bead Array (CBA), utilizando o \n\nKit anti-mouse Th1,Th2,Th17 (BD Bioscience, USA) conforme instru\u00e7\u00f5es do fabricante.  \n\nPara dosagem de citocinas intracitoplasm\u00e1ticas, 0,5 X 106 esplen\u00f3citos foram mantidos \n\nem cultura \u00e0 37\u00baC e 5% CO2 em meio (RPMI) na presen\u00e7a de mit\u00f3geno (ConA-5\u00b5g/mL) ou \n\nant\u00edgenos por 18 horas. A secre\u00e7\u00e3o de citocinas foi interrompida pela adi\u00e7\u00e3o de brefeldina A \n\n(1\u00b5g/mL) \u00e0 cultura nas 4 \u00faltimas horas de cultura. Ap\u00f3s este per\u00edodo as c\u00e9lulas foram \n\ncentrifugadas e os receptores Fc foram bloqueados pela adi\u00e7\u00e3o de anticorpo anti-CD16/CD32 \n\nde camundongo (BD-bioscience). As c\u00e9lulas foram ent\u00e3o lavadas, centrifugadas a 387 x g por \n\n7 minutos e marcadas com anticorpo anti-CD4 de camundongo ou anti-CD8 de camundongo \n\ne seus controles de isotipo por 15 minutos \u00e0 4\u00baC. Ap\u00f3s marca\u00e7\u00e3o de superf\u00edcie, as c\u00e9lulas \n\nforam lavadas, fixadas com formalde\u00eddo a 2% por 30 minutos \u00e0 temperatura ambiente e \n\npermeabilizadas com uma solu\u00e7\u00e3o de saponina 0,5% por 10 minutos \u00e0 temperatura ambiente. \n\nAp\u00f3s permeabiliza\u00e7\u00e3o da membrana plasm\u00e1tica, essas c\u00e9lulas foram marcadas com anticorpos \n\nmonoclonais anti IFN-?, anti IL-10 , anti-TNF-a e anti IL-4 (e seus controles de isotipo por 30 \n\n\n\n\u00a0\n\n\u00a0\n\n62\u00a0\n\n\u00a0\n\nminutos \u00e0 temperatura ambiente. Ap\u00f3s serem novamente lavadas, as c\u00e9lulas foram fixadas e a \n\naquisi\u00e7\u00e3o dos dados (30000 eventos dentro do gate de linf\u00f3citos) foi realizada no cit\u00f4metro \n\nFACSCalibur (Becton Dickinson, San Jos\u00e9, CA).Os dados foram analisados usando o \n\nsoftware FlowJo (Tree star, Ashland). \n\n Para o ensaio de marca\u00e7\u00e3o ex vivo, c\u00e9lulas do ba\u00e7o provenientes de 4 \n\ncamundongos/grupo foram ajustadas para 5 X 105 c\u00e9lulas por po\u00e7o. Antes da marca\u00e7\u00e3o, estas \n\nc\u00e9lulas foram bloqueadas com anti-mouse CD16/CD32 mAbs (Fc-Block, BD bioscience). As \n\nsuperf\u00edcies dessas c\u00e9lulas foram marcadas com os seguintes anticorpos monoclonais: anti-\n\nCD4, anti-CD8, anti-CD19, anti-F4/80 , anti-CD86, anti- IaB, anti- CD25 e anti- CD69, , anti-\n\nCD44 ,anti-CD62, anti-CD27 e seus respectivos controle de isotipo por 20 minutos a 4\u00baC. \n\nAp\u00f3s este tempo as c\u00e9lulas foram lavadas com PBS 0,15M, 0,5%BSA, 2mM NaNO3 e \n\nsubmetidas a incuba\u00e7\u00e3o com uma solu\u00e7\u00e3o de estreptavidina-Percp ou estreptavidina-APC-Cy7 \n\n(e-bioscience) na dilui\u00e7\u00e3o 1:200 a 4\u00baC por 20 minutos. As c\u00e9lulas foram, ent\u00e3o, lavadas e \n\nfixadas com formalde\u00eddo. A aquisi\u00e7\u00e3o dos dados foi obtida utilizando FACS Calibur (Becton \n\nDickinson) ou LSR Fortessa (Becton Dickinson, San Jos\u00e9, CA) para as an\u00e1lises referentes a \n\ncultura de c\u00e9lulas provenientes da imuniza\u00e7\u00e3o com DNA. Os dados foram analisados usando \n\no software FlowJo (Tree star, Ashland). \n\n3.11 Detec\u00e7\u00e3o de anticorpos espec\u00edficos na superf\u00edcie de esquistoss\u00f4mulos \n\nCerc\u00e1rias foram transformadas mecanicamente em esquistoss\u00f4mulos utilizando o meio \n\nde cultura Glasgow segundo a t\u00e9cnica de Ramalho Pinto e colaboradores (1974) com algumas \n\nmodifica\u00e7\u00f5es. Os esquistoss\u00f4mulos foram incubados por 90 minutos em banho maria \u00e0 37\u00baC \n\npara que ocorresse a transforma\u00e7\u00e3o morfofisiol\u00f3gica. Ap\u00f3s esse processo, os \n\nesquistoss\u00f4mulos foram acondicionados em tubos eppendorfs de 1,5mL e lavados com \n\nDMEM sem soro fetal bovino atrav\u00e9s da centrifuga\u00e7\u00e3o a 1800 x g por 5 minutos, repetiu-se \n\neste procedimento por tr\u00eas vezes. Os esquistoss\u00f4mulos foram fixados em PBS + 1% de \n\nformalde\u00eddo por 1h \u00e0 4 \u00baC. Ap\u00f3s este per\u00edodo os esquistoss\u00f4mulos foram lavados em PBS \n\ncomo descrito anteriormente por tr\u00eas vezes. Os esquistoss\u00f4mulos foram incubados em RPMI \n\npor 30 minutos, lavados e incubados em PBS + BSA 1% por 30 minutos, e novamente \n\nlavados e incubados com soro de camundongos inoculados com salina + CFA/IFA ou \n\n\n\n\u00a0\n\n\u00a0\n\n63\u00a0\n\n\u00a0\n\nimunizados Smteg + CFA/IFA conforme descrito em Teixeira de Melo (2010) na propor\u00e7\u00e3o \n\nde 1:100overnight sob agita\u00e7\u00e3o. Ap\u00f3s este processo, os esquistoss\u00f4mulos foram lavados com \n\nPBS + BSA 1% por 3 vezes como descrito anteriormente, incubados com RPMI por 30 \n\nminutos, lavados e incubados em PBS + BSA1% por 30 minutos. Incubou-se ent\u00e3o os \n\nesquistoss\u00f4mulos com anti-soro secund\u00e1rio fluorescente (anti-IgG conjugado a FITC) \n\n(Sigma) por 2h a temperatura ambiente e na aus\u00eancia de luz. Ap\u00f3s este tempo os \n\nesquistoss\u00f4mulos foram lavados com PBS por centrifuga\u00e7\u00e3o a 1800 x g por 5 minutos por 3 \n\nvezes. Tr\u00eas l\u00e2minas foram montadas: esquistoss\u00f4mulos apenas fixados e lavados; \n\nesquistoss\u00f4mulos sem passar pelo anticorpo prim\u00e1rio (soros de camundongos); \n\nesquistoss\u00f4mulos incubados com soros de camundongos e anticorpo secund\u00e1rio fluorescente \n\nutilizando do antifading mowiol para preservar a fluoresc\u00eancia. A liga\u00e7\u00e3o dos anticorpos aos \n\nesquistoss\u00f4mulos foi avaliada por microscopia de fluoresc\u00eancia. A intensidade m\u00e9dia de \n\nfluoresc\u00eancia foi determinada por an\u00e1lise da imagem dos esquistoss\u00f4mulos pelo software \n\nImageJ. \n\n3.12 Ensaio de citotoxicidade \n\nCerc\u00e1rias foram transformadas mecanicamente em esquistoss\u00f4mulos utilizando o meio \n\nde cultura Glasgow conforme descrito no item 3.9. Cinquenta esquistoss\u00f4mulos/po\u00e7o em \n\n100\u00b5L de meio de cultura Glasgow suplementado com 10% de soro fetal bovino foram \n\nplaqueados em placas de cultura de 96 po\u00e7os de fundo chato. Foi acrescentado em cada po\u00e7o: \n\nsoro inativado de camundongos inoculados com salina + CFA/IFA, soro inativado de \n\ncamundongos imunizados com Smteg + CFA/IFA na dilui\u00e7\u00e3o1:10. A placa de cultura foi \n\nlevada \u00e0 estufa por 30 minutos \u00e0 37\u00baC\u20135%CO2. Ap\u00f3s esse per\u00edodo, foi acrescentado em cada \n\npo\u00e7o complemento (Guinea pig- Sigma) ativo ou inativado na dilui\u00e7\u00e3o1:10, de forma que se \n\ntivesse todas as combina\u00e7\u00f5es poss\u00edveis para a an\u00e1lise do envolvimento do sistema do \n\ncomplemento na morte do esquistoss\u00f4mulos. Incubou-se esta placa por 16h em estufa \u00e0 37\u00baC\u2013\n\n5%CO2. Ap\u00f3s este per\u00edodo, acrescentou-se 5 ?L/po\u00e7o das sondas fluorescentes acridine \n\norange [0,3 mg/mL] (marca\u00e7\u00e3o de c\u00e9lulas vi\u00e1veis) e brometo de et\u00eddio [1mg/mL] (marca\u00e7\u00e3o \n\nde c\u00e9lulas mortas). A placa foi mantida por 20 minutos em estufa \u00e0 37\u00baC, 5%CO2. Ap\u00f3s este \n\ntempo, centrifugou-se a placa a 1800 x g por 5 minutos retirando metade do meio de cultura \n\n(50\u00b5L/po\u00e7o) e acrescentando a mesma quantidade do meio Glasgow a 37\u00baC antes da pr\u00f3xima \n\n\n\n\u00a0\n\n\u00a0\n\n64\u00a0\n\n\u00a0\n\ncentrifuga\u00e7\u00e3o. Repetiu-se este procedimento por tr\u00eas vezes. A viabilidade dos \n\nesquistoss\u00f4mulos foi observada por microscopia de fluoresc\u00eancia atrav\u00e9s de tr\u00eas contagens de \n\n20 ?L/po\u00e7o. \n\n3.13 Transfer\u00eancia passiva de anticorpos \n\nSoro de camundongos inoculados com PBS + CFA/IFA ou Smteg + CFA/IFA \n\nconforme descrito por Teixeira de Melo e colaboradores (2010) foram coletados 30 dias ap\u00f3s \n\na \u00faltima imuniza\u00e7\u00e3o e inativados para serem utilizados nos protocolos de transfer\u00eancia de \n\nanticorpos. Ap\u00f3s a obten\u00e7\u00e3o do soro, 45 camundongos C57BL/6 f\u00eameas foram utilizados no \n\nensaio de transfer\u00eancia passiva de anticorpos, sendo que os mesmos foram divididos em tr\u00eas \n\ngrupos de 15 camundongos cada. Um grupo controle da Infec\u00e7\u00e3o, um grupo que recebeu soro \n\nde camundongos inoculados com PBS CFA/IFA (grupo PBS) e um grupo que recebeu soro de \n\ncamundongos imunizados com Smteg + CFA/IFA (grupo Smteg). Os camundongos \n\nreceberam tr\u00eas doses de 200\u00b5L de soro por via intravenosa atrav\u00e9s da veia da cauda, sendo a \n\nprimeira 8 dias antes da Infec\u00e7\u00e3o, a segunda 3 dias antes da Infec\u00e7\u00e3o e a terceira no mesmo \n\ndia em que foi realizada a Infec\u00e7\u00e3o percut\u00e2nea desses animais com 100 \n\ncerc\u00e1rias/camundongo. Quarenta e cinco dias ap\u00f3s Infec\u00e7\u00e3o, os camundongos foram \n\nperfundidos (Pelegrino &amp; Siqueira, 1956) para a recupera\u00e7\u00e3o de vermes e tiveram f\u00edgado e \n\nintestino coletados para a contagem do n\u00famero de ovos (Figura 10). \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n65\u00a0\n\n\u00a0\n\n \n\nFigura 10: Transfer\u00eancia passiva de anticorpos. Os camundongos dos grupos controle da \n\nInfec\u00e7\u00e3o, PBS e Smteg receberam tr\u00eas doses (200 microlitros) de soro por via intravenosa \n\natrav\u00e9s da veia da cauda, sendo a primeira no dia -8, a segunda no dia -3 e a terceira no dia 0. \n\nNeste mesmo dia, foi realizada a Infec\u00e7\u00e3o percut\u00e2nea desses animais com 100 \n\ncerc\u00e1rias/camundongo e 45 dias ap\u00f3s Infec\u00e7\u00e3o, os camundongos foram perfundidos \n\n(Pelegrino &amp; Siqueira, 1956) para a recupera\u00e7\u00e3o de vermes. \n\n3.14 Eletroforese Bidimensional (2-DE) \n\n3.14.1 Primeira dimens\u00e3o - Focaliza\u00e7\u00e3o Isoel\u00e9trica \n\n Antes de realizar a separa\u00e7\u00e3o das prote\u00ednas por eletroforese uni ou bidimensional, o \n\nextrato prot\u00e9ico bruto (Smteg) foi precipitado com acetona. Para isso, a cada 400?L da \n\namostra (1,6?g/?L) foram adicionados 1,6mL de acetona (Merck) gelada, sendo esta solu\u00e7\u00e3o \n\nmantida \u00e0 -20\u00baC por cerca de 16 horas. Ap\u00f3s este per\u00edodo, a amostra foi centrifugada por 15 \n\nminutos \u00e0 4\u00baC, 16.000 x g. O sobrenadante foi descartado e o pellet foi ressuspendido em 200 \n\n\u00b5L de tamp\u00e3o de rehidrata\u00e7\u00e3o IEF incompleto (Ur\u00e9ia 8M, Tiour\u00e9ia 2M, CHAPS 4%).  \n\nAp\u00f3s serem dosadas pelo m\u00e9todo de Bradford, as prote\u00ednas do tegumento de \n\nesquistoss\u00f4mulos foram separadas, primeiramente, por eletroforese unidimensional para \n\n-8 -3 0\n45 \n\nTransfer\u00eancia passiva de anticorpos\n\nPerfus\u00e3o\n\ninfec\u00e7\u00e3o percutanea\n(100cerc\u00e1rias)\n\n-8 -3 0\n45 \n\nTransfer\u00eancia passiva de anticorpos\n\nPerfus\u00e3o\n\n\u00e7\u00e3o\n\n\n\n\u00a0\n\n\u00a0\n\n66\u00a0\n\n\u00a0\n\navaliar a qualidade dos extratos obtidos. Para isso, 1, 3 e 5\u00b5g de prote\u00ednas foram submetidos \u00e0 \n\nsepara\u00e7\u00e3o eletrofor\u00e9tica em SDS-PAGE 12% e o gel foi corado por Nitrato de Prata.  \n\nOs mesmos extratos prot\u00e9icos foram utilizados para a separa\u00e7\u00e3o das prote\u00ednas na \n\nprimeira dimens\u00e3o por focaliza\u00e7\u00e3o isoel\u00e9trica. Para tal, ao volume equivalente a 100?g de \n\nprote\u00ednas totais foi acrescentado tamp\u00e3o de reidratar\u00e3o IEF [Ur\u00e9ia 8M, Tiour\u00e9ia 2M, CHAPS \n\n4%, Azul de Bromofenol,0025%, DTT 65mM e 1% anf\u00f3lito Biolyte 3-10 buffer 100x (Bio - \n\nRad) para um volume final de 125?L. As amostras foram mantidas sob agita\u00e7\u00e3o por uma hora \n\ne centrifugadas a 16.000 x g, 20-25\u00baC por 30 minutos para retirada de material n\u00e3o \n\nsolubilizado.O sobrenadante foi aplicado sobre fitas de IPG de 7cm com gradiente de pH 3-10 \n\nn\u00e3o linear (NL). As fitas foram submetidas \u00e0 rehidrata\u00e7\u00e3o e focaliza\u00e7\u00e3o isoel\u00e9trica no \n\nequipamento Protean IEF Cell (Bio - Rad) a 50?A/gel a 20\u00baC. As condi\u00e7\u00f5es de rehidrata\u00e7\u00e3o e \n\nfocaliza\u00e7\u00e3o isoel\u00e9trica foram: re-hidrata\u00e7\u00e3o passiva por 4h, re-hidrata\u00e7\u00e3o ativa a 50V por 12h \n\ne focaliza\u00e7\u00e3o isoel\u00e9trica a 500V por 30 minutos, 1000V por 30 minutos, 4000V por 1h e \n\n4000V at\u00e9 16000V/h. Ap\u00f3s o t\u00e9rmino da focaliza\u00e7\u00e3o isoel\u00e9trica, as fitas foram retiradas do \n\nequipamento e congeladas a -70 \u00baC ou utilizadas imediatamente para separa\u00e7\u00e3o das prote\u00ednas \n\npor SDS-PAGE. \n\n3.14.2 Segunda dimens\u00e3o- SDS-PAGE \n\n Para a realiza\u00e7\u00e3o da separa\u00e7\u00e3o das prote\u00ednas pela segunda dimens\u00e3o, as fitas de IPG \n\nforam submetidas \u00e0s etapas de equil\u00edbrio (redu\u00e7\u00e3o e alquila\u00e7\u00e3o das prote\u00ednas). As fitas foram \n\nincubadas por 10 minutos, \u00e0 temperatura ambiente, sob agita\u00e7\u00e3o, em tamp\u00e3o de equil\u00edbrio \n\n[6M Ur\u00e9ia, 30% glicerol, 2% SDS, 50mM Tris-HCL (pH 8,8) e 0,001% azul de Bromofenol] \n\ncontendo DTT 130mM, e, em seguida, por mais 15 minutos no mesmo tamp\u00e3o contendo \n\niodocetamida 135mM. \n\n Na segunda dimens\u00e3o, as prote\u00ednas foram separadas em SDS-PAGE 12%. O padr\u00e3o de \n\npeso molecular Benchmark (Invitrogen) foi aplicado em um peda\u00e7o de papel filtro, colocado \n\nsobre o gel de poliacrilamida e selado com agarose 0,5% contendo azul de bromofenol. As \n\nfitas de IPG foram lavadas em tamp\u00e3o de corrida 1X antes de serem colocadas sobre o gel de \n\npoliacrilamida. Assim como o padr\u00e3o de peso molecular, as fitas foram seladas ao gel com \n\n\n\n\u00a0\n\n\u00a0\n\n67\u00a0\n\n\u00a0\n\nagarose 0,5% contendo azul de bromofenol para facilitar o acompanhamento da corrida \n\neletrofor\u00e9tica no sistema Mini-Protean III (Bio-Rad). A eletroforese foi realizada a 50V por \n\naproximadamente 10 min e a 100V at\u00e9 o corante atingir a por\u00e7\u00e3o IFNerior do gel. \n\n As r\u00e9plicas dos g\u00e9is de poliacrilamida que n\u00e3o foram utilizadas nos ensaios de \n\nWestern blotting foram coradas pelo protocolo compat\u00edvel com a espectrometria de massas o \n\nqual utiliza o Azul de Coomassie Coloidal G-250 (Neuhoff et al., 1988). De acordo com este \n\nm\u00e9todo os g\u00e9is foram fixados em tr\u00eas solu\u00e7\u00f5es: \u00e1cido ortofosf\u00f3rico 2% e etanol 30%; \u00e1cido \n\nortofosf\u00f3rico 2%; \u00e1cido ortofosf\u00f3rico 2%, etanol 18% e sulfato de am\u00f4nio 12%. Em seguida \n\nfoi adicionado Azul de Comassie Coloidal G-250 0,02% \u00e0 \u00faltima solu\u00e7\u00e3o. Os g\u00e9is foram \n\nmantidos nesta solu\u00e7\u00e3o por at\u00e9 72 horas. \n\n3.15 Western-blotting bidimensional \n\n Logo ap\u00f3s a eletroforese em SDS-PAGE, as prote\u00ednas foram transferidas para \n\nmembranas Immun-Blot PVDF 0,2\u00b5m (Bio-Rad) em cuba de transfer\u00eancia mini Trans-Blot \n\nEletrophoretic Tranfer Cell (Bio-Rad) usando tamp\u00e3o de transfer\u00eancia (25 mM Tris, 192 mM \n\nGlicina, 20% metanol) por 2h a 100V. As membranas foram bloqueadas por 16h em TBS-\n\nT/BSA 3% (TBS: 20mM Tris-HCl, 500mM NaCl, pH 7,5; Tween-20 0,1%, BSA 3%) \u00e0 \n\ntemperatura ambiente, e ent\u00e3o, incubadas por 16h com o pool de soro de camundongos \n\nimunizados com salina + CFA/IFA ou Smteg + CFA/IFA na dilui\u00e7\u00e3o 1:100 em TBS-\n\nT/BSA1%. Ap\u00f3s duas lavagens em TBS-T/BSA1%, as membranas foram incubadas com \n\nanticorpo secund\u00e1rio anti-IgG total de camundongo conjugado a peroxidase (Southern Biotec) \n\nna dilui\u00e7\u00e3o 1:2000 em TBS-T/BSA1%. Ap\u00f3s duas lavagens em TBS-T e uma em TBS, a \n\nrea\u00e7\u00e3o foi revelada utilizando Diaminobenzidina (DAB). Para a detec\u00e7\u00e3o, as membrans foram \n\nincubadas com 15 mL da solu\u00e7\u00e3o de PBS 1x por 5 minutos em agita\u00e7\u00e3o. Ap\u00f3s este per\u00edodo, \n\npesou-se 3mg de DAB (Sigma) para cada 15mL de solu\u00e7\u00e3o. A solu\u00e7\u00e3o de PBS foi aspirada e \n\na solu\u00e7\u00e3o de DAB foi acrescentada \u00e0s membranas e nesta solu\u00e7\u00e3o acrescentou-se 15 ?L de \n\nper\u00f3xido de hidrog\u00eanio. A rea\u00e7\u00e3o foi interrompida lavando as membranas em \u00e1gua.  \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n68\u00a0\n\n\u00a0\n\n3.16 Digest\u00e3o tr\u00edptica in gel de prote\u00ednas \n\nOs spots reconhecidos pelos anticorpos espec\u00edficos foram localizados visualmente em \n\num gel corado por Azul de Coomassie Coloidal id\u00eantico ao que foi utilizado para \n\ntransfer\u00eancia, e extra\u00eddos manualmente para identifica\u00e7\u00e3o das prote\u00ednas por espectrometria de \n\nmassas. Inicialmente, os spots excisados do gel foram transferidos para tubos siliconados pr\u00e9-\n\nlavados com metanol P.A (Merck) e \u00e1gua Milli-Q. Os spots foram lavados em 1mL de \u00e1gua \n\nMilli-Q por 15 min, seguido de 400\u00b5L de uma solu\u00e7\u00e3o de acetonitrila (ACN) 50% (Fisher \n\nScientific)/ bicarbonato de am\u00f4nio (AB) 25mM (Sigma) pH 8,0 para descolora\u00e7\u00e3o. Este \n\nprocedimento foi realizado com duas lavagens de 15min cada, sob agita\u00e7\u00e3o constante. Em \n\nseguida, os peda\u00e7os de gel foram desidratados pela adi\u00e7\u00e3o, por 5 min, de 200?L de \n\nacetonitrila (Fischer Scientific). Os spots foram incubados em 200?L AB 100mM por 5 min e \n\nap\u00f3s este tempo foi acrescentado o mesmo volume de ACN por mais 5 minutos. Esta solu\u00e7\u00e3o \n\nfoi removida e os g\u00e9is foram completamente secos em Speed Vac (Eppendorf) por cerca de 20 \n\nmin. Para a digest\u00e3o das prote\u00ednas, foram adicionados 0,3?g de Tripsina (Promega) em um \n\nvolume de 10?L, e, posteriormente, cerca de 20?L de uma solu\u00e7\u00e3o AB 25mM pH 8,0 para \n\nevitar o ressecamento do spot. A digest\u00e3o foi conduzida \u00e0 37\u00baC por cerca de 16h. O conte\u00fado \n\nde cerca de 30?L de solu\u00e7\u00e3o foi transferido para novos tubos. Aos antigos tubos foram \n\nacrescentados 30?L de solu\u00e7\u00e3o de \u00e1cido f\u00f3rmico 5% (Merck)/ ACN 60% para extra\u00e7\u00e3o de \n\npept\u00eddeos tr\u00edpticos. Este procedimento foi realizado por duas vezes sob agita\u00e7\u00e3o constante de \n\n30 minutos cada, sendo que, ap\u00f3s o t\u00e9rmino do tempo referido, a solu\u00e7\u00e3o de extra\u00e7\u00e3o \n\ncontendo os pept\u00eddeos foi transferida para o respectivo tubo contendo os 30 ?L iniciais. As \n\namostras foram concentradas em Speed Vac para um volume de cerca de 10?L e, em seguida, \n\nos pept\u00eddeos foram purificados em microcolunas de fase reversa Zip Tip C18 (Eppendorf \n\u00ae) de \n\nacordo com as instru\u00e7\u00f5es do fabricante. Os pept\u00eddeos purificados foram novamente \n\nconcentrados em Speed Vac para um volume final de 4 ?L e encaminhados para a Plataforma \n\nde Espectrometria de Massas - IOC/FIOCRUZ para identifica\u00e7\u00e3o das prote\u00ednas por \n\nespectrometria de massas. \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n69\u00a0\n\n\u00a0\n\n3.17 Espectrometria de massas \n\n A identifica\u00e7\u00e3o das prote\u00ednas por espectrometria de massas do tipo MALDI-ToF-ToF \n\nfoi realizada em um espectr\u00f4metro de massas modelo 4700 Proteomic Analyser (Applied \n\nBiosystems). Esta etapa foi realizada no Laborat\u00f3rio de Toxinologia do Departamento de \n\nFisiologia e Farmacodin\u00e2mica do Instituto Oswaldo Cruz/ Fiocruz, em colabora\u00e7\u00e3o com o Dr. \n\nJonas Perales e Dr. Andr\u00e9 Teixeira, respons\u00e1veis pela Plataforma de Espectrometria de \n\nMassas-RJ, PDTIS- FIOCRUZ. \n\n Um volume de 0,5?L da amostra de pept\u00eddeos purificados foi misturado a 0,2?L de \n\nmatrix \u00e1cido alpha-cyano-4-hydroxycinnamic (20mg/mL na mesma solu\u00e7\u00e3o). A amostra em \n\nmatrix foi aplicada \u00e0 placa de MALDI para a ioniza\u00e7\u00e3o dos pept\u00eddeos. Os par\u00e2metros \n\nestabelecidos foram: 2.000 tiros de MS e 4.000 tiros de MS/MS dos 10 picos mais intensos. \n\n3.18 Identifica\u00e7\u00e3o das prote\u00ednas \n\n O espectro de massas dos pept\u00eddeos gerados pela digest\u00e3o com tripsina e dos \n\nfragmentos de pept\u00eddeos foram analisados utilizando o programa MASCOT (Matrix Science, \n\nBoston, MA) e o banco de dados de sequ\u00eancias de prote\u00ednas n\u00e3o redundantes do NCBInr.Os \n\npar\u00e2metros utilizados foram: toler\u00e2ncia de pept\u00eddeos MS de + 0.6 Da, toler\u00e2ncia de fragmento \n\nde massa MS/MS de + 0.2 Da, duas falhas de clivagem por tripsina permitidas, carga de \n\npept\u00eddeo +1 e modifica\u00e7\u00f5es vari\u00e1veis em ciste\u00edna (carbamidometila\u00e7\u00e3o e adi\u00e7\u00e3o de \n\npropionamida) e em metionina (oxida\u00e7\u00e3o). A fim de evitar identifica\u00e7\u00f5es aleat\u00f3rias, foram \n\nconsideradas seguramente identificadas apenas prote\u00ednas que apresentaram pelo menos 1 \u00edon \n\ncom valor de score individual acima do valor fornecido pela an\u00e1lise do MASCOT, o qual \n\nindica identidade e homologia extensiva (p<0,05). \n\n3.19 An\u00e1lise in silico das prote\u00ednas \n\n3.19.1 Predi\u00e7\u00e3o de localiza\u00e7\u00e3o celular \n\nAp\u00f3s an\u00e1lise dos par\u00e2metros disponibilizados pelo software MASCOT (tais como: \n\npeso molecular, ponto isoel\u00e9trico, dentre outros), as prote\u00ednas selecionadas foram submetidas \n\n\n\n\u00a0\n\n\u00a0\n\n70\u00a0\n\n\u00a0\n\n\u00e0 predi\u00e7\u00e3o de dom\u00ednio transmembrana, solubilidade e predi\u00e7\u00e3o de localiza\u00e7\u00e3o celular. Para a \n\npredi\u00e7\u00e3o de regi\u00e3o transmembrana e an\u00e1lise de solubilidade, usou-se o programa SOSUI \n\n(SOSUI engine ver. 1.11) (http://bp.nuap.nagoya-u.ac.jp/sosui_submit.html - Outubro, 2010). \n\nAs sequ\u00eancias de amino\u00e1cidos das prote\u00ednas foram inseridas individualmente e o resultado foi \n\ngerado utilizando os par\u00e2metros padr\u00f5es do programa. A predi\u00e7\u00e3o de localiza\u00e7\u00e3o celular foi \n\nrealizada utilizando o programa SherLoc (http://www-bs.IFNormatik.uni-\n\ntuebingen.de/Services/SherLoc/-Outubro,2010). Primeiramente escolheu-se o m\u00e9todo de \n\npredi\u00e7\u00e3o de localiza\u00e7\u00e3o para c\u00e9lulas de organismo animal, em seguida, as sequ\u00eancias de \n\namino\u00e1cidos das prote\u00ednas foram inseridas individualmente e o valor de e-value do blast de \n\n0.1, par\u00e2metro padr\u00e3o do algor\u00edtmo, foi utilizado. Para libera\u00e7\u00e3o dos resultados, foi \n\nselecionado o formato avan\u00e7ado, no qual 3 predi\u00e7\u00f5es de localiza\u00e7\u00e3o celular com seus scores \n\nforam geradas. Para se ter maior confiabilidade da predi\u00e7\u00e3o de localiza\u00e7\u00e3o celular, foi \n\nrealizada uma segunda predi\u00e7\u00e3o utilizando-se o programa TargetP 1.1 \n\n(http://www.cbs.dtu.dk/services/TargetP/ - Outubro, 2010).  \n\n3.19.2 Similaridade com prote\u00ednas humanas e de outros helmintos \n\n A sequ\u00eancia das prote\u00ednas identificadas foram submetidas a uma busca por sequ\u00eancias \n\nhom\u00f3logas utilizando o programa BLAST (Basic Local Alignment Search Tool) do NCBI \n\n(National Center for Biotechnology IFNormation) (http://blast.ncbi.nlm.nih.gov.blast- \n\nOutubro, 2010). A busca foi feita utilizando a ferramenta BLASTp  e o banco de dados de \n\nsequ\u00eancias de prote\u00ednas n\u00e3o redundantes do NCBI.  \n\n3.19.3 Predi\u00e7\u00e3o de epitopos de c\u00e9lulas B e T \n\n As sequ\u00eancias de prote\u00ednas selecionadas pelas tr\u00eas an\u00e1lises anteriores (predi\u00e7\u00e3o de \n\nlocaliza\u00e7\u00e3o celular, predi\u00e7\u00e3o de dom\u00ednio transmembrana e similaridade com prote\u00ednas \n\nhumanas e de outros helmintos) foram submetidas \u00e0 predi\u00e7\u00e3o de epitopos de c\u00e9lulas B no \n\nprograma BCPRED (B-cell Epitope Prediction Server- \n\nhttp://ailab.cs.iastate.edu/bcpreds/predict.html - Outubro, 2010). No Bcpred foi realizada uma \n\nsele\u00e7\u00e3o de busca por epitopos com comprimento de 20 amino\u00e1cidos com especificidade \n\n\n\n\u00a0\n\n\u00a0\n\n71\u00a0\n\n\u00a0\n\npadr\u00e3o de 75%. Para libera\u00e7\u00e3o dos resultados selecionou-se a op\u00e7\u00e3o de apresentarem epitopos \n\nque n\u00e3o continham sobreposi\u00e7\u00e3o de sequ\u00eancias. \n\n Para a predi\u00e7\u00e3o de epitopos para c\u00e9lula T, utilizou-se o programa Rankpep \n\n(http://imed.med.ucm.es/tools/rankpep.html - Outubro, 2010),no qual foi inserida a sequ\u00eancia \n\nde amino\u00e1cidos no formato FASTA, alinhando aos ligantes do MHCII em posi\u00e7\u00f5es \n\nespec\u00edficas (HLA-DR1, HLA DR2, etc). Ap\u00f3s libera\u00e7\u00e3o dos resultados foi poss\u00edvel identificar \n\no score \u00f3timo, o limiar de liga\u00e7\u00e3o e o ranqueamento das posi\u00e7\u00f5es na sequ\u00eancia de pept\u00eddeos \n\ncom maiores escores de liga\u00e7\u00e3o. Para a s\u00edntese dos pept\u00eddeos sint\u00e9ticos, no programa \n\nRankpep, realizou-se a predi\u00e7\u00e3o alinhando aos ligantes de MHCII IaB que \u00e9 espec\u00edfica para a \n\nlinhagem de camundongos em estudo: C57BL-6.  Ap\u00f3s as predi\u00e7\u00f5es, dois pept\u00eddeos sint\u00e9ticos \n\nforam comprados: SmCyp 94-108 (SLSMANAGPNTNGSQ) e SmCyp 107-121 \n\n(SQFFITTVPCSWLDG)  para serem usados no experimento de cultura de c\u00e9lulas e ELISA \n\n3.19.4 Predi\u00e7\u00e3o de s\u00edtios de glicosila\u00e7\u00e3o e de adi\u00e7\u00e3o de \u00e2ncora de GPI \n\n Para an\u00e1lise das regi\u00f5es de glicosila\u00e7\u00e3o utilizou-se o programa YinOYang \n\n(www.cbs.dtu.dk/services/YinOYang/- Outubro, 2010). Submeteu-se a sequ\u00eancia da prote\u00edna \n\nem formato FASTA e aperfei\u00e7oou-se para que fossem apresentados apenas os s\u00edtios positivos. \n\nAp\u00f3s obten\u00e7\u00e3o dos resultados foi poss\u00edvel identificar quantas e quais sequ\u00eancias possu\u00edam \n\npotenciais s\u00edtios de glicosila\u00e7\u00e3o. Utilizou-se o programa bigPI Predictor \n\n(mendel.imp.ac.at/goi_server.html- Outubro, 2010) para avaliar se a prote\u00edna possui potencial \n\ns\u00edtio para adi\u00e7\u00e3o de \u00e2ncora de GPI.  Submeteu-se a sequ\u00eancia em formato FASTA e \n\naperfei\u00e7oou-se para o reino Metazoa. O programa apresentou os poss\u00edveis s\u00edtios com os \n\nmaiores scores. \n\n3.20 Clonagem  \n\nUma vez identificadas as prote\u00ednas de interesse, selecionamos a prote\u00edna identificada \n\nno Spot 29 a qual denominamos de \u201cSmCyp\u201d(por ter sido anotada como  ciclofilina de S. \n\nmansoni) para ser testada como potencial ant\u00edgeno vacinal na forma de DNA. O gene sint\u00e9tico \n\nque codifica esta prote\u00edna foi desenhado utilizando-se o software  ApE \n\n(www.apesoftware.com) e otimizado para express\u00e3o em bact\u00e9rias e Mus musculus. O mini \n\n\n\n\u00a0\n\n\u00a0\n\n72\u00a0\n\n\u00a0\n\ngene foi desenhado inserindo s\u00edtios para as enzimas de restri\u00e7\u00e3o: BamHI (GGATCC) a 5` e \n\nXhoI (CTCGAG) eAgeI (ACCGGT) a 3`. Assim, foi poss\u00edvel fazer a clonagem do inserto \n\ntanto no vetor para express\u00e3o em c\u00e9lulas de mam\u00edfero pcDNA 3.1 V5/ His A (utilizando os \n\ns\u00edtios das enzimas de restri\u00e7\u00e3o BamHI e AgeI) como no vetor para express\u00e3o em procariotos \n\npETtev (utilizando os s\u00edtios das enzimas de restri\u00e7\u00e3o BamHI e XhoI). Ap\u00f3s esta otimiza\u00e7\u00e3o, \n\nrealizamos a compra deste gene sint\u00e9tico clonado no vetor de clonagem IDTSmartamp que \u00e9 \n\ncomercializado liofilizado pela empresa IDT. ODNA liofilizado foi ressuspendido em \u00e1gua e \n\nincorporado por E. coli da cepa XL1Blue por choque t\u00e9rmico. Clones contendo o gene \n\nsint\u00e9tico foram utilizados para extra\u00e7\u00e3o do DNA plasmidiano com o kit de mini-prep \n\n(Promega), de acordo com as instru\u00e7\u00f5es do fabricante. \n\nPara a clonagem do mini-gene que codifica a prote\u00edna presente no Spot29 (SmCyp) em \n\npcDNA 3.1 V5/His A (Invitrogen), a constru\u00e7\u00e3o contendo o gene sint\u00e9tico foi digerida com as \n\ndevidas enzimas de restri\u00e7\u00e3o nas seguintes condi\u00e7\u00f5es: 0,5?L do produto de mini-prep do gene \n\nsint\u00e9tico SmCyp, 16,3 ?L de \u00e1gua (DEPEC), 0,2 ?L de BSA (10mg/mL - Promega), 2 ?L de \n\ntamp\u00e3o D (10x- Promega), 0,5 ?L BamHI(10 U/ ?L - Promega), 0,5 ?L de AgeI (10 U/ ?L \n\nPromega). O plasm\u00eddeo pcDNA 3.1 V5/His A foi primeiramente digerido com BamHI: 30?L \n\ndo produto do mini-prep, 5,1 ?L de \u00e1gua (DEPEC), 0,4 ?L de BSA (10mg/mL- Promega), 4 \n\n?L de tamp\u00e3o E (10x- Promega), 0,5 ?L BamHI(10 U/ ?L - Promega), e, posteriormente, \n\nrealizou-se a digest\u00e3o com AgeI: 30?L do produto da extra\u00e7\u00e3o da banda, 5,1 ?L de \u00e1gua \n\n(DEPEC), 0,4 ?L de BSA (10mg/mL- Promega), 4 ?L de tamp\u00e3o K (10 x- Promega), 0,5 ?L \n\nAgeI (10 U/ ?L - Promega). A clonagem foi realizada utilizando a enzima de liga\u00e7\u00e3o T4 ligase \n\n(1,5 ?L do vetor pcDNA 3.1 V5/His, 7,2 ?L do fragmento correspondente ao mini-gene \n\n(SmCyp, 0,3 ?L de T4 ligase (3U/ ?L), 1 ?L do tamp\u00e3o de liga\u00e7\u00e3o (10x -300mM \u2013 Promega) \n\ntotalizando um volume de 10 ?L por 18h \u00e0 16\u00ba C. \n\n3.21 Transforma\u00e7\u00e3o de E. coli  DH5-alpha eletrocompetentes \n\nA rea\u00e7\u00e3o de liga\u00e7\u00e3o entre o inserto que codifica a prote\u00edna SmCyp e o vetor pcDNA \n\n3.1 V5/His A foi utilizada para a transforma\u00e7\u00e3o em bact\u00e9rias E. coli da cepa DH5-alpha por \n\neletropora\u00e7\u00e3o. Para isso, 2?L da rea\u00e7\u00e3o de liga\u00e7\u00e3o foram adicionados \u00e0 60?L da bact\u00e9ria \n\neletrocompetente. Vagarosamente, toda a solu\u00e7\u00e3o foi transferida para uma cubeta de \n\n\n\n\u00a0\n\n\u00a0\n\n73\u00a0\n\n\u00a0\n\neletropora\u00e7\u00e3o (0,2cm). A cubeta foi acondicionada no gelo at\u00e9 o seu uso no eletroporador \n\n(GenePulser Xcell-BioRad). Realizou-se a seguinte calibra\u00e7\u00e3o do aparelho: voltagem: 250V; \n\ncapacit\u00e2ncia (25?F); resist\u00eancia (200?). Imediatamente ap\u00f3s a eletropora\u00e7\u00e3o, acrescentou-se \n\n500 ?L de meio de cultura SOC (20mM-pht) \u00e0 temperatura ambiente. Esta solu\u00e7\u00e3o foi \n\ntransferida para um tubo autoclavado de 5mL o qual foi incubado a 37\u00baC por 1h sob agita\u00e7\u00e3o \n\nconstante. A cultura foi ent\u00e3o plaqueada em meio LB-\u00e1gar contendo ampicilina (100 ?g/mL), \n\nutilizando 250 ?L por placa, e incubou-seas mesmas \u00e0 37\u00baC por 16h. \n\nAp\u00f3s a sele\u00e7\u00e3o das col\u00f4nias de bact\u00e9rias que cresceram na placa, as mesmas foram \n\nestriadas em uma nova placa e, posteriormente, cultivadas em 5mL de meio LB com \n\nampicilina (100 ?g/mL) em agitador a 200 rpm, \u00e0 37\u00baC por 16h. Os mesmos foram utilizados \n\npara a extra\u00e7\u00e3o do DNA plasmidiano com o kit de mini-prep (Promega), de acordo com as \n\ninstru\u00e7\u00f5es do fabricante. \n\n3.22 PCR \n\nO DNA plasmidiano dos clones selecionados foi utilizado em uma Rea\u00e7\u00e3o da Cadeia \n\nde Polimerase (PCR) para confirma\u00e7\u00e3o da inser\u00e7\u00e3o do gene que codifica a prote\u00edna SmCyp no \n\nplasm\u00eddeo pcDNA 3.1 V5/HisA. Para isto, utilizou-se os iniciadores BGH (reverso) e T7 \n\n(forward) que se anelam no DNA do vetor utilizado. Para a rea\u00e7\u00e3o de PCR foram usados 1,5 \n\n?L PCR Taq buffer 1X, 1?L DNTP mix (10mM- concentra\u00e7\u00e3o estoque), 0,5 ?L MgCl2 \n\n(50mM), 1 ?L do primer BGH (10 picomoles/?L), 1 ?L do primer T7(10 picomoles/?L), 0,4 \n\n?L Platinum taq (5U/?L- Invitrogen), 9,3 ?L de \u00e1gua Milli-Q, 2 ?L do produto da mini-prep. \n\nA PCR foi realizada em termociclador com a etapa inicial de ativa\u00e7\u00e3o de 94\u00baC por 3 min, \n\nseguido por 40 ciclos de: desnatura\u00e7\u00e3o \u00e0 94\u00baC por 30 seg, anelamento \u00e0 55\u00baC por 45 seg e \n\nextens\u00e3o \u00e0 72\u00baC por 5 minutos. Ap\u00f3s a PCR, os produtos de amplifica\u00e7\u00e3o foram submetidos \u00e0 \n\nan\u00e1lise em gel de agarose 1%. A col\u00f4nia confirmadamente positiva foi cultivada em 10mL de \n\nmeio LB com ampicilina (100 ?g/mL) em agitador \u00e0 200 rpm, \u00e0 37\u00baC por 16h (pr\u00e9-in\u00f3culo) e, \n\nposteriormente, foi realizado um in\u00f3culo distribuindo esta cultura em 2,5L de meio LB com \n\nampicilina (100 ?g/mL) em agitador \u00e0 200 rpm, \u00e0 37\u00baC por 16h. Esta cultura bacteriana foi \n\nutilizada para a extra\u00e7\u00e3o do DNA plasmidiano com o kit Endofree Giga-Prep (QIAGEN\u00ae) de \n\nacordo com as instru\u00e7\u00f5es do fabricante. \n\n\n\n\u00a0\n\n\u00a0\n\n74\u00a0\n\n\u00a0\n\n3.23 Digest\u00e3o do DNA plasmidiano com BamHI e AgeI \n\nO DNA plasmidiano do clone contendo o gene que codifica a prote\u00edna SmCyp \n\ninserido no plasm\u00eddeo pcDNA 3.1 V5/His A foi submetido a uma digest\u00e3o com as enzimas de \n\nrestri\u00e7\u00e3o BamHI (Promega) e AgeI (Promega) para verifica\u00e7\u00e3o da correta clonagem. Para esta \n\ndigest\u00e3o utilizou-se: 1,5ul de tamp\u00e3o multi-core (10x - Promega); 1,5ul de BSA \n\n10x(10mg/mL), 2ul do DNA plasmidiano (1ug/ul),1ul da enzima AgeI (10U/?L-Promega); \n\n1ul da enzima BamHI(10U/?L-Promega); 8ul de \u00e1gua. Essa rea\u00e7\u00e3o foi incubada \u00e0 37\u00baC por 5 \n\nhoras. Ap\u00f3s este per\u00edodo, os produtos de digest\u00e3o foram submetidos \u00e0 an\u00e1lise em gel de \n\nagarose 1% corado com Sybr Gold (Invitrogen). \n\n3.24 Sequenciamento do DNA plasmidiano \n\n O sequenciamento parcial de DNA do clone selecionado foi realizado no Laborat\u00f3rio \n\nde Parasitologia Celular e Molecular do Centro de Pesquisas Ren\u00e9 Rachou/ Fiocruz - \n\nplataforma de Sequenciamento de DNA-BH, PDTIS- FIOCRUZ. Para esta rea\u00e7\u00e3o, utilizou-se \n\no kit BigDye Terminator Cycle Sequencing (Life Technologies). Na placa de PCR para \n\nsequenciamento foram adicionados 300ng do DNA plasmidiano recombinante, 0,5 \u00b5L de Big \n\nDye, 1,75\u00b5L de tamp\u00e3o, 1\u00b5L do iniciador (10 pmol/\u00b5L) (forward e reverso espec\u00edficos para o \n\ngene SmCyp, T7 e BGH) e completou-se com \u00e1gua apirog\u00eanica para um volume total de \n\n10\u00b5L. Para a rea\u00e7\u00e3o de sequenciamento foi utilizado o programa: 96\u00baC por 1 min \n\n(desnatura\u00e7\u00e3o), ap\u00f3s esta etapa utilizou-se 96\u00baC por 15 seg, 50\u00baC por 15 seg e 60\u00baC por 4 \n\nminutos (extens\u00e3o final) por 40 ciclos consecutivos. Adicionou-se 1 \u00b5L de EDTA (125mM) a \n\ncada po\u00e7o. Em seguida, foram adicionados 1\u00b5L de acetato de am\u00f4nio 7,5M e 50\u00b5L de etanol \n\n100% para precipita\u00e7\u00e3o do DNA. A placa foi selada e agitada brevemente em vortex. Esta \n\nplaca foi ent\u00e3o incubada por 15 minutos a T.A e centrifugada a 4800 x g por 45 min a \n\ntemperatura ambiente. Verteu-se a placa para descartar o sobrenadante e adicionou-se 100 \u00b5L \n\nde etanol 70%. Centrifugou-se novamente por 15 min a 4800 x g T.A. O sobrenadante foi \n\ndescartado e a placa foi centrifugada invertida por 1 minuto. A rea\u00e7\u00e3o de sequencimento foi \n\nressuspendida em 10\u00b5L de tamp\u00e3o de amostra contendo 70% de formamida, 1mM EDTA. A \n\nplaca foi inserida no sequenciador de DNA (ABI3730 DNA Analyzer) e os cromatogramas \n\nfornecidos foram analisados. \n\n\n\n\u00a0\n\n\u00a0\n\n75\u00a0\n\n\u00a0\n\n3.25 Express\u00e3o e an\u00e1lise de prote\u00ednas recombinantes em c\u00e9lulas HEK293T   \n\n3.25.1 Transfec\u00e7\u00e3o transiente de c\u00e9lulas HEK293T por lipossomos \n\nPara verificar a express\u00e3o da prote\u00edna heter\u00f3loga SmCyp em c\u00e9lulas de mam\u00edfero foi \n\nutilizada a linhagem HEK293T, derivada de c\u00e9lulas de rim de embri\u00e3o humano, previamente \n\ncultivada em meio Dulbecco\u2019s Modified Eagle Medium \u2013 DMEM (GIBCO, \n\nInvitrogen),suplementado com 10% de soro fetal bovino (SFB) e com1% dos antibi\u00f3ticos \n\npenicilina/estreptomicina, a 37\u00baC em 5% de CO2. A transfec\u00e7\u00e3o foi realizada por meio da \n\nt\u00e9cnica de lipofec\u00e7\u00e3o (transfec\u00e7\u00e3o por lipossomos) com o uso de Lipofectamine 2000 \n\n(Invitrogen) edo plasm\u00eddeo pcDNA3.1/V5-His Aque cont\u00e9m a regi\u00e3o codificadora do gene de \n\nSmCyp de S. mansoni em fus\u00e3o com os c\u00f3dons para o epitopo V5 e 6xHis. Os plasm\u00eddeos \n\npcDNA 3.1/V5-His-TOPO/lacZ (Invitrogen), que cont\u00e9m o gene de ?-galactosidase tamb\u00e9m \n\ninserido em fus\u00e3o com o epitopo V5 e 6xHis, e o plasm\u00eddeo pcDNA 3.1/V5-His B, que \n\ncont\u00e9m a regi\u00e3o codificadora de SmPGM (fosfoglicerato mutase de S. mansoni), foram \n\nutilizados como controles da transfec\u00e7\u00e3o, bem como do experimento de Western blotting \n\nutilizando anticorpo anti-6xHis. Al\u00e9m deste, foi utilizado tamb\u00e9m como controle positivo da \n\ntransfec\u00e7\u00e3o o plasm\u00eddeo pcDNA3-RFP, que cont\u00e9m o gene rep\u00f3rter da Red Fluorescent \n\nProtein (RFP - Prote\u00edna vermelha fluorescente). Este plasm\u00eddeo foi gentilmente cedido pelo \n\nDr. Alexandre Magalh\u00e3es/FIOCRUZ. Esta prote\u00edna emite luz vermelha quando excitada por \n\nluz ultravioleta que pode ser observada em microscopia de fluoresc\u00eancia. Foi utilizado o \n\nmicrosc\u00f3pio de fluoresc\u00eancia AXIO \u2013 Observer. A1 (Zeiss), com c\u00e2mera integrada AxioCam \n\nMRc, do Laborat\u00f3rio de Biomarcadores de Diagn\u00f3stico e Monitora\u00e7\u00e3o/CPqRR. \n\nComo controle negativo do experimento foi utilizado o plasm\u00eddeo pcDNA3.1/V5-\n\nHisB vazio, ou seja, sem inserto, assim como c\u00e9lulas n\u00e3o transfectadas que foram mantidas na \n\npresen\u00e7a e aus\u00eancia de lipofectamina. Em cada po\u00e7o da placa de cultura de 24 po\u00e7os foram \n\ninoculadas 2,0x105 c\u00e9lulas em 500?L de meio DMEM com 10% SFB e sem antibi\u00f3ticos. Esta \n\nplaca foi incubada \u00e0 37\u00baC e 5% de CO2 por cerca de 24 horas, de forma que no momento da \n\ntransfec\u00e7\u00e3o houvesse uma conflu\u00eancia de aproximadamente 80%. \n\n\n\n\u00a0\n\n\u00a0\n\n76\u00a0\n\n\u00a0\n\nCada amostra de DNA e a lipofectamina foram separadamente dilu\u00eddos em meio \n\nDMEM, sendo utilizado 0,8?g de DNA em 50?L de meio de cultura e 2?L de lipofectamina \n\nem 50?L de meio de cultura para cada po\u00e7o. Ap\u00f3s 5 min de incuba\u00e7\u00e3o \u00e0 temperatura \n\nambiente, a lipofectamina dilu\u00edda foi misturada a cada uma das amostras de DNA. Esta \n\nmistura foi incubada por 20 min \u00e0 temperatura ambiente, permitindo a forma\u00e7\u00e3o dos \n\ncomplexos DNA-lipossomo. Decorrido esse tempo, cada mistura foi adicionada aos \n\nrespectivos po\u00e7os da placa de cultura, sendo esta mantida por aproximadamente 5hr a 37\u00baC \n\nem 5% CO2. As c\u00e9lulas haviam sido previamente lavadas para retirada do SFB e adi\u00e7\u00e3o \n\napenas de meio DMEM. Ap\u00f3s as 5 hr de incuba\u00e7\u00e3o foi realizada uma nova lavagem das \n\nc\u00e9lulas, sendo adicionado meio DMEM sem antibi\u00f3tico e contendo 10% SFB. A placa foi \n\nent\u00e3o incubada por 48 hr a 37\u00baC em 5% CO2. O experimento foi realizado utilizando todas as \n\namostras em duplicata. \n\nAp\u00f3s 48 hr, as c\u00e9lulas transfectadas com o plasm\u00eddeo pcDNA3-RFP foram analisadas \n\nem microsc\u00f3pio de fluoresc\u00eancia para verifica\u00e7\u00e3o da express\u00e3o do gene rep\u00f3rter (RFP). As \n\ndemais culturas transfectadas foram submetidas \u00e0 lise para extra\u00e7\u00e3o de prote\u00ednas. \n\n3.25.2 Extra\u00e7\u00e3o de prote\u00ednas a partir da lise das c\u00e9lulas HEK293T transfectadas \n\nQuarenta e oito horas ap\u00f3s a transfec\u00e7\u00e3o, as c\u00e9lulas transfectadas foram lavadas com \n\n1mL de PBS gelado. A placa de cultura foi analisada em microsc\u00f3pio invertido trinocular \n\n(OLYMPUS - CK2, ULWCD 0.30) para certificar que as c\u00e9lulas n\u00e3o haviam sido removidas \n\ncom a lavagem. Em seguida, estas foram lisadas em 100?L de tamp\u00e3o Laemmli 2X (4% SDS, \n\n20% glicerol, 10% ?-mercaptoetanol, 0,004% azul de bromofenol e 0,125M Tris HCl, pH6,8 - \n\nBioRad) acrescido de ?-mercaptoetanol (950?L do tamp\u00e3o Laemmli 2X + 50?L de ?-\n\nmercaptoetanol). Os extratos de c\u00e9lulas foram recolhidos em tubos de 1,5mL e estes foram \n\nmantidos no gelo. Os po\u00e7os foram lavados com 50?L adicionais do tamp\u00e3o Laemmli 2X e \n\nesta solu\u00e7\u00e3o foi posteriormente adicionada aos tubos descritos anteriormente. Em seguida, as \n\namostras foram fervidas a aproximadamente 100\u00baC por 5 min para desnatura\u00e7\u00e3o das prote\u00ednas \n\ne inativa\u00e7\u00e3o de proteases. Em seguida, as mesmas foram brevemente centrifugadas a 14.000 x \n\ng e armazenadas a -70\u00baC. A qualidade dos extratos prot\u00e9icos obtidos foi avaliada por SDS-\n\nPAGE 12%. \n\n\n\n\u00a0\n\n\u00a0\n\n77\u00a0\n\n\u00a0\n\n3.25.3 An\u00e1lise dos extratos prot\u00e9icos por SDS-PAGE \n\nNo sistema de eletroforese unidimensional foram montados dois mini-g\u00e9is com \n\nresolu\u00e7\u00e3o a 12% utilizando o sistema Mini-Protean III (Bio-Rad). Aos 2 g\u00e9is foram aplicadas \n\nas mesmas amostras, por\u00e9m em quantidades diferentes devido \u00e0s suas finalidades distintas, \n\nsendo 15?L para o Western blotting e 10?L para colora\u00e7\u00e3o do gel por Coomassie Brillant \n\nBlue G-250 e an\u00e1lise da qualidade do extrato prot\u00e9ico. O sistema de eletroforese foi \n\nsubmetido a uma voltagem inicial de 50V para a entrada das amostras no gel de separa\u00e7\u00e3o, e \n\ndepois de 100V, para a corrida eletrofor\u00e9tica. A eletroforese estendeu-se at\u00e9 a sa\u00edda do azul de \n\nbromofenol do gel. \n\n3.25.4 An\u00e1lise das prote\u00ednas por Western blotting unidimensional \n\nO outro gel de poliacrilamida mencionado no item anterior, no qual foram aplicados 10?L \n\ndo marcador de peso molecular BenchMark Prestained Protein Ladder (Invitrogen)e 15?L \n\ndos extratos prot\u00e9icos das c\u00e9lulas transfectadas e controles, j\u00e1 em tamp\u00e3o de amostra, foi \n\nutilizado para transfer\u00eancia de prote\u00ednas para membrana Imuno-Blot PVDF (Bio-Rad), \n\nutilizando-se o sistema de transfer\u00eancia mini Trans-Blot Eletrophoretic Transfer Cell (Bio-\n\nRad). Para isso, foi montado um sistema do tipo sandu\u00edche contendo o gel e a membrana. Este \n\naparato foi colocado em tamp\u00e3o de transfer\u00eancia (25mM Tris, 192mM glicina, 20% metanol) \n\ne a transfer\u00eancia das prote\u00ednas foi realizada em gelo, a 100V na primeira hora e a 110V na \n\nsegunda hora. Ap\u00f3s a transfer\u00eancia, a membrana foi bloqueada por aproximadamente 16 hr \n\nem TBS-T/BSA 3% (TBS: 20Mm Tris-HCl, 500 mM NaCl, pH 7,5; Tween-20 0,1%; BSA \n\n3%) sob leve agita\u00e7\u00e3o \u00e0 temperatura ambiente. Ap\u00f3s lavagem r\u00e1pida com TBS 1X, a \n\nmembrana foi incubada por 3 hr com anticorpo anti-6xHis conjugado a HRP (Horseradish \n\nPeroxidase) (Invitrogen), dilu\u00eddo 1:5000 em TBS-T/BSA 1%. Em seguida, a membrana foi \n\nsubmetida a 2 lavagens de 15 min cada com TBS-T e a uma lavagem, tamb\u00e9m de 15 min, \n\ncom TBS 1X. A rea\u00e7\u00e3o foi revelada utilizando ECL Plus Western Blotting Detection System \n\n(GE-Healthcare) e a imagem foi capturada em Image Quant LAS 4000 (GE-Healthcare) pelo \n\nm\u00e9todo quimioluminescente. \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n78\u00a0\n\n\u00a0\n\n3.26 An\u00e1lises estat\u00edsticas \n\nAs an\u00e1lises estat\u00edsticas foram realizadas utilizando o software GraphPad Prism 5.0 \n\n(San Diego, Ca, USA). Os resultados que apresentaram distribui\u00e7\u00e3o normal foram analisados \n\nutilizando: an\u00e1lise de vari\u00e2ncia, seguida dos testes de compara\u00e7\u00f5es m\u00faltiplas de Tukey \n\nquando as compara\u00e7\u00f5es envolveram mais de duas vari\u00e1veis. O teste T de Student foi \n\nempregado quando comparadas somente duas vari\u00e1veis. \n\nOs resultados que n\u00e3o apresentaram distribui\u00e7\u00e3o normal foram analisados atrav\u00e9s do \n\nteste n\u00e3o param\u00e9trico Kruskall-Wallis, seguido pelo teste de compara\u00e7\u00f5es m\u00faltiplas de Dunn \n\nquando as compara\u00e7\u00f5es envolveram mais de duas vari\u00e1veis. O teste Mann-Whitney foi \n\nempregado quando comparadas somente duas vari\u00e1veis. Foram considerados estatisticamente \n\nsignificativos os resultados com p &lt;0,05. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n79\u00a0\n\n\u00a0\n\n4  RESULTADOS \n\nComo demonstrado em trabalhos anteriores realizados por nosso grupo, o Smteg foi \n\ncapaz de ativar c\u00e9lulas dendr\u00edticas da medula \u00f3ssea (BMDC) aumentando a express\u00e3o de \n\nmol\u00e9culas co-estimulat\u00f3rias, tais como CD40 e CD86 e induzindo a produ\u00e7\u00e3o de quantidades \n\nsignificativas de IL-12p40 e TNF-? (Dur\u00e3es et al., 2009). Al\u00e9m disso, em camundongos \n\nimunizados com Smteg juntamente com adjuvante Completo/Incompleto de Freund, \n\nobservou-se uma redu\u00e7\u00e3o da carga parasit\u00e1ria de 43%-48%, bem como diminui\u00e7\u00e3o do n\u00famero \n\nde ovos nas fezes e no f\u00edgado (Teixeira de Melo et al., 2010). A fim de saber se a imuniza\u00e7\u00e3o \n\ncom Smteg sem a adi\u00e7\u00e3o de adjuvantes ou com a administra\u00e7\u00e3o de outros tipos de adjuvantes \n\nseria capaz de induzir uma resposta imune protetora, camundongos foram imunizados com \n\nSmteg, Salina, Alum, Smteg/Alum, Salina/Alum/CpG e Smteg/Alum/CpG.  \n\n A imuniza\u00e7\u00e3o de camundongos com Smteg na aus\u00eancia de adjuvante, \n\nsurpreendentemente n\u00e3o resultou na diminui\u00e7\u00e3o significativa da carga parasit\u00e1ria al\u00e9m de n\u00e3o \n\ndiminuir o n\u00famero de ovos presos no intestino e f\u00edgado de forma significante. Este resultado \n\ndemonstra a import\u00e2ncia do adjuvante em uma formula\u00e7\u00e3o vacinal. Entretanto, a imuniza\u00e7\u00e3o \n\ncom Smteg na aus\u00eancia de adjuvante foi capaz de ativar uma resposta imune, pois resultou em \n\numa significativa produ\u00e7\u00e3o de anticorpos espec\u00edficos al\u00e9m de um aumento da porcentagem de \n\nc\u00e9lulas espl\u00eanicas CD4+IFN-?+ e CD4+IL10+ com um aumento estatisticamente significativo \n\nna produ\u00e7\u00e3o das citocinas IFN-? e IL-10. Al\u00e9m disso, foi observado neste trabalho que c\u00e9lulas \n\ndendr\u00edticas derivadas da medula \u00f3ssea (BMDC) estimuladas in vitro com Smteg aumentaram \n\nsignificativamente a produ\u00e7\u00e3o de IL-10. Esta alta produ\u00e7\u00e3o de IL-10 pode ter contribu\u00eddo por \n\numa menor resposta inflamat\u00f3ria pelas c\u00e9lulas do sistema imune e consequentemente pela \n\naus\u00eancia de prote\u00e7\u00e3o (Ara\u00fajo JM, 2012). \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n80\u00a0\n\n\u00a0\n\n \n\n \n\nA c ta  Tropi ca  12 4 (2 012 ) 1 40\u20131 46 \n \n \n\nCon ten ts lists  availab le at SciVerse ScienceDirect \n\n \nActa Tropica \n\n \n\n \nj o u r  n a l  h o m e p  a g e :  w w w . e ls ev i er . c o m / l o c at e / a c t a t ro p i c a  \n\n \n \n \n \n\nSchistosoma mansoni schistosomula tegument (Smteg) immunization in absence \nof adjuvant induce IL-10 production by CD4+ cells  and failed to protect m ice \nagainst challenge infection \n\n \nJ uliano M ichel A raujo a,1 , Tatiane Teixeira de M elo a,1 , Isabela Cam pos de S ena  a , Clarice Carvalho Alves a , \nNeusa A raujo a , Fernanda do Valle Dur\u00e3es b , Sergio Costa O liveira b , Cris tina Tos cano F ons eca a,c,* \n\n \na  Ce ntro de P esquis as Re n\u00e9  Rac hou, F iocruz-MG , Be lo Horiz ont e, Mi nas Ge ra is, Brazi l \nb  De pa rta me nt o de Bi oqu\u00ed mica  e im unolo gia , In stit uto de Ci\u00ea ncia s Biol\u00f3gica s, U nive sidade Fede ral  de Mina s G erai s, Belo Horiz onte, Minas Ge ra is, Brazi l \nc  Ins titu to Na c iona l d e Ci\u00ea ncia s e Tec nol ogi a em  Doe nc? as Tropic ais  ( INCT- DT),  Braz il \n\n \n \n\na  r t i c  l e    i n f o a  b  s  t r a  c  t \n \n\nA rt icle  h istory:  \n\nR e ce ive d 6 D e c e mb e r 20 11 \nR e c e ive d in  re vi se d fo rm  18  July  2 012  \n\nA cc e pte d 19 Ju ly  2 012  \n\nA v ai la ble  onli ne 2 7 July  201 2 \n\n \nK e ywords:  Sc histosom a \n\nm a nso ni Sc h ist osom ul a \ntegument Immunization \n\nR e gul at ory response \n\nThe  Schistosoma mansoni tegument interaction with the immune system plays a  key  role i n  disease \nestablishment or elimination. We  have recently demonstrated that S. mansoni schistosomula tegument \n(Smteg) is   able to activate innate immune response and to induce protective immunity in  a  vaccine \nformulation with Freunds adjuvant. In this work, we evaluated the ability of Smteg to elicit protection in \nthe absence of adjuvant. Smteg mice immunization resulted in signi? cant antibody production, increased \npercentage of CD4 + IFN-g+ and C D4 + IL-10+ cells in spleen and increased production of IFN-g and IL-10 by \nspleen cells, but failed to reduce parasite burden, female fecundity and morbidity. We also demonstrated \nth at BMDC stimulation with Smteg resulted in signi? cant IL-10 production. Our  results demonstrate th at \nSmteg has immune modulatory proprieties. \n\n\u00a9 2012 Elsevier B.V. All rights reserved. \n \n \n \n\n1.  Introduction \n \n\nThe   success in  dev elo ping  an   ef? cien t vaccine fo rm ulation  \nd ep end s on  the use  of  i mm un og enic an tigen s tog ether w i th an  \nap prop riated  ad juv an t able to  in duce an  in? am mato ry  resp on se \nthat will polarize th e resp on se to th e d esirable immun olog ical p ro- \n? le.  In  the case of  s ch istos omi as is, p ro tectiv e immu nity  in  mice \nhas  b een d es crib ed  to  be  d epen den t on  an tib od y  res po n se an d to  \nin volve a cel lular imm un e res po nse d epend ent on  CD4+  and IFN- \ng (Jankov ic et al., 1 99 9; Sm yth ies et al. , 199 2; Vig nali et al., 19 89 ; \nW ilson  et al., 199 6). A dd itio nally , the use  of rIL-12  as adju van t h as \nb een prov ed  to  en han ce the p ro tective im mu nity  in du ced by the \nan tigen  alo ne or  associated w ith oth ers adju vants (Wy nn  et al., \n1 99 5; Wyn n an d Cheever, 1 995 ), ind icatin g th at a Th1  p ro ?le is \nd esirab le. \n\nThe  Schistosoma manson i s chisto somula  tegument  (Smteg ) is \na n   interestin g parasite s tru cture  to   be   u sed in  a  vaccine fo r- \nm ulation   agains t  sch istoso miasis . The   tegu m ent is  a  d yn am ic \n\n \n\n \n \n\n* C orres pond ing au tho r a t: La bo ra t \u00f3rio de  E squi sto sso mos e , C e ntro  de  P e squi sa s \nR e n\u00e9 R ac hou, A ve nid a A ugu sto de  Lima , 1715,  Ba rro Pre to, CEP 30 190-002,  Be lo \nH oriz onte , M ina s G e ra is, B raz il. Tel .:  + 55 31 334 978 28. \n\nE-ma il  ad dre ss:  ct osc an o@c pqrr.? oc ruz .br (C.T. Fons ec a ). \n1   Th es e  a uth ors c ont ribu te d e qua l ly t o th is stu dy.  \n\nh ost-interactive layer in volv ed in n utritio n, im m un e evas ion  an d \nm odu lation, ex cretio n, os moregu lation, sen sory receptio n and  sig - \nnal  transd uctio n (Jo nes et al. , 2 00 4; Van  H ellemo n d et al.,  2 006 ). \nIn add ition , the larval sch isto som ula h av e b een  d escrib ed  to be the \nm os t sus cep tib le parasite life s tag e to h os t imm un e sys tem attack \n(Fo ley et al.,  19 88; James, 198 1; Simpso n et al. , 1 98 3). \n\nRecently we   hav e d em on strated  th at  Smt eg  is  ab le to  acti- \nv ate b one marro w  dend ritic cells   (BMDC)  by  up -regu lating  the \nexp ress ion of essential co-stimu lato ry mo lecu les, su ch as CD40 an d \nCD86,  and  also  by  in du cing  th e p rod uctio n of IL-1 2p40 and TNF- \na  cy tokin es  in  a  TLR-4 d epen den t m ann er (D u r\u00e3es et al. ,  2 009 ). \nWe  h ad also  d emo nstrated th at mice im mu nizatio n w it h Sm teg \np lus Freu nd s adju vant is able to red uce paras ite bu rd en, egg elim - \nin ati on an d d isease m orbid ity. The  imm un e resp on se elicited  by \nim mun izatio n, ch aracterized by IFN-g, IgG1 and  IgG2c prod uction , \nw as ab le to in du ce damag e in parasite teg ument (T eix eira de M elo \net a l.,  2 01 0). Th ese res ults ind icate th at Smteg co ntains  p rotective \nan tig ens as w ell as in? amm atory  in du cin g molecules in its formu- \nlation. \n\nIn this  stud y, we  h ave ev al uated the imm uno log ical res po nse \ntrigg ed  by  Smteg  imm unization  in  the absen ce of adju van ts an d \nits  ability to ind uce protection  ag ai nst S.  manso ni challenge in fec- \ntio n. We  d emon strated t hat alth ou gh  Smteg  imm un ization  in the \nabs en ce of adju van t in du ced  sig ni? cant p ro ductio n of sp eci? c anti- \nb odies it  failed to  indu ce protective imm un e res po nse in  mice \n\n \n0 001-7 06X / $ \u2013 se e  front  m a tte r \u00a9 20 12 El se vie r B.V. All rig hts  res e rve d. \nh tt p:/ /dx. doi .org/ 10.1 016 /j.a c ta t ropic a .2 012. 07.0 07 \n\n\n\n\u00a0\n\n\u00a0\n\n81\u00a0\n\n\u00a0\n\n \n\n \n\nprob ably du e to IL-10 p rod ucti on  and  im paired antig en  p res enta- \ntio n to C D4+  cells. \n\n \n\n \n2.   M aterials  and methods \n\n \n2. 1.  Mic e and  parasites  \n\n \nFemale C57BL/6 m ice aged  6\u20138  week s were o btain ed  fro m the \n\nCen tro de  Pesqu isas Ren\u00e9  Rachou  (CPqRR) Fiocruz. All pro ced ures \ninvolv in g an im als were approved by the local Ethics Co mmission on  \nAnimal Use (CEUA) from Fio cruz (no. L -005/08 ). Cercariae of S . man- \nsoni (LE strain ) w ere main tained  ro utin ely in Biomphalaria glabrata \nsn ails at C PqRR an d ob tained  by  exp osin g infected  s nails to  lig ht \nfor  1\u20132 h  to  in du ce cercariae shedd ing. The  n u mb er of cercariae \nand their viab ility were d etermin ed us ing a light micro sco pe. \n\n \n\n \n2. 2.  Antibodies \n\n \nThe  follo w ing an tib od ies w ere u sed for  ? o w cy tom etry analy- \n\nsis:  an ti-mo us e CD 4-Bio tin  and FITC (clo ne GK1.5,  e-b io science), \nanti -m ou se CD8-FITC (clon e 53-6-7, e-bio scien ce), anti-mo use IL- \n10-PE  (clon e JESS-16E3, e-b io scien ce), anti-mou se IFN-g-PE (clone \nXMG1. 2,    e-bios cien ce), anti-mo use  TNF-  -PE  (clone  MP6XT 22, \nebios cien ce) an d anti-mo us e IL-4-PE (clone 11 B11, BDbioscience), \nstreptavid in-Percp   (e-bioscience), anti-mou se  CD2 5-Biot (clon e \n7D4,    BDbioscience) and  an ti-mo use   Foxp 3-PE  (clon e  JFK-16a \ne-bio science). The follo wing  iso type co ntrols were used: Rat IgG2a- \nF ITC , Ra t IgG2b-FITC,  Rat Ig G2b-biotin, Rat IgM-b iotin , Rat IgG1-PE, \nRat IgG2a-PE,  Rat IgG2b-PE. A nti-m ouse CD16/CD32, Fc Block (BD \nBioscience) was also  u sed for ? o w cy tometry  assays. \n\n \n\n \n2. 3.  Tegument puri? cation (Smteg) \n\n \nCercariae fro m S. manson i were m echanically transfo rm ed in to \n\nschisto som ula according  to  Ramalho -Pinto  et al.  (1974). Brie? y, \ncercariae w ere incub ated on  ice  for  30 m in  and  th en cen trifu ged \nat 18 00 \u00d7 g for  3 m in at  4 ? C .  The  cercariae w ere resus pend ed in \ncold  ELAC  (Earle\u2019s salts plus  lactalb um in h yd ro lysate) contain ing  \n0. 5% lactoalbu min, 1% p enicillin /strep tom ycin  an d 0.17% glucose. \nThe  tails  w ere brok en by  v ortexing  in  hig h speed for  2 m in and  \nrem ov ed  th ro ug h s everal wash ing  steps  with  ELAC.  The  s ch isto-  \nsom ula were cultu red  for  90 m in at 37 ? C in  ELA C . The  teg um ent  \n\n2.5.  Challenge infection and  worm burden reco very \n\n \nT hirty d ay s aft er th e l ast bo ost, mice w ere ch al len ged th ro ug h  \n\npercu taneou s exp osu re of ab do min al skin  for 1 h in w ater co ntain - \ning  100  cercariae (LE s train ) as  d es cribed  by  Smithers and  Terry  \n(19 65). Fifty days after ch alleng e, adu lt w o rm s w ere p erfu sed from  \nthe po rtal sys tem  and  m esenteric v ein s acco rd ing to Pellegrino and  \nSiq ueira (1956 ). The p ro tection  level was calcu lated  co mparing the \nnu mb er of w o rm recov ered from  the imm un izat ion  grou p with the \nco ntrol group . \n\n \n2.6.  Measu remen t of the nu mber of eggs in the intestine and  liver \nof immunized mice \n\n \nIntestin e and liver fro m each  mo use fro m bo th co ntrol (saline) \n\nan d  Smt eg  im mun ized   grou ps  w ere  co llect ed   50   day s p os t- \ninfectio n. T hese o rg an s were weig hed and  d igested with 10% KOH \nov ern ig ht at 4 ? C an d for  2 h at 37 ?C . The  eggs  were o btained b y \ncentrifug ation  at 900 \u00d7 g for  10 min  and  ressu sp end ed  in  1 mL of \nsalin e. Egg nu mb er w as cou nt ed  u sin g a ligh t microscope. \n\n \n2.7.  Measu remen t of speci? c  antibodies \n\n \nThe meas urem ent of sp eci? c anti-Smteg  IgG antib od ies was  per- \n\nfo rm ed  by EL IS A . M axsorp 96-w ells  micro titer p lates (N un c) were \ncoated with 1    g/mL of the Smteg in carbon ate\u2013b icarbon ate bu ffer, \npH  9.6,  for  16 h at 4 ? C . The  p lat es  w ere then  blo cked  for  16 h at \n4 ?C  w ith  300    L/well of PB ST (ph osp hate-bu ffered saline, pH 7 .2 \nwith 0.05% T w een-20 ) plu s 10% FBS (fetal bov ine s erum , GIBCO, \nUSA). One hun dred microliters of each  serum  d ilu ted 1 :10 0 (IgG and  \nIgG1) or 1:2 00  (IgG2c )  in PBST was add ed p er w ell and  in cu bated  \nfor  1 hr at roo m t em p erature. Plate-bo un d an tib od y w as d etected  \nby  perox id as e-co nju gated ant i-m ou se IgG, IgG1  or  IgG2c  (Sou th- \nern Bio tech, USA),  dilu ted  1:5 000 , 1:1 0,000  or 1:40 00  respectively. \nColor reactio n w as d ev elop ed  by add ition  of 100    L p er w ell of TMB \n(M icrow ell Perox idase Su bstrate System) an d s topp ed  w ith 50    L \nof 5% sulfu ric acid  per w ell. A bso rb ance was measu red  at 450 n m  \nin E LIS A  reader. \n\n \n2.8.  In tracellu lar staining  \n\n \nFor  in tracytop lasmatic cytok ine stainin g, spl een cells  from 8  \n\nmice/group  (10  d ays after the last  im mu nizatio n ) were ad ju sted \n5\n\n \n\nwas  remo ved  w ith CaC l2   0.3 M by  v ortex  ag itatio n, acco rd ing to \nto  5 \u00d7 10 cells  per w ell. Sp leen  c ells  were m aintain ed in  cu lture \n\n \nCaldas et al.  (200 0). The  tegu men t w as sep arated  fro m d enu ded  \nbod ies by cen trifu gation at 900 \u00d7 g for 1 min. The s up ern atan ts w ere \npooled and  cen trifu ged at 5 0,000  \u00d7 g for 1 h at 4 ? C. The pellet w as \ndialy zed  against ph ysiolo gical salin e 1. 7%. This  preparation  was  \ntermed  Sm teg . \n\n \n\n \n2.4.  Mice immunization \n\n \nFemale C 57BL/6 mice (10 mice p er g ro up) were immu nized s ub- \n\ncu tan eou sly in the nap e of th e neck  w ith  25    g Sm teg on  d ays 0, \n15 an d 30. In th e co ntrol grou p, salin e w as  adm inist ered usin g the \nsame im mu nization  p ro tocol. B lood  s amples w ere co llected  from  \nretro orb ital sin us of each  mo use with  an in terv al of 15 d ay s beg in- \nning  15  d ays after the ? rs t imm un izatio n. Serum  sam ples w ere \nco llected  and  sto red at - 20 ?C  un til use. Three ind epen den t ex peri- \nmen ts were perfo rmed to co n? rm the resu lts obs erved. In the third \ntrial tw o add ition al g ro up s were in clu ded  in  im mu nizatio n  p ro - \nto co l: Saline + CFA/IFA ad juvants  and Smteg + CFA/IFA ad juv an ts, \nco mp lete freun d adju van t (CFA) w ere ad ded  to v accine form ulation  \nin the ?rst imm unizatio n do se wh ile in com plete freun d adju vants  \n(IFA) were u sed in seco nd  and th ird  imm un izatio n dos e. \n\nat 37 ? C in  5% of CO2  in  mediu m al on e or  stimu lated  w ith Sm teg  \n(25   g/mL)  or Con A (5   g/mL).   After  16 h of culture, 1   g/w ell of \nb refeld in A (Sigma Chemical Co.,  St. Louis, MO) w as add ed for 4 h to \nim pair cyto kine secretion. Cells were th en  blocked w it h ant i-m ou se \nCD16/CD32 mAbs (Fc-Block), an d incu bated for 20 m in at 4 ?C  w ith  \nanti-CD4, anti-CD 8, monoclonal an tib odies or th eir resp ectiv e iso - \nty pe con tro ls. After  a w ash  step  w ith  PBS 0.15 M, 0.5% BSA, 2 mM \nNaN3   cells   were incub ated for  20 min  wi th  s trep tavid in-Percp  \n(1: 20 0) at 4 ?C . Th en cells  were wash ed , ? x ed usin g 2% fo rmalde- \nh yd e solu tion , p erm eab ilized and  further stain ed  w ith PE -\nlabeled  anti-IFN-g, anti-TN F-a, anti-IL-4 or anti-IL-10 mon oclo nal \nan tibo d- ies  d iluted  in  PBS w ith 0.5% s ap onin  (Perm eabilization \nso lution ). After  30 mi n at roo m tem p eratu re, cells  w ere  w ash ed \nw ith  perm e- ab ilizatio n so lution  and  PBS, ressu sp en ded  in PBS an d \nth e data were acqu ired us ing FACSCalibur  (Becto n Dickinso n, San \nJose, CA). D ata an aly sis w as perfo rm ed  using  FlowJO softw are \n(Tree Star, Ashland, OR). \n\n \n2.9.  Cytokine  analy sis in spleen cells su pernatant \n\n \nMice  were im mu nized w ith  th ree d os es of Sm teg or  salin e in  \n\na 15  d ay-interv al regimen. Ten  d ay s aft er th e l as t im mu nizatio n, \n\n\n\n\u00a0\n\n\u00a0\n\n82\u00a0\n\n\u00a0\n\n \n\n \n\nS m te g 1 6 \u00b1 6 1 8 \u00b1 4  3 3 \u00b1 1 0 13.2% a ns\nS al ine + CFA/IFA 1 7 \u00b1 4 2 3 \u00b1 7  4 0 \u00b1 1 0 \u2013\n\ns pleens  w ere  ob tain ed   from  ind ivid ual\u2019s m ice  in   each   grou p. \nSp leen c ells  w ere w ash ed tw ice in  sterile sali ne an d  ad jus ted  t o \n1 \u00d7 1 06 cells/well. Cells w ere cultu red  at  37 ?C  in 5%  CO2 in m ed ium  \nalo ne or stimu lated  w ith Smteg  (25    g/mL) or concanavalin A (Con \nA) (5    g/mL).  Cu lture s upernatants w ere collected after 24 h stim - \nu lation  for  IL-4 an d TNF-    me asurem ent or  72 h  stim ulation  for \nIFN-   and  IL-10 measu rem en t. IL-4, IFN-g, IL-10 and  TNF-a  cy tok ine \nass ay  w as perfo rm ed  usin g the D o uset ELISA kit  (R&amp;D sy stem, \nM inneapolis, MN)  or  Ready set  GO (e-bioscience, Sa n  Diego,   CA),  \naccord ing to manu facturer\u2019s in stru ction s. \n\n \n2.10.    Cytokine  an alysis in BMDC \n\n \nBMDC  (95% MHC II+ , CD11c+  pure) were generated from the \n\nb on e m arro w  of C57BL-6 m ice us ing a method  adapted from L utz \net al.  (19 99) as previou sly describ ed  by D u r\u00e3es  et  al.  (2009). After \nB MDC differen tiatio n, no n-ad heren t DCs w ere collected an d seeded  \nat 3 \u00d7 105 cells/w ell in roun d-bottom  96 -w ell culture p lates. Cells \n\nTa ble  1 \n\nP rot ec t ive  im m une  res pon se  i ndu ce d  in m ic e  by  S mt e g im mu niz a t ion.    \n\nW orm burden recovered (mean \u00b1 SD) \n\nG roups c                               F e ma le           Ma le               Tot al              P ro te ct ion l ev el  \n \n\nTrial  1 \n\nS al ine                          29 \u00b1 7          25  \u00b1 5          54 \u00b1 2           \u2013 \nS mt eg                          2 3 \u00b1 8          21  \u00b1 8          44 \u00b1 1 5          18.5 %a  ns \nTrial  2 \n\nS al ine                          28  \u00b1 9          35  \u00b1 11        63 \u00b1 2 0         \u2013  \nS mt eg                          2 0 \u00b1 9          3 9 \u00b1 15        62 \u00b1 22         2.3%a  ns \nTri al 3  \n\nS al ine                          18 \u00b1 7          2 0 \u00b1 7          38 \u00b1 14         \u2013 \n\n \n    S mt eg  + CFA/IFA              9 \u00b1 7             13  \u00b1 9              22 \u00b1 1 6            45%b  , *   \n\n*  S igni? c a nt red uc tio n in t ota l  w orm  burde n c om pa red  t o sa l ine  + CFA/IFA g roup  \n\np &lt;0.05 . \na   Re d uc ti on i n to ta l w orm  bu rde n co mp a re d to sa li ne  g roup . \nb   R ed uc ti on i n to ta l w orm  bu rde n co m pa re d  to sa li ne  + CFA/I FA group . \nc\n\n \n\nw ere cu ltured in th e p res ence of m ed ia alon e, SmTeg  (25    g/mL) \nor  LPS (1   g/mL  InvivoGen). In o rder to  con tro l for  low  lev els of \nn aturally  occurrin g end oto xin in Smteg  (0.445 endo toxin u nits/   g  \np rotein), LP S at th e eq uiv alent con centration  of end oto xin  con tam- \nin ation (0.09 ng /5   g p ro tein) was  us ed to  s tim ulate DCs, bu t no  \nactivatio n or cyto kin e p ro du ctio n w as  ob served (data no t sho w n). \n\nIL-10 p ro du ctio n w as measured in BMDC s up ern atant co llected \n24 h after stimu lation us ing the Do uset ELISA  kit (R&amp;D system, M in - \nn eap olis, MN) acco rdin g to m anufactu rer\u2019s instru ctio ns . \n\n \n2.11.    Statistical analysis \n\n \nStatis tical analys es w ere p erfo rm ed w ith  paired an d u np aired  \n\nS tud ent\u2019s t-t es t or  ANOVA follow ed by  the T uk ey  p os t tes t us ing  \nth e softw are package Grap hPad  Prism 4. 0 (G raphPad So ftware, San \nDiego,   CA, USA). \n\n \n3.  Resu lts \n\n \n3.1.  Smteg immun ization  in the absence of adju vant failed to \nreduce w orm burden , n umber of eggs trapp ed  in host  organs and  \nfecundity \n\n \nSince   Smteg preparati on had b een  d emon strated  to  activ ate \n\nin n at e im mu ne res po nse and  also  to  co ntain  pro tectiv e ant igens  \nfrom th e p arasite (D ur\u00e3es  et al., 2 009; T eixeira de Melo et al.,  201 0), \nwe  ev aluated th e ab ility of  Smteg immu nization in  the absen ce \nof  ad juv an ts to  in duce protection  against  ch all en ge S. man so ni \nin fectio n. As sh ow n  in Table  1,  Smteg immu nizatio n did  n ot  alter \ns ign i? cantly  the w orm b urden  in  im mu nized m ice and a lso  had  \nno  effect in th e n u mb er of e ggs  trap ped  in th e l iver and  int estin e \nor on fem ale fecun dity (Fig. 1),  as previous ly reported (T eix eira d e \nM elo et al., 2 010) mice immun ization w ith Smteg +CFA/IFA in du ced  \np artial protection  ag ain st ch alleng e infectio n (T ab le 1). \n\n \n3.2.  Humoral immune response induced  by Smteg immunization  \n\n \nThe  k inetics  of  speci? c IgG  p rodu ction  alon g the im mu niza- \n\nti on  p ro toco l w as  d et erm ined in  mice sera by  ELISA. In creas ed  \np rodu ction  of speci? c IgG antib odies was o bserved in  sera from  \nm ice immun ized w ith Sm teg  and Smteg + CFA/IFA in  com parison  \nto  th eir respectiv ely  co ntrol grou p at  days  45,  60  an d 75  p os t \n? rs t im mu nization  to  Sm teg g roup  and  at all  time po ints eval- \nu ated  for  Sm teg + CFA/IFA group   (Table 2).  Regarding  IgG1  and  \nIgG2a p ro du ctio n, sig ni? cant prod uction  of speci? c IgG1 an d Ig G2c \nw ere detected  in  Smteg + CFA/IFA im mun ized  gro up in  co mp ari- \nson  to Salin e + CFA/IFA g ro u p at all time p oin ts ev alu ated for IgG1 \nan d at days  3 0,45 ,60  and  75  po st ? rst im mu nization  (Table 2).  In \n\n10 a ni ma l s pe r gro up/ tria l . \n\n \n \ncon tras t, in Smteg im mu nized  g ro up sig ni? can t p ro duction  of sp e- \nci? c  IgG1  an tibo dy  w ere d etect ed  at d ay s 30 ,4 5,6 0 an d 75  po st \n? rst im mu nization  co mp ared  to  saline g roup , wh ile sign i? cant \np ro du ct io n of  IgG2c  was detected   only  pos t-infectio n (T ab le 2 ). \nSign i? cant differences in IgG,  IgG1 an d IgG2c betw een  Sm teg  an d \nSmteg + CFA/IFA gro up s w ere ob served  at alm ost  all  tim e po int \nevaluated  (T ab le 2).  A n tibod ies titl es evaluated in  a poo l of sera \nfrom each gro up at day  45  p ost  ? rs t im mu nizatio n dem o ns trat ed \nthat Smteg + CFA/IFA immu nization indu ced  high er produ ction o f \nsp eci? c IgG  (1:102 .4 00), IgG1  (1 :102 .400 ) and  IgG2c  (1 :2 5.600 ) \nthan Smteg immun ization, in w hich Smteg speci? c an tib odies titles \n\n \n \n\n \n \nFig.  1 .  Egg burden in the liver and intestine of i mm uniz e d mic e . Mi c e were immu- \n\nnized with three doses of  a  va c c i ne  fo rmu la ti on co nt ai ni ng Sm te g  (2 5   g /m ic e ) or \ns a lin e , 3 0 da ys  a ft er t he  la st  im m un iz a ti on m i c e w e re  c h a lle n ge  w it h 1 00 c e rc a ria e  \n\nof S. ma nson i, 50 da ys a fte r cha ll e nge infe c tion, mic e we re  s ac ri? c e d a nd t he  li ve r and \n\ni nte s ti ne  w e re  ob ta in e d, w e igh te d a n d di ge st ed  i n KOH10%. The  nu mbe r of e ggs  w as  \ndetermined b y  op tic a l  m i cro sc op y. B a rs re pre se nt  t he  me a n nu mbe r of e ggs /gra m  \n\nof orga n \u00b1 SD ( A)  or e ggs/ gra m  of orga n /fe m al e  w orm \u00b1 SD (B)  for   m ic e  im m uni z e d \nw i th S mt e g or sa li ne . R e su lts  represent mean from two independent experiments. \n\n\n\n\u00a0\n\n\u00a0\n\n83\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n \n\nFig .  2.  Int ra c e ll ula r s ta ini ng in lym ph oc yte  sub pop ula ti ons . Mic e  w e re  im m uni ze d w ith  thre e  do se s of a  va c c ine  form ula t ion c on ta ini ng S mt e g (25   g /m ic e ) or sa l ine . Te n \n\nda ys  a fte r t he  la st  i m mu niz a ti on,  m ic e  w e re  sa c ri? c e d a nd sp le e n ce l ls w e re  ob ta ine d  fro m e a c h in div idu al  m ous e . CD4 +   and CD8+   production of IF N-g, IL-4,  TNF -a, IL-10 \nin re s pons e to S mte g  (2 5   g/m L) in vit ro sti m ula ti on w ere  de te rm in ed . A \u2013 R e pre se nt a tiv e D ot -bl ots o f c yt oki ne  pro duc in g CD4+  c e lls i n c on trol a nd S mt e g group s under \n\nS mte g  sti mu la ti on. B \u2013  B a rs re pre s en t the  m e a n \u00b1 SD of  the percentage of   CD4 +   or CD8+   c ytok ine +  c e lls  in non  s tim ul a te d (w hit e ba rs) a nd  S m te g s tim u la te d ce l ls (bl a ck  \nba rs). S ta ti st ic a ll y si gn i? c an t di ffere nc e s  i n t he  pe rc en ta ge  of do uble  pos iti ve  c e ll s be tw e e n sa li ne  a nd S mt e g im m uni ze d gro up a re  poi nte d i n t he  ?gure and between non \nst im ul at e d a n d s tim u la te d c e ll s a re  de no te d by  a st e risk  ( * p  &lt;0.05 ; ** p &lt;0 .01). D a t a re pres e nt the  m ea n va lu es  of t w o ind e pe nd e nt e xp e rim e nts  w ith  4 a n im a ls /gro up e a c h. \n\n \n \n\nwere 1 :25 ,600  (IgG), 1:2 5.600  (IgG1)  and  1 :64 00  (IgG2c)  (d ata n ot \nsho wn ). \n\n \n3.3.  Cytokine  pro? le  induced by immu nization \n\n \nCyto kine p ro duction u nder in vitro  stim ulation  with Sm teg was \n\nmeasu red by  intracellu lar st ain ing . Fig.  2 dem o nst rates  a signi? - \ncan t increas e in the freq uen cy  of CD4+ IFN-g+  cells  and  CD4+ IL-10+ \n\ncells in immu nized  group  after Sm teg  s timulation  in co mp ariso n to  \nno n sti mul at ed  cells.  Also a sign i? can t increase in t he p ercentag e \n\nof CD4+ IFN-g+  cells after Smteg in vitro s timulatio n was o bserved  in  \nimmu nized group  in co mpariso n to co ntrol g ro up  (Fig. 2).  No sig- \nni? can t differen ces were ob served  b etw een no n-im mu nized  an d \n\nim mun ized  grou ps con cernin g IL-4 and  TNF-a  prod uctio n by CD4+ \n\nan d CD8+   cells   an d IFN-g  and  TNF-a  prod uctio n by  CD8+   cells \n(Fig. 2). In ad dition , sig ni? cant prod uction  of TNF-a, IFN-g and  IL- \n10  was d etected in resp on se to  Sm teg  stimu lation  in spleen cells \nsu p ern atan t reg ard less of prev iou s in vivo priming  (Fig.  3).  H ow- \never sign i? can t differen ces in  IL-10  p ro du ction w as detected  in \nsp leen cells  sup ernatant from  mice im mu nized w ith Smteg al one \nin comp ariso n to con trol group and Sm teg + CFA/IFA group  and  sig - \nn i? cant d ifferences in  IFN-g prod uction  in  co mp arison  to  co ntrol \ng ro up  w ere detected in Smteg an d Smteg + CFA/IFA grou ps (Fig. 3 ). \nAs previou sly d em on strated  (Teixeira de  Melo  et a l.,  20 10 ), mice \nimmu nization   with Smteg + CFA/IFA lead s to  s ign i? can t p ro du c- \ntio n  IFN-g and  IL-4 in resp on se to Smteg stimulation  (Fig. 3), Smteg  \n\n\n\n\u00a0\n\n\u00a0\n\n84\u00a0\n\n\u00a0\n\n \n\n \n \n\nFig.  3.  Type of im m une  re s pon se  e l ic it e d by Sm te g im m uniz a tio n. M ic e  w e re im m uniz e d w i th th re e  do se s of a  va cc i ne  form ul at io n c ont a ini ng S m te g (25   g/m i ce ) or sa li ne  \n\nin the absence or presence o f F re und a dj uva nt . Te n d ay s a ft e r the  la st i mm uni za t ion , mic e  w e re sa c ri? c ed a nd  spl ee n c el ls w e re  obta i ne d from  e a ch  indi vid ua l m ouse . TN F-a , \nIFN -g, I L-4  a nd IL-10 p ro duc tio n in re spons e t o Sm te g (25   g/ mL) in  vitro stimulation were measured in the culture supernatant of  sple e n c e lls  by  sa nd w ic h ELI SA. B ars \n\nrepresent the mean \u00b1 SD of c yto kine  p roduc t ion  from  7 a n im a ls/ group . S ta t ist ic a lly  si gni ? ca n t di ffe re nc e  be tw e e n n on-st im ul at e d an d S m te g-s tim ul at e d c e lls  are denoted \nb y  an asterisk (p  &lt;0. 05). S ta t ist ic a ll y si gni? c a nt  d iffere n ce  b e tw e e n grou ps a re  poi nte d  in  t he  g rap hic  (p &lt;0. 05). Re s ult s a re  re pres en ta ti ve   of  one o f  three independent \ne x pe rim e nt s. \n\n \nim mu nizatio n in th e ab sence of adju van ts w as  also  ab le to ind uce \ns ign i? can t am ou nt of IFN-g (Fig. 3 ). \n\n \n3.4.  IL-10 p rodu ction by BMDC \n\n \nWe   h av e p rev io usly  d emo nst rated  that  BM DCs  s tim ulated  \n\nin  vitro  w ith Smteg w ere able to  up  regu late surface ex pres sion  \nof CD40 an d CD86 and  also to prod uce TNF-a and  IL-12 th rou gh  the \nin teractio n of ex isting  PAM Ps  in  Smteg w ith TLR4 (D ur\u00e3es et al., \n2 009 ). H ow ev er IL-10 p ro du ction  by BMDCs in res po nse to Smteg  \ns timu lation w as no t inv estigated . To ev alu ate if Smteg  sti mu lation  \na lso  in duced  IL-10 prod uction  by BM DC, we  m easu red  IL-10 in the \ns u pernat ant of BMDC cultu re. Fig. 4 dem ons trat es  t hat Smt eg  and  \nLPS indu ce sig ni? cant p ro du ctio n of IL-10 by BMDC in com parison  \nto non  stimulated cells . \n\n \n4.  D iscus sion  \n\n \nS. manson i is an impo rtant blo od ? uk e p arasite that cau ses schis- \n\nto somiasis, a sign i? can t pu blic h ealth  prob lem in tro pical co un tries  \nw h ich  is  recog nized  as  the m ost  im po rt ant hu m an helm in thes  \nin fection  in  term s of morbid ity  and mortality  (D onald and  A lex , \n2 00 8). A ltho ugh  the exis tin g antischis to som al drugs  are   highly  \neffective, they do  no t p rev ent again st reinfection  or  g ran ulom a \nformatio n. In add ition  mass ch emot herap y has  been p rov ed  to b e \nin effective in con trolling tran smission (Rezende et al. , 2011 ). T here- \nfore,  vaccin e d ev elopm en t is an alternativ e strategy  to co n tro l this  \nd isease (Rezende et al.,  2 011; Teixeira de Melo et al., 201 0). Recen tly  \nour  grou p has  sho w ed  th at S. mansoni schi sto som u la teg um en t \n(Smteg ) is ab le to ind uce d en dritic cells  up regu lation  of CD40 and  \nC D86,  and  also  IL -1 2p4 0 and TNF-a  produ ctio n. T hese cy tok in es \np lay  an  essent ial role in  the d ev elop men t of p ro tective imm un e \nrespo nse against sch istoso mes (D ur\u00e3es et al. , 200 9; H ew itson et al., \n2 00 5; Hogg et al.,  2003 ). Add ition ally, Smteg immu ni zatio n in as so- \nciation  w ith Freun d\u2019s  ad juvan t ind uced a sig ni? cant reductio n in  \nw o rm b urden  (43\u201348%) demon strating that Sm teg  has in its con sti- \ntu tion  p ro tective antig en s as well as im mu no stimul ato ry  mo lecu les \n(Teixeira de Melo  et al., 201 0). \n\nH erein  we  im mu nized mice w ith  sch isto som ula t eg um ent in  \nt he ab sen ce of ad ju vant. Surprising ly  no  sig ni? cant red uction  in  \nth e w orm bu rden (Table 1),  n eith er in th e nu m ber of eggs  trapp ed  \nin  the liv er and  i ntestin e no r in  female fecun dity (Fig.  1)  w as \n\no bserved in  imm unized mice co mp ared to  con trol group . A dju - \nv ants n ot o nly  pro mo te imm un e resp on ses bu t also  are  molecules \nth at release th e an tigen slo wly  in the org an ism an d in th at w ay can \nincrease th e half-life of the an tigen  an d imp rov e u pt ak e by profes - \nsio nal p hagocytes (Am y et al. , 2010 ; Mo sca et al. , 200 8;). Altho ugh \nSm teg s timu lates the pro du ction of  molecules in volved  in  anti- \ngen  present at ion  an d  Th1 p olarization , its rapid  clearance fro m the \nsi te of injection  co uld  exp lain  w eak immu ne respo nse activ atio n \nan d the abs ence of protectiv e respo nse. N everth eless , w hile m ea- \nsu rin g speci? c antib ody  pro du ctio n, an  in creas ed  lev el of speci? c \nIgG prod uction  against Sm teg  was ob serv ed in im mu nized grou p \nfrom the b egin nin g of th e imm unization  proto col (T able 2).  This \nresu lt dem on strates  that Sm teg im mu nizatio n activ ates im mu ne \nresp ons e in  m ice, and  su gg ests t hat  th e abs ence of  protectio n \ncou ld be  expl ain ed by  th e im mun e res po nse pro? le ind uced b y \nim m un izatio n rath er than  by  th e ab sence of  im mu ne res po nse \nactiv ation . Reg arding  i mm une respo ns e p ro ? le, w h ile im mun iza- \ntion w ith Smteg + CFA/IFA in du ces a sig ni? can t p ro du ctio n of IgG2c, \nm ice imm unization w ith Smteg failed  to indu ce prod uction  of th is \nisoty pe  (Table 2),   also   h igh er titles of  sp eci? c an tibo d ies  w ere \nd etected  in  sera from mice immun ized  w ith Smteg + CFA/IFA in \ncom parison  to  th e titles  d etected  in  sera from  m ice im mu nized \nw ith Sm teg  in t he abs ence of adju vants. \n \n \n\n \n \nFig.  4.  S m te g sti m ula te s  IL-10 production by BMDC. IL-10 le ve l s w e re  m e a sure d b y \n\nELI SA in culture supernatants of  BMDC  a fte r 24h -s ti mu la ti on. C yto kin e measure- \n\nment of  IL-10  w a s pe rfo rm e d us ing the  D uo se t ELI SA ki t. S ta ti st ic a lly  si gni ? ca n t \nd iffere n ce s  be t w e e n S mt e g o r LPS stimulated cells and non stimulated cells are \n\ndenoted by  a st e risk s (p &lt;0.0 01). D a ta  re pre se nt s m e an  va lu es  \u00b1 SD of  three inde- \np en de nt  ex pe rim e nt s w it h 3 mi c e /gro up e a c h. \n\n\n\n\u00a0\n\n\u00a0\n\n85\u00a0\n\n\u00a0\n\n \n\n \n\nT\na\n\nb\nle\n\n 2\n \n\nH\nu\n\nm\no\n\nra\nl \n\nim\nm\n\nu\nn\n\ne\n r\n\ne\ns\n\np\no\n\nn\nse\n\n i\nn\n\nd\nu\n\nc\ne\n\nd\n b\n\ny \n S\n\nm\nte\n\ng\n i\n\nm\nm\n\nu\nn\n\niz\na\n\nti\no\n\nn\n. \n\nS\na\n\nli\nn\n\ne\n \n\nS\na\n\nli\nn\n\ne \n+ \n\nC\nF\n\nA\n/I\n\nF\nA\n\n \nS\n\nm\nte\n\ng\n \n\nS\nm\n\nte\ng\n\n +\n C\n\nF\nA\n\n/I\nF\n\nA\n \n\nIg\nG\n\nd\n \n\n0\n.0\n\n7\n \u00b1\n\n 0\n.0\n\n1\n \n\n0\n.1\n\n2\n \u00b1\n\n 0\n.0\n\n8\n \n\n0\n.1\n\n7\n \u00b1\n\n 0\n.1\n\n2\n \n\n0\n.0\n\n6\n \u00b1\n\n 0\n.0\n\n6\n \n\n0\n.0\n\n5\n \u00b1\n\n 0\n.0\n\n1\n \n\n0\n,5\n\n0\n \u00b1\n\n 0\n.0\n\n5\n \n\nIg\nG\n\n1\nd\n\n \n\n0\n.0\n\n1\n \u00b1\n\n 0\n.0\n\n0\n \n\n0\n.0\n\n0 \n\u00b1 \n\n0\n.0\n\n0  \n0\n\n.0\n1\n\n \u00b1\n 0\n\n.0\n1\n\n \n0\n\n.0\n0\n\n \u00b1\n 0\n\n.0\n0\n\n \n0\n\n.0\n0 \n\n\u00b1 \n0\n\n.0\n0  \n\n0\n,0\n\n5\n \u00b1\n\n 0\n.0\n\n1\n \n\nIg\nG\n\n2\nc\n\nd\n \n\n0\n.0\n\n2\n \u00b1\n\n 0\n.0\n\n1\n \n\n0\n.0\n\n7 \n\u00b1 \n\n0\n.0\n\n7  \n0\n\n.0\n9\n\n \u00b1\n 0\n\n.0\n8\n\n \n0\n\n.0\n2\n\n \u00b1\n 0\n\n.0\n4\n\n \n0\n\n.0\n1 \n\n\u00b1 \n0\n\n.0\n1  \n\n0\n.2\n\n4\n \u00b1\n\n 0\n.1\n\n2\n \n\nIg\nG\n\nd\n \n\n0\n.1\n\n1\n \u00b1\n\n 0\n.0\n\n8\n \n\n0\n.1\n\n3 \n\u00b1\n\n 0\n.1\n\n1  \n0\n\n.0\n8\n\n \u00b1\n 0\n\n.0\n3\n\n \n0\n\n.0\n8\n\n \u00b1\n 0\n\n.0\n6\n\n \n0\n\n.1\n4 \n\n\u00b1\n 0\n\n.0\n3  \n\n0\n,3\n\n0\n \u00b1\n\n 0\n.0\n\n9\n \n\nIg\nG\n\n1\nd\n\n \n\n0\n.0\n\n0\n \u00b1\n\n 0\n.0\n\n0\n \n\n0\n.0\n\n0 \n\u00b1 \n\n0\n.0\n\n0  \n0\n\n.0\n0\n\n \u00b1\n 0\n\n.0\n0\n\n \n0\n\n.0\n0\n\n \u00b1\n 0\n\n.0\n0\n\n \n0\n\n.0\n0 \n\n\u00b1 \n0\n\n.0\n0  \n\n0\n,0\n\n3\n \u00b1\n\n 0\n.0\n\n1\n \n\nIg\nG\n\n2\nc\n\nd\n \n\n0\n.0\n\n3\n \u00b1\n\n 0\n.0\n\n2\n \n\n0\n.0\n\n2 \n\u00b1\n\n 0\n.0\n\n3  \n0\n\n.0\n4\n\n \u00b1\n 0\n\n.0\n5\n\n \n0\n\n.0\n3\n\n \u00b1\n 0\n\n.0\n2\n\n \n0\n\n.1\n0 \n\n\u00b1\n 0\n\n.0\n4  \n\n0\n.2\n\n4\n \u00b1\n\n 0\n.1\n\n0\n \n\nIg\nG\n\nd\n \n\n0\n.1\n\n7\n \u00b1\n\n 0\n.0\n\n5\n \n\n0\n.3\n\n2 \n\u00b1 \n\n0\n.0\n\n8  \n0\n\n.4\n8\n\n \u00b1\n 0\n\n.1\n6\n\n*\n \n\n0\n.4\n\n1\n \u00b1\n\n 0\n.1\n\n2\n*\n\n \n\n0\n.4\n\n5 \n\u00b1 \n\n0\n.1\n\n1*\n \n\n0\n,5\n\n3\n \u00b1\n\n 0\n.6\n\n5\n \n\nIg\nG\n\nd\n \n\n0\n.0\n\n0\n \u00b1\n\n 0\n.0\n\n0\n \n\n0\n.0\n\n2\n \u00b1\n\n 0\n.0\n\n1\n \n\n0\n.0\n\n6\n \u00b1\n\n 0\n.0\n\n3\n \n\n0\n.0\n\n4\n \u00b1\n\n 0\n.0\n\n2\n \n\n0\n.0\n\n6\n \u00b1\n\n 0\n.0\n\n2\n \n\n0\n,0\n\n7\n \u00b1\n\n 0\n.0\n\n2\n \n\nIg\nG\n\n2\nc\n\nd\n \n\n0\n.0\n\n6\n \u00b1\n\n 0\n.0\n\n3\n \n\n0\n.0\n\n9 \n\u00b1 \n\n0\n.0\n\n3  \n0\n\n.0\n9\n\n \u00b1\n 0\n\n.0\n6\n\n \n0\n\n.0\n8\n\n \u00b1\n 0\n\n.0\n4\n\n \n0\n\n.0\n7 \n\n\u00b1 \n0\n\n.0\n3*\n\n \n\n0\n.1\n\n8\n \u00b1\n\n 0\n.1\n\n3\n \n\nIg\nG\n\nc  \n\n0\n.3\n\n6 \n\u00b1 \n\n0\n.2\n\n0\n*\n\n \n\n0\n.8\n\n0 \n\u00b1 \n\n0\n.2\n\n3*\n , \n\nc  \n\n0\n.8\n\n2 \n\u00b1 \n\n0\n.2\n\n1\n* \n\n, c\n \n\n0\n.7\n\n9\n \u00b1\n\n 0\n.2\n\n2\n* \n\n, c\n \n\n0\n.8\n\n4 \n\u00b1 \n\n0\n.3\n\n9*\n , \n\nc  \n\n0\n,7\n\n4\n \u00b1\n\n 0\n.2\n\n0\n* \n\n, c\n \n\nIg\nG\n\nc  \n\n0\n.0\n\n2 \n\u00b1 \n\n0\n.0\n\n1\n*\n\n \n\n0\n.0\n\n8 \n\u00b1 \n\n0\n.0\n\n4*\n , \n\nc  \n\n0\n.1\n\n1 \n\u00b1 \n\n0\n.0\n\n7\n*\n\n \n\n0\n.1\n\n1\n \u00b1\n\n 0\n.0\n\n5\n* \n\n, c\n \n\n0\n.1\n\n3 \n\u00b1 \n\n0\n.0\n\n8*\n \n\n0\n,1\n\n1\n \u00b1\n\n 0\n.0\n\n4\n*\n\n \n\nIg\nG\n\n2\nc\n\nc  \n\n0\n.0\n\n8\n \u00b1\n\n 0\n.0\n\n6\n \n\n0\n.1\n\n5\n \u00b1\n\n 0\n.1\n\n0\n*  \n\n0\n.2\n\n1\n \u00b1\n\n 0\n.1\n\n0\n* ,\n\n c\n \n\n0\n.1\n\n3\n \u00b1\n\n 0\n.0\n\n3\n* ,\n\n c\n \n\n0\n.2\n\n7\n \u00b1\n\n 0\n.1\n\n2\n* ,\n\n c\n \n\n0\n.2\n\n2\n \u00b1\n\n 0\n.0\n\n8\n*  \n\n1\n5\n\na\n \n\n3\n0a\n\n \n\n4\n5\n\na\n \n\n6\n0\n\na\n \n\n7\n5\n\na\n , \n\nb\n \n\n1\n0\n\n5\na\n\n \n\n* \n S\n\nta\nti\n\ns\nti\n\nc\na\n\nll\ny\n\n s\nig\n\nn\ni?\n\nc\nan\n\nt \nd\n\nif\nfe\n\nre\nn\n\nc\ne\n\ns \nc\n\no\nm\n\np\na\n\nre\nd\n\n t\no\n\n r\ne\n\ns\np\n\ne\nct\n\niv\ne\n\n c\no\n\nn\ntr\n\no\nl \n\ng\nro\n\nu\np\n\n, \np\n\n&lt;\n 0\n\n.0\n5\n\n. \na\n\n   \nD\n\na\ny\n\ns \na\n\nft\ner\n\n ?\nrs\n\nt \nim\n\nm\nu\n\nn\niz\n\na\nti\n\no\nn\n\n. \nb\n\n  \n 1\n\n5\n d\n\na\ny\n\ns \na\n\nft\ne\n\nr \nc\n\nh\na\n\nll\ne\n\nn\ng\n\ne\n i\n\nn\nfe\n\nc\nti\n\no\nn\n\n. \nc \n\n  \nS\n\nta\nti\n\ns\nti\n\nc\na\n\nll\ny\n\n s\nig\n\nn\ni?\n\nca\nn\n\nt \nd\n\nif\nfe\n\nre\nn\n\nc\nes\n\n c\no\n\nm\np\n\na\nre\n\nd\n t\n\no\n S\n\nm\nte\n\ng\n g\n\nro\nu\n\np\n, \n\np \n<\n\n 0\n.0\n\n5\n. \n\nd \n  \nR\n\ne\nsu\n\nlt\ns\n\n a\nre\n\n e\nx\n\np\nre\n\nss\ne\n\nd\n a\n\ns \nm\n\ne\na\n\nn\n +\n\n S\nD\n\n a\nb\n\nso\nrb\n\na\nn\n\nc\ne \n\nin\n O\n\nD\n4\n\n5\n0\n\n n\nm\n\n. \n\n \nIFN-g   is   a   pro-in? ammatory cytokine that  augments the \n\nimm un e respo ns e to  in fection  by prom otin g leuko cyte activ ation  \nan d, its  ro le in  protectiv e im mu nity  again st sch isto som iasis has  \nalready  b een  demo ns trated  (Fons eca et al., 20 04; Ho ffmann et al., \n2000; Jank ovic et al.,  19 99 ; Yu et al., 2 011). A sign i? can t increase in  \n\nthe frequ en cy of CD4+ IFN-g+  cells w as ob serv ed in stimu lated  cells \nfrom  imm unized grou p in com parison  to con tro l grou p an d to n o n- \nstim ulated  cells  (Fig. 2).  Also a sig ni? cant p rodu ctio n of IFN-g w as  \ndetected  in  resp on se to  Smteg, in vitro,   stimu lation  in  th e su per- \nnatant of spleen c ells  from  im mun ized  and  no n-imm un ized  mice \n(Fig. 3).  T hese res ults  in dicate that alth ou gh  Smt eg  im mun ization  \nlead s to IFN- g prod uction  by CD4+ cells,  Smteg also stim ulate oth er \ncells  to prod uce IFN-g th rou gh  an u nsp eci? c m anner. One p oss ible \nsou rce of IFN-g  prod uction  in  no n-im mu nized  mice cou ld be  NK \nand  NKT cells  sin ce th ese cells  are  the m ajo r prod u cers of IFN-g \nduring innate immun e respo nse (M allevaey et al. , 200 6). Ho wever \nthe sou rces of this cytok ine in non -im mu nized m ice still n eed to b e \nelu cid ated . A lthou gh s igni? cant p ro duction  of IFN-g w as  d etected  \nin  spleen cell  su pernatant  from  m ice im mun ized  w ith Smteg as  \nwell as from  m ice immunized with  Smteg + CFA/IFA in com parison  \nto  con tro l g ro up, in  Sm teg  im mu nized mice sign i? cant prod uc- \ntion  of IL-10 in comp ariso n to control and Sm teg + CFA/IFA grou ps \nwas ob served  (Fig. 3). Also an  in creased frequen cy  of CD4+ IL-10+ \ncells  in Smteg im mun ized  grou p (Fig. 2) w as obs erved after Smteg  \nin vitro  stimu lation . No sign i? cant differen ce in CD4 + IL-10+ cells  \nwas o bserved betw een  no n-vaccin ated  an d v accinated mice u nd er \nSmteg-stimu lated , while a sign i? can tly high er co ncentratio n of IL- \n10 was detected in spleen cells s up ernatan t from Smteg  i mmu ni zed  \nmice com pared to control and  Smteg + CFA/IFA g ro ups  (Fig. 3), prob - \nably  b ecau se alth ou gh  th e p ercen tage of CD4 + IL-10+ cells  do  n ot  \ndiffer betw een grou ps th ese cells  in  Smteg group  are  prod ucing  \nlarg er am ou nt of IL-10. \n\nM oreover, BMDC stim ulated  in vitro  with Sm teg sho w ed  sign if- \nican t prod uctio n of IL-10  in comp ariso n to  no n s timu lated BMDC \n(Fig. 4).  IL-10 d etection  in Smteg-stim ulated B MDC was sp eci? cally  \nprod uced , sin ce the am ou nt of en do tox ine detected in Smteg was  \nno t able to activate BMDC neith er to in du ce any  cyto kin e prod uc- \ntion  (data no t sho wn). IL-10  is a cyto kin e th at reg ul at es  imm un e \nresp on se by s ev eral d istinct mech an ism s (Fiorentin o et al., 19 91 ; \nFlo res-V illanueva et al.,  1996 ; M oore et al., 20 01; Sad ler et al.,  20 03 ; \nTeixeira-C arvalho et al., 20 08). DC secretin g IL-10  d riv es  n aiv e T \ncells in to  IL-10 s ecretin g Tr1 cells (Greg ori et al.,  2 010 ; Ig yarto et al., \n200 9; Wakk ach  et al., 2003). This regu lato ry statu s can be rev erted  \nby TLR9 s tim ulatio n w ith  CpG or TLR4 st imu latio n w ith  LPS lead - \ning  DCs  to  ind uce Th1  an d T h1/T h17  respectively (Z hou  et al., \n201 0). \n\nOur res ults s ho w ed  that Smteg  im mu nization  in the abs en ce of \nad juv an t ind uces a predom inant m od ulatory  respon se w ith h igh  IL- \n10 prod uctio n th at  may  h ave resul ted in an imp aired  in? am mato ry  \nan d effecto r resp ons e and in the lack of protection . Sm teg m olecu les  \nin volv ed in imm un e resp ons e m od ulatio n still need  to be identi? ed. \n\n \n\n \nAckn ow l edg men ts  \n\n \nThe au tho rs  than ks th e p ro gram  for techn olog ical D ev elopm en t \n\nin too ls for Health-PDTIS FIOCRUZ for use  of it facilities . This w o rk  \nwas  su pp orted by CNPq; INCT-DT/CNPq,  Ripag/CPqRR-Fiocruz. \n\nFellowships:  CPqRR/Fiocruz (TTM);  PIB IC/CNP q  (JMA);  Capes \n(FVD) P IB IC/CNPq (ICS); Fapem ig (CCA); PQ/CNPq (CTF). \n\n \n\n \nAppen dix  A.   Supplementary data \n\n \nSu pp lem entary d ata asso ciated w ith this article c an  be  fou nd, \n\nin  the  on line version , at h ttp://d x.do i.org/1 0.10 16 /j.actatrop ica. \n2012 .0 7.0 07. \n\n\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n86\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n\n \n\n \n\n \nR eferen ces \n\n \nA my, S.M.,  Mega n, K.L.M.,  John, W.K.,  Phil ipa , M.,  2010 . Imm une  m ec ha ni sm s  o f \n\npro te c ti on:  c a n a dj uva nt s ri se  to  the  c ha ll e nge ?  BMC B iology 8, 37. \nC al das, I.R., C orre a -Ol ive ira , R., Colo simo, E., Ca rval ho, O.S., M as sa ra , C.L., Colle y, D.G ., \n\nG az z ine lli , G., 200 0. S u sc e ptib il ity a nd re si ste nc e  to  Sc histo soma ma nsoni rei fec - \nti on:  pa ral le l c e llu la r a nd is oty pic  i mm un olo gic  a ss es sm e nt. A me ric a n Jo urna l \nof T ro pic al  Me di ci ne  an d H yg ie ne  6 2,  57\u201364 . \n\nD o nal d, P.M.,  Ale x, L., 200 8. C urren t S ta t us of v ac c ine s  for   sc histo somi asi s. Cl inic a l \nMic robi ology R evi ew s  21  (1) ,  2 25\u201324 2. \n\nD u r\u00e3 e s, F.V., Ca rva lho, N.B., Mel o, T.T., Ol ive ira, S.C., Fo nsec a , C.T ., 2009. IL-12 and \nTNF-    production by d en drit ic  c e ll s s tim ul at e d w it h S chi stosoma  m ansoni  s ch is- \ntosomula tegument is TLR4-  a nd M yD 88-de pe n de nt. Im m unol ogy  Le tte rs 12 5, \n72\u20137 7. \n\nF i oren tino , D.F.,  Zlot nik, A., M osm a nn, T.R.,  H ow ard,  M.,  O\u2019Ga rra , A., 1991. Il-10 \nin hib its  c yto kin e prod uc ti on by ac t iva te d ma c ropha ge s.  Journ al  of Im m unol ogy \n147,  3 815. \n\nF lore s-V ill anu eva , P.O.,  Zhe ng, X.X.,  S trom , T.B.,  S ta de ck er, M.J.,  1996. R ec om bi- \nna nt  IL-10 a nd IL-10/F c  tre a tm e nt do w re gul a te  e gg  a nti ge n-e s pe ci ? c  d el a ye d \nhyp e rs e nsi tiv ity  rea c ti ons  a nd e gg  gra nul om a  forma t ion  in sc h ist oso mi as is . The  \nJou rna l  of Imm un olo gy 156 , 3 315\u2013 332 0. \n\nF oley, M.,  K usse l, J.R., G arla nd, P.B., 198 8. C ha n ge s in th e  orga n iz a tio n of  the sur- \nfa ce  me m bra ne  u pon tra n sform at io n of c e rc a ria e  t o sc hi sto som u la  of helminth \nparasite S chi stosom a ma nsoni. Pa ra sit ology 9 6 (Pt  1), 8 5\u201397. \n\nF onse c a, C.T .,  Brito, C.F.,  A lves, J.B.,  O li vei ra , S.C.,  2004. IL-12 enhances protec- \nti ve  im m un ity  i n m ic e  e nge n de re d by  i mm un iz a tio n w it h re co mb ina nt  14 kD a  \nSc hi stos oma  ma nsoni  fa tty  a cid -bindi ng  p rot ei n  through   a n I FN-  (an d TN F -   \ndependent pathway. V a cc ine  22,  50 3\u201355 1. \n\nG re gori , S.,  Toma soni , D.,  Pa c ci ani , V.,  S c irpoli, M.,  Ba tt agl ia , M.,  Ma gnani,  C.F., \nH a ube n, E., Ronc a rol o, M.G.,  201 0. D iffe ren tia ti on of  t ype  1  T re gula to ry c e ll s \n(Tr1) by   tole rogen ic D C -1 0 re qui re s t he  IL-10 -d e pe nde n t ILT4/HLA -G pa th w a y. \nBlo od  1 16, 935 \u2013944 . \n\nH ew i ts on, J.P.,  H am bli n, P.A.,  M ount ford, A.P.,  2 005.  Im mu nit y in duc e d by   the \nradiation-attenuated schistosome va c c ine . Pa ra sit e Im m unol ogy 27,  271 \u2013280.  \n\nH o ffm an n, K.F., Che ev er, A.W.,  W ynn , T.A., 200 0. I L10  and the dangers o f immune \npo la riz a ti on : e xc e s siv e  ty pe  1  a nd  t ype  2 c yt ok ine  re sp ons e s  ind uc e  di s- \nti nc t form s of  le tha l  i mm uno pa tho logy  in m urin e s c hist oso mi as is.  J ourna l of \nImm uno log y 164 (1 2), 64 06\u20136 416.  \n\nH ogg, K.G.,  K umka te , S.,  A nde rson , S.,  M ount ford, A.P.,  200 3. Int e rle uk in-1 2p4 0 \nse c re ti on b y  c uta ne ousC D 11c + a nd F 4/80+  c el ls is a  m a jor fe a tu re of the innate \n\nim m un e re s pon se  in m ic e  th a t d e ve lo p T h1-m e dia t e d pro te c ti ve  im m uni ty to \nSc hist osoma  ma nsoni . Infec tion an d Im mu ni ty 71,  3 563\u2013 3571.  \n\nIgya rto, B.Z., Jeni son, M.C., D udda , J.C., R oers, A., M ulle r, W., K oni, P.A., Ca mpbell, D.J., \nSh lom chi k, M.J., K a pla n, D.H., 2009 . La nge rha ns c el ls suppre ss c on ta ct  hypersen- \nsi tiv ity  re spo nse s via c o gna te  CD4 i nte ra c tion  a nd  la nge rha ns c el l-de rive d IL-\n10. Journa l of Im m unol ogy  183, 50 85\u20135 093.  \n\nJ ankovi c, D., W ynn , T.A., K ull berg, M.C., H ie ny, S., Ca spa r, P., J am es, S., Che eve r, A .W., \nShe r, A., 1 999. O pt im al  va c ci na tion  aga in st S c hist osom a ma nsoni  requires the \nin duc t ion  of both B c e ll  a nd IFN-     de p en de nt effe c tor me c ha ni sms . Jo urna l of \nImm uno log y 162,  34 5\u20133 51. \n\nJ am es, S.L., 1981. In  v itro  p roli fe ra ti ve  re sp ons e t o li vi ng sc hi sto som u la  by  T ly m- \nphoc yte s fro m mi ce  in fe c te d wi th Sc hi stoso ma  ma nsoni . P ara sit ology 83(Pt 1 ), \n147 \u2013162 . \n\nJ ones,   M.K.,   Gobe rt,  G.N.,   Zhang ,  L.,  S und erl an d,  P.,   M cM ana us,  D.P.,   2004 . \nThe  c y tos ke le t on  a nd  m oto r  pro te in s  of   human  schistosomes and  their \nrole s i n su rfa c e  ma in te na nc e   a nd hos t\u2013p ara s ite   inte ra c ti ons.   B io es sa ys  26,  \n752 \u2013765 . \n\nLutz , M.B.,  Ku kutsc h, N., O gilvie , A.L., Rossn er, S., Koch, F., R oma ni, N., S chuler,  G ., \n1999 . An a dv a nc e d c ul ture  m et ho d for  ge n era t in g la rg e  qua n ti tie s  o f h ighl y pure \nde nd ri ti c c el ls fro m m ous e b one  m arro w . Jo urna l of  Imm uno log ic a l M et hod s \n223,  7 7\u201392.  \n\nM al le vae y, T.,  Za net ta , J.P.,  F a vee uw , C.,  F onta in e,  J., Mae s, E.,  Pl at t, F.,  Ca pron, \nM.,   de -M orae s,   M.L.,   Trot te in,   F.,  2006.  A c ti vat io n  of   in va ria nt   NKT   c ell s \nby  the helminth parasite S chi stoso ma  ma nsoni . Jou rna l o f  Im m unolo gy 176,  \n247 6\u201324 85. \n\nM oore, K.W., de Wa ll  M al efyt , R., Coffma n, R.L ., O\u2019Ga rra , A., 2 001 . Int e rle uki n-10 and \nthe  int erl e ukin -10 re c e ptor. A nn ua l R e vi ew  of Imm un olo gy 19,  6 83. \n\nMos ca , F., Trit to, E., Muz z i, A., Mona c i, E., Ba gnolli, F., Lava rore , C., O \u2019H ag an, D., Ra p- \npuol i, A., De  Grego ri o, E., 2 008. Mol e cu la r a nd  c e ll ula r s igna t ure s o f  human \nva c ci ne  ad juv an ts.  P roc e ed ing s of   the   N a ti ona l  A c a de m y o f   S ci en ce s 105 , \n1050 1\u20131 0506.  \n\nP el le grino, J., Siqu ei ra , A.F., 19 56. T\u00e9 c ni ca  d e pe rfu s\u00e3 o pa ra c olh ei ta  de  S ch ist osom a  \nma nso ni em  c oba ia s e x pe rim e nta l me n te  in fe sta da s.  R ev ista  Bra sile ira  De Ma la r- \niol ogia  e D oe nc as  Tro pic a is 8, 58 9\u201359 7. \n\nR a ma lho -P int o, F.J., G az z ine lli , G., Ho we ll s, R.E., M ota -S a ntos,  T.A., Fi gue iredo, E.A ., \nPe le grino , J., 1974 . Sc hist osoma  ma nso ni: de ? ned syste m f or  stepwise transfor- \nmation of c e rc a ri a e  to s ch is tos som u le  in vit ro. Expe rime nt al  Pa ras itol ogy 3 6 (3), \n360\u2013 372.  \n\nR ez e nde , C.M.,  S ilva, M.R.,  S ant os, I.G.,  Sil va , G.A.,  G ome s, D.A.,  Go es, A.M.,  20 11. \nImm uniz a tio n  wi th  rP22 i nduc e s  prot ec ti ve   i mm unit y  aga i nst  Sc hi stos oma  \nma n son i: e ffe c ts  on  gra nul om a  do w n-m od ula ti on  a nd c yto kin e  p roduc t ion . \nImm uno logy  Le tte rs 141  (1) ,  1 23\u201313 3. \n\nS adl e r, C.H., Rut itz ky, L.I ., S ta de c ke r,  M.J., W il son, R.A., 2003. IL-10 is c ruc ia l for  the \ntra ns it ion  fro m a c ut e  t o ch roni c  dis e a se  st a te  du ring  in fe ct io n of  mice with \nSc hist osoma  ma nsoni . Europea n J ourna l of Im m unol ogy 3 3 (4) ,  8 80\u20138 88. \n\nS my thie s, L.E .,  C oulson,  P.S.,  W il son, R.A.,  1992.  Mon ocl ona l a nt ibod y  t o  IF N - \ngamma modi?es pulmonary in?ammatory responses and abrogates immunity \nto Sc histosom a ma nsoni in m ic e  va c c ina t ed  w it h a t te nua te d  c e rc a ri a e.  J ourna l of \nImm uno logy  149,  36 54\u20133 658.  \n\nS im pson, A.J., Jam es,  S.L., S her, A., 1 983. Ide nt i? ca t ion of  s urfa c e a nt ige ns  of sc hi st o- \nsom ul a  of S chi stosoma  m a nson i re c ogn iz ed  b y an ti bod ie s from  m ic e  im m uni z e d \nby  c hron ic  infe c ti on a nd by  e xpo sure  t o hi ghl y i rra d ia te d c e rc a ria e . Infe ct io n \na nd Im m un ity  41,  591\u2013 597.  \n\nS m ith ers,  S.R.,  Te rry, R.J.,  1965. Th e i nfe cti on  of  l a bora t ory hos ts w it h c e rc \u00e1 ri a  \nof  S ch isto som a  ma ns oni a nd the   re c ove ry of  ad ult s w o rm s.  Pa ra sit olog y 55 , \n695\u2013 700.  \n\nTe ixe ira -C arva lh o, A., Ma rt ins -F il ho, O.A., Ma ga l h\u00e3e s, V.P., Le mos n, D.S., Ma la qui a s, \nL.C.C.,  Olive ira ,  L.F.A.,  Si lve ira,  A.M.S.,   G az z ine lli ,  A.,  G a zz ine lli ,  G.,  C orrea - \nO live ira , R., 2008. C yt oki ne s, c he mo kin e rec e pt ors, CD4 + CD 25 HIGH+  T-c el ls \na nd c l ini ca l  forms  of hu ma n s ch sit osom ia si s. A c t a T ro pic a  108 , 1 39\u20131 49. \n\nTe ix ei ra  de  Me lo, T., Mi ch el de A ra ujo, J., Do Val le Dur\u00e3e s, F., Ca lia ri, M.V., O li vei ra , \nS.C., Coel ho , P.M.,  F onse ca , C.T., 2010. Immunization with newly transformed \nSc hist osoma  ma nsoni schistosomula tegument elicits tegument damage, reduc- \nti on i n e gg a nd pa ra s ite  burd e n. P a ras ite  Im mu nol ogy 32  (1 1\u20131 2), 7 49\u20137 59.  \n\nVan  H e ll em ond , J.J., Re tra, K., Brouw e rs, J.F., Van  Bal kom, B.W.,  Ya z dan bakhsh , M., \nS hoe ma ke r, C.B., Tie le ns, A.G., 2006 . F un ct ions  o f the tegument of s c his to som e s:  \nc lue s from  the  pro te ome  a nd l ipid om e. Inte rna ti ona l J ourna l for Pa ras itol ogy  36 , \n691\u2013 699.  \n\nV ignal i, D.A., Croc ker, P., B ickle , Q.D., Cobb old, S., W a ldm a nn,  H., Ta yl or, M.G., 1989. \nA rol e for CD4+  but not CD8 +  T c el ls i n i mm uni ty to  Sch istosom a ma nsoni in duc e d \nby  2 0 k ra d -irra dia t e d a nd Ro 11-3 128 -te rmi na te d  i nfe c ti ons.  Im m uno logy  6 7, \n466\u2013 472.  \n\nYu, L., Sun,  X., Y ang, F., She n, J., W u, Z., 2 011. In? a mm a tory c yto kine s IFN -g, IL-4, \nIL-13 a nd TNF -a a lt era t ion s in s c his tos om ia is is : a  m e ta -a na lys is.  Pa ra si tol og y \nRe se a rc h, Ep ub a he a d of print. \n\nZhou, Y., K aw a saki , H., H su, S.C., Lee,  R.T., Yao,  X., Pl unke t t, B., Fu,  J., Yang, K., Le e, \nY.C., H u ang , S.K., 2 010. O ral  t ole ra nc e  to foo d-ind uc e d sys te mi c a na phy la xi s \nmediated by  t he  C -ty pe  le c t in SIGNR1. N a ture  M ed ic ine  16,  112 8\u201311 33. \n\nW a kka ch,  A., F ournie r, N.,  Brun, V., B rei ttm a ye r, J.P., C ott rez , F., G roux, H.,  2003 . \nCh ara c te riz a ti on of de n drit ic  c e ll s t ha t i ndu c e t ol era n ce  a nd  T re gula t ory 1 c e ll \ndiffe ren tia ti on in  vivo . Imm uni ty 18,  60 5\u201361 7. \n\nW il son, R.A., C oulson , P.S., B eti s, C., D ow king, M.A.,  S myt hie s, L.E., 19 96. Imp ai re d \nim m uni ty  a n d a lt ere d  pul m ona ry  re sp ons e  in m ic e  with a disrupted interferon- \n    re c e ptor  ge ne   e xpo se d  t o  the   irra dia t ed   S c hi st osom a  ma ns oni  va cc i ne . \nImm uno logy  87,  275 \u2013282 . \n\nW ynn , T .A., C he eve r, A.W., J ankovic , D., P oi nde xte r, R.W., C aspa r, P., Lew is, F.A., She r, \nA., 19 95. An IL-12 -ba se d va c c ina ti on m e tho d for  pre ve n tin g ? brosi s ind uc e d b y \nsc his tos om e in fe c ti on. N a ture  3 76, 594 \u2013596 . \n\nW ynn , T.A., C hee ve r, A.W.,  19 95. C yto kine  reg ula tio n of  gra n ulo ma  forma t io n i n \nsc his tos om ia sis . Cu rre nt  O pi nio n i n Imm uno logy  7, 5 05\u2013 511.  \n\n\n\n\u00a0\n\n\u00a0\n\n87\u00a0\n\n\u00a0\n\nPara avaliar a capacidade de duas formula\u00e7\u00f5es vacinais com diferentes adjuvantes \n\n(Alum e CPG-ODN) induzirem prote\u00e7\u00e3o em camundongos, n\u00f3s imunizamos camundongos \n\ncom: Smteg + alum ou Smteg + alum + CpG-ODN. Nossos resultados demonstraram que os \n\ncamundongos imunizados com Alum como adjuvante n\u00e3o apresentaram redu\u00e7\u00e3o significativa \n\nda carga parasit\u00e1ria. J\u00e1 o grupo imunizado com Smteg + alum + CpG-ODN apresentou uma \n\nsignificativa redu\u00e7\u00e3o da carga parasit\u00e1ria (43%) al\u00e9m de redu\u00e7\u00e3o no n\u00famero de ovos \n\neliminados nas fezes dos camundongos. Em rela\u00e7\u00e3o \u00e0 resposta humoral, ambas as \n\nformula\u00e7\u00f5es vacinais induziram n\u00edveis significativos de IgG, mas apenas os camundongos \n\nimunizados com CpG-ODN apresentavam altos n\u00edveis de IgG2c. O aumento dessa \n\nimunoglobulina pode estar relacionado \u00e0 prote\u00e7\u00e3o j\u00e1 que quando se imunizou camundongos \n\ncom Smteg mais Freund tamb\u00e9m foram verificados n\u00edveis significativos desse isotipo de \n\nanticorpo. Em rela\u00e7\u00e3o \u00e0 resposta celular, a imuniza\u00e7\u00e3o com Alum como adjuvante induziu um \n\nperfil de resposta imune predominantemente do tipo Th2 com alta produ\u00e7\u00e3o de IL-4, enquanto \n\na imuniza\u00e7\u00e3o com CPG-ODN levou a um perfil misto de resposta com alta produ\u00e7\u00e3o de IFN-g \n\ne IL-4. Nossos resultados tamb\u00e9m demonstraram que a imuniza\u00e7\u00e3o com CpG-ODN levou a \n\nativa\u00e7\u00e3o de c\u00e9lula CD4+, macr\u00f3fagos e aumento no percentual de c\u00e9lulas B (Teixeira de Melo  \n\net al., 2012). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n88\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n \n\nMicrobes and Infection 15 (2013) 28e36 \n \n\n \nOriginal article \n\n \n\n \nwww. elsevier.com/locate/micinf \n\n \n\nEvaluation of the protective immune response induced in mice by \nimmunization with Schistosoma mansoni schistosomula tegument (Smteg) \n\nin association with CpG-ODN \n \n\nTatiane Teixeira de Melo a,1, Juliano Michel Araujo a,1, Isabela Campos de Sena a, \nClarice Carvalho Alves a, Neusa Araujo a, Cristina Toscano Fonseca a,b,* \n\n \na Centro de Pesquisas Rene? Rachou,  Fiocruz-M G, Belo Horizonte,  Minas Gerais, Brazil \nb Instituto Nacional de Cie?ncias e Tec nologia em Doenc?as Tropicais (INC T-DT ),  Brazil \n\n \nReceived 25 June 2012; accepted 9 October 2012 \n\nAvailable online 23 October 2012 \n \n \n \n\nA b stract \n \n\nIn schistoso miasis, the cu rrent con trol strategy does no t prevent reinfection, therefore, vaccin e strategies are essential to co mbat the \nSchistosoma mansoni. The efficacy vaccine dep ends on  parasite stage and effective adjuvant. We have recently demo nstrated that S. manson i \nschisto somu la tegu ment (Smteg) is ab le to  activate dendritic cells up regulate CD4 0 and CD 86 molecules and induce a partial protection in mice \n(43e48%) wh en fo rmulated  with Freu nd\u2019s adjuvant. In this stud y w e evaluated the ability of Smteg \u00fe alu m or Smteg \u00fe alum \u00fe CpG-ODN to \ninduce p rotection in mice. Ou r results demonstrate that Smteg \u00fe alu m \u00fe CpG-ODN in duced a partial reduction in wo rm burden (43.1%), \nreduction in the number of eggs eliminated in the feces. The protective response was associated  with a predominant Th1 type of immune \nrespon se, w ith increased p roduction  of specific IgG2c, IFN -g an d TN F-a, B cells pro liferatio n and CD4 cells and macro phages activation. \n  2012 Institut Pasteur. Published by Elsevier Masson  SAS. All righ ts reserved . \n\n \nKeywords: Schistosoma mansoni; Vaccine; Alum; CpG-ODN; Parasite \n\n \n\n \n \n\n1. Introduction \n \n\nSchistosomiasi s i s a helmint hic infecti on that affect s more \nthan 200 mil lion people worldwide with 779 mil lion people at \nrisk of infection [1]. Actually, t he control strategy is mainly \nbased on chemot herapy but, in spite of decades of mass \ntreat ment, the number of infected people re mains constant. \nMoreover,  chemotherapy  cannot  prevent  re-infection,  and \nthere is evidence support ing the developme nt of drug-resist ant \nparasites [2,3]. Therefore alternative cont rol strategi es, such as \nvaccine development, that could be integrated into ongoing \ncontrol programs are needed [4]. \n\n \n \n \n\n* Corresponding author. Laborato? rio de Esquistossomose, Centro de Pes- \nquisas Rene? Rachou, Avenida Augusto de Lima, 1715, Barro Preto,  CEP: \n30190-002, Belo Horizonte,  Minas Gerais, Brazil. Tel. : \u00fe55 31 33497828. \n\nE-mail address: c toscano@cpqrr.fiocruz.br (C. Toscano Fonseca). \n1   These authors contributed equally to this study. \n\nSuccessful vaccine formul ation depends on the  use of \nimmunogenic anti gens toget her with an appropriat e adjuvant  \nable to induce the desirable i mmunologica l response. Adju- \nvants have  empiricall y been used to enhance t he adaptive \nimmune responses el icited by the vaccination, however \nadvances in the st udy of the  inna te i mmune syste m revealed \nthat  many adj uvants act through the inna te immune receptors \nincl uding Tol l-Like Receptors, Nod-Like Receptors, RIG-I- \nLike Receptors, and C-type Lectin Receptors directly acti- \nvating  dendritic cells  (DC) antigen  presentation and T-cell  \nactivation [5,6]. Aluminum salts have been commonly used as \nan adj uvant for years, however, their mechanisms of action are \nonly partiall y understood [7,8]. Recently, Flach et  al . [9] \ndemonstrated  that  alum  tri ggers  lipid  sorting  on  dendrit ic \ncells that leads t o phagocyti c response and ant igen uptake. \nRegardless t he mechanism of action, al uminum hydroxide \ninduces a Th2 response i n mice, causing i nduct ion of IgG1 and \nIgE, but has low capacit y to sti mulate strong cellular immune \nresponses [10,11]. \n\n \n1286-4579/$ - see front \nmatter     2012 Institut \nPasteur.  Published by \nElsevier Masson SAS. All \nrights reserved. \n\nhttp://dx.doi. org/10.1016/j. m\nicinf.2012.10.007 \n\n\n\n\u00a0\n\n\u00a0\n\n89\u00a0\n\n\u00a0\n\n \n\n \n\nDue to its immunostimulatory activi ty through TLR9, \nsynthetic  unmethylat ed  CpG   ol igodeoxynucleotides  (O DN) \nhas been used as experimental adjuvant  i n vaccine formula- \ntions [5]. CpG-OD N is able to stimula te NK  cell s and murine \nB cel ls to prol iferate and secrete immunoglobulin in vitro and \nto express activat ion markers and to secret e pro-infl ammatory \ncytokines in vivo [12,13]. The Th1-l ike response genera lly \ninduced by CpG-ODN might be useful  in vaccines a gainst  \nintracellular pathogens [14] and against schi stosomiasis si nce  \nprotec tive  immunity  induced  by  immunization  depends on \nIFN-g  and T N F -a  production [1 5 e1 7].  Indeed, the  use of \nCpG-OD N as adj uvant in a genet ic immunization with Sm- \np80 resul ted in signifi cant reduction in worm burden [18]. \n\nRecently, our group demonst rat ed that  Schisto so ma mansoni  \nschistosomula (Smteg) tegument plays an important role in \ntriggeri ng t he immune response against the parasite. Smteg is \nable to activate DC leading t o an increase i n t he expression of \nCD40 and CD86 mol ecul es on its surface and i n the production \nof IL-12 and T N F -a  [19] a nd i nduc es partial prot ection in mi ce \n(4 3e4 8 %) when formulated with Freund\u2019s adjuvant [20]. \n\nHerein, we showed that immunization of mice with Smteg \nplus alum a nd CpG -O DN induced partial reduction in worm \nburden and also reduction in the number of eggs eliminated \nwit hin  the  feces.  Smteg/ alum/CpG -OD N  formulation \nincreased the percentage of CD 4\u00feC D 25\u00fe cells in spleen, \nIgG2c antibodies  in  sera, IFN-g,  IL-4 and T N F-a  speci fi c \nproduction by spl een cells and macrophage activat ion. \n\n \n2. Materials and methods \n\n \n2.1. Mice and parasites \n\n \nFemale  C57BL/6  mi ce  aged  6 e8  weeks  were  obtained \n\nfrom the Centro de P esqui sas Rene? Rac hou (CP qRR) fac ili- \nties. Al l proce dures involving animals were approved by the \nlocal Ethi cs Commission on Animal Use (CEUA) (L-005/08). \nCerca ri ae of S. mansoni (LE strain) were routinely maintained \nin  Biomphalaria  gla brata  snails and  obtained  by exposing \ninfected snails t o l ight for 1 h e2  h to induce cercariae shed- \nding. The number of cercari ae and their viability were deter- \nmined using a light  microscope. \n\n \n2.2. Tegument purificati on (S mt eg) \n\n \nCercariae from S. mansoni were mec hanically transformed \n\ninto ski n-sta ge schi sto so mu la according to R amalh o-Pi nto  et al. \n[21]. The tegume nt was removed with CaCl 2  0.3 M by vortex \nagitation [22]. The tegument was separated from denuded \nbodies by centrifugation at 900 g for 1 min. The supernatants \nwere pooled and cent ri fuged at 50,000 g for 1 h at  4   C. The \npellet was dialyzed against 1.7%  saline for 48 h and physio- \nlogical sali ne for 24 h. This preparation was terme d S mte g. \n\n \n2.3. Immuniza tion of mice \n\n \nFemale C57BL/6 mice (10 mice per group) were subcut a- \n\nneousl y immunized in the nape of the neck with 25 mg Smteg \n\non days 0, 15 and 30. The anti gen was formulated with alum \nor alum plus 50 mg of CpG-O DN. In the cont rol groups, sal ine \nwith alum or alum plus CpG-OD N was admini stered using the \nsame i mmuniz ation protocol. Blood samples were collect ed \nfrom retro orbital  sinus of each mouse with an interval of \nfi fteen days beginning 15 days aft er the first immunization. \nSerum sa mples were collected and stored at    20   C until use. \nThree i ndependent  experiments were performed to confirm the \nresult s observed. \n \n2.4. Challe nge infection and parasite bu rden \ndete rmin ati on \n \n\nThirty  da ys  aft er  the  last  boost,  mice  were  challenge \nthrough percutaneous exposure of abdominal skin for 1 h in \nwater contai ni ng 100 cercariae (LE strain) as described by \nSmithers and Terry [23]. F ift y days a fter chal lenge, adult \nworms were perfused from the portal syste m a nd mese nteric \nveins accordi ng to P ellegrino and Siqueira [24]. On days 48, \n49 and 50 after chal lenge i nfection, 0.5 g of fecal material \nfrom each mouse group were analyzed for egg burden deter- \nmi nation by HPJ me thods [25]. In HPJ, whole sedi me nt was \nevaluated to determine egg per gram of feces (epg). \n \n2.5. Measureme nt of specific an tib od ies \n \n\nThe mea surement of specific anti-Smteg IgG, IgG 1 and \nIgG2c anti bodies was performed in individual bases by ELISA \nas previously described [20]. \n \n2.6. Cytokine an aly sis  \n \n\nExperiments were performed using spleen cell culture \nsupernatants from fi ve individual mice per group immunized \nwith S mteg/alum; Smteg/alum/CpG and a non immunized \ngroup, one week after the la st i mmuniz ation. The cel ls ob- \ntained from mice  spl een were wa shed twice in sterile sal ine  \nand then adjusted to 1     106   cell s/well. Spleen cel ls were \nmai ntai ned in culture at 37   C i n 5% of CO2  i n medium alone \nor stimulated wit h Smteg (25 m g/mL) or concana valin A (Con \nA) (5 mg/mL). Culture supernatant s were col lected after 24 h \nstimulation to measure IL-4 and T N F-a  or 72 h stimulat ion to \nmeasure IFN-g. Cyt okine assay was performed usi ng the  \nDuoset ELIS A kit (R&amp;D syste m, Mi nneapoli s, MN) or Ready \nset GO (e-bioscience, S an Diego, CA) according to manu- \nfact urer\u2019s instructions. \n \n2.7. Intra cytopl asmatic cytokine st ain ing  \n \n\nFor i ntracytoplasmati c cytokine  staini ng, spleen cells from 4 \nmice/ group/experiment were adjusted to 5    105 cells per well. \nCells were maintai ned in c ult ure at 37   C in 5% of CO2   in \nmedium alone or stimulated wit h S mte g (25 mg/ mL) or Con A  \n(5 m g/mL). After 16 h of culture, 1 m g/w ell  of brefel din A  \n(S igma Chemical Co., St Louis, MO) was added to impair \ncytoki ne secretion. A fter 4 h of inc ubation, these cells were \nstained for surface markers a nd intracel lular c ytoki nes. Before \n\n\n\n\u00a0\n\n\u00a0\n\n90\u00a0\n\n\u00a0\n\n \n\n \n\nstaining t he cells were generall y blocked with anti-mouse \nCD16/CD32 mAbs (Fc-Block, BD Pharmingen). After that, \ncell s were stai ned for surface markers using ant i-CD4 biotin \n(clone  GK 1.5, B D-Ph armi ng en), ant i-CD8 FITC (clone 53-6-7, \ne-bioscience), a nti -CD19 F ITC (clone 1D3, BD Pharmi ngen) \nand anti-F4/80 bi otin (clone BM8, e-bioscience) monoclonal \nantibodies and their respective isotype controls by incubation \nfor 20 mi n with antibody solut ion (P BS  0.15 M, 0.5%  BSA, \n2 mM NaN 3) at 4   C. After a wash step with PBS 0.15 M, 0.5% \nBSA, 2 mM Na N3 cells were submitt ed to a further incubation \nstep of 20 min wit h streptavi din-Percp l abeled di luted 1: 200 \nwit h antibody solution at 4  C, wa shed and submitt ed to fixation \nusing 2%  formaldehyde solut ion. These cells were per- \nmeabilized and further stai ned wi th PE-labeled anti-IFN -g \n(clone  XMG1.2, e-bioscience), ant i-T N F -a (clone MPGXT22, \ne-bioscience), anti-IL-4 (clone 11B11, BD P harmingen) and \nanti-IL-10 (clone JES5-16E3, e-biosc ience) or AP C labeled \nanti-IL-10  (clone  JES5-16E3, BD Pharmingen) monoclonal  \nantibodies in P BS  with 0.5% saponi n. After 30 min at room \nte mperature, cells were washed with permea bil ization solution, \nresuspended in  P BS  and  read  usi ng  FACSCalibur (Becton \nDi ckinson, San Jose, CA). Data anal ysis was performed using \na F lowJO i nterface (Tree S tar, Ashland, OR). \n\n \n2.8. Immune cells activation p att ern \n\n \nFor ex vivo cellular staining, spleen cells from 4 mice/  \n\ngroup/experiment were adjusted to 5     105   cells per wel l. \nBefore st aining, the cells were generally blocked with anti- \nmouse CD16/CD32 mAbs (Fc-Block, BD  bioscience), after \nthat cells were sta ined for surface markers using anti -CD4 \nBiotin  (clone  GK1.5,  e-biosci ence),  anti-CD8 FITC  (clone  \n53-6-7, e-bioscience), anti-CD19 FITC (clone 1D3, BD \nP harmingen),  anti-F4/80  FITC  (clone  BM8,  e-bioscience), \nanti-CD86 Bioti n (cl oneGL.1, e-bioscience), anti -IaB P E \n(clone  M5/11414.2, e-bioscience), ant i-CD25 PE (clone \nP C61.5, e-bi oscience) and anti-CD69 P E (clone H1.2F3, e- \nbioscience) monoclonal antibodies and their respective isotype \ncontrols by incubation for 20 min wit h anti body sol uti on at \n4   C, after washed with PBS 0.15 M, 0.5% BSA, 2 mM NaN3, \ncell s were submit ted to a further incubation step of 20 min \nwit h streptavidin-Percp (e-bioscience) labeled dil uted 1:200 in \nantibody soluti on at 4   C, followed by t wo washes steps and \nfixation usi ng 2% formaldehyde solution. The l abeled cells \ndata were obtai ned usi ng FACSCalibur (Bect on  D icki nson, \n\nSan Jose, CA). Dat a analysi s was performed using a FlowJO \ninterface (Tree Star, Ashland, OR). \n \n2.9. St atisti cal an aly sis  \n \n\nStat istical   anal ysis  wa s  performed  with  Student\u2019s  t-test \nusing t he soft ware package G raphPad Prism 4.0 (G raphPad \nSoft ware, San Diego Ca lifornia USA). \n \n3. Re sults \n \n3.1. Protective response induced by Sm teg immunization \nin association with two different a djuvant formulations \n \n\nTwo   different   adjuvant    formulations   were   evalua ted \ntogether with Smteg: S mteg/alum and S mt eg/alum/CpG-ODN . \nImmunizat ion with Smteg/alum did not result in si gnificant  \nreduction in worm burden or i n the number of eggs eliminated \nin the feces compared to sal ine/alum control  group (Table 1) \nwhil e immunizati on with S mte g/al um/CpG-OD N eli cited \nsigni fica nt reduc tion in the number of adult  parasi tes (43.1% ) \nand a signifi cant  reduction of 55.21%  i n the numbers of eggs \neliminate d in the feces (Table 1). \n \n3.2. A ntibo dy  responses to Smtege al um  or Smtege al um e \nCpG-ODN immunization \n \n\nSignificant  increased levels of anti-Smteg IgG antibodies \nwere det ected in the sera of S mt eg immunized mice compared \nto control groups at all ti mepoint anal yzed (Fig. 1A) re gardless \nadj uvant. S mte g/al um or Smteg/alum/CpG-ODN immuniza- \ntion i nduced a significant increased production of speci fic ant i- \nSmteg IgG 1 compared to control groups at all ti mepoint  \nanal yzed (Fig. 1B). However, only in the group of mice  \nimmuni zed  with  S mt eg/a lum/CpG-O DN  a  significant  \nincreased production of specific ant i-S mteg IgG2c was \nobserved (Fig. 1C). \n \n3.3. Immune cell profi le induced by i mmuni zation \n \n\nBoth adj uvant formulations induced an increase in the \npercentage of CD 4\u00feCD 2 5\u00fe cells in comparison to control  \ngroup and no significant difference in t he percentage of \nCD8\u00feCD2 5\u00fe   cells   was   observed   (Fig.   2).   Regarding \nthe  CD69  expression,  an  increase  in  the  percentage  of \n\n \n\nTable 1 \nProtective immune response induced in mice by Smteg immunization in different adjuvant formulation. \n\nGroups Worm burden recovered (mean \u00fe SD from \nthree independent experiments) \n\nFem ale                Ma le                   Total \n\nProtection levela                          Eggs/gram of \nfec es (mean     SD) \n\nReduction of \negg in fecesb \n\nSaline \u00fe alum                                       18     5                21     4                40     8                                                            748     113 \nSmteg \u00fe alum                                       17     5                17     5                34     8                    8.1%                                625     6                                 16. 4% \nSaline \u00fe alum \u00fe CpG-ODN                21     4                23     6                44     1                                                            824     295 \nSmteg \u00fe alum \u00fe CpG-ODN               13     5                12     7                25     12                43. 1%*                              369     80                               55.2%* \n\n*p &lt;0.05 compared to respective c ontrol group. \na   Reduction in worm burden in immunized groups compared to their respective control groups (mean of three independent trials). \nb   Reduction in the number of eggs eliminated with the feces from immunized groups compared to their respective controls (mean of three independent trials). \n\n\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n91\u00a0\n\n\u00a0\n\n \n\n \n\nA\nB\n\nS\n 4\n\n5\n0\n\n n\nm\n\n \nA\n\nB\nS\n\n 4\n5\n0\n\n n\nm\n\n \nA\n\nB\nS\n\n 4\n5\n\n0\n n\n\nm\n \n\nA 0, 70 \n0, 60 \n\n0, 50 \n\n0, 40 \n\n0, 30 \n\n0, 20 \n\n0, 10 \n\n0, 00 \n\n \n \n\nB \n0,80 \n\n0,70 \n\n0,60 \n\n0,50 \n\n0,40 \n\n0,30 \n\n0,20 \n\n0,10 \n\n0,00 \n\n \n \n \n \n \n \n \n \n \n \n15       30       45       60       75       90      1 05 \n\nDays after 1st  immunization \n \n \n \n \n \n \n \n \n \n \n \n \n15      30      45      60      75      90     105 \n\ns t\n \n\n \n\n \n \n \n\nSaline/Alu m \n\nSmt eg/Alum  \n\nSaline/Alu m/Cp G \n\nSmt eg/Alum /CpG  \n\n \n \n \n \n \n \n \n \n       Saline/Alum \n\nSmT eg/Alu m \n\nSaline/Alum/ CpG  \n\nSmT eg/Alu m/Cp G  \n\nthan t he IL-4 level detected in S mteg/alum/CpG-ODN group. \nAdditionally a si gnificant hi gher production, by spleen cells, \nof IF N-g a nd T N F-a were detect ed in S mt eg/alum/CpG-OD N \nimmunized group when compared to control group (Tabl e 2), \nand also, a significant increased spleen cells production of \nIFN-g  and T N F-a were dete cted in S mt eg/al um/CpG -OD N \nimmunized  group  when  compared  to  S mt eg/al um  group \n(Table 2). Significant i ncreased T NF -a production was al so \ndet ected in Smteg/alum group in comparison to control group, \nbut the levels of T N F -a  det ected i n this group was 3.5-fold \nlower  than  t he  levels  detected  in  S mt eg/alum/CpG-OD N \ngroup. To determi ne t he major source of cyt okine produc- \ntion, we performed intracellular cytokine staining in CD 4\u00fe \nand C D 8\u00fe cells in spleen from control, Smteg/alum, Smteg/ \nalum/CpG-ODN i mmuni zed mice and control group. A \nsigni fica nt increase in the percentage of C D 4\u00feT N F-a\u00fe cells \nwere observed in Smteg/alum and S mt eg/alum/CpG-ODN  \nunder Smteg in vitro stimulation. In comparison to control \ngroup, an increase i n the percentage of CD 4\u00feTN F\u00fe cell s and \nCD4\u00feIL -4\u00fe cells were observed i n S mteg/alum group under \nSmteg in vitro st imulation. Also an increase in the percenta ge \n\n \n\nC \n0,35 \n\n0,30 \n\n0,25 \n\n0,20 \n\n0,15 \n\n0,10 \n\n0,05 \n\n0,00 \n\nDays after 1 immunization  \n \n \n \nSaline /Alum \n\nSm Te g/Alum \n\nSaline /Alum/C pG  \n\nSm Te g/Alum/ CpG  \n\nof    CD 4\u00feT N F-a\u00fe,     CD 8\u00feIFN -g,     CD 8\u00feT N F-a\u00fe     and \nCD 8\u00feIL -4\u00fe  cells  was  observed in  Smteg/al um/CpG -O DN \ngroup   compared   to   control   group   and   in   C D 4\u00feT N F- \na\u00fe ce lls compared to Smteg/alum group (Fig. 3). \n \n3.5. Immunization effect on m acro p ha ges  \n \n\nAct ivation status and cytokine production by macrophages \nwas accessed by fl ow cytometry. Smteg/ alum and Smteg/ alum/ \n\n15      30       45      60      75      90     105  \n\nDays after 1st  immunization \n \n\nFig. 1. Kinetics of specific anti-Smteg IgG(A),  IgG1(B) and IgG2c(C) \nproduction in immunized mic e.  Mice were immunized with three doses of \na vaccine formulation containing Smteg (25 mg/mice) or saline. The antigen \nand saline was formulated with alum or alum \u00fe CpG-ODN. Sera samples were \nobtained from 10 individual mic e from each group on days 15,  30, 45, 60,  75, \n90 and 105 after the first immunization dose and used in ELISA in a Smteg \n(1 mg/mL) coated plate diluted 1:100 (IgG a nd IgG1) or 1:200 (IgG2c).  Results \nare presented as mean absorbance     SD measured at 450 nm. Statistically \nsignificant differences between Smteg/alum or Smteg/alum CpG and saline \nimmunized groups are denoted by asterisks ( p &lt;0.05). Representative result \nof one from two independent experiments. \n\n \nC D 4\u00feCD 6 9\u00fe and CD8\u00feC D 69\u00fe cells was observed in \nS mteg/alum formulat ion (Fig. 2A). An increased pe rcentage in \nC D 19 \u00fe cel ls was observed i n non-stimulat ed and S mteg- \nstimulated  spleen cell s from mice  immunized  with Smteg/ \nalum/CpG-ODN i n comparison to control group a nd to \nS mteg/alum group (Fig. 2B). \n\n \n3.4. Cytokine profile induced by immunization \n\n \nSignificant IL-4  production, a  signature  of  Th2-type  of \n\nimmune response, was det ected in the spleen cells supernatant  \nfrom the a nimals immunized with Smte g/alum and S mt eg/  \nalum/CpG-ODN in comparison to control  group (Table 2), \nhowever i n Smteg/alum group IL-4 levels was 2-fold higher \n\nCpG-ODN groups presented an increa sed percentage of F 4/ \n80\u00feC D 8 6\u00fe cell s in comparison to cont rol group. Both groups \nalso showed an increased percentage of F4/8 0\u00feIFN-g\u00fe cells \ncompare d to cont rol group. Nevertheless, in Smteg/alum group \nan increase in F4 /80\u00feIL -4\u00fe c ells was observed in comparison \nto cont rol and Smteg/ alum/CpG -O DN groups. Immunizati on, \nregardl ess of vaccine formula tion, also induced a decrease in \nthe percentage of F4 /80\u00feIL -1 0\u00fe cells compared to control \ngroup (Fi g. 4). \n \n4. Disc us sio n  \n \n\nDue to the  inabili ty of chemotherapy to limit reinfection \nand control transmission, schistosomiasis is still  at the top of \nthe list of endemic disease s of public healt h importance in the \nworld [26]. The development of an effective vaccine against \nthis disease is desirable to be used as an al ternative tool  in \ndisease control [4]. In this cont ext, both antigen and adj uvant \nchoice represents important steps in vaccine design. Recent ly \nour group has demonstrated that   S. mansoni schistosomula \ntegument  (S mteg) plays an important role in activating host \nimmune response. In vitro, S mteg is recogni zed by bone \nmarrow  dendritic  cells  (BMDC)  inducing  up-regulat ion of \nCD40 and CD86 expression and the production of IL-12 and \nT N F -a cytokines [19], F urthermore, mi ce immunization wi th \nSmteg and Freund\u2019s adjuvant, induces parti al protection \n(43%e 48 %) i n mice [20]. \n\n\n\n\u00a0\n\n\u00a0\n\n92\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n \n\nFig.  2. Immune cells profile. Spleen cells obtained from four mice per group: immunized with Smteg/alum; Smteg/alum/CpG-ODN and a non immunized were \ncultured and adjusted to 5     105  c ells/well, these cells were stained for surface markers using anti-CD4, anti-CD8,  anti-CD25, CD69 and anti-CD19 monoclonal \nantibodies with their respective isotype controls. (A) Bar c hart representing the perc entage of CD4\u00feCD25\u00fe cells or CD4\u00feCD69\u00fe cells from control, Smteg/alum \nand Smteg/a lum/CpG-ODN groups. (B) Bars represent the percentage of CD19\u00fe cells in control, Smteg/alum and Smteg/alum /CpG-ODN groups. The white bars \nrepresent the percentage of CD19\u00fe cells in non-stimulated culture,  gray ba rs represent Con A-stimulated culture and black bars represent Smteg-stimulated \nculture.  Asterisk denotes differences between non-stimulated cells and Con A or Smteg in the sam e group while statistically significant differences to control, \nSmteg/alum or Smteg/alum CpG-ODN groups are indicated to the letter a, b or c  respectively ( p &lt;0. 05). Representative result of one from two independent \nexperiments.  \n\n \n\n \n \n\nHerein we immunized mice with S mt eg/alum or S mteg/  \nalum/CpG-ODN in order to eval uate the abilit y of both \nformulations to induce protection. Mice immunization w ith \nS mteg/alum elici ted no protection whi le immunization wi th \nS mteg/alum/CpG-ODN  led to a significant reduction i n worm \nburden and in the number of eggs eliminated with the feces. \nAlt hough  alum  has  been  safel y  and  successfully  used  in \n\nseveral  of  licensed   vacci ne,  its   i nabilit y   to   elicit   cel l- \nmediated   immune   response   and   [27,28]   Th1   response  \n[29,30] has been described. On the other hand, several re- \nsearchers ha ve shown that CpG-ODN up regulates antigen- \npresentation molecules expression, induces a Th1 type of \nimmune response and promotes immunoglobuli n (Ig) isotype  \nswitc hing [3 1e 3 3]. \n\nTable 2 \nCytokine production by immunized mice. \n\nControl                                                                   Smteg \u00fe alum                                                          Smteg \u00fe alum \u00fe CpG-ODN \n\nNon-stimulated             Smteg-stimulated             Non-stimulated             Smteg-stimulated                Non-stimulated            Smteg-stimulated \n\nIFN-g              50.0     28.9                  1224.0     522.1                 0.4     0.2                    1735.0     485.3                   86.1     86.1                  7834.0     535.9***aaa \nIL-4                   0.0     0.0                          0.0     0.0                   25.0     25.0                  5963.0     1506.0**               0.3     0.3                    3288.0     789.0* \nTNF-a            23.5     23.5                      49.6     28.5                   0.0     0.0                      166.7     71.9*                     0.4     0.2                      591.0     77.1***a \n\nSignificant difference compared to Smteg \u00fe alum group ap &lt;0.05, aaap &lt;0.001. \nSignificant difference compared to non-stimulated cells *p &lt;0.05, **p &lt;0.005, ***p &lt;0.001. \n\n\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n93\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n \n\nFig.  3.  Intracytoplasmatic cytokine staining in lymphocyte subpopulations. Mice were immunized with three doses of a vaccine formulation containing Smteg/ \na lum, Smteg/alum/CpG-ODN or saline. Ten days after the last im munization dose, mice were sacrificed a nd spleen cells were obtained from each individual \nmouse. CD4\u00fe and CD8\u00fe production of IFN-g, IL-4, TNF-a, IL-10 in response to Con A (5 mg/mL) or Smteg (25 mg/mL) in vitro stimulation were determined. \nB ars represent the mean     SD of the percenta ge of CD4\u00fe or CD8\u00fe c ytokine\u00fe cells in non-stimulated, Con A-stimulated and Smteg-stimulated cells. Statistically \nsignificant differences between Con A or Smteg stimulated cells and non-stimulated cells are denoted by an asterisk. Statistically significant differences to control, \nSmteg/alum or Smteg/alum CpG-ODN groups are indicated to the letter a, b or c respectively ( p &lt;0.05). Data represent the mea n values of two independent \nexperiments with 4 animals/group each. \n\n \n \n\nProtective immunity a gai nst  S . mansoni involves both \ncellular and humoral i mmune responses [15]. In our study, \nboth Smteg/alum and Smteg/ alum/CpG -O DN i nduced signif- \nicant production of specific IgG antibodies, but only i n S mteg/ \nalum/CpG-ODN group a significant producti on of IgG 2c \nagainst S mteg was detected. The same immunoglobulin profil e \nwas observed in S mteg/CFA/IFA formulation that a lso elicit ed \nprotec tion against chal lenge infecti on i n mi ce [20]. S imi lar \nimmunoglobul in profile has been associated wit h protection \nwhen other schistosome anti gens were te sted [17,34,35]. \n\nThe abil ity of CpG motifs to induce B cell prol iferation \nhas been described by Krieg and co-workers in 1995 [13]. \nIndeed CpG-ODN (1826) used in our i mmunizati on prot ocol  \nbelongs to cla ss B CpG, that is know n to i nduce strong B cell  \nresponses [36]. Indeed a hi gher percentage of CD1 9 \u00fe ce lls \nwere det ected in spl een from Smteg/alum/CpG-ODN  \ni mmunized mi ce in comparison t o S mteg/al um and control \n\ngroups eve n under no stimulation. Also, Smteg in vit ro \nsti mula tion resulte d i n significant increase in the perce nta ge \nof C D 19\u00fe ce lls i n S mteg/alum/CpG -ODN i mmunized mice , \nindic ating t ha t this formulat ion induce B cell proliferati on in \nsplee n. \n\nCD69 and CD25 are early and late activation markers for \nanti gen-specific stimula ted T-cells, respectively [37]. Both \nformulat ions tested in our st udy were able to activate CD 4\u00fe \ncells, alt hough S mt eg/al um see ms to induce a delayed CD 4\u00fe \nactivation, supported by the hi gh percent age of C D 4\u00feCD 6 9\u00fe \nearl y activated cells observed in t his group 10 days aft er the l ast \nimmuni zation dose. CD 8 T cel l pri me has been reported in \nhuman immuni zation with alum as adjuvant [38,39], herein \na significant  increa se in C D 8\u00feC D69\u00fe cells was observed in \nSmteg/al um group. \n\nCytokine measureme nt in spleen cells cul ture supernata nt \ndemonstrated  that  the  cyt okine  profi le induced  by  vaccine \n\n\n\n\u00a0\n\n\u00a0\n\n94\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n \n\nFig.  4. Sm teg \u00fe alum  and Smteg \u00fe alum \u00fe CpG-ODN induce up-regulation of CD86 expression on macrophages and increased cytokine production. Spleen cells \nobtained from four mice per group: immunized with Smteg/alum; Smteg/alum/CpG-ODN and a non-immunized were cultured and stained for surfa ce m arkers \nusing anti-F4/80,  anti-IaB and anti-CD86 monoclonal antibodies with their respective isotype controls. For cytokine a ssay,  intracellular staining of IFN-g, IL-4, \nTNF-a, IL-10 of F4/80\u00fe cells in response to Smteg (25 mg/mL) or Con A (5 mg/mL) in vitro stimulation. (A) Graphics show the mean fluorescence intensity (MFI) \nof CD86 in F480\u00feIaB\u00fe cells in the control, Smteg \u00fe alum and Smteg \u00fe alum \u00fe CpG-ODN groups measured by flow cytometry. (B,  C , D): Bars represent the \nmean     SD of ex vivo cytokine production in control (B), Smteg/alum  (C) and Smteg/alum/CpG-ODN (D) gr oups. Statistically significant differences between \nSmteg/alum or Smteg/alum/CpG group compared to control group are denoted by the letter a ( p &lt;0. 05). Statistically significant differences in the percentage F4/ \n80\u00fe cytokine\u00fe cells between control, Smteg/alum and Smteg/a lum/CpG groups are denoted by the letters a, b and c respectively (*p &lt;0. 05). \n\n \n\n \n \n\nformulations differs, while immunization wi th Smteg/alum \nleads to a predominant Th2 t ype of immune response wit h \nsignificant production of IL-4, i mmuni zation wi th S mt eg/  \nalum/CpG-ODN  leads to a mixed type of immune re sponse  \nwit h significant product ion of IFN-g and IL-4. Both formu- \nlat ions lead to signi fica nt production of T N F-a. The role of \nIFN-g and T N F -a  in protective i mmunit y against sc histoso- \nmiasis has bee n descri bed [15 e1 7,4 0,4 1]. The protection \ninduced by irradiated cercaria vaccine, an important immu- \nnization model to st udy protection mechanism in schistoso- \nmiasis, i nvolves a  cell -mediated immune mechanism, \ndependent on CD 4\u00fe T l ymphocyte s, IFN-g and T NF-a  t hat  \ncorrelates with macrophages activation and nitric  oxide \nproduction [15,1 6,4 2e 44 ]. \n\nThe major source of T N F-a produc tion i n Smteg/alum and \nS mteg/alum/CpG-ODN  groups seems to be C D4\u00fe and both \nCD4\u00fe and C D8\u00fe cells, respectively, since an increased \npercent age of these double positive cells were detected in the  \nspleen from immunized mice. C D 8\u00fe cel ls may contribute to \nIFN-g and IL-4 production in Smteg/alum/CpG-ODN group, \nsince a significant increase in the percentage of these c ytokine  \nproducing cells were observed in comparison to cont rol group. \nMacrophages and N itric Oxi de (NO) production have  been \ndescribed to be important i n mediati ng parasite ki lling in \nvaccinat ion-induced protective i mmunit y [44]. Both Smteg/ \n\nalum and Smteg/ alum/CpG-O DN formulations were able to \ninduce macrophage activation as demonstrated by an increased \nexpression of CD 86 in F4/8 0\u00fe spleen cells from both groups. \nNevertheless, different cytokine produc tion in F4/ 80 \u00fe cells \nwas observed in these groups. Whi le macrophages from \nSmteg/al um immunized mic e produced signi fic ant l evels of \nIF N-g and IL-4 compared to control group, Smteg/ alum/CpG- \nODN macrophages produced only significant levels of IFN -g. \nIL-4 production by macrophage has been described in vivo and \nin vi tro [45e4 7] and contribut es t o the T h1/Th2 balance. \n\nSeveral   studies   demonstrate   that   microbi al   products \ntogether wit h IFN -g activate macrophages to induce micro- \nbici dal activity in Th1-dominant response, while Th2 profile \nalternatively activate macrophages using IL-4 and IL-13 \n[48e5 0]. Alternati vely, activated macrophages play an \nimportant  role in resolving the damage  caused by parasite \ninfection [4 8e 50 ]. Our results, demonstrate that CpG-ODN \nused as adjuvant together with Smteg in a vaccine formula- \ntion agai nst schistosomiasis induces a protective i mmune \nresponse associated wit h B cell prolifera tion, CD4 and \nmacrophage activation and a mixed Th1/Th2 response with \na predominant t ype 1 response wi th high IFN-g and T NF-a \nproduction that  results in increased IgG2c speci fi c production. \nAlthough  Smteg/alum/ CpG-ODN did  not  significantly \nincrease the protect ion levels i nduced by Smteg plus Freund\u2019s \n\n\n\n\u00a0\n\n\u00a0\n\n95\u00a0\n\n\u00a0\n\n \n\n \n\n \n\nformulation, it represents an alternative adjuvant to be used \ninstead of F reund\u2019s that i s known to induce a strong inflam- \nmatory response and t herefore is not consi der a safe adjuvant \nto be used in humans. \n\n \n\n \nA c k no w l ed g m ents \n\n \nThe authors thanks the program for technologi cal Deve l- \n\nopment in tools for Health-PDTIS FIOCRUZ for use of it \nfaciliti es. This work was supported by CNPq; INCT-DT/ \nCNPq, Ripag/CPqRR-Fiocruz. \n\nFellowships: CP qRR/ Fiocruz (TTM); PIBIC/CN Pq (JMA); \nP IBIC/CNPq (ICS); Fapemig (CCA); PQ/CNP q (CTF). \n\n \n\n \nReferences \n\n \n[1] B. Gryseels,  K. Polma n, J. Clerinx, L.  Kestens,  Human schistosomia sis, \n\nLancet 368 (2006) 1106e1118. \n[2] P.G. Fallon,  M. J.  Doenhoff,  Drug-resista nce schistosomiasis: resistance \n\nto praziquantel a nd oxamniquine induced in Schistosoma mansoni in \nmice is drug spec ific , Am. J.  Trop. Med. Hyg.  51 (1994) 83e88. \n\n[3] M. Ismail, A.  Metwally, A.  Farghaly,  J. Bruce,  L. F. Tao, J.L.  Bennet, \nCharacterization  of  isolates  of  Schistosoma mansoni  from  Egyptian \nvillagers that tolerate high doses of praziquantel,  Am.  J. Trop. Med. Hyg.  \n55 (1996) 214e218. \n\n[4] P.J.  Hotez, M .T. Ferris, The antipoverty vaccines,  Vaccine 24 (2006) \n5787e5799. \n\n[5]  D.  Kim , S.  Kwon,  C. S. Ahn, Y. Lee,  S. Y. Choi, J.  Park, H.Y. Kwom, \nAdjuvant effec t of liposome-encapsulated natural phosphodiester CpG- \nDNA, BMB Rep.  44 (2011) 758e763. \n\n[6]  D. Van Duin, R. M edzhitov, A. C. Shaw, Triggering TLR signaling in \nvaccination, Trends Immunol. 27 (2006) 49e55. \n\n[7]  P. Marrack, A.S.  Mckee, M. W. Munks, Towards an understanding of the \nadjuvant action of aluminium, Nat. Rev.  Imm unol. 9 (2009) 287e293. \n\n[8]  R. Spreafico,  P.  Ricciardi-Castagnoli, A.  Mortellaro, The controversial \nrelationship between NLRP3, alum, danger signa ls and the next- \ngeneration adjuva nts, Eur.  J. Immunol. 40 (2010) 638e642. \n\n[9]  T.L.  Flach,  G.  Ng,  A. Hari, M. D. Desrosiers, P. Zhang, S.W. Ward, \nM.E.  Seamone,  A.  Vilaysane,  A. D.  Mucsi,   Y.  Fong,   E.   Prenner, \nC.C.  Ling,   J.   Tschopp, D.A.  Muruve,   M .W.  Amrein,   Y.  Shi,   Alum \ninteraction with dendritic cell membrane lipids is essential for its adju- \nvanticity,  Nat. Med. 17 (2011) 479e487. \n\n[10] E. M. Agger, J.P. Cassidy,  J. Brady, K.S.  Korsholm, C. Vingsbo-Lund- \nberg, P. Andersen, Adjuvant modulation of the cytokine balance in \nMycobacterium tuberculosis subunit vaccines: immunity, pathology and \nprotection,  Immunology 124 (2008) 175e185. \n\n[11] T.R. Mosmann, S. Sad, The expanding universe of T-cell subsets: Th1, \nTh2 and more,  Immunol.  Today 17 (1996) 138e146. \n\n[12] T.  Sparwasser,  E.S.  Koch,   R.M.  Vabulas,  K.  Heeg,  G.B.   Lipford, \nJ. W. Ellwart, H. Wagner, Ba cterial DNA and immunostimulatory CpG \noligonucleotides trigger maturation and activation of murine dendritic \ncells, Eur. J. Immunol. 28 (1998) 2045e2054. \n\n[13] A. M.   Krieg,  A.K.  Yi,   S.   Matson,  T.J.  Waldschmidt,  G.A.   Bishop, \nR. Teasdale, G.A. Koretzki,  D. M. Klinman, CpG motifs in bacterial DNA \ntrigger direct B-cell activation,  Nature 374 (1995) 546e549. \n\n[14] A. M. Krieg, L. Love-Homan, A.K. Yi,  J. T.  Harty,  CpG DNA induces \nsustained IL-12  expression in  vivo  and  resistance  to  Listeria  mono- \ncytogenes challenge,  J. Immunol.  161 (1998) 2428e2434. \n\n[15] D. Jankovic,  T.A. Wynn,  M.C. Kullberg, S. Hieny, P. Caspar, S. James, \nA. W. Cheever, A.  Sher,  Optimal vaccination against Schistosoma man- \nsoni requires the induction of both B cell and IFN-gamma-dependent \neffector mechanisms, J. Immunol. 162 (1999) 345e351. \n\n[16] M.  Street,  P.S.  C oulson,  C.  Sadler,  L.J.   Warnock,   D.  McLaughlin, \nH.  Bluethmann, R .A. Wilson,  TNF is essential for the cell-mediated \n\nprotective immunity induced by the radiation-attenuated schistosome \nvaccine, J.  Immunol.  163 (1999) 4489e4494. \n\n[17] C. T.   Fonseca,  C. F.  Brito,  J.B.  Alves,  S. C.  Oliveira,  IL-12  enhances \nprotective immunity in mice engendered by immunization with \nrecombinant  14 kDa Schistosoma  mansoni fa tty  acid-binding  protein \nthrough an IFN-gamma and TNF-alpha dependent pa thway, Vaccine 22 \n(2004) 503e510. \n\n[18] W. Torben, G. Ahmad,  W.  Zhang, A.A.  Siddiqui, Role of antibodies in \nSm-p80-mediated protection against Schistosoma mansoni challenge \ninfection in murine and nonhuman primate m odels,  Vaccine 29 (2011) \n2262e2271. \n\n[19] F. V. Dura?es,  N.B.  Carvalho, T.T. Melo, S.C.  Oliveira, C .T. Fonseca, IL- \n12 and TNF-alpha production by dendritic cells stimulated with Schis- \ntosoma mansoni sc histosomula tegument is TLR4- and MyD88- \ndependent,  Immunol. Lett.  125 (2009) 72e77. \n\n[20] T. Teixeira de Melo, J. M. Ara ujo, F. V. Dura?es, M.V. Caliari, S.C.  Oliveira, \nP.M .Z.  Coelho, C.T.  Fonseca,  Immunization  with  newly  transform ed \nSchistosoma mansoni tegument elicits tegument da mage, reduction in egg \nand parasite burden,  Parasite Immunol. 32 (2010) 749e759. \n\n[21] F. J.   Ramalho-Pinto, G.  Gazzinelli,  R. E.  Howells,  T.A.   Mota-Santos, \nE.A.  Figueiredo, J. Pellegrino,  Schistosoma mansoni: defined system  for \nstepwise  transformation of  cerc ariae  to  schistosomule in  vitro,  Exp. \nParasitol. 36 (1974) 360e372. \n\n[22] I.R.    Caldas,   R.   Correa-Oliveira,   E.   Colosimo,   O.S.   Carvalho, \nC. L. M assara, D. G. Colley, G.  Gaz zinelli, Susceptibility and resistance to \nSchistosoma mansoni reinfection: parallel cellular and isotypic immu- \nnologic assessment,  Am . J. Trop. Med. Hyg.  62 (2000) 57e64. \n\n[23] S.R. Smithers, R .J.  Terry,  The infection of laboratory hosts with cercariae \nof Schistosoma mansoni and the recovery of adults worms, Parasitology \n55 (1965) 695e700. \n\n[24] J.   Pellegrino,   A.F.  Siqueira,  Te?cnica  de  perfusa?o  para   c olehira  de \nSchistosoma mansoni em cobaias experimentalmente infestadas, Bras. \nMalariol. Doenc?as Trop. 8 (1956) 589e597. \n\n[25] W.A. Hoffma n, J. A. Pons, J. L. Janer, The sedimentation concentration \nmethod in schistosomiaisis mansoni, Puerto R ico J. Publ. Health 9 (1934) \n281e298. \n\n[26] A.   Fenwick,  J.P.   Webster,  Schistosomiasis:  challenges  for  control,  \ntreatment  and  drug  resistance,  Curr.  Opin.  Infect.  Dis.  19  (2006) \n577e582. \n\n[27] R. K. Gupta, Aluminium compounds as vaccine adjuvants, Adv. Drug \nDeliv.  Rev. 32 (1998) 155e172. \n\n[28] J.C.  Cox, A.R.  Couter, Adjuvants-a classification and review of their \nmodels of action,  Vaccine 15 (1997) 248e256. \n\n[29] A.M.  Harandi, D.  Medaglini, R.J.  Shattoc, Vacc ine adjuvants: a priority \nfor vaccine research, Vaccine 28 (2010) 2363e2366. \n\n[30] S.G. Reed,  S. B ertholet, R. N.  Coler, M. Friede, New horizons in adju- \nvants for vac cine development, Trends Immunol.  30 (2009) 23e32. \n\n[31] D.M. Klinman, D. Currie, L. Gursel,  D. Verthelyi, Use of CpG oligo- \ndeoxynucleotides  as  immune  adjuvants,  Immunol.  Rev.  199  (2004) \n201e216. \n\n[32] R. S. Chu, O.S. Targoni, A.M. Krieg,  P.V.  Lehmann, C. V. Harding, CpG \noligodeoxynucleotides act as a djuvants that switch on T helper 1 (Th1) \nimmunity, J.  Exp. Med. 186 (1997) 1623e1631. \n\n[33] D. A. Carson,  E.  Raz,  Oligonucleotide adjuvants for T helper 1 (Th1)- \nspecific vaccination, J. Exp.  Med. 186 (1997) 1621e1622. \n\n[34] T.C.  Garcia,  C. T. Fonseca, L. G. Pac??fico, F. do V.  Dura?es, F.A. Marinho, \nM. L. Penido, M.V.  Caliari, A. L. de Melo, H. A.  Pinto,  M.M . Barsante, \nE. Cunha-Neto, S.C.  Oliveira, Peptides containing T cell epitopes,  derived \nfrom Sm14, but not from paramyosin, induce a Th1 type of immune \nresponse,  reduction  in  liver  pathology and  partial  protection  a gainst \nSchistosoma mansoni infection in mice,  Acta Trop.  106 (2008) 162e167. \n\n[35] T.A. Wynn, A. W.  Cheever,  D. Jankovic, R. W. Poindexter, P. Caspar, \nF. A. Lewis,  A. Sher, An IL-12-based vaccination method for preventing \nfibrosis induced by schistosome infection,  Nature 376 (1995) 594e596. \n\n[36] J.  Vollmer, M.  Jurk, U. Samulowitz, G. Lipford, A.  Forsbach,  M.  Wu? llner, \nS. Tluk, H. Hartmann, A. Kritzler,  C.  Mu? ller, C. Schetter, A. M. Krieg, CpG \noligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 \nproduction in human B cells, J.  Endotoxin Res. 10 (2004) 431e438. \n\n\n\n\u00a0\n\n\u00a0\n\n96\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[37]  R. Testi,  J.H. Phillips, L.L.  Lanier, T cell activation via Leu-23 (CD69), \nJ.  Immunol. 143 (1989) 1123e1128. \n\n[38]  H.  Hu? hn, C.  Neukirch, K. Freitag, A. Necker, W.  Hitzler, B. Seliger, \nM.J. Maeurer, Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB \nrepertoire in CD8\u00fe T cells from  individuals immunized with recombinant \nhepatitis B surface antigen, Clin. Exp.  Immunol.  129 (2002) 309e317. \n\n[39]  F.  Rahman,  A.  Dahmen, S. Herzog-Hauff, W.O. Bo? cher,  P. R. Galle, \nH. F. Lo? hr, Cellular and humoral immune responses induced by intra- \ndermal or intramuscular vaccination with the major hepatitis B surface \nantigen,  Hepatology 31 (2000) 521e527. \n\n[40]  K. F. Hoffmann,  A.W. Cheever,  T.A.  Wynn, IL-10 and the dangers of \nimmune polarization: excessive type 1 and type 2 cytokine response \ninduce distinct forms of letha l immunopathology in murine schistoso- \nmia sis, J. Im munol. 164 (2000) 6406e6416. \n\n[41]  L.  Yu, X. Sun, F.  Yang,  J.  Shen, Z.  Wu, Inflammatory cytokines IFN-g \nIL-4, IL-13 and TNF-a alterations in schistosomiasis: a meta-analysis, \nParasitol.  Res. 110 (2012) 1547e1552. \n\n[42]  D. A.  Vignali,   P.  Crocker,  Q.D.  Bickle,  S.  Cobbold,  H.   Waldmann, \nM.G. Taylor, A role for CD4\u00fe but not CD8\u00fe T cells in immunity to \nSchistosoma mansoni induced by 20 Krad-irradiated and Ro 11-3128- \nterminated infec tions, Immunology 67 (1989) 466e472. \n\n[43]  S.L. Jam es, P.C . Natovitz, W. L.  Farrar, E.J.  Leonard, Macrophages as \neff ector cells of protective immunity in murine schistosomiasis: macro- \nphage a ctivation in mice va ccinated with radiation-attenuated cerc ariae, \nInfect. Immun.  44 (1984) 569e575. \n\n[44] S. L. James,  A.W. Cheever, P. Ca spar, T.A. Wynn, Inducible nitric oxide \nsynthase-deficient mic e develop enhanced Th1 cytokine-associated \ncellular and humoral immune responses after vaccination with attenu- \nated Schistosoma mansoni cercariae but display partially r educed resis- \ntance,  Infect.  Im mun. 66 (1998) 3510e3518. \n\n[45] S.  Mukherjee,  L.Y.   Chen,  T. J.   Papadimos,  S.  Huang,  B.L.  Zuraw,  \nZ.K.  Pan, Lipopolysaccaride-driven Th2 cytokine production in macro- \nphages is regulated by both MyD88 and TRAM,  J. Biol. Chem.  284 \n(2009) 29391e29398. \n\n[46] P.  Pouliot,  V.  Turmel,  E.  Ge?linas,  M.  Laviolette,  E.Y.  Bissonnette, \nInterleukin-4 production by human alveolar ma crophages, Clin.  Exp. \nAllergy 35 (2005) 804e810. \n\n[47] C.  Bu? ttner, A.  Skupin, T.  Reimann, E. P. R ieber, G. Unteregger, P.  Geyer, \nK.H.  Frank, Local production of interleukin-4 during ra diation-induc ed \npneumonitis and pulmonary fibrosis in rats: macrophages as a prom- \ninent source of interleukin-4, Am. J.  Respir. Cell. Mol.  Biol. 17 (1997) \n315e325. \n\n[48] F.O.  Martinez,  L.  Helming,  S. Gordon, Alternative a ctivation of macro- \nphages: an immunologic functional perspective, Annu.  Rev. Im munol. 27 \n(2007) 451e483. \n\n[49] P.J.  Murray,  T.A. Wynn, Obstacles and opportunities for understanding \nmacrophage polarization, J. Leukoc. Biol. 89 (2011) 557e563. \n\n[50] L. Barron, T.A. Wynn, Macrophage activation governs schistosomiasis- \ninduced   inflammation  and   fibrosis,  Eur.   J.   Immunol.  41   (2011) \n2509e2514. \n\n\n\n\u00a0\n\n\u00a0\n\n97\u00a0\n\n\u00a0\n\nUma vez que verificamos que os anticorpos espec\u00edficos contra o tegumento \n\nencontravam-se em n\u00edveis mais elevados em camundongos imunizados e protegidos (Teixeira \n\nde Melo et al., 2010; Teixeira de Melo et al., 2012), passamos a investigar se estes anticorpos \n\nestavam diretamente envolvidos na elimina\u00e7\u00e3o do parasito ou simplesmente representavam \n\num marcador de ativa\u00e7\u00e3o da resposta do hospedeiro.  Sendo assim, avaliamos se os anticorpos \n\neram capazes de se ligar \u00e0 superf\u00edcie de esquistoss\u00f4mulos de Schistosoma mansoni in vitro \n\npor fluoresc\u00eancia. Apenas esquistoss\u00f4mulos que entraram em contato com soro de \n\ncamundongos vacinados com Smteg tornaram-se fluorescentes ao serem incubados com o \n\nanticorpo secund\u00e1rio. Este resultado confirma que os anticorpos produzidos em resposta a \n\nimuniza\u00e7\u00e3o s\u00e3o capazes de reconhecer e se ligar a prote\u00ednas da superf\u00edcie dos parasitos, \n\nsugerindo que estes poderiam estar envolvidos na elimina\u00e7\u00e3o dos mesmos. Foi avaliado \n\ntamb\u00e9m se a ativa\u00e7\u00e3o do sistema do complemento pela via cl\u00e1ssica seria capaz de promover a \n\nmorte de esquistoss\u00f4mulos in vitro. Para isso, foram realizados ensaios de citotoxicidade in \n\nvitro com cultura de esquistoss\u00f4mulos rec\u00e9m transformados e que entraram em contato com \n\nsoro inativado de camundongos inoculados com salina + CFA/IFA ou Smteg + CFA/IFA \n\njuntamente com o complemento ativo ou inativado. Demonstrou-se que o sistema do \n\ncomplemento \u00e9 capaz de promover a morte dos parasitos in vitro e que a presen\u00e7a de \n\nanticorpos espec\u00edficos, levando a ativa\u00e7\u00e3o do complemento pela via cl\u00e1ssica aumenta ainda \n\nmais a capacidade do complemento eliminar os esquistoss\u00f4mulos. Para avaliar, in vivo, o \n\npapel dos anticorpos na elimina\u00e7\u00e3o do parasito em nosso modelo de vacina\u00e7\u00e3o, foi realizado \n\num ensaio no qual os anticorpos espec\u00edficos foram transferidos para um camundongo \n\nrecipiente \u201cnaive\u201d. Soro proveniente de camundongos vacinados com Salina + CFA/IFA ou \n\nSmteg + CFA/IFA foi transferido para camundongos que foram, ent\u00e3o, Infectados com 100 \n\ncerc\u00e1rias. Observou-se uma redu\u00e7\u00e3o significativa de 27% da carga parasit\u00e1ria de \n\ncamundongos que receberam soro contendo anticorpos anti-Smteg em rela\u00e7\u00e3o aos \n\ncamundongos que receberam soro n\u00e3o imune, al\u00e9m de uma redu\u00e7\u00e3o significativa de 37% e \n\n47% no n\u00famero de ovos presos no intestino e f\u00edgado destes animais, respectivamente (Melo et \n\nal., 2014). \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n98\u00a0\n\n\u00a0\n\n \n\nParasite  Immunology,  2014, 36,  107\u2013111 DOI: 10.1111/pim.12091 \n \n \n\nBrief Definitive Report \n \n\nAntibodies  are involved  in the protective  immunity  induced  in mice \n\nby Schistosoma  mansoni  schistosomula tegument  (Smteg) \n\nimmunization \n \n \n\nT. T. D E  MELO,1,a I. C. D E  SENA,1 ,a   N.  ARAUJO1  &amp; C. T. FO NSECA1 ,2  \n\n \n1C entro  de Pesquisa s Ren e Rachou, Fiocruz-MG, Belo Horizonte, Brazil,  2Instituto Nacional  de Ci?encias e Tecnologia   em Doen cas \nTropicais  (INCT-D T), Belo Horizonte, Brazil \n\n \n \n \n \n\nSU M MA RY  \n \n\nThe Schistosoma  mansoni  schistosomula tegument (Sm teg ) \n\nplays  an  imp ortant   role  in   triggering   the  host  immune \nrespo nse  an d  mice  immunization  with  Smteg  fo rmulated \nwith  Freun ds ad ju vant or alum + CpG in duce partial  protec- \n\ntion    against    S. mansoni    infection    associated    with   an  \n\nin creased antibody prod uction. In this study, we investigated  \nth e role of th ese antibodies in p arasite  killing b oth in vitro \nand  in   vivo.  We  demon strated   that  th ese  antibodies  were \n\nable  to  b ind   to  the  surface  of  S. mansoni  recently  trans- \nformed  schistosomula an d that  these antibodies significantly \n\nin crease  th e  percen tage  of schistosomula killed in vitro  by \ncomplement activatio n.  Passive tran sferen ce  of immune sera \n\ndecreased   the  parasite   bu rden  and    the  number  of  eggs \ntrapped  in the organs  of mice that  received sera  contain in g \n\nanti-Smteg  antibodies.  T hese results  demonstrate  that  anti- \nbodies specific to  surface  tegumental  antigens  are  involved \n\nin  parasite  eliminatio n in mice immunized with Smteg. \n\n \nKeywords antischistosomula    surface    proteins    antibodies, \nprotectio n, Schistoso ma  manson i,  schisto somu la \n\n \n \n\nIN T R O D U C T I O N  \n \n\nSchistosomiasis  remains a serious public health  problem  in  \n\n76 countries  and  territories  of  the  world  with   more  th an \n \n \n\nCorrespondence: Cristina  Toscano  Fonseca,  L aborato rio de \nEsquistossomose, Centro  de Pesquisas Ren e Rachou, Avenida \nAugusto  de Lima, 1715,  B arro  Preto,  CEP: 30190-002, Belo Hori- \nzonte, Minas Gerais,  B ra zil.  (e-mail: ctoscano@cpqrr.fiocruz.br) \naThese authors  contributed equally to this study. \nDisclosures:  None. \nReceived: 6 September 2013 \nAccepted for publication: 21 November 2013 \n\n200 million individuals  infected  an d  causing  annual  losses \nof 10 4 million in DALY s  (1, 2). The current  control  p ro- \n\ngramme  is based  on chemo therapy  w ith praziq uantel th at \nhas  limit  effect  in  disease  tran smiss ion and   also  do  n o t \n\nprevent  re-infection  (3, 4). T he  control  of schistosomiasis \nwould   be   greatly   improved    by   the   develo pment   of   a \n\nvaccine,  an d  to   develop  an  effective vaccine  fo rmulatio n, \nthe choice of a good   antigen  and  the study of the protec- \n\ntive immune  mechanisms  involved   in  parasite  elimination  \nare essential. \n\nRecently,   our   group    dem on strated   that   Schistosoma \nmanso ni schisto somula  (Smteg)  tegument  plays  an  impo r- \n\ntant   ro le  in   triggering  the  immune  respon se  against  the \nparasite.  This  antigen  is able  to  activate  upregulation  of \n\nCD40  an d  CD 86  expression s  in  dendritic   cells  (5)  and  \ninduce  a partial  protection  in  mice when  formu lated w ith \nFreund s  adjuvant  (43\u201348%) (6) or alum + Cp G-O DN   (7 ). \n\nThe  protective  resp onse  was  associated  with  a  predo mi- \nnant  Th1 type of immu ne respon se, with increased p ro du c- \n\ntion of specific an tibo dies. \nAntibod ies    have    previo usly    being    rep orted     to    b e \n\ninvo lved in schistosome  elimination.  In rats,  IgG2a  is otype \nagainst  the parasite  has been reported  as a lethal ant ibo dy \n(8 ). In  the  irradiated cercariae  vaccine,  B cells as w ell as \n\nIFN-g  and  CD 4\n+ \n\ncells play im po rt ant roles in p arasite \nelimination  (9, 10). Antibodies  against  Sm-p80,  a vaccine \ncandidate,  have also been rep orted  to  be involved in p ara- \n\nsite elimination  through  an   antibo dy-d ep end en t  cell-m ed i- \nated   cytotoxicity   (ADCC)   mech anism   (11 ).  In  hum ans, \n\nan tibod ies against surface parasite antigens have been \nassociated  with  resistance to re-infection  (12). \n\nThe   mechan isms   by   which   antibodies    may   m ed iate \n\nparasite   d eath   are   ADCC   and   complement   activatio n. \n\nAlthough  parasite  became  resistan t  to  killin g  by co mp le- \nment activation  as it matures  in the ho st (13), so me studies \n\n \n\u00a9 2013 John  Wiley &amp; Sons Ltd                                                                                                                                                                                   \u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n99\u00a0\n\n\u00a0\n\n \n\n \n\ndemo nstrate that  complement  activation   must be an impo r- \n\ntant  parasite  elimination  mechanism  in  the  begin ning  of \n\nth e infection (14). Regarding  an tibod y-depend en t cell- \nmediated   cytotoxicity  (ADCC)  mechanism, many cells h ave \ndemo nstrated  to  promote  parasite killing as eosin ophils, \n\nmacro ph ages and platelets (15\u2013 17). \nIn  this  study,  we investigated  the  ro le of the  an tibod ies  \n\nproduced   by  Smteg-immunized   mice  in   parasite   killin g \nboth   in  vitro  and   in  vivo. We  dem ons trated  that   these \n\nantibodies  were ab le to  bind  to  the  surface  o f S. mansoni \nrecently  transformed  sch istosomula   and  that   these  an ti- \n\nbodies  significantly  increase  the  percentage   of  s ch isto so- \nmula killed in vitro by co mp lement  activation .  Passive \n\ntransference   of  immune   sera  significantly  decreased   the \nparasite  burden   an d  the  nu mber  of  eggs  trapped   in  th e \n\norgans of mice that received sera containing  anti-Sm teg  \nantibodies  indicating  that  antibodies  play a role in parasite \n\neliminatio n  in those mice immu nized with  Smteg. \n \n \n\nME TH O DS  \n \n\nMice and parasites \n \n\nFemale  C57BL/6 mice aged 6\u20138 weeks w ere obtained  from  \nCentro  de Pesquisas  Ren e Rach ou  (CPq RR) facility \u2013 FI- \n\nO CRU Z (Funda cao O sw aldo  Cru z).  Cercariae  of Schisto- \nsoma man soni (LE  satrain)  w ere maintain ed  routinely  on  \n\nBiomphalaria  glabrata  snails at CPq RR  and were ob tained  \nby  exposing  infected  sn ails  to  light  for  1\u20132 h  to  induce \n\nshedding.  Cercarial  nu mbers  and   its  viability  were deter- \nmined using a light microscop e.  Cercariae  from S. mansoni \n\nwere  mechanically  tran sfo rm ed  into  skin-stage  sch isto so- \nmula  according  to   Ramalh o-Pint o  et al.  (18)  with  some \n\nmod ifications.  Briefly, cercariae  were incubated  on  ice fo r \n30 min  and  then   centrifu ged  at  1800 g fo r  3 min  at  4\u00b0C. \n\nThe  cercariae  were resuspen ded  in  cold  G lasgow  medium  \n(Sigma-A ld rich,  St. Louis, MO, USA) containing  1% peni- \n\ncillin /streptomycin   supp lemented   with   10%  foetal  b ov ine \nsera.  The tails were broken   by vortexin g  in h igh  sp eed for \n2 min  and  removed  through   several  washing  step s  with  \n\nGlasgow   medium.   Th e  schistosomula   were  cultured   for \n90 min at 37\u00b0C in  mediu m. \n\n \n \n\nDetection of specific antibodies on the surface of \nschistosomula \n\n \n\nSchistosomula  were  placed  in  microtubes   o f  1 5 mL   and  \nwashed  three  times  with  D M E M   without   fo etal  bovine \n\nsera by centrifu gation  at  180 0 g/5 min. The schistoso mula \nwere  fixed  in  PBS + 1%  formald ehyd e   fo r  1 h  at  4\u00b0 C. \n\nAfter  this  p eriod,  schistosomu la  were washed  in PBS an d \nin cubated  in RPMI  for  30 min.  A  second  w ash  step  w as \n\nperformed,   an d   parasites   were  incubated   in  PBS + 1% \n\nBSA   for  30 min.  After  a  third   wash  step,  schistoso mula \n\nwere incubated  overnight  with  sera  from  mice in oculated  \nwith saline + co mplete/in co mplete Freund  adjuvant  (CFA / \nIFA)  or  immunized  with  Smteg  + CFA / IFA  as  d es cribed \n\nby  Teixeira   de  Melo   et al.  (2010)  (6)  d iluted    1:100  in \nPBS + 1%  BSA .  A fter  this  process,   schistosomula   w ere \n\nwashed  with  PBS + 1% BSA  for  three  times  as d es cribed \nabove,  incubated  in RPMI  for  3 0 min,  washed  an d  in cu- \n\nbated   in  PBS + BSA  1%  for  30 min .  The  detection   o f \nbound   antib odies  in schisto so mula  tegument  was obs erved \n\nby  incu bating   th e  parasite  w ith  a  FIT C-conju gated anti- \nmouse IgG  (Sigma-Aldrich)  fluo rescent  secon dary  antis era \n\nfor 2 h at room  tem perature, in the dark.  Finally,  schistos- \nomula were washed three times  with PBS by cen trifugation  \n\nat 1800  g/5  min, and th ree slides were assembled using the \nan tifading   Mow io l   (Sigma-Aldrich)   to   preserve  fluo res- \n\ncence. A ntib ody binding to schistosomula tegument was \nevaluated   by  fluorescence   microscopy,   ImageJ   p rog ram  \n\nwas u sed to  determine  fluorescence  level in the  sch istoso- \nmula teg ument. \n \n \nCytotoxicity assay  \n \nFifty  sch istosomula   p er  w ell were  p laced  in  96-well flat \n\nbottom  with  100 lL of  Glasgow  culture  medium  supp le- \nmented with 10 % foetal bovine sera. In activ ated sera from  \n\nmice  ino culated   with    saline + CFA /IFA   or   fro m   mice \nimmun ized   with  Smteg + CFA /IFA  d iluted  1 :10 in  Glas- \ngow medium  were added  to  plate  wells and   incubated  fo r \n\n30 min at 37\u00b0C, 5% CO2.  After  this period ,  inactivated  o r \nactive  complement   from  guinea  pigs  (Sigma-Aldrich)   at \n\n1:10 dilu tion  was added   to   each  well. As con tro ls  to  the \nassay,  schistoso mula  were  incubated  with  medium  alo ne, \nwith  sera  alone   o r  with   complement   from   guinea  pigs \n\nalon e.  The plate  was then  incubated  for 16  h at  37\u00b0C, 5 % \nCO2,   and  to evaluate  parasite  viability, schistosomula  w ere \n\nstained   with    1.5 lg/well  of  acridine   orange   fluorescent \n\nprobes  (stain  viable  p arasite)   and  5 lg/well  of  ethidiu m \nbromide   (stain  dead   parasites).   T he  plate  w as  incu bated \nfor 20 min at 37\u00b0C, 5% CO2    and washed  three  times w ith \n\nGlas gow  medium  at 37\u00b0C to remove un bo un d pro bes.  T he \n\npercentage  of  dead/live  schistoso mula  w as determined  b y \nco untin g  three  times  2 0 lL/well in  a  fluorescence  micro- \nsco pe. Two independent  assays were perfo rmed. \n \n \nPassive transfer of antib odies \n \nSera   from   mice   inoculated   with   saline + CFA /IFA   o r \n\nSmteg + C FA /IFA  as describ ed  b y Teixeira de Melo  et al. \n(2 010) (6) were collected 30 days  after  the  last immu niza- \ntion  and  in activated  at  56\u00b0C/30  min to  be u sed in passive \n\n\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n100\u00a0\n\n\u00a0\n\n \n\nVolume 36, Number 2, February 2014 Anti-Smteg antibodies mediate parasite  death \n\nsera transfer protocols.  Forty-five animals were d ivided  \nran domly   in  three  groups  of  15  animals  each:  a  con tro l \n\ngroup  that  did  not  received  s era  transfer;  a  saline  gro up  \nth at     received    sera    fro m     an imals     inoculated     with  \n\nsaline + CFA /IFA  and  a  Smteg  group  that  received  sera \nfrom   animals   immunized   with  Smteg + CFA/IFA .  Mice \n\nreceived   th ree  intravenously   ino culation of  sera  (20 0 lL) \nvia the  tail  vein.  The  in ocul ation  occurred  8 days  before \n\nin fectio n,  the  second  3 days  before  the  infectio n  and  the \nth ird  on th e day of the percutaneous  infection  of the ani- \nmals  with  10 0  cercariae/mouse   from  de  S. mansoni  L E  \n\nstrain.  Fifty  days  after  infectio n,  mice were  perfu sed  fo r \n\nth e recovery of worms  accordin g  to Pellegrino  and  Siq ue- \nira,  1956 techniq ue  (19). At  the  same  time,  the  liver and  \nin testine  from  each mouse were collected, digested in 10% \n\nKOH   as previously  describ ed  (6 ) to determine  th e num ber \nof  eggs trapp ed   in  th ese  organs.  Two   in dependent   assays \n\nwere performed. \n \n \n\nStatistical  an al ysis  \n \n\nStatistical  analyses were performed  using t-student  test fo r \nparasitolog ical analyses and ch i-square test fo r in vitro \n\ncytotoxicity assay an alyses usin g th e softw are pack age \nG rap h Pad  Prism   5.0   (G raph Pad   Software,   San   D iego, \n\nCA , USA ). \n \n \n\nEth ics \n \n\nAll  procedures   invo lving  animals  were  approved   by  th e \nlo cal Ethical Commission of Animal Use (CEUA) from  \n\nFIO CRU Z  under  licence number:  LW-26 /1 2. \n \n \n\nRE SU L TS  \n \n\nTo  evaluate  whether  the  antibodies  produ ced  in   respo nse \nto  mice immu nizatio n with Smteg + CFA / IFA  were able to  \n\nbind proteins expressed in schistosomula surface, an  \nim muno fluorescence staining was performed in newly \ntrans form ed  schistosomula.  The  Figure  1(a\u2013d)  is a  repre- \n\nsentative  picture  o f the results o bserved in immu no fl uo res- \ncence stain in g,  and  fluorescence  intensity  was d etermin ed  \n\nin   schistoso mula  incubated  with  sera  from  saline + C FA / \nIFA  o r  Smteg + C FA /IFA  immu nized  mice using  imageJ \n\nprogram;  the results (Figure  1e) demo nstrate that  anti bo d- \nies   present    in   the   sera   from   mice   immunized   with  \n\nSmteg + CFA /IFA   recognized    molecules  in  th e  parasite \nsurface. \n\nFurth erm ore, we evaluated  whether  complement  activa- \ntion   could  promote  schistosomu la  death  in vitro. For  this, \n\na  cytotoxicity   assay  was  performed   using  n ewly  tran s- \nformed  schistosomula  that  came  into  contact  with  inacti- \n\nvated sera from mice inocu lated  with saline + CFA / IFA  o r \nSmteg + CFA / IFA  together  with  an  active  or  inactivated  \n\nco mplement  sou rce  from  guinea  pigs. Figure  1f represen ts \nthe  results  obtained  in two  independent  assays  an d  d em- \n\nonstrates    that    altern ative    complemen t    activation    can  \npromote   schistosomula  d eath  in  vitro,  but  the  p ercen tage \n\nof dead schisto so mula  significantly increase when  the clas- \nsical complement  pathway is activated by Smteg-specific \n\nantib odies. \nIn  o rder  to  evaluate  the ro le of Smteg-sp ecific an tibo d- \n\nies in  parasite  elimin ation  in vivo, sera  fro m  mice immu- \n\nnized  with  Saline + C FA /IFA  or  Smteg + CFA / IFA  were \n\ntran sferred   to  na\u20ac?ve  recipients.  Analyses  of  the  p arasite \nburd en  and  of th e numb er  of eggs trap ped  in host o rgan s, \nperformed fifty days after challenge infection with 100 \n\ncercariae,  demo nstrate a sign ificant  decrease of 27% in the \nparasite  burden  in mice that  received sera con taining  anti- \n\nSmteg  an tibod ies  compared  with  mice that  received  no n- \nimmun e  sera  (Figu re  1g). Also  a  significant  reduction  of \n\n37% and  47 % in number  of eggs trapped  in the  intestine \nan d  liver of  these  animals,  respectively  (Fig ure1 h  and  i), \nwas o bserved  in mice that  received immune sera. \n \n \nD IS CU SS I ON  \n \nRecently,   stud ies  performed   by  our  group   have  d em on- \n\nstrated   th at   mice  im mun ization   with  Smteg  in  different \nvaccine fo rmu latio ns ind uced a sign ifican t pro du ctio n of \n\nspecific antibodies (6, 7). Wheth er these antibodies w ere \ndirectly  involved  in parasite  eliminatio n  or  only  rep resent \n\na hallmark  of host  immune  response  activation   still und e- \ntermin ed.  The  results  on  immuno fluores cence staining  of \n\nsch istosomula  using sera from mice immunized w ith Smteg \nor  saline dem on strated that  the antibodies  produced  after \n\nimmu nizatio n recognize and  bind  to parasite  surface  anti- \ngen s.  D emo nstrat ing  that   surface  schistosomula   p ro tein s \n\nare co nstituents  of the Smteg preparation  an d suggest th at \nthese  antibodies  cou ld   be involved  in parasite  elimination  \n\neither by classical complement  activation  or by A D CC. \nClassical   and   altern ative    complement   activation    has \n\nbeen previously  d em ons trated to promote  the death  of the \nyoung  schistosomula   in   vitro  and  in   vivo (13,  14 ).  O ur \n\nresults d em on strate that  either alternative  or classical com- \nplement  activation  is ab le to promote  schistosomu la  d eath  \n\nin vitro; h ow ever,  the  presence  of anti-Smteg-specific  anti- \nbodies  bounds   to  parasite   surface  increased   significantly \n\nthe  p ercentage  of killed parasite.  If these  classical activ a- \ntion are involved in the elimination  of skin-stage sch istoso- \n\nmula  in  vivo still  to  be  determined,   n evertheless  p as sive \ntransfer   of  sera   from   mice  immunized   with   Smteg   o r \nSaline  to  a  n a\u00efve  recip ient  demo nstrated that  anti-Smteg \n\nan tibod ies   are  involved  in  parasite   elimination    in  vivo, \n\n\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n101\u00a0\n\n\u00a0\n\n \n\n \n\nw\no\nrm\n\n b\nu\nrd\n\ne\nn\n r\ne\nc\no\nv\ne\nre\n\nd \n\nF\nlu\n\no\nre\n\nsc\nen\n\nce\n i\n\nnt\ne\n\nn\nsi\n\nty\n (\n\np\nix\n\nel\n) \n\ne\ng\ng\ns/\n\ng\nra\n\nm\n o\n\nf \nin\n\nte\ns\ntin\n\ne\n \n\n%\n o\n\nf \nd\n\ne\nad\n\n s\nch\n\nis\nto\n\ns\nom\n\nu\nla\n\n \n\ne\ng\ng\ns\n/g\n\nra\nm\n\n o\nf \nliv\n\ne\nr \n\n \n \n \n\n \n(a) \n\nSaline                    Smteg \n\n(c) \n\n \n \nP = 0\u00b70001 \n\n \n \n \nP = 0\u00b70001 \n\n \n\n \n(b) \n\n \n \n \n \n\n280 \n\n \n(d) \n\n \n \n \nP = 0\u00b70294 \n\n35   \n(f) \n\n30 \n25 \n\n20 \n\n15 \n\n10 \n\n5 \n\n0 \n\nP = 0\u00b70005 \n\n \n260 \n\n \n240 \n\n \n220 \n\n \n200 \n\n \n180 \n\n(e) \n \n \n \n \n \n \n \n \n\nSaline + CFA/IFA             Smteg + CFA/IFA \n\nSchistosomula                            +            + \n\nSer a fr om saline group \n\nSera from smteg group \n \nComplement                                             + \n\nInactivated complement \n\n+             +            + \n \n+                            + \n \n\n+ \n \n\n+ \n\n+            +             + \n \n\n+ \n \n+                           + \n \n+ \n \n\n+            + \n\n \n \n\n50   (g)  \n \n\n40 \n \n\n30 \n \n\n20 \n \n\n10 \n \n\n0 \n\nP &lt;0\u00b70001 \n\nP = 0\u00b70064 \n\n \n \n \n \n27% \n\n \n20000 \n\n \n15000 \n\n \n10000 \n\n \n5000 \n\n \n0 \n\n \n(h) \n\n \nP = 0\u00b7046 \n\n \nP = 0\u00b7 0419 \n\n \n\n \n \n \n \n \n37% \n\n \n\n \n20000 \n\n \n15000 \n\n \n10000 \n\n \n5000 \n\n \n0 \n\n \n(i) \n\nP = 0\u00b7 0039 \n \n\nP = 0\u00b70001 \n\n \n\n \n \n \n \n \n52% \n\ninfected animals   Saline          Smt eg                             infected mice Saline          Smt eg                             infected mice      Saline          S mteg \n\nFigure 1 The role of anti-Smteg  antibodies  in S. m ansoni elimination.  Newly transformed schistosomula  were incubated  with sera  from \nmice inoculated  with saline + CFA/IFA (a\u2013b) or immunized with Schistosoma mansoni schistosomula  tegument  (Smteg) + CFA/IFA (c\u2013d). \nAntibody  reactivity to surface schistosomula  proteins  were detected by a secondary  anti-mouse  IgG-FITC-conjugated antibody, the mean \nfluorescence intensity in the schistosomula  tegument  a fter incubation with sera from mice immunized with saline or with Smteg and anti- \nIgG-FITC-conjugated antibody  was determined  using ImageJ in four schistosomula   per treatment (e). Significant differences between \ntreatments determined  by Mann\u2013Whitney test are pointed  in the graphic  (e). Complement  activation  and cytotoxicity  in schistosomula \nwere assessed in vitro (f). The viability of sc histosomula  was observed  by fluorescence microscopy.   Ba rs represent  the percentage  of dead \nschistosomula  of two independent  experiments  + SD. Three wells per treatment wer e analysed in each experiment.   Significant differences in \nthe percentage  of dead parasite  in comparison with wells that  contain  schistosomula  with medium are denoted  by an asterisk  (P &lt;0 05). \nOther  statistically  significant differences are pointed  in the graphic.  Post-challenge  infection determination of worm burden  (g), eggs \nnumber  in the intestine (h) or liver (i) from mice that  received intravenous transference  of sera from saline inoculated  animals (white bars) \nand Smteg-im munized  animals (black bars). Grey bars represent  the results from challenge infection control  group.  Bars represent  the \nmean values      SD of two independent  assays with 15 animals for group  in each assay. Statistically  significant differences between groups \nare pointed  in the graphic. \n\n \nbecause  a sign ificant  reduction  in parasite  bu rden   and  in  \n\nth e number  of eggs trapp ed  in the liver and  intestine  w ere \nobserved  in ch allenged  mice, which received  immune  sera. \n\nThe  redu ction   in  th e  number   of  eggs  trapped   in   these \norgans  reflects the reductio n  in the worm burden  and d oes \n\nnot  represen t   a  reduction   in  wo rm  fecundity  (data   n ot  \nshow n). \n\nThe  ro le  of  B  cells  and  an tibodies   has  been  d emo n- \nstrated  in  mice imm unization protocols  using formu lati on  \n\nwith   irrad iated cercariae  and  Sm-p8 0.  Passive  transfer  of \n\nsera fro m mice that had been  exposed  to two or th ree \n\nimmu nization s  w ith   50-kilo rad   g am ma-irradiated    cerca- \nriae, a vaccine formulatio n that  induces high levels of \n\nprotectio n  reduced   sign ificantly   (20\u201350%)  the   parasite \nburd en   in  ch allenged  recip ients  (2 0).  Passive  transfer   of \n\nsera from  mice or  IgG  pu rified   from  bab oons  immunized  \nwith  Sm-p80   conferred  a  31\u201345 % p ro tection in   the  chal- \n\nlenged recipients (11). \nThe  mechanism  involved  in in vivo parasite  eli min atio n \n\nmediated  by  anti-Smteg  antibodies  still  to  be  elucid ated. \n\n\u00a0\n\n\n\n\u00a0\n\n\u00a0\n\n102\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBo th   classical co mplement  activation  and   ADCC  may  be \n\ninvolved.  Classical  complement  activation  cou ld  b e acting  \nat  skin  level p ro moti ng newly transformed  sch istosomu la \n\ndeath,  because th e parasite  d evelop s evasion strategies  and  \nbecame  refractio nal  to  complement   activatio n   (21) while \n\nADCC  co uld be taking  place in both  skin and lu ng levels. \nThis hypothesis  is still to b e investigated.  N evertheless,  ou r \nresults  d em on strate  that   antibodies   can  be  used  in  the \n\niden tification  o f p rotective antigens in  the schistosomu la \n\ntegument,  to b e used  in a subunit  vaccine formu lat ion . \n \n \nA CK N O W L E D G M E N T S  \n \n\nThis work was su pp orted by CNPq; IN CT -D T/CN P q, \nRip ag /CPq RR-Fio cru z, Fapemig.  Fellowships:  PIBIC/ \n\nCNPq  (ICS); PQ /CN Pq  (CT F). \n \n \n\nREF ERE N CES  \n \n\n1  Engels D, C hitsulo  L, Montresos  A &amp; Savio- \nli L. The Global  epidemiological  situat ion  of \nschi stosomiasis   and  new  a p proa c h e s t o \ncontrol   and  research.   Acta  Trop  2002;  82:  \n139\u2013146. \n\n2  PA H O /W HO-P an am eri ca n Health  O rga niz a- \nti on/ World Health  O rga ni za ti on. P re pa rat ory \nMeeting on Epidemiological  Data  Needed  t o \nPlan El iminat ion  of Schis tosomiasis in the  \nCa ri bb ea n.  St. George: 13\u201314, 2007. \n\n3 World  Heal th   O rga ni za ti on  WHO.  TD R \nStrat egic  Direction for Research: Sc histosomi - \nas is.   Geneve,   World   Health    O rga ni za ti on \nWHO,   2002. \n\n4  Loukas  A, Tran  M  &amp; Pearson  MS.  S c histo- \nsome   membrane    proteins    as   vaccine.   In t \nJ Parasitol  2007; 37: 257\u2013263. \n\n5  Duraes  FV,  C arvalho  NB, Melo TT, Ol ivei ra  \nSC   &amp;   Fo nseca   CT.  IL-12  and  TNF-a   p ro- \nducti on  by dendrit ic  cells st imulated  w it h \nSchistosoma mansoni schistosomula  te gum e nt \nis  TLR4-   and  MyD 88 -de pe nde nt.  Immunol \nLett  2009; 31: 432\u2013439. \n\n6  Teixeira de Mel o  T, Michel  de Araujo  J, D o \nValle  Duraes   F,   et al.   Im muni za ti on  w it h \nnewly t ran sfo rme d Schis tosoma mansoni \nschi stosomula  tegument  el icits  te gum e nt \ndamage,  reduct ion  in  egg and  parasit e  b ur- \nden. Parasite  Immunol 2010; 32: 749\u2013759.  \n\n7  Teixeira de Melo  T, Araujo  JM ,  C ampos  de \nSena   I,   Carvalho   Al ves  C,   Araujo   N   &amp; \nToscano  Fonseca  C.  Eva l uat ion o f  the  p ro- \ntective immune  response  induced  in mi ce by \nim muni z ati on with Schistosoma mansoni \nschi stosomula   t egument    (Smt eg)  in  as soc ia - \ntion  with  Cp G-O D N. Microbes  Infect  2013;  \n15: 28\u201336. \n\n8  Horta  MFM  &amp; Ra ma lh o-P int o FJ.  Levels of \nlet hal  anti bod y   during  the  course  of  i nfe c- \ntion  with  Schistoso ma  mansoni  in  rats  a n d \nmice.  Mem Inst  Oswaldo Cruz 1987;  82(S up- \npl. 4): 283\u2013284. \n\n9  Jankovic  D,  Wynn  TA,  Kullberg  MC,  et a l. \nOpt imal vaccination against  Sc histosoma  \nmansoni  requires   t he  induction   o f  bo th   B \ncell- and IF N -c -de pe nde nt  effector me c ha - \nnisms. J Imm unol 1999; 162:  345\u2013351. \n\n10  Vignali  DA,  Crocker  P, B ickle QD,  C obbol d \nS,  Wa l dma nn H  &amp; Taylor  MG.  A  role  for \nC D 4+  but  not  C D 8 +  T cells in immuni ty  t o \nSchistosoma mansoni induced by 20 kra d- \nirra dia te d and  Ro  11-3128-terminated  infe c- \ntions. Immunology 1989; 67: 466\u2013472.  \n\n11  Torben  W, Ahmad  G,  Zhang  W &amp;  Si ddiq ui \nAA.  Role  of antibodi es  in S m-p80-me dia te d \npro te c ti on against Schistosoma mansoni \nchallenge infection  i n muri ne  and  nonh um a n \npri mate   models.   Vacci ne   2011;  29:  2262\u2013 \n2271. \n\n12  Dunne  DW,  B utt e rwo rt h AE,  Fulford  A JC , \net al.  Immunity   after   tre at me nt   of  hum a n \nschist osomias is: association bet ween IgE \nanti bodies  t o adult  worm  ant igens  and  re sis- \ntance  to  reinfect ion.   Eur  J Imm uno l  1992; \n22: 1483\u20131494. \n\n13  Santoro    F,   La c hma n n  PJ,   C apron    A   &amp; \nCapron  M. Activatio n of complement by \nSchistosoma  mans oni   schistos omula:   kill ing \nof parasit es by t he alt ernati ve pat hway a n d \nrequirement of IgG for classical pa th wa y \nactivati on.  J Immunol 1979;  123: 1551\u20131557. \n\n14  C orre a -Ol ive ira R,  Mo ta -Sa nt os TA &amp; G az - \nzinelli G. Schistoso ma mansoni: in vitro and in \n\nvivo ki lling of a nti body-c oa te d sc histos omul a.  \nAm J Trop Med Hyg 1982; 31: 991\u2013998. \n\n15  David   JR,  Bu tt erw orth   AE  &amp;  Vadas  MA . \nMechanism    of   the   i nt eraction    me dia ting  \nki lling of Schistosoma mansoni by hu ma n  \neosinophils.  Am J Trop  Med  Hyg  1980; 29 : \n842\u2013848. \n\n16  James   L.  In  vitro  proli ferative   response  to  \nl iving schistosomula  b y T lymphocy tes  from  \nmi ce infected with Schistoso ma mansoni. Pa r- \nasitology 1981; 1: 14 7\u2013162. \n\n17  Joseph  M,  Auri ault  C,  Capron  A,  Vorng  H  \n&amp; Viens P. A new funct ion  fo r platelet s: IgE- \ndependent   killing   of   schistosomes.    Na ture \n1983; 303: 810\u2013812. \n\n18  Ra ma l ho-P int o  FJ,   Gazzinelli   G,   H ow ells  \nR E,  M ota -S an tos  TA,  Figueredo  EA  &amp; Pe - \nlegrino  J.  Schistosoma  manso ni : defined   sys- \nt em  for  stepwise  tra nsform a tion   of  c e rc a ri a  \nt o schistosomule  i n vitro. Exp Parasit ol  1974; \n36: 360\u2013372.  \n\n19  Pellegrino  J &amp; Siqueira  AF.  T ecnica de pe r- \nfusao  para  colheita  de  Schistosoma  mansoni  \nem   cobaias    ex peri me nta me nte    infec ta d a s.  \nR ev  Bras  Malariol   D oe n cas  Trop  1956;  8: \n589\u2013597. \n\n20  Mangold   BL  &amp; Dean  DA.  Passive  tran sfe r \nwit h sera and IgG ant ibodies of irra dia t ed  \nc e rc a ri a -i nduc ed resist ance  against   S chi stoso- \nma  mansoni  in  mice.  J Imm unol  1986; 136: \n2644\u20132648. \n\n21  Ruppel  A, Rother  U &amp; Diesfeld HJ.  S chis to- \ns oma mansoni:  loss of the ability of sc hist os - \nomula to bind mouse complement follow ing  \ni ntrave nou s i njection into mi ce. Tropenme d \nParasitol  1984; 35: 23\u201328. \n\n\n\n\u00a0\n\n\u00a0\n\n103\u00a0\n\n\u00a0\n\nUma vez observada a import\u00e2ncia dos anticorpos presentes no soro de camundongos \n\nimunizados com Smteg na elimina\u00e7\u00e3o do parasito, foi realizada uma combina\u00e7\u00e3o de an\u00e1lises \n\nprote\u00f4micas e sorol\u00f3gicas atrav\u00e9s do Western-blotting bidimensional (2D-WB) para \n\nidentificar as prote\u00ednas presentes no tegumento de esquistoss\u00f4mulos que s\u00e3o reconhecidas por \n\nanticorpos presentes neste soro. Antes de iniciarmos a eletroforese bidimensional das \n\nprote\u00ednas presentes no tegumento, a amostra do Smteg foi submetida \u00e0 eletroforese \n\nunidimensional para observarmos a qualidade do extrato prot\u00e9ico. Foram aplicadas nas \n\ncanaletas do gel de poliacrilamida 1?g (canaleta 1), 3?g (canaleta 2) e 5?g (canaleta 3) de \n\nprote\u00ednas do Smteg e este gel foi corado por Nitrato de Prata. Como observado na figura 11,as \n\nprote\u00ednas encontravam-se \u00edntegras, n\u00e3o degradadas, uma vez que foram observadas bandas \n\nbem definidas tanto de alta quanto de baixa massa molecular. \n\n \n\n \n\nFigura 11: Perfil eletrofor\u00e9tico unidimensional de extrato proteico do tegumento \n\n(Smteg) de esquistoss\u00f4mulos de S. mansoni. 1?g (canaleta 1), 3?g (canaleta 2) e 5?g \n\n(canaleta 3) de prote\u00ednas do Smteg foram separadas por eletroforese unidimensional e corado \n\npor nitrato de prata. PM: Padr\u00e3o de peso molecular Broad Range (Bio-Rad). \n\n  \n\n200 \n\n116,25 \n97,4 \n\n66,2 \n\n45 \n\n31 \n\nKDa \n\n21,5 \n\n14,4 \n\nPM  1           2            3 \n\n6,5 \n\n\n\n\u00a0\n\n\u00a0\n\n104\u00a0\n\n\u00a0\n\nAp\u00f3s esta etapa, realizou-se a separa\u00e7\u00e3o das prote\u00ednas do tegumento de \n\nesquistoss\u00f4mulos de Schistosoma mansoni atrav\u00e9s da eletroforese bidimensional (2-DE). \n\nForam aplicados 100?g de extrato proteico sobre as fitas de IPG de 7 cm, pH 3-10NL, para \n\nsepara\u00e7\u00e3o das prote\u00ednas na primeira dimens\u00e3o e, na segunda dimens\u00e3o, as prote\u00ednas foram \n\nseparadas por SDS-PAGE 12%. A colora\u00e7\u00e3o do gel foi realizada por Azul de Coomassie \n\nColoidal. Foi observado um grande n\u00famero de spots bem definidos e com poucos arrastes ao \n\nlongo de toda faixa de pH e massa molecular (Fig. 12). \n\n \n\nFigura 12: Perfil eletrofor\u00e9tico bidimensional do extrato proteico do tegumento de \n\nesquistoss\u00f4mulos de Schistosoma mansoni (Smteg). 100 ?g de prote\u00edna total foi separada \n\npor eletroforese bidimensional utilizando fitas de IPG de 7cm, pH 3-10NL e SDS-PAGE \n\n12%. O gel foi corado com Azul de Coomassie Coloidal. Utilizou-se 7?L do padr\u00e3o de peso \n\nmolecular Benchmark (Invitrogen). \n\n Uma vez estabelecidas as condi\u00e7\u00f5es de separa\u00e7\u00e3o das prote\u00ednas de Smteg por \n\neletroforese bidimensional foram realizados os experimentos de Western-blotting \n\nbidimensional (2D-WB) utilizando pool de soro de camundongos inoculados com PBS ou \n\nimunizados com Smteg. Foram realizados dois experimentos independentes. V\u00e1rios spots \n\n3 \npH \n\n10 \n\n180 \n\n115 \n\n82 \n\n49 \n37 \n\nKDa \n\n26 \n\n19 \n\n15 \n\n\n\n\u00a0\n\n\u00a0\n\n105\u00a0\n\n\u00a0\n\nimunorreativos foram observados quando foi utilizado o soro de camundongos imunizados \n\ncom Smteg (Fig. 13 A2 e B2), enquanto nenhum spot foi visualizado com soro dos \n\ncamundongos inoculados com PBS (Fig 13 A3 e B3). Alguns spots imunorreativos foram \n\nlocalizados no gel correspondente corado por Azul de Coomassie Coloidal (Fig. 13 A1 e B1), \n\nsendo excisados destes g\u00e9is um total de 63 spots. Os mesmos foram digeridos com tripsina e \n\nsubmetidos \u00e0 identifica\u00e7\u00e3o por espectrometria de massas. Alguns destes spots est\u00e3o \n\nrepresentados por c\u00edrculos na figura 13. \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n106\u00a0\n\n\u00a0\n\nFigura 13: 2D-PAGE e respectivos 2D-WB de extrato proteico do tegumento de \n\nesquistoss\u00f4mulos do Schistosoma mansoni.  (A) e (B) representam dois experimentos \n\nindependentes. (A.1) e (B.1) indicam 2D-PAGE de 100?g do extrato prot\u00e9ico de Smteg e os \n\ng\u00e9is foram corados por Azul de Coomassie Coloidal. Padr\u00e3o de peso molecular Benchmark \n\n(Invitrogen). Foram utilizadas fitas de IPG de 7cm, pH 3-10NL e SDS-PAGE 12%. (A.2) e \n\n(B.2) representam seus respectivos 2D-WB, nos quais, ap\u00f3s transfer\u00eancia das prote\u00ednas para \n\nmembranas de PVDF, estas foram incubadas com soro de camundongos imunizados com \n\nSmteg e, posteriormente incubadas com anti-IgG total de camundongo conjugado a \n\nperoxidase. C\u00edrculos indicam as prote\u00ednas reconhecidas pelos anticorpos no 2D-WB e que \n\n180 \n115 \n82 \n\n49 \n\n37 \n\n26 \n\n19 \n\n15 \n\nKDa \n180 \n115 \n82 \n\n49 \n\n37 \n\n26 \n\n19 \n\n15 \n\nKDa \nA.3 B.3 \n\n\n\n\u00a0\n\n\u00a0\n\n107\u00a0\n\n\u00a0\n\nforam excisadas do gel correspondente corado por Azul de Coomassie Coloidal. A.3 e B.3 \n\nrepresentam os controles negativos do 2D-WB, nos quais as membranas foram primeiramente \n\nincubadas com soro de camundongos inoculados com PBS e, posteriormente, incubadas com \n\nanti-IgG total de camundongo conjugado a peroxidase.  \n\nDos 63 spots excisados, 42 foram identificados por espectrometria de massas. Uma \n\nvez que tais spots foram excisados de dois g\u00e9is independentes correspondentes aos dois \n\nexperimentos de 2D-WB realizados, alguns foram identificados como sendo a mesma \n\nprote\u00edna. Al\u00e9m disso, spots com pequena varia\u00e7\u00e3o de pI foram identificados como sendo a \n\nmesma prote\u00edna, possivelmente com diferentes modifica\u00e7\u00f5es p\u00f3s-traducionais.  \n\nDos 42 spots identificados, 22 apresentaram identifica\u00e7\u00e3o com prote\u00ednas do S. \n\nmansoni, sendo 18 deles com pelo menos 1 pept\u00eddeo que possui score indicativo de \n\nidentidade ou extensiva homologia. Estes correspondem \u00e0s prote\u00ednas listadas na tabela 4. Por \n\noutro lado, outros 20 spots n\u00e3o apresentaram hit de identifica\u00e7\u00e3o com nenhuma prote\u00edna de S. \n\nmansoni, sendo que 10 destes possu\u00edam pelo menos 1 pept\u00eddeo com score indicativo de \n\nidentidade ou extensiva homologia com prote\u00ednas de outras esp\u00e9cies. Entretanto, ao se realizar \n\num BLAST contra apenas prote\u00ednas de esp\u00e9cies de Schistosomas com a sequ\u00eancia de prote\u00edna \n\ncorrespondente a estes spots com score significativo, todos apresentaram identidade acima de \n\n80% com actina do Schistosoma mansoni. \n\nPara dar continuidade \u00e0s an\u00e1lises in s\u00edlico, foram selecionadosos 18 spots identificados \n\ncomo sendo prote\u00ednas do Schistosoma mansoni e que apresentaram pelo menos 1 pept\u00eddeo \n\ncom score significativo. Ap\u00f3s a avalia\u00e7\u00e3o da localiza\u00e7\u00e3o celular, solubilidade, similaridade \n\ncom prote\u00ednas de outras esp\u00e9cies (1. Humana, 2. Outros Schistosomas. 3. outros helmintos),  \n\npredi\u00e7\u00e3o para epitopos de c\u00e9lulas B e T, s\u00edtios de glicosila\u00e7\u00e3o e adi\u00e7\u00e3o de \u00e2ncoras de GPI foi \n\nelaborada uma tabela que mostra tais resultados (Tabela 3). \n\n\n\n\u00a0\n\n\u00a0\n\n108\u00a0\n\n\u00a0\n\nTabela 3: An\u00e1lise in silico das prote\u00ednas do tegumento do esquistoss\u00f4mulo do Schistosoma mansoni identificadas por espectrometria de \n\nmassas. \n\nSpots Massa Molecular \nTe\u00f3rica \n\n(Da) \n\nPonto \nIsoel\u00e9trico \n(te\u00f3rico) \n\nLocaliza\u00e7\u00e3o celular Solubilidade Similaridade com \nprote\u00ednas de outras \nesp\u00e9cies: 1.Humana         \n\n2. Outros Schistosomas \n 3. outros helmintos \n\nEpitopos de C\u00e9lulas B Epitopos de C\u00e9lulas T S\u00edtios de \nglicosila\u00e7\u00e3o \n\nS\u00edtio de adi\u00e7\u00e3o de \u00e2ncora de GPI \n\n6 (36) 28736 4.85 Citoplasm\u00e1tica Sol\u00favel 1. 95% 14.3.3 episilon; 2. \n100% S. japonicum; 3. N\u00e3o \n\n- - N\u00e3o glicosilada N\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n12, 19 (20, \n33,46) \n\n41705 5.3 Citoplasm\u00e1tica Sol\u00favel 1. N\u00e3o; 2.98% S. \njaponicum; 3. N\u00e3o \n\nEm 7 s\u00edtios; score entre \n0,783 e 0,996 \n\nPresente Em 1 amino\u00e1cidos \nda sequ\u00eancia \n\nN\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n25 28104 7.64 Mitocondrial Sol\u00favel 1. 99% TPI 2. 99% \nHaematobium japonicum \n\n3. N\u00e3o \n\n- - N\u00e3o Glicosilada N\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n29 (52) 17660 8.26 Extracelular Sol\u00favel 1. N\u00e3o \n2. 98% S. japonicum3. \n\nTaenia 99% \n \n\nEm 2 s\u00edtios; score entre \n0,863 e 0,999 \n\nPresente Em 2 amino\u00e1cidos \nda sequ\u00eancia \n\nN\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n34  8680 5.31 Extracelular Sol\u00favel 1. 89% isoform CRA \n90% calpain \n\n90% unnamed protein \n2. 100% Hematobium \n87%, 99%-100% S. \njaponicum;3. N\u00e3o \n\n- - N\u00e3o Glicosilada N\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n45 (57) 42060 5.56 Citoplasm\u00e1tica Sol\u00favel 1. 96% Actina; 2. N\u00e3o; 3. \nN\u00e3o \n\nEm 5 s\u00edtios; score entre \n0902 e 0,999 \n\nPresente Em 1 amino\u00e1cidos \nda sequ\u00eancia \n\nN\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n48 24045 6.54 Citoplasm\u00e1tica Sol\u00favel 1.N\u00e3o ;2. 89%-87% ,100 % \nS. japonicum, 88% bovis \n\n88% Haematobium \n3. Taenia 24% \n\nEm 3 s\u00edtios; score entre 0, \n762 e 0,998 \n\nPresente Em 4 amino\u00e1cidos \nda sequ\u00eancia \n\nN\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n49 (50, 55) 13642 9.02 Citoplasm\u00e1tica Sol\u00favel 1. N\u00e3o 2. 82%-100% S. \njaponicum3. N\u00e3o \n\nEm 2 s\u00edtios; score entre \n0,968 e 0,973 \n\nPresente Em 4 amino\u00e1cidos \nda sequ\u00eancia \n\nN\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n60 55763 5.21 Mitocondrial Sol\u00favel 1. Atp syntetase. 93% \n2. 100% S. japonicum-  \n\n3. N\u00e3o \n\n- - N\u00e3o Glicosilada N\u00e3o encontrado nenhum potencial \n\ns\u00edtio \n\n\n\n\u00a0\n\n\u00a0\n\n109\u00a0\n\n\u00a0\n\nEscolhemos, inicialmente, testar o potencial da prote\u00edna identificada no spot 29, a qual \n\ndenominamos SmCyp, como ant\u00edgeno vacinal contra esquistossomose.A regi\u00e3o codificadora \n\ndo seu respectivo gene possui 483 nucleot\u00eddeos correspondentes a 161 amino\u00e1cidos, n\u00famero \n\nde acesso: XP_002575376.1, gi/256078182, sequ\u00eancia de amino\u00e1cidos: \n\nMAAKAFFDIKAGDERLGRIIFELFNDVPDTTRNFRELCTHKNNFGYKGSVFHRIIPGF\n\nMCQGGDFTNGDGTGGKSIYGNKFKDENFNHKHEAFSLSMANAGPNTNGSQFFITTVP\n\nCSWLDGKHVVFGKVVSGIDVVKKMESLGSTSGKPSKKIIIEDCGEC.Esta prote\u00edna foi \n\ndenominada de SmCyp por ser caracterizada como uma ciclofilina do Schistosoma mansoni. \n\nAs ciclofilinas (Cyps) ou peptidilprolil cis-trans isomerases s\u00e3o prote\u00ednas ubiquinonas \n\ncitos\u00f3licas altamente conservadas. Na esquistossomose as ciclofilinas s\u00e3o capazes de catalisar \n\na interconvers\u00e3o de liga\u00e7\u00f5es pept\u00eddicas no lado amino-terminal dos res\u00edduos de prolina de \n\nconforma\u00e7\u00f5es Cis para Trans (Fischer et al., 1989). Al\u00e9m disso, as ciclofilinas s\u00e3o prote\u00ednas \n\nligadoras espec\u00edficas de uma droga imunossupressora: ciclosporina A (CsA). Estudos \n\nsugerem que tal droga reduz a carga parasit\u00e1ria, fecundidade das f\u00eameas e atividade de \n\nhemoglobinase do S. mansoni na esquistossomose murina (Bueding, 1981). Sendo assim, \n\ninfere-se que as ciclofilinas possuem importante papel nos danos causados no parasito e, \n\nconsequentemente na sua elimina\u00e7\u00e3o (Kiang et al., 1996; Handschumacher et al., 1984).Ap\u00f3s \n\na compra do gene sint\u00e9tico, a regi\u00e3o codificadora do gene que codifica a prote\u00edna SmCyp foi \n\ninserida em vetor pcDNA3.1/V5-His A (Invitrogen) para o ensaio de imuniza\u00e7\u00e3o g\u00eanica. \n\nAp\u00f3s a transforma\u00e7\u00e3o, houve crescimento de 9 col\u00f4nias de bact\u00e9rias da cepa DH5? no meio \n\nseletivo LB-\u00e1gar contendo ampicilina. Realizou-se mini-prep de todas as col\u00f4nias e, para \n\nconfirmar a presen\u00e7a do inserto, foi feita uma PCR utilizando os iniciadores BGH e T7. \n\nApenas a col\u00f4nia 5 apresentou um fragmento amplificado de massa molecular esperada, \n\nsendo ent\u00e3o a escolhida para os pr\u00f3ximos passos deste trabalho (Fig.14). \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n110\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 14: Amplifica\u00e7\u00e3o da regi\u00e3o codificadora do gene correspondente a SmCyp. Foi \n\nutilizado DNA plasmidiano de 9 col\u00f4nias da bact\u00e9ria E. coli (cepa DH5?) como DNA molde \n\nem rea\u00e7\u00f5es de PCR utilizando os iniciadores BGH (Reverse) e T7 (Foward). PM: Padr\u00e3o de \n\npeso molecular (100bp- BioLabs). Est\u00e1 circulada de vermelho a banda que apresentou o \n\ntamanho esperado (col\u00f4nia 5). \n\nA col\u00f4nia 5 foi crescida em 5mL de meio LB contendo ampicilina e, \n\nposteriormente,repicada para 2,5L do mesmo meio de cultura para a extra\u00e7\u00e3o do DNA \n\nplasmidiano livre de endotoxinas em grande escala. Ainda para confirmar a presen\u00e7a do \n\ninserto no clone selecionado, o DNA plasmidiano extra\u00eddo foi submetido a uma digest\u00e3o com \n\nas enzimas de restri\u00e7\u00e3o BamHI (Promega) e AgeI (Promega). Como observado na figura 15 \n\nhouve libera\u00e7\u00e3o do inserto de tamanho esperado. \n\n \n\n \n\nC\no\n\nl\u00f4\nn\n\nia\n1\n\nC\no\n\nl\u00f4\nn\n\nia\n2\n\nC\no\n\nl\u00f4\nn\n\nia\n3\n\nC\no\n\nl\u00f4\nn\n\nia\n4\n\nC\no\n\nl\u00f4\nn\n\nia\n5\n\nC\no\n\nl\u00f4\nn\n\nia\n6\n\nC\no\n\nl\u00f4\nn\n\nia\n7\n\nC\no\n\nl\u00f4\nn\n\nia\n8\n\nC\no\n\nl\u00f4\nn\n\nia\n9\n\n500\n600\n700\n800\n900\n\n1000\n\n1200\n\n400\n\n300\n\nPM\n\nC\no\n\nl\u00f4\nn\n\nia\n1\n\nC\no\n\nl\u00f4\nn\n\nia\n2\n\nC\no\n\nl\u00f4\nn\n\nia\n3\n\nC\no\n\nl\u00f4\nn\n\nia\n4\n\nC\no\n\nl\u00f4\nn\n\nia\n5\n\nC\no\n\nl\u00f4\nn\n\nia\n6\n\nC\no\n\nl\u00f4\nn\n\nia\n7\n\nC\no\n\nl\u00f4\nn\n\nia\n8\n\nC\no\n\nl\u00f4\nn\n\nia\n9\n\n500\n600\n700\n800\n900\n\n1000\n\n1200\n\n400\n\n300\n\nPM\n\n\n\n\u00a0\n\n\u00a0\n\n111\u00a0\n\n\u00a0\n\n \n\nFigura 15: Digest\u00e3o do DNA plasmidiano  pcDNA3.1/V5-His A vazio e contendo o gene \n\ncodificador da prote\u00edna SmCyp. 2?g de DNA plasmidiano foram digeridos com as enzimas \n\nde restri\u00e7\u00e3o AgeI e BamHI e analisados em gel de agarose 1% corado com Sybr gold.  PM: \n\nPadr\u00e3o de peso molecular 1Kb (BioLabs) \n\n Este clone foi tamb\u00e9m sequenciado parcialmente e ap\u00f3s a confirma\u00e7\u00e3o da correta \n\njanela aberta de leitura entre a regi\u00e3o codificadora de SmCyp e o epitopo V5 e 6xHis do vetor, \n\no DNA foi dosado por espectrofotometria para dar in\u00edcio \u00e0s imuniza\u00e7\u00f5es g\u00eanicas e ao \n\nexperimento de  transfec\u00e7\u00e3o de c\u00e9lulas de mam\u00edfero em cultura para avaliar a express\u00e3o da \n\nprote\u00edna pelo plasm\u00eddeo utilizado. Pela an\u00e1lise do Western blotting com extratos prot\u00e9icos \n\nprovenientes das c\u00e9lulas transfectadas usando anticorpos contra a cauda de Histidina (anti-6-\n\nHIS) foi poss\u00edvel observar a express\u00e3o da prote\u00edna recombinante rSmCyp e seu esperado peso \n\nmolecular 17.7kDa.  \n\n Observou-se que a imuniza\u00e7\u00e3o com o DNA plasmidiano n\u00e3o alterou de forma \n\nestatisticamente significativa a carga parasit\u00e1ria dos camundongos imunizados e desafiados. \n\nAl\u00e9m disso, ao se avaliar o n\u00famero de ovos presentes nas fezes, n\u00e3o foi observado diminui\u00e7\u00e3o \n\n\n\n\u00a0\n\n\u00a0\n\n112\u00a0\n\n\u00a0\n\nde forma significativa do n\u00famero de ovos presentes no pool de fezes dos camundongos \n\nimunizados com o plasmideo contendo o inserto (pcDNA 3.1/V5-His A/SmCyp) em rela\u00e7\u00e3o \n\nao grupo inoculado com o plasm\u00eddio vazio (pcDNA 3.1/V5-His A).Observou-se, al\u00e9m disso, \n\nque n\u00e3o houve diminui\u00e7\u00e3o estatisticamente significativa do n\u00famero de ovos retidos no f\u00edgado \n\ne intestino dos animais imunizados com o DNA plasmidiano contendo o inserto (pcDNA \n\n3.1/V5-His A/SmCyp) em rela\u00e7\u00e3o ao DNA plasmidiano vazio (pcDNA 3.1/V5-His A). \n\nConsequentemente, ao se analisar a interfer\u00eancia da imuniza\u00e7\u00e3o na fecundidade da f\u00eamea, n\u00e3o \n\nhouve altera\u00e7\u00e3o estatisticamente significativa. A fim de avaliar a produ\u00e7\u00e3o de anticorpos \n\ninduzida pela imuniza\u00e7\u00e3o com DNA plasmidiano contendo o inserto que codifica o gene de \n\nSmCyp, foi realizado o teste de ELISA sensibilizando as placas com dois pept\u00eddeos sint\u00e9ticos \n\ncorrespondentes a epitopos preditos de c\u00e9lulas T e B na sequ\u00eancia da prote\u00edna: SmCyp (94-\n\n108) e SmCyp(107-121). N\u00e3o houve diferen\u00e7a estatisticamente significativa entre os n\u00edveis \n\ndos anticorpos obtidos em camundongos imunizados com o plasm\u00eddeo contendo o inserto e o \n\nplasm\u00eddeo vazio. Ao se avaliar a patologia da doen\u00e7a observou-se que a imuniza\u00e7\u00e3o g\u00eanica \n\ncom SmCyp foi capaz de induzir uma modula\u00e7\u00e3o da \u00e1rea do granuloma de forma significativa \n\no que, consequentemente diminuiu a morbidade nos camundongos imunizados com o \n\nplasm\u00eddeo contendo o inserto. Ao se avaliar o perfil de citocinas produzido pelos esplen\u00f3citos, \n\nobservou-se que a imuniza\u00e7\u00e3o com SmCyp induz um aumento significativo na produ\u00e7\u00e3o  IFN-\n\n?, quando estimuladas com SmCyp (94-108). Por outro lado houve uma redu\u00e7\u00e3o da produ\u00e7\u00e3o \n\nde IL-10 por estas c\u00e9lulas quando estimuladas com SmCyp (94-108) ou SmCyp (107-121). \n\nHouve tamb\u00e9m produ\u00e7\u00e3o estatisticamente significativa de IL-17 quando estas c\u00e9lulas foram \n\nestimuladas com Smteg. Em rela\u00e7\u00e3o \u00e1s c\u00e9lulas de mem\u00f3ria, a imuniza\u00e7\u00e3o com pcDNA \n\n3.1/V5-His A/SmCyp n\u00e3o induziu aumento significativo de c\u00e9lulas TCD4 de mem\u00f3ria efetora \n\nou central apesar de tais c\u00e9lulas terem sido estimuladas por esta imuniza\u00e7\u00e3o uma vez que se \n\nobservou aumento significativo da porcentagem de CD4+CD25+ quando comparado ao grupo \n\ninoculado com DNA plasmidiano vazio (pcDNA 3.1/V5-His A). J\u00e1 em rela\u00e7\u00e3o aos linf\u00f3citos \n\nTCD8, a imuniza\u00e7\u00e3o com pcDNA 3.1/V5-His A/SmCyp n\u00e3o induziu ativa\u00e7\u00e3o de tais c\u00e9lulas, \n\nmas diminuiu de forma estatisticamente significativa a porcentagem de c\u00e9lulas de mem\u00f3ria \n\ncentral TCD8+.. Al\u00e9m disso, a imuniza\u00e7\u00e3o com pcDNA 3.1/V5-His A/SmCyp n\u00e3o induziu \n\naumento significativo de c\u00e9lula B de mem\u00f3ria (artigo n\u00e3o publicado). \n\n\n\n\u00a0\n\n\u00a0\n\n113\u00a0\n\n\u00a0\n\nA DNA vaccine containg the Schistosoma mansoni Cyclophylin A (SmCyp) gene induce \n\nmodulation of liver granuloma in mice.  \n\nTatiane Teixeira de Melo1, Paola Rezende Patroc\u00ednio1, Clarice Carvalho Alves1, Gard\u00eania \n\nBraz Carvalho1, Neusa Araujo1,MarceloVidigal Caliari4, Rosiane Aparecida da Silva \n\nPereira1and Cristina Toscano Fonseca1,2,*.  \n\n \n\n1Centro de Pesquisas Ren\u00e9 Rachou, Fiocruz-MG, Belo Horizonte, Minas Gerais, Brazil. \n\n2Instituto Nacional de Ci\u00eancias e Tecnologia em Doen\u00e7as Tropicais (INCT-DT), Brazil. \n\n3Funda\u00e7\u00e3o Ezequiel Dias, FUNED, Belo Horizonte, Minas Gerais, Brazil. \n\n4Departamento de Patologia Geral, Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de \n\nMinas Gerais, Belo Horizonte, Minas Gerais, Brazil. \n\n \n\n* Corresponding author: Laborat\u00f3rio de Esquistossomose, Centro de Pesquisas Ren\u00e9 Rachou, \n\nAvenida Augusto de Lima, 1715, Barro Preto, CEP: 30190-002.  \n\nBelo Horizonte, Minas Gerais, Brazil. Tel: +55 31 33497828. \n\nE-mail address: ctoscano@cpqrr.fiocruz.br \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n114\u00a0\n\n\u00a0\n\n1 Introduction \n\nSchistosomiasis is a debilitating disease caused by flatworm parasites of the \n\nSchistosoma genus which affects over 200 million individuals worldwide causing more than \n\n200.000 deaths per year, with almost 800 million people at risk of IFNection (Bergquist et al., \n\n2002; Engels et al., 2002; Steinmann et al., 2006). Due to limitations of the control strategy \n\nbased on chemotherapy with praziquantel (PZQ), on limiting disease transmission alternative \n\nstrategies as vaccination are necessary (Bergquist et al., 2002). \n\nThe Schistosoma tegument plays an important role in nutrient uptake and immune \n\nevasion (Loukas et al., 2007) and has currently become targets of vaccine studies. However, \n\nmost of these studies aimed to identify antigens in adult worm tegument (Von Balkom et al., \n\n2005; Braschi &amp; Wilson, 2006) although schistosomula is the parasite stage most susceptible \n\nto the host immune system attack. In recent vaccinations studies, the S. mansoni \n\nschistosomula tegument (Smteg) was able to induce a protective immune response against \n\nparasite challenge IFNection (Teixeira de Melo et al., 2010; Teixeira de Melo et al., 2012), \n\nbeing the antibodies produced against tegument proteins able to transfer protection to na\u00efve \n\nrecipients (Melo et al., 2014). \n\nCyclophilins (Cyps) or peptidil-prolyl cis-trans isomerases are highly conserved \n\nubiquitous cytosolic proteins that carry out a wide range of functions as protein folding, \n\ntrafficking, assembly and chaperoning (Fischer et al., 1989; Gothel et al., 1999; Schonbrunner \n\net al., 1991).  These proteins are classified into isoforms according to their cellular \n\nlocalization and amino acid sequence conservation (Mi H et al, 1996). Cyps cloned from a \n\nwide range of species and from parasites, as well as schistosomes, have shown a high degree \n\nof sequence conservation (Trandinh et al., 1992). The Cyps are able to catalyze the \n\ninterconversion of peptide bonds on the amino side of proline residues that are in cis \n\nconformation to the trans conformation (Fischer et al, 1989).Kiang et al. (1996) showed that \n\ncyclophilin is located in the tegument, muscle layers, intestine epithelium and in the interior \n\nof the worm, and therefore, it is in contact with the host immune system. The cyclophilins are \n\nspecific proteins receptors for the immunossupressive drug: cyclosporine A (CsA).  This drug \n\nis able to induce the complete elimination of a wide range of parasites, including \n\n\n\n\u00a0\n\n\u00a0\n\n115\u00a0\n\n\u00a0\n\nschistosomes, even if administered once during the experimental IFNection (Chappell et al., \n\n1987; Chappell et al., 1988, Bueding et al., 1981). The complex Cyclosporine/Cyclophilin \n\ninhibits the translocation to the nucleus of the parasite nuclear factor homolog to the human \n\nNFAT (nuclear factor of activated T-cells), therefore inhibiting parasite development (Serra et \n\nal., 1999). Besides its role in parasite development and it accessibility to the host immune \n\nsystem, S. mansoni cyclophilin has never been used in vaccine formulation against \n\nschostosomiasis. However, recently Han et al. (2012) demonstrated that theS. japonicum \n\ncyclophilin A induces a protective immune response in immunized mice (Han et al., 2012). \n\nHerein, the gene encoding the S. mansoni cyclophilin A was cloned into a mammalian \n\nexpression vector and its ability to induce protective immunity in mice was evaluated using a \n\nDNA immunization strategy. This immunization protocol induced a type 1 immune profile \n\nthat regulated the granuloma area and, consequently, the disease morbidity. \n\n2 Methodology \n\n2.1 Mice and parasites \n\nFemale C57BL/6 mice aged 6-8 weeks were obtained from the Centro de Pesquisas \n\nRen\u00e9 Rachou (CPqRR) facilities. All procedures involving animals were approved by the \n\nlocal Ethics Commission on Animal Use (CEUA) (LW26/12). Cercariae of S. mansoni (LE \n\nstrain) were routinely maintained in Biomphalaria glabrata snails and obtained by exposing \n\nIFNected snails to light for 1h to 2h to induce cercariae shedding. The number of cercariae \n\nand their viability were determined using a light microscope. \n\n2.2 Schistosomula tegument (Smteg) purification \n\nCercariae from S. mansoni were mechanically transformed into skin-stage \n\nschistosomula according to Ramalho-Pinto et al. (1974). Briefly, cercariae were incubated on \n\nice for 30 min and then centrifuged at 1800 x g for 3 min at 4\u00baC. The cercariae were \n\nresuspended in cold ELAC (Earle\u00b4s salts plus lactalbuminhydrolysate) containing 0.5% \n\nlactoalbumin, 1% penicillin/streptomycin and 0.17% glucose. The tails were broken by \n\nvortexing in high speed for 2 minutes. After this, the tails were removed through several wash \n\n\n\n\u00a0\n\n\u00a0\n\n116\u00a0\n\n\u00a0\n\nsteps with ELAC. The schistosomula were cultured for 90 min at 37\u00baC in ELAC. The \n\ntegument was removed with CaCl2 0.3M by vortex agitation. The tegument was separated \n\nfrom denuded bodies by centrifugation at 200 xg for 1 min. The supernatants were pooled and \n\ncentrifuged at 50000 x g for 1h at 4\u00baC. The pellet, ressuspended in saline, was dialyzed \n\nagainst physiological saline. This preparation was termed Smteg and used to stimulate spleen \n\ncells in vitro culture assays. \n\n2.3 In silico analysis of SmCyp \n\n A protein spot of the schistosomula tegument preparation, which was recognized by \n\nsera from mice immunized with Smteg + CFA/IFA (Teixeira de Melo et al., 2010) in a \n\nbidimensional Western blotting (2D-WB), was submitted to mass spectrometry analyses and \n\nwas identified as a S. mansoni cyclophilin A (access number: XP_002575376.1).In silico \n\nanalysis of the protein sequence was performed using SOSUI Engine version 1.11 \n\n(bp.nuap.nagoya-u.ac.jp/sosui/) to transmembrane domain and solubility prediction and \n\nSherLoc software (bs.IFNormatik.uni-tuebingen.de/Services/SherLoc/) to cellular location \n\nprediction. To assess the similarity between human or helminthic proteins, the amino acid \n\nsequences were compared with the National Center for Biotechnology IFNormation protein \n\ndatabase using the BlastP (BLAST - Basic Local Alignment Search Tool) algorithm \n\n(blast.ncbi.nlm.nih.gov/Blast.cgi) (using the default parameters of this algorithm. \n\n The amino acid sequence of our identified protein spot and other S. mansonicy \n\nclophilins (XP_002575376.1; AAC47317.1; Q26551.1) were aligned using ClustalW2 \n\nmultiple sequence alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/). T cell and B cell \n\nepitope prediction were performed using Rankpep \n\n(http://imed.med.ucm.es/Tools/rankpep.html) and BCPred \n\n(http://ailab.cs.iastate.edu/bcpreds/), respectively. In Rankpep, T cell prediction was \n\nperformed using default parameters and selecting IaB to predict C57BL-6 T cell epitopes in \n\nthe protein sequence. In BCPred, B cell epitope predictions were performed using Flexible \n\nLength Prediction (FLP) and 75% specificity.  \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n117\u00a0\n\n\u00a0\n\n2.4 Plasmid construction \n\n SmCyp synthetic gene was designed using ApE software (www.apesoftware.com) and \n\nthe coding region sequence of SmCyp (access number:XP_002575376.1). The mini-gene was \n\ndesigned with restriction sites for the enzymes BamHI (GGATCC) at 5\u2019end and AgeI \n\n(ACCGGT) at 3\u2019end. The SmCyp coding region was inserted into the mammalian expression \n\nvector pcDNA 3.1 V5/His A (Invitrogen). Escherichia coli DH5?was transformed with the \n\npcDNA 3.1 V5/His A/SmCyp construct. Clones containing the insert were selected by the \n\nresistance to ampicilin. The presence of SmCyp gene in the pcDNA 3.1/SmCyp construct was \n\nconfirmed by restriction enzymes digestion using BamHI and Age and DNA sequencing. \n\nPlasmid DNA purification was performed using end toxin free Giga-prep kit according to \n\nmanufacturer\u2019s instructions (Siegen, Valencia, CA). \n\n2.5 SmCyP expression in mammalian cells \n\n The construct pcDNA 3.1 V5/His A/SmCyp was transfected into mammalian cells \n\nHEK293T maintained in DEMEN (Dulbecco\u2019s Modified Eagle Medium- GIBCO-Invitrogen) \n\nsupplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37\u00baC and \n\n5% CO2. Transfection was performed by lipofection technique using Lipofectamine 2000 \n\n(Invitrogen). The plasmid pcDNA 3.1 V5/His B, containing a non-correlated gene with C-\n\nterminal 6xHis-tag was used as positive control, and the empty plasmid pcDNA3.1/V5-His A \n\nand non-transfected cells were used as negative controls. The protocol below was optimized \n\nfor transfection in 24-well plate format. In each well, 2.0 x 105 cells were seeded in 500?L of \n\nDMEM with 10% FBS. This plate was maintained at 37\u00b0C and 5% CO2 for 24 hours. Each \n\nplasmid DNA sample and lipofectamine was diluted separately in DMEM (0.8\u00b5g of plasmid \n\nDNA and 2?L of lipofectamine in 50\u00b5L of culture medium). After 5 min at room temperature, \n\nthe diluted lipofectamine was mixed with each DNA sample. This mixture was incubated for \n\n20 min at room temperature, allowing formation of DNA-liposome complexes. Each mixture \n\nwas added to the cells in a DMEM pre-washed culture plate, which was maintained for \n\napproximately 5hr at 37\u00b0C in 5% CO2  and  washed again in DMEM containing 10% FBS. \n\nAfter a 48 hr at 37\u00b0C in 5% CO2   incubation step, the transfected cell cultures were subjected \n\nto lysis for total protein extraction in 150\u00b5L of 2X Laemmli buffer  (BioRad) plus ?-\n\n\n\n\u00a0\n\n\u00a0\n\n118\u00a0\n\n\u00a0\n\nmercaptoethanol (950?L of 2X Laemmli buffer + 50\u00b5L of ?-mercaptoethanol). The samples \n\nwere boiled at 100\u00b0C for 5 min and and stored at -70\u00b0C until the use. The quality of the \n\nprotein extracts was assessed by 12% denaturing polyacrylamide gel by electrophoresis \n\n(Laemmli 1970) and the SmCyp protein expression was verified by Western blotting using \n\nanti-6xHis antibody conjugated to HRP (Invitrogen). The proteins were transferred to Immun-\n\nBlot PVDF membrane (Amersham Biosciences) as previously described by Towbin et al. \n\n(1979). The membrane was blocked in Tris-buffered saline (TBS)/ 0.1% Tween 20 (TBS-\n\nT)/3% BSA at room temperature for 16 hr and incubated with anti-6xHis antibody diluted \n\n1:5.000 in TBS-T/1% BSA for 1h. After two washes in TBS-T and one wash in TBS the \n\nreaction was revealed using ECL Plus Western Blotting Detection System (GE-Healthcare) \n\nand the image was captured in ImagebQuant LAS 4000 (GE-Healthcare) by \n\nchemiluminescence method. \n\n2.6 Immunization of mice \n\nFemale C57BL/6 mice (10 mice per group) received four doses of 100\u00b5g of purified \n\nplasmid DNA in the quadriceps muscle with an interval of 15 days between each dose. Five \n\ndays before de first immunization the mice received 100 \u00b5L/animal of cardiotoxin \n\n(0,06mg/mL).Two groups were included in this study: one group received 100\u00b5g of empty \n\npcDNA 3.1 V5/His A, another received 100\u00b5g of pcDNA 3.1 V5/His A/SmCyp. Blood \n\nsamples were collected from retro-orbital sinus of each mouse with an interval of 15 days \n\nbegging 15 days after the first immunization. Serum samples were collected and stored at -\n\n20\u00baC until use. Fifteen days after the last boost, mice were challenge through percutaneous \n\nexposure of abdominal skin for 1h in water containing 100 cercariae (LE strain) as described \n\nby Smithers and Terry (1965). Fifty days after challenge, adult worms were perfused from the \n\nportal system and mesenteric veins according to Pellegrino and Siqueira (1956).On days 48, \n\n49 and 50 after challenge IFNection, 0.5g of fecal material from each mouse group were \n\nanalyzed for egg burden determination by HPJ methods (Hoffman et al., 1934). In HPJ, whole \n\nsediment was evaluated to determine egg per gram of feces (epg). Two independent \n\nexperiments were performed to confirm the results observed. \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n119\u00a0\n\n\u00a0\n\n2.7 Measurement of eggs in the intestine and the liver of immunized mice \n\n Intestine and liver from each mouse group were collected 50 days post-IFNection. \n\nThese organs were weighed and digested with 10% KOH for 16hr at 4\u00baC and for 2 hours at \n\n37\u00baC. The eggs were obtained by centrifugation at 900 x g for 10 min and ressuspended in \n\n1mL of saline. Egg number was counted using a light microscope. \n\n2.8 Measurement of specific anti-SmCyp antibodies \n\nThe measurement of specific anti-SmCypIgG was performed by ELISA. Maxsorp 96-\n\nwells microtiter plates (Nunc) were coated with 1\u00b5g/mL of the SmCyp(94-108) \n\nSLSMANAGPNTNGSQ or SmCyp(107-212) SQFFITTVPCSWLDG synthetic peptides in \n\ncarbonate-bicarbonate buffer, pH 9.6, for 16hr at 4\u00baC. The plates were then blocked for 2hr at \n\n4\u00baC with 300\u00b5L/well of PBST (phosphate-buffered saline, pH 7.2 with 0.05% Tween-20) plus \n\n10% FBS (fetal bovine serum, GIBCO, USA). One hundred microliters of each serum diluted \n\n1:50 in PBST was added per well and incubated for 1hr at room temperature. Plate-bound \n\nantibody was detected by peroxidase-conjugated anti-mouse IgG (Southern Biotech, USA) at \n\ndilution 1:10.000. Color reaction was developed by addition of 100\u00b5L per well of TMB \n\n(Microwell Peroxidase Substrate System) and stopped with 50\u00b5L of 5% sulfuric acid per well. \n\nAbsorbance was measured at 450nm in microplate reader (BIO-RAD). \n\n2.9 Measurement of number and area of the hepatic granuloma  \n\n Liver sections from control mice group immunized with empty pcDNA 3.1 V5/His A \n\nand from the group immunized with with pcDNA 3.1 V5/His A/SmCyp were collected 50 \n\ndays post-IFNection to evaluate the effect of immunization on granuloma formation. The \n\nliver sections removed from the central part of the left lateral lobe were fixed in 10% buffered \n\nformaldehyde in PBS. Histological sections wer eperformed using microtome and the slides \n\nwere stained with Hematoxylin and Eosin (H&amp;E). To perform the measurement of granuloma \n\narea, 100 granulomas from each group with a single well-defined egg and at the exsudative-\n\nproductive stage were randomly obtained at 10x objective lens through a JVC TK-1270/RGB \n\nmicrocamera. Using a digital pad, the total area of the granulomas was measured and the \n\nresults were expressed in square micrometers (\u00b5m2). To determine the number of granulomas, \n\n\n\n\u00a0\n\n\u00a0\n\n120\u00a0\n\n\u00a0\n\nall section from the same slides mentioned above were counted using a microscope with 10x \n\nobjective lens and the total area of the liver histological section was calculated using the same \n\nsoftware. The results were expressed as the number of granuloma per area of liver (mm2). \n\n2.10 Cytokine analysis \n\nExperiments were performed using spleen cell culture supernatants from five \n\nindividual mice per group immunized with empty pcDNA 3.1 V5/His A or pcDNA 3.1 \n\nV5/His A/SmCyp, one week after the last immunization. The cells obtained from mice spleen \n\nwere washed twice in sterile saline and then, adjusted to 1 x 106 cells/well. Spleen cells were \n\nmaintained in culture at 37oC in 5% of CO2 in medium alone or stimulated with SmCyp 94-\n\n108 (10\u00b5g/well), SmCyp107-121 (10\u00b5g/well), Smteg (5\u00b5g/well) or concanavalin A (Con A) \n\n(1\u00b5g/well). The supernatant was collected 24h after stimulation for quantification of IL-10, \n\nIL-2, IL-4, IL-6, IL-17, TNF-? and IFN-? production using mouse Th1/Th2/Th17 Kilometric \n\nBead Array (CBA) Kit (BD Biosciences, USA). The cytokines were evaluated as \n\nrecommended by the manufacturer. Data were acquired in a Facscan flow cytometer (Becton \n\nDickinson) and the analyses were performed using BD CBA software (Becton Dickinson). \n\n2.11 Immune cells activation pattern   \n\nFor ex vivo cellular staining, spleen cells from 4 mice/group/experiment were adjusted \n\nto 5 X 105 cells per well. Before staining, the cells were generally blocked with anti-mouse \n\nCD16/CD32 mAbs (Fc-Block), after that cells were stained for surface markers using anti-\n\nCD4 FITC labeled (clone GK1.5, BD-Pharmingen), anti-CD8Percp labeled (clone 53-6-7, e-\n\nbioscience), anti-CD44 pacific blue labeled (clone IM7, BioLegend),  anti-CD62 alexa-700 \n\nlabeled (clone MEL-14, e-bioscience), anti-CD25 Biotin-labeled (clone 7D4, BD-\n\nPharmingen), anti-CD27 Biotin labeled (clone LG.7F9, e-bioscience), anti-CD19PE-Cy7 \n\nlabeled (clone 1D3, BD-Pharmingen),  and anti-CD127 PE-CY7 labeled (clone A7R34, e-\n\nbioscience) monoclonal antibodies and their respective isotype controls by incubation for 20 \n\nmin with antibody solution (PBS 0.15 M, 0.5% BSA, 2 mM NaN3) at 4\u00b0C.After  a washed \n\nstep with PBS 0.15 M, 0.5% BSA, 2 mM NaN3, cells were submitted to a further incubation \n\nstep of 20 minutes with streptavidin-APC-CY7 labeled diluted 1:200 in PBS 0.15 M, 0.25% \n\n\n\n\u00a0\n\n\u00a0\n\n121\u00a0\n\n\u00a0\n\nBSA, 1mM NaN3 at 4\u00b0C,  followed by washes and fixation using 2% formaldehyde solution. \n\nThe labeled cells data were obtained using LSR fortessa cytometer. Data analysis was \n\nperformed using a FlowJO interface (Tree Star, Ashland, OR). \n\n2.12 Statistical analysis \n\n Statistical analyses were performed using the software package GraphPad Prism 5.0 \n\n(Graph-Pad Software, San Diego, CA, USA).Data normality was tested using D\u2019Agostino e \n\nPearson omnibus normality test. Statistical analyses were performed using paired student T \n\ntest or Wilcoxon matched pair test, depending on data distribution, for cytokine measurement \n\n(Intracellular staing). Student T test was applied for parasitological, histological, CBA and \n\nELISA analyses. \n\n3. Results \n\n3.1 SmCyp identification and in silico characterization \n\n A spot of approximately 17.1 kDa and 8.26 Pi was recognized by sera from mice \n\nimmunized with Smteg + CFA/IFA (Teixeira de Melo et al., 2010) in a bidimensionalWestern \n\nblotting of the schistosmomula tegument preparation. Peptides obtained from this spot were \n\nanalyzed by mass spectrometry and the corresponding protein was identified as a S. mansoni \n\ncyclophilin (SmCyp) using Mascot software (Matrix Science, Boston, MA) and NCBI \n\ndatabase. The predicted protein localization performed by SherLoc algorithm indicates that \n\nSmCyp is an extracellular protein, with predicted molecular weight and pI of 17660 Ad and \n\n8.26, respectively. By aminoacid sequences alignment with other described isoforms of S. \n\nmansoni cyclophilin, the sequence of the protein identified in this study by bidimensional \n\nWestern blotting followed by mass spectrometry correspond to Smp17.7 cyclophilin \n\ndescribed by Kiang et al., 1996 (Fig. 1).  \n\n B and T cells epitopes predicted by RankPep and BCpred with the highest scores are \n\ndescribed in Table 1. Two synthetic peptides SmCyp 94-108 (SLSMANAGPNTNGSQ) and \n\nSmCyp 107-121 (SQFFITTVPCSWLDG) containing B and T cell predicted epitopes from \n\n\n\n\u00a0\n\n\u00a0\n\n122\u00a0\n\n\u00a0\n\nSmCyp were purchased from Genescript (NJ, USA) with&lt;95% purity to be used as antigen in \n\nELISA and spleen cell culture assays. \n\n3.2 SmCyp expression in mammalian cells \n\n Before begging the DNA immunization protocol, we evaluated the SmCyp expression \n\nin mammalian cell cultures. Western blotting analysis of transient transfected cells HEK293T, \n\nusing antibody against the 6xHis tag, demonstrated the successful expression of the rSmCyp \n\nin the expected molecular weight of 17.1kDa(Fig. 2).  \n\n3.3 Protective response induced by pcDNA 3.1 V5/His A/SmCyp immunization \n\n In order to assess the ability of DNA vaccination with pcDNA 3.1 V5/His A/SmCyp to \n\ninduce protection in marine model, 15 days after the last immunization mice were challenge \n\nand the protection level was determined. Mice immunization with pcDNA 3.1 V5/His \n\nA/SmCyp did not result in significant reduction in worm burden nor in the number of eggs \n\neliminated in the feces or trapped in intestine and liver when compared to empty pcDNA 3.1 \n\nV5/His A (Table 2).  \n\n3.4 Liver pathology \n\n To assess the effect of DNA immunization with pcDNA 3.1 V5/His A/SmCyp in liver \n\npathology, the mice were euthanized50 days post-challenge and the liver pathology analyzed \n\nby digital morphometry of H&amp;E sections. Granuloma modulation, with a significant reduction \n\nin granuloma area, was observed in pcDNA 3.1 V5/His A/SmCyp immunized group \n\ncomparing to the control group (Figs 4a and b). Nevertheless, any significant reduction in the \n\nnumber of liver granuloma was observed between pcDNA 3.1 V5/His A/SmCyp immunized \n\ngroup and the control group immunized with empty plasmid (Fig. 4B). \n\n3.5 Antibody responses to pcDNA 3.1 V5/His A/SmCyp immunization \n\n Specific antibody production were measured in the sera samples from immunized and \n\ncontrol groups, using synthetic peptides (SmCyp 94-108 and SmCyp107-121) containing T \n\nand B cells SmCyp predicted epitopes as antigen. Any significant production of IgG \n\n\n\n\u00a0\n\n\u00a0\n\n123\u00a0\n\n\u00a0\n\nantibodies were detected in the sera of pcDNA 3.1 V5/His A/SmCyp immunized mice \n\ncompared to control group at all time point analyzed (Fig 3).  \n\n3.6 Cytokine profile induced by immunization \n\nA significant increase in IFN-? production was detected in the spleen cells supernatant \n\nfrom the mice immunized with pcDNA 3.1 V5/His A/SmCyp when stimulated with SmCyp \n\n(94-108) in comparison to the group of mice immunized with empty pcDNA 3.1 V5/His A. In \n\ncontrast, a significant reduction in IL-10 production by SmCyp (94-108) or SmCyp (107-121) \n\nstimulated spleen cells was observed in immunized animals compared to control group (Fig \n\n5).  Smteg stimulation induced increased production of IL-17 in pcDNA 3.1 V5/His A/SmCyp \n\nimmunized group in comparison to control group (Fig 5). \n\n3.7 Immune cell profile induced by immunization \n\n Mice immunization with pcDNA 3.1 V5/His A/SmCyp did not induce any significant \n\nincrease in the percentage of CD4 central or effector memory cells although immunization \n\nwas able to activate CD4+ cells, once a significant increase in  the percentage of CD4+CD25+ \n\nin comparison to  the group immunized with  pcDNA 3.1 V5/His A was observed (Fig 6). In \n\ncontrast, CD8+ cells were not activated, and immunization induced a significant reduction in \n\npercentage of CD8+ central memory cell (Fig 6). pcDNA 3.1 V5/His A/SmCyp immunization \n\nalso failed to increase the number of memory B cells (Fig. 6). \n\n4 Discussion \n\nSchistosomiasis is a serious public health problem in Brazil and worldwide. The \n\ncurrent control programs, based in PZQ chemotherapy, have reduced morbidity and mortality \n\nbut have failed to reduce disease transmission. And also, due to constant reIFNection and \n\nPZQ treatment, a risk of drug resistance development exists (Kalinna, 1997). Therefore, one \n\nmajor goal in the research on the immune response to Schistosoma mansoni is to develop a \n\nvaccine (Kojima et al., 2004).  Proteins from the S. mansoni tegument as Tetraspanin, \n\nSm22.6, Sm200 and Sm29 have shown to be good vaccine targets (Tran et al., 2006; Santiago \n\net al.,1998; Sauma &amp; Strand, 1990; Cardoso et al.,2006). Other important molecule present in \n\n\n\n\u00a0\n\n\u00a0\n\n124\u00a0\n\n\u00a0\n\nthe tegument of Schistosoma is the cyclophilin (Cyp). Its ability to interact with the \n\nimmunosuppressive drug cyclosporine A (CsA) made this protein become an interesting \n\ncandidate to vaccine (Kiang et al, 1996). The CsA have been shown to promote parasite death \n\nin S. mansoni IFNected mice. This effect of CsA is believe to be mediated by CyP-CsA \n\ncomplex, which inhibit phosphatase calcineurin and blocks signal transduction (Klinkert et al, \n\n1996; Serra et al, 1999). \n\nIn this study, we evaluated the ability of SmCyp gene to induce protective immunity \n\nagainst S. mansoni in mice using DNA immunization strategy. SmCyp was identified as one \n\nof the immunogenic proteins of the schistosomula tegument. The similarity analysis of amino \n\nacid sequence with other S. mansoni cyclophilins demonstrated that SmCyp is identical to the \n\nSmp17.7 protein identified and characterized by Kiang et al. (1996). In their study, Kiang et al \n\nused the purified antibodies against tegumental components of schistosomula to screen a S. \n\nmansoni adult worm cDNA library and one of reactive clones was determined by sequence \n\nanalysis to encode a protein homologous to cyclophilin A. Our in silico analysis of SmCyp \n\npredicted an extracellular localization to this protein. However Kiang et al (1996) have \n\ndemonstrated by immune fluorescence that this protein is located in the tegument and gut \n\nepithelium and thus, even if the protein is secreted by parasite cells, it remains attached to the \n\nepithelium. Due to the contact to the host immune system, the predicted immunogenicity \n\n(Table1) and the role on parasite development, SmCyp represent an interesting target to \n\nvaccine development. Indeed mice immunization with a recombinant form of the S. \n\njaponicum cyclophilin (SjCypA) induced significant reduction in worm burden (Han et al., \n\n2012). Our immunization strategy, however, failed to induce a significant reduction in worm \n\nburden, in the number of eggs eliminated with the feces and in the number of eggs trapped in \n\nthe liver or intestine (Table2). In addition, SmCyp DNA immunization, did not induced \n\nsignificant levels of specific antibodies (Fig3). The absence of protection and specific \n\nantibody production cannot be attributed to an absence of protein expression in the cells of \n\nimmunized animals, since SmCyp expression in fusion with a 6xHis tag was detected in \n\nHEK293T transfected cells (Fig2) by Western blotting assay using anti-6xHis antibody that \n\npresented molecular weight of 17.1kDa as predict by in s\u00edlico analysis. Also, in mice \n\nimmunized with pcDNA 3.1 V5/His A/SmCyp an increase on the percentage of CD4+CD25+ \n\n\n\n\u00a0\n\n\u00a0\n\n125\u00a0\n\n\u00a0\n\nactivated cells was observed, indicating that the cellular immune response has been activated \n\n(Fig 6).  \n\nSeveral studies have demonstrated that in a successful vaccine formulation against \n\nschistosomiasis both humoral and cell-mediated immunity are essential (Jankovic et al., 1999; \n\nTorben et al., 2012). In the mouse model, it has been showed that B cell-deficient mice singly \n\nvaccinated with radiation cercariae-attenuated S. mansoni cercariae are significantly less \n\nprotected against challenge IFNection than wild type mice (Jankovic et al, 1999). Moreover \n\nserum transference in rabbits, mice and rats showed that sera from vaccinated animals can \n\nprotect them against IFNection with S. mansoni when transferred to non-immunized animals \n\n(Ford et al, 1984; Melo et al., 2014; Bickle et al, 1985). This demonstrated the crucial \n\nimportance of antibodies in protection against S. mansoni. Herein we observed a weak \n\nactivation of humoral response with low titers of specific IgG antibodies in sera from mice \n\nimmunized with pcDNA 3.1 V5/His A/SmCyp. This poor activation of humoral response may \n\nhave contributed to the absence of protection in our immunization strategy. \n\nImmunological memory is the basis for vaccination. Memory cells have the ability to \n\nproduce a fast immune response upon exposure to the same pathogen (Crotty et al, 2004). \n\nImmunization with pcDNA 3.1 V5/His A/SmCyp was not able to increase the percentage of \n\nCD4, CD8 or B memory cells (Fig6), which also might have contributed to the absence of \n\nprotective immune response. \n\nAlthough our immunization strategy failed to reduce worm burden, a significant \n\nreduction in granuloma size was observed in immunized mice (Fig. 4). The granulomatous \n\nreaction represents the major pathology consequence associated with schistosomiasis, and \n\nalso the intensity of these reaction correlates with host morbidity (Stadecker et al., 1999; \n\nWynn &amp; Cheever, 1995; Abath et al., 2006). Although egg-induced granulomas detrimental to \n\nthe IFNected host, the absence of granulomatous reaction has also detrimental effect \n\n(Hoffman et al., 2000). Therefore the modulation of the granulomatous reaction leading to \n\nreduced granuloma area represents the best scenario in the host-parasite interaction. \n\n\n\n\u00a0\n\n\u00a0\n\n126\u00a0\n\n\u00a0\n\nWhile it has been know that the granulomatous response is largely CD4+ cell-\n\ndependent, cytokines roles in granuloma orchestration remains unclear (Matthew et al., 1986, \n\nPearce et al., 1996; Phillips &amp; Lammie, 1986; Hsu et al., 1976).IL-4 was proposed to play \n\nmajor role in granuloma formation, indeed IL-4 neutralization in IFNected mice result in \n\nreduced lesion size (Yamashita et al.,1992) and collagen deposition (Cheever et al. 1994). On \n\nthe other hand, Pearce et al. (1996) showed that there are no differences in granuloma size \n\nbetween IL-4 knockout (KO) and wild type mice. Same contradictories results have been \n\ndescribed in IFN-? role in granuloma formation. Some studies report that IFN-? stimulates \n\ngranuloma formation (Rezende et al. 1997) while others describe a role for IFN-? in \n\ngranuloma modulation (Wynn &amp; Cheever, 1995; Rutitzky &amp; Stadecker, 2011).  Besides \n\nTh1/Th2 balance in granuloma modulation, others immunological mechanisms, as \n\nalternatively macrophages activation (aaM?) (Herbert et al., 2004), regulatory T cell \n\nactivation (Singh et al., 2005) or increased production of IL-10 (Wynn et al., 1998),  have also \n\nbeen described in granuloma modulation. Cytokines measurement in spleens cells culture \n\nsupernatant demonstrated that immunization with pcDNA 3.1/V5-His/A-Smcyp induced \n\nsignificant increase in IFN-? production and a significant decrease in IL-10 production (Fig. \n\n5). Therefore IL-10 and aaM? seems not to be involved, and IFN-? role in these modulation \n\nstill to be determined. \n\n5 References \n\n1. Abath FG, Morais CN, Montenegro CE, Wynn TA, Montenegro SM. Immunopathognic \n\nmechanism in schistosomiasis: what can be learnt from human studies? Trends Parasitol, \n\n2006; 22: 85-91. \n\n2. Bergquist NR. Schistosomiasis: from risk assessment to control. Trends Parasitol. 2002 \n\nJul;18(7):309-14. \n\n3. Bickle QD, Andrews BJ, Doenhoff MJ, Ford MJ, Taylor MG. Resistance against \n\nSchistosoma mansoni induced by highly irradiated IFNections: studies on species specificity \n\nof immunization and attempts to transfer resistance. Parasitology. 1985;90 (Pt 2):301-12. \n\n\n\n\u00a0\n\n\u00a0\n\n127\u00a0\n\n\u00a0\n\n4. Braschi S, Borges WC, Wilson RA. Proteomic analysis of the schistosome tegument and its \n\nsurface membranes. Mem Inst Oswaldo Cruz, 2006; 101 (Suppl 1): 205-12. \n\n5. Bueding E, Hawkins J, Cha YN. Anti Schistosomal effect of cycloporine A. Agents \nActions, 1981; 4: 380-383. \n\n6. Cardoso FC, Pacifico RN, Mortara RA, Oliveira SC. Human antibody responses of patients \n\nliving in endemic \u00e1reas for schistosomiasis to the tegumental protein Sm29 identified through \n\ngenomic studies. Clin Exp Immunol, 2006\u00aa; 144: 382-391. \n\n7. Chappell LH, Thomson AW, Barker GC, Smith SWG. Dosage, timing and oute of \n\nadministration of cyclosporin A and no immunosuppressive derivatives of dihydrocyclosporin \n\nA and cyclosporin C. Antimicrob Agents Chemother, 1987; 31: 1567-77 \n\n8. Chappell LH, Thomson AW. Studies on the action of cyclosporin A against Schistosoma \n\nmansoni and other parasitic IFNections. Transplant Proc., 1988; 20: 291-97. \n\n9. Cheever AW, williamn ME, Wynn TA, Finkelman FD, Seder RA, Cox T, Hieny S, Caspar \n\nP, Sher A. Anti-IL-4 treatment of Schistosoma mansoni-IFNected mice inhibits development \n\nof T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced \n\nhepatic fibrosis. J Immunol. 1994;153(2):753-9. \n\n10. Crotty S., Aubert R. D., Glidewell J., Ahmed R. Tracking human antigen-specific memory \n\nB cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods, . (2004); 286: \n\n111\u2013122  \n\n 11. G\u00f6thel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases, a superfamily of \n\nubiquitous folding catalysts. Cell Mol Life Sci, 1999;55(3):423-36. \n\n12. Engels D, Chitsulo L, Montresos A, Savioli L. The global epidemiological situation of \n\nschistosomiasis and new approaches to control and research. Acta trop. 2002; 139-146. \n\n13. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and \n\npeptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature, 1989; 337: 476-78. \n\n\n\n\u00a0\n\n\u00a0\n\n128\u00a0\n\n\u00a0\n\n14. Ford MJ, Bickle QD, Taylor MG, Andrews BJ. Passive transfer of resistance and the site \n\nof immune-dependent elimination of the challenge IFNection in rats vaccinated with highly \n\nirradiated cercariae of Schistosoma mansoni. Parasitology. 1984;89 ( Pt 3):461-82. \n\n15. Han H, Peng J, Hong Y, Fu Z, Xu J, Lin J, Tao J. Molecular cloning and characterization \n\nof a cyclophilin A homologue from Schistosoma japonicum. Parasitol Res. 2012 \n\nAug;111(2):807-17. \n\n16. Herbert D. R., Holscher C., Mohrs M., Arendse B., Schwegmann A., Radwanska M., et al. \n\n(2004). Alternative macrophage activation is essential for survival during schistosomiasis and \n\ndownmodulates T helper 1 responses and immunopathology. Immunity 20, 623\u2013635. \n\n17. Hoffman WA, Pons JA, Janer JL. The sedimentation concentration method in \n\nschistosomiasis mansoni. Puerto Rico J Publ Hlth1934; 9: 281-298 \n\n18. Hoffmann KF, Cheever AW, Wynn TA. IL10 and the dangers of immune polarization: \n\nexcessive type 1 and type 2 cytokine responses induce distinct forms of lethal \n\nimmunopathology in murine schistosomiasis. J Immunol, 2000;164 (12): 6406-16. \n\n19. Hsu CK, Hsu SH, Whitney RA, Hansen CT. Immunopathology of schistosomiasis in \n\nanthymic mice. Nature, 1976; 262: 397-99. \n\n20. Jankovic D, Wynn TA, Kullberg MC, Caspar R, James S,  Cheever AW, et al.. Optimal \n\nvaccination against Schistosoma mansoni requires the induction of both B cell and IFN-? \n\ndependent effector mechanisms. J Immunol 1999; 162 (1): 345-351 \n\n21. Kalinna BH.DNA vaccines for parasitic IFNections. Immunol Cell Biol. 1997;75(4):370-\n\n5. Review. \n\n22. Kiang D, El Ghazalie NE, Medhat AM, Abdel-Fattah M, Karim AM, LoVerde PT. \n\nIdentification and characterization of Schistosoma mansoni p17.7, a cyclophilin. Mole Bioch  \n\nParasitol. 1996; 76 (1-2): 73-82. \n\n\n\n\u00a0\n\n\u00a0\n\n129\u00a0\n\n\u00a0\n\n23. Klinkert MQ, Bugli F, Cruz J, Engels B, , Cioli D. Sequence conservation of schistosome \n\ncyclophilins. Mol Biochem Parasitol 1996; 81: 239-42. \n\n24. Kojima S. Overview: from the horse experimentation by Prof. Akira Fujinami to \n\nparamyosin. Parasitol Int. 2004; 53(2):151-62. \n\n25. Loukas A, Tran M, Pearson MS. Schistosome membrane proteins as vaccines. Int J \n\nParasitol. 2007; 37(3-4):257-63. \n\n26. Mathew Arc, Boros DL. Anti-L3T4 antibody treatment suppresses hepatic granuloma \n\nformation and abrogates antigen-induced interleukin2 production in Schistosoma mansoni \n\nIFNection. IFNect Immun, 1986; 54: 820-26. \n\n27. Melo TT, Sena IC, Ara\u00fajo N, Fonseca CT. Antibodies are involved in the protective \n\nimmunity induced in mice by Schisosoma mansoni schistosomula tegument (Smteg) \n\nimmunization. Parasite immunology, 2014; 36: 107-111. \n\n28. Mi H, Kops O, Zimmermann E, J\u00e4schke A, Tropschug M. A nuclear RNA-binding \n\ncyclophilin in human T cells.FEBS Lett. 1996; 398(2-3):201-5 \n\n29. Pearce EJ, Cheever A, Leonard S, Covalesky M, Fernandez-Botran R, Kohler G, Kopf M. \n\nSchistosoma mansoni in IL-4-deficient mice. Int Immunol. 1996; 8(4):435-44. \n\n30. Phillips SM, Lammie PJ. Immunopathology of granuloma formation and fibrosis in \n\nschistosomiasis. Parasitol Today. 1986 Nov;2(11):296-302. \n\n31. Ramalho-Pinto FJ, Gazzinelli G, Howells RE, Mota-Santos TA, Figueiredo EA, \n\nPelegrino. Schistosoma mansoni: defined system for stepwise transformation of cercariae to \n\nschistossomule in vitro. Exp Parasitol, 1974; 36 (3):360-72. \n\n32. Rezende SA, Oliveira VR, Silva AM, Alves JB, Goes AM, Reis LF. Mice lacking the \n\ngamma interferon receptor have an impaired granulomatous reaction to Schistosoma mansoni \n\nIFNection. IFNect Immunol, 1997; 65: 3457-61. \n\n\n\n\u00a0\n\n\u00a0\n\n130\u00a0\n\n\u00a0\n\n33. Rutitzky L. I., Stadecker M. J. (2011). Exacerbated egg-induced immunopathology in \n\nmurine Schistosoma mansoni IFNection is primarily mediated by IL-17 and restrained by \n\nIFN-gamma. Eur. J. Immunol. 41, 2677\u20132687 \n\n34. Santigo ML, Hafalla JCR, Kurtis JD, et al. Identification of the Schistosoma japonicum \n\n22.6-kDa antigen as a major target of the human IgE response: similarity of IgE-binding \n\nepitopes to allergen peptides. International archives of Allergy and Immunology, 1998; 117 \n\n(2): 94-104. \n\n35. Sauma SY, Strand M. Identification and characterization of glycosylphosphatidylinositol-\n\nlinked Schistosoma mansoni adult worm immunogens. Molecular and Biochemical \n\nParasitology, 1990; 38: 199-210. \n\n36. Sch\u00f6nbrunner ER, Mayer S, Tropschug M, Fischer G, Takahashi N, Schmid FX. Catalysis \n\nof protein folding by cyclophilins from different species. J Biol Chem, 1991; 266(6):3630-5. \n\n37. Serra EC, Lardans V, Dissous C. Identification of NF-AT-like transcriptionfactor in \n\nSchistosoma mansoni: its possible involvement in the antiparasitic action of cyclosporin A. \n\nMol Biochem Parasitol. 1999 Jun 25;101(1-2):33-41. \n\n38. Singh K. P., Gerard H. C., Hudson A. P., Reddy T. R., Boros D. L. (2005). Retroviral \n\nFoxp3 gene transfer ameliorates liver granuloma pathology in Schistosoma mansoni IFNected \n\nmice. Immunology 114, 410\u2013417 \n\n39. Stadecker MJ. The development of granulomas in schistosomiasis: genetic backgrounds, \n\nregulatory pathways, and specific egg antigen responses that IFNluence the magnitude of \n\ndisease. Microbes and IFNect, 1999; 505-510. \n\n40. Steinmann P, Keiser  J, Bos J, Tanner M, Utzinger J. Schistosomiasis and water resources \n\ndevelopment: systematic review, meta-analysis, and estimates of people at risk. Lancet IFNect \n\nDis 2006; 6 (7): 411-25. \n\n41. Teixeira de Melo T, Araujo JM, Do Valle Dur\u00e3es F, Caliari MV, Oliveira SC, Coelho PM, \n\nFonseca CT. Immunization with newly transformed Schistosoma mansoni schistosomula \n\n\n\n\u00a0\n\n\u00a0\n\n131\u00a0\n\n\u00a0\n\ntegument elicits tegument damage, reduction in egg and parasite burden. Parasite Immunol, \n\n2010; 32 (11-12): 749-59. \n\n42. Teixeira de Melo T, Araujo JM, Campos de Sena I, Carvalho Alves C, Ara\u00fajo N, Toscano \n\nFonseca C. Evaluation of the protective immune response induced in mice by immunization \n\nwith Schistosoma mansoni schistosomula tegument (Smteg) in association with CpG-ODN. \n\nMicrobes and IFNection, 2012; 15 (2013): 28-36. \n\n43. Torben W, Ahmad G, Zhang W, Nash S, Le L, Karmakar S, Siddiqui AA. Role of \n\nantibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection \n\nagainst Schistosoma mansoni. Vaccine. 2012 Nov 6;30(48):6753-8 \n\n44. Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al..Tetraspanins \n\non the sufarce of Schistosoma mansoni are proctetive antigens against schistosomiasis. Nat \n\nMed, 2006; 12 (7): 835-40. \n\n45. Trandinh CC, Pao GM, Saier MH. Structural and evolutionary relationships among the \n\nimmunophilins: two ubiquitous families of peptidyl-prolyl cis trans isomerases. FASEB J, \n\n1992; 6: 3410-20 \n\n46. Van Balkom BW, Van Gestel RA, Brouwers JF, Krijgsveld J, Tielens AG, Heck AJ, Van \n\nHellemond JJ. Mass spectrometric analysis of the Schistosoma mansoni tegumental sub-\n\nproteome. J. Proteome Res, 2005; 4: 958-66. \n\n47. Wynn TA, Cheever AW. Cytokine regulation of granuloma formation in schistosomiasis. \n\nCurr Opin Immunol 1995; 7 (4): 505-511. \n\n48.  Wynn TA, Cheever AW, Williams ME, Hieny S, Caspar P, K\u00fchn R, M\u00fcller W, Sher A. \n\nIL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required \n\nfor immune down-modulation of chronic disease. J Immunol. 1998;160(9):4473-80. \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n132\u00a0\n\n\u00a0\n\nFigures \n\n \n\nFigure 1: Alignment of schistosome cyclophilins protein sequences. Common amino acid \n\nresidues from all cyclophilins protein sequences were aligned using ClustalW2 multiple \n\nsequence alignment. Identical residues are indicated by an asterisk, similar and less similar \n\nresidues are indicated by double and single dots, respectively. T and B cell predited epitope is \n\nhighlight by a dashed square.  A T cell predicted epitope is underlined in the protein \n\nsequence. \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n133\u00a0\n\n\u00a0\n\n \n\nFigure 2: Western blotting analysis of SmCyp expression by transient transfected \n\nHEK293T cells.  HEK293T culture cells were transient transfected by lipofection technique \n\nwith Lipofectamine 2000 (Invitrogen). The protein extracts of cells transfected with \n\npcDNA3.1/V5-His A plasmid containing the coding region of SmCyp gene of S. mansoni \n\nfused to V5 epitope and 6xHis codons (line 1); pcDNA3.1/V5-His B plasmid containing the \n\ncoding region of a non-correlated gene of S. mansoni also fused to V5 epitope and 6xHis \n\ncodons (line 2); empty pcDNA3.1/V5-His A (line 3) and the protein extract of non-transfected \n\ncells (line 4) were used in a Western blotting assay with anti-His (Cterm)-HRP antibody \n\n(Invitrogen) (1:5.000). The reaction was revealed using ECL Plus Western Blotting Detection \n\nSystem (GE-Healthcare) and the image was captured in ImageQuant LAS 4000 (GE-\n\nHealthcare) by chemiluminescence method. The BenchMark Protein Ladder (Invitrogen) was \n\nused as the molecular weight marker (kDa). \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n134\u00a0\n\n\u00a0\n\n \n\nFigure 3: Kinectics of specific anti-SmCyp IgG. Mice were immunized with four doses of a \n\nvaccine formulation containing pcDNA 3.1 V5/His A/SmCyp (Black bars)or empty pcDNA \n\n3.1 V5/His A (White bars). Five days before de first immunization mice received 100 \n\n\u00b5L/animal of cardiotoxin (0,06mg/mL). Sera samples, diluted 1:50 , were obtained from 10 \n\nindividual mice from each group on days 15, 30, 45, 60, 75, 90 and 105 after the first \n\nimmunization dose and used in ELISA against  SmCyp (94-108) or SmCyp (107-121) \n\n(1\u00b5g/mL) coated plate (. Specific IgG antibodies were detected by an anti-mouse IgG-HRP \n\n(1:10000) conjugated. Results represent the mean absorbance + SD measured at 450nm. \n\nArrows indicate the timing of each immunization dose and challenge IFNection. Statistically \n\nsignificant differences between Groups are pointed in the graphic. \n\n\n\n\u00a0\n\n\u00a0\n\n135\u00a0\n\n\u00a0\n\n \n\nFigure 4: Hepatic granuloma number and area in SmCyp immunized mice. (A) \n\nGranuloma area/mm2 measured on 100 granulomas from each group with a single well-\n\ndefined egg, using a digital pad. (B) Number of granulomas measured on slide of liver \n\nhistological sections. The total diameter of granulomas was measured, and the results were \n\nexpressed as mean square micrometers (\u00b5m2). White bars represent empty pcDNA 3.1 V5/His \n\nA group and black bars represent pcDNA 3.1 V5/His A/SmCyp group. Statistically significant \n\ndifference compared to empty pcDNA 3.1 V5/His A group is denoted in the graphic.  \n\n \n\n  \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n136\u00a0\n\n\u00a0\n\n \n\nFigure 5: Type of immune response elicited by pcDNA 3.1 V5/His A/SmCyp and empty \n\npcDNA 3.1 V5/His immunization. Spleen cell culture supernatants from eight individual \n\nmice per group immunized with empty pcDNA 3.1 V5/His A or pcDNA 3.1 V5/His \n\nA/SmCyp, one week after the last immunization was performed. IL-10, IL-17, TNF-a, IFN-g, \n\nIL-6,IL-4 and IL-2 production in response to SmCyp(94-108); SmCyp (107-121) and Smteg \n\nin vitro stimulation were measured in the supernatant of splenocytes culture using mouse \n\nTh1/Th2/Th17 Cytometric Bead Array (CBA) Kit (BD Biosciences, USA). Bars represent the \n\nmean + SD of the difference on cytokine production in response the SmCyp(94-108); SmCyp \n\n(107-121) or Smteg stimulation and basal cytokine production observed in nonstimulated \n\nsplenocytes. White bars represent empty pcDNA 3.1 V5/His A group and black bars represent \n\npcDNA 3.1 V5/His A/SmCyp group .Statistically significant difference between group are \n\npointed in the graphic. \n\n\n\n\u00a0\n\n\u00a0\n\n137\u00a0\n\n\u00a0\n\n \n\nFigure 6: Immune cells profile. Spleen cells obtained from five mice per group: immunized \n\nwith empty pcDNA 3.1 V5/His A or pcDNA 3.1 V5/His A/SmCyp were cultured and adjusted \n\nto 5 x 105 cells/well, the percentage of CD4+ and CD8+ activated, central and effector \n\nmemory cells and memory B cells were determined. White bars represent the the cells from \n\nthe group immunized with empty pcDNA 3.1 V5/His A. Black bars represent the cells from \n\nthe group immunized with pcDNA 3.1 V5/His A/SmCyp. Statistically significant difference \n\nbetween groups are pointed in the graphic. \n\n\n\n\u00a0\n\n\u00a0\n\n138\u00a0\n\n\u00a0\n\nTable 1: Predicted B and T cells epitopes in SmCyp amino acids sequence. \n\nB cell epitopes Position Score \n\nGGDFTNGDGTGGKS 62 1 \n \n\nNDVPDTTRNFRELC \n\nSMANAGPNTNGSQF\n\n25 \n \n\n96 \n\n0.999 \n \n\n0.999 \n\nT cell epitopes  \n\n(Iab restricted) \n\nPosition  Score  \n\nMANAGPNTN \n\nFFITTVPCS \n\nITTVPCSWL \n\n97 \n \n\n109 \n \n\n111 \n\n16077 \n \n\n13364 \n \n\n10183 \n\n   \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n139\u00a0\n\n\u00a0\n\nTable 2: Protective immune response induced in mice with SmCyp. \n\n Worm burden \nrecovered \n\n  Protection \nlevel  \n\nReduction \nof egg in \n\nfeces a \n\nReduction of egg \nin tissues b \n\nGroups Female Male Total   Intestine Liver \n\npcDNA3.1/V5-\nHisA \n\n \n\n18+ 4 18+ 3 36 + 5     \n\npcDNA \n3.1/V5-\n\nHisA/SmCyP \n\n \n\n17 + 5 19 + 4 36 + 8 0% 20% 12.7% 0% \n\npcDNA3.1/V5-\nHisA \n\n \n\n22 + 5 25 + 4 47 + 8     \n\npcDNA 3.1V5-\nHisA/SmCyP \n\n \n\n20 + 7 24 + 5 44 + 10 6.3%  0 % 23.9% 0.0% \n\n        \n\na reduction  of eggs eliminated with the feces of immunized groups compared to control \n\ngroups \n\nbreduction  of eggs in tissues (intestine and liver) of immunized groups compared to control \n\ngroups \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n140\u00a0\n\n\u00a0\n\n5 CONSIDERA\u00c7\u00d5ES FINAIS \n\n As vacinas est\u00e3o entre as estrat\u00e9gias menos dispendiosas e mais poderosas para a \n\npreven\u00e7\u00e3o de doen\u00e7as e \u00f3bitos decorrentes das mesmas. O desenvolvimento de vacinas contra \n\ndoen\u00e7as Infecciosas e parasit\u00e1rias se torna particularmente importante dado que estas doen\u00e7as \n\npermanecem sendo importantes causas de \u00f3bitos no mundo (WHO, 2002). As vacinas \n\ndesenvolvidas e licenciadas mais bem sucedidas at\u00e9 hoje s\u00e3o as que agem contra Infec\u00e7\u00f5es \n\nagudas bacterianas e vir\u00f3ticas. Para algumas doen\u00e7as Infecciosas, vacinas eficazes foram \n\ndesenvolvidas de maneira emp\u00edrica e com base em um conhecimento m\u00ednimo dos \n\nmecanismos imunol\u00f3gicos envolvidos (Elevam et al., 1998). Entretanto, no caso das doen\u00e7as \n\ncausadas por pat\u00f3genos que exibem varia\u00e7\u00e3o antig\u00eanica extensa ou causam Infec\u00e7\u00f5es cr\u00f4nicas \n\ne persistentes, como \u00e9 o caso das doen\u00e7as parasit\u00e1rias, as dificuldades e fracassos sugerem \n\nque um entendimento muito claro da biologia dos organismos envolvidos e da natureza da \n\nresposta imune estimulada seja necess\u00e1rio antes que se consiga uma vacina protetora. O \n\nsucesso no desenvolvimento de vacinas est\u00e1 no conhecimento dos mecanismos efetores e \n\nprotetores e no uso de ant\u00edgenos e estrat\u00e9gias capazes de desencadear resposta protetora. No \n\ncaso do S. mansoni a dificuldade em se desenvolver uma vacina efetiva contra este parasito \n\nesbarra na complexidade do mesmo, que apresenta diferentes est\u00e1gios evolutivos e uma s\u00e9rie \n\nde mecanismos de escape contra a imunidade do hospedeiro.  \n\n Recentemente, bastante aten\u00e7\u00e3o tem sido dada ao tegumento do parasito para \n\nidentifica\u00e7\u00e3o de ant\u00edgenos vacinais, j\u00e1 que este representa a interface entre hospedeiro-\n\nparasito (Tran et al., 2006) estando envolvido com a nutri\u00e7\u00e3o, evas\u00e3o e modula\u00e7\u00e3o da resposta \n\nimune, excre\u00e7\u00e3o, osmorregula\u00e7\u00e3o, recep\u00e7\u00e3o sensorial e transdu\u00e7\u00e3o de sinais (Jones et al., \n\n2004; Van Hellemond et al., 2007). Em um trabalho realizado por nosso grupo estudando a \n\nativa\u00e7\u00e3o de c\u00e9lulas dendr\u00edticas pelo tegumento do esquistoss\u00f4mulo (Smteg), foram \n\nobservados um aumento na express\u00e3o de CD40 e CD86 e uma elevada produ\u00e7\u00e3o de IL-12 e \n\nTNF-? pelas c\u00e9lulas dendr\u00edticas estimuladas (Dur\u00e3es et al., 2009). A IL-12 \u00e9 uma importante \n\ncitocina envolvida na diferencia\u00e7\u00e3o da resposta adaptativa para um perfil Th1 (Abbaset al., \n\n1996) que tem sido descrito como o perfil protetor no caso de Infec\u00e7\u00e3o parasit\u00e1ria no modelo \n\nmurino (Fonseca et al., 2004). J\u00e1 o TNF-? tem sido descrito como uma importante citocina \n\nenvolvida na elimina\u00e7\u00e3o do parasito (Fonseca et al., 2004). \n\n\n\n\u00a0\n\n\u00a0\n\n141\u00a0\n\n\u00a0\n\n O objetivo central da tese foi avaliar o potencial protetor do tegumento do \n\nesquistoss\u00f4mulo do Schistosoma mansoni (Smteg) sozinho ou associado a diferentes \n\nadjuvantes em um protocolo de imuniza\u00e7\u00e3o em modelo murino a fim de se identificar perfis \n\nimunol\u00f3gicos associados \u00e0 imunidade protetora contra o parasito. Al\u00e9m disso, como o \n\ntegumento do parasito \u00e9 composto de v\u00e1rias prote\u00ednas, e \u00e9 dificilmente obtido em grandes \n\nquantidades, neste trabalho utilizamos t\u00e9cnicas de imunoproteomica utilizando anticorpos \n\nespec\u00edficos para identificar as prote\u00ednas imunog\u00eanicas do tegumento. A utiliza\u00e7\u00e3o de \n\nanticorpos para sele\u00e7\u00e3o de candidatos vacinais em nosso estudo foi de extrema import\u00e2ncia \n\numa vez que demonstramos que anticorpos contra as prote\u00ednas do tegumento est\u00e3o envolvidos \n\nna elimina\u00e7\u00e3o do parasito in vivo.  Testamos ainda, por meio de imuniza\u00e7\u00e3o na forma de \n\nDNA, o potencial antig\u00eanico da SmCyp, uma das prote\u00ednas do Smteg reconhecida por soro de \n\ncamundongos imunizados e protegidos e identificada por espectrometria de massas.  \n\n Foi observado aqui que a imuniza\u00e7\u00e3o com Smteg na falta de adjuvante n\u00e3o elicitou \n\nprote\u00e7\u00e3o, o mesmo perfil de resposta foi observado ao se imunizar camundongos adicionando \n\nalum como adjuvante. Por outro lado, a imuniza\u00e7\u00e3o de camundongos utilizando CpG-ODN \n\ncomo adjuvante  elicitou uma prote\u00e7\u00e3o parcial de 43% da carga parasit\u00e1ria. Esses resultados \n\ncorroboram com o trabalho realizado por nosso grupo no qual a utiliza\u00e7\u00e3o de Smteg mais \n\nadjuvante de Freund em protocolos vacinais foi capaz de reduzir de 43% a 48% a carga \n\nparasit\u00e1ria induzindo, assim, uma prote\u00e7\u00e3o parcial (Teixeira de Melo, 2010). \n\nProte\u00ednas do tegumento como as tetraspaninas e a Sm29 foram capazes de induzir prote\u00e7\u00e3o de \n\n57% (TSP 2) e de 34% (TSP 1)(Tran et al.2006)  e 56,7 % (Sm29)(Cardoso et al.2008). Os \n\nn\u00edveis de prote\u00e7\u00e3o encontrados induzidos por estas prote\u00ednas\u2013(TSP-2 e Sm29) foram maiores \n\ndo que o n\u00edvel de prote\u00e7\u00e3o da nossa formula\u00e7\u00e3o, entretanto o Smteg \u00e9 um composto contendo \n\nv\u00e1rias prote\u00ednas que podem ou n\u00e3o serem imunog\u00eanicas, sendo ainda capazes de modular a \n\nresposta imune interferindo na habilidade do mesmo induzir prote\u00e7\u00e3o como visto nos estudos \n\nde imuniza\u00e7\u00e3o com o tegumento na aus\u00eancia de adjuvante (Araujo et al., 2012). Um exemplo \n\nclaro da interfer\u00eancia de epitopos n\u00e3o imunog\u00eanicos foi observado por Garcia et al. (2008) no \n\nestudo que demonstrou que, quando camundongos eram imunizados com epitopos \n\nimuNODominantes da Sm14 observava-se uma redu\u00e7\u00e3o na patologia da doen\u00e7a que n\u00e3o era \n\nobservada quando utilizava-se a prote\u00edna recombinante em protocolo de imuniza\u00e7\u00e3o. Outra \n\n\n\n\u00a0\n\n\u00a0\n\n142\u00a0\n\n\u00a0\n\nexplica\u00e7\u00e3o para o percentual menor de redu\u00e7\u00e3o do n\u00famero de vermes em nossos experimentos \n\ncomparados aos estudos com a TSP e a Sm29 \u00e9 a concentra\u00e7\u00e3o do ant\u00edgeno vacinal. N\u00f3s \n\nvacinamos com a mesma concentra\u00e7\u00e3o vacinal da Sm29 purificada, ou seja, nosso ant\u00edgeno \n\ntinha uma concentra\u00e7\u00e3o de Sm29 muito menor, o que justifica tamb\u00e9m uma menor \n\nporcentagem de prote\u00e7\u00e3o.  \n\n A fim de ampliar nossos conhecimentos a respeito do papel individual das prote\u00ednas \n\npresentes no tegumento do esquistoss\u00f4mulo do Schistosoma mansoni (Smteg), n\u00f3s realizamos \n\nan\u00e1lises prote\u00f4micas e sorol\u00f3gicas atrav\u00e9s do Western-blotting bidimensional (2D- WB) para \n\nidentifica\u00e7\u00e3o das prote\u00ednas reconhecidas por soro de camundongos previamente imunizados \n\ncom Smteg. Dos 63 spots submetidos \u00e0 espectrometria de massas,42foram identificados:22 \n\nspots apresentaram identifica\u00e7\u00e3o com prote\u00ednas do S. mansoni sendo que, 18 deles \n\napresentaram pelo menos um pept\u00eddeo que possui score indicativo de identidade ou extensiva \n\nhomologia com Schistosoma mansoni. Outros 20 spots n\u00e3o apresentaram hit de identifica\u00e7\u00e3o \n\ncom S. mansoni, sendo que 10 possu\u00edam pelo menos um pept\u00eddeo que possui score indicativo \n\nde identidade ou extensiva homologia com outras esp\u00e9cies, mas que ao ser realizado BLAST \n\ncom o Schistosoma, todos apresentaram identidade acima de 80% com este helminto. Uma \n\nposs\u00edvel explica\u00e7\u00e3o para falha na identifica\u00e7\u00e3o das prote\u00ednas presentes em 21 spots poderia ser \n\na aus\u00eancia de ioniza\u00e7\u00e3o dos pept\u00eddeos de tais prote\u00ednas impossibilitando o reconhecimento da \n\nmassa dos mesmos ou a aus\u00eancia de prote\u00ednas hom\u00f3logas depositadas no banco de dados \n\nanalisado. Tais justificativas, entretanto, necessitam serem melhores elucidadas. \n\nEscolhemos primeiramente trabalhar com a prote\u00edna presente no spot 29 a qual \n\ndenominamos de SmCyp por ser caracterizada como uma ciclofilina de S. mansoni. J\u00e1 foi \n\ndemonstrado em um experimento de imuniza\u00e7\u00e3o com camundongos no qual utilizou-se como \n\nant\u00edgeno vacinal a ciclofilina recombinante de Schistosoma jap\u00f4nico (rSJCyPA) uma \n\ndiminui\u00e7\u00e3o estatisticamente significativa da carga parasit\u00e1ria (17,2%) e no n\u00famero de ovos \n\npresos no f\u00edgado (52,7%) (Hongxiao et al., 2012). Uma vez que ainda n\u00e3o h\u00e1 nenhum trabalho \n\nde imuniza\u00e7\u00e3o com a ciclofilina do S. mansoni resolvemos test\u00e1-la sob a forma de vacina de \n\nDNA. Em rela\u00e7\u00e3o \u00e0 carga parasit\u00e1ria n\u00e3o houve redu\u00e7\u00e3o estatisticamente significativa do \n\nn\u00famero de vermes presentes nos camundongos imunizados com pcDNA3.1V5/His.A/SmCyp \n\nquando comparado ao grupo controle. \n\n\n\n\u00a0\n\n\u00a0\n\n143\u00a0\n\n\u00a0\n\n Dentre as formula\u00e7\u00f5es vacinais, apenas os camundongos imunizados com o Smteg \n\nassociado ao adjuvante CpG-ODN apresentaram  redu\u00e7\u00e3o significativa no n\u00famero de ovos \n\neliminados nas fezes. Esse resultado demonstra a import\u00e2ncia da escolha de um bom \n\nadjuvante em uma formula\u00e7\u00e3o vacinal.  \n\n Estudos indicam que o CpG-ODN \u00e9 capaz de aumentar a apresenta\u00e7\u00e3o do ant\u00edgeno \n\npelas Ap\u00f3s, induzindo uma resposta IFNlamat\u00f3ria do tipo Th1 com alta produ\u00e7\u00e3o de \n\nanticorpos (Klinman et al., 2004; Chu et al., 1997; Carson &amp; Raz, 1997).Ao analisarmos o \n\nperfil de imunoglobulinas presentes nos soros de camundongos imunizados com Smteg, \n\nSmteg + alum, Smteg + alum +CpG-ODN e pcDNA3.1V5/His.A/SmCyp, observamos um \n\naumento estatisticamente significativo dos n\u00edveis de: IgG (45, 60 e 75 dias ap\u00f3s a primeira \n\ndose de imuniza\u00e7\u00e3o) IgG2c (75 dias ap\u00f3s a primeira dose de imuniza\u00e7\u00e3o) no grupo imunizado \n\ncom Smteg sem adi\u00e7\u00e3o de adjuvante; IgG (em todos os dias de coleta) e IgG 1 (em todos os \n\ndias de coleta)  no grupo imunizado com Smteg/alum; IgG (em todos os dias de coleta) e IgG \n\n1 (em todos os dias de coleta) e IgG 2c (em todos os dias de coleta)  no grupo imunizado com \n\nSmteg/alum/CpG.Percebe-se que somente o grupo que recebeu como adjuvante o CpG-ODN \n\napresentou durante todo o curso do experimento n\u00edveis significativos de IgG2c. O mesmo \n\nperfil foi apresentado pelo estudo de Teixeira de Melo et al. (2010) o qual utilizou Smteg mais \n\nadjuvante de Freund em protocolo de imuniza\u00e7\u00e3o e que tamb\u00e9m verificou o aumento no n\u00edvel \n\nde IgG2c correlacionando esta imunoglobulina a um perfil protetor. Al\u00e9m disso, outros \n\ntrabalhos que observaram n\u00edveis de prote\u00e7\u00e3o significativos diante de diferentes formula\u00e7\u00f5es \n\nvacinais contendo ant\u00edgenos do S. mansoni apresentaram o mesmo perfil de imunoglobulinas \n\naqui demonstrado (Fonseca et al., 2004; Garcia et al., 2008; Wynn &amp; Cheever, 1995).N\u00e3o \n\nhouve aumento estatisticamente significativo de nenhuma das imunoglobulinas avaliadas no \n\nsoro de camundongos imunizados compcDNA3.1V5His.A/SmCyp. S. mansoni.  \n\n Uma resposta imune protetora contra a esquistossomose envolve ambas as respostas \n\ncelular e humoral (Jankovic et al., 1999).  Como observamos anteriormente, as formula\u00e7\u00f5es \n\nvacinais que foram capazes de induzir n\u00edveis significativos de IgG2c espec\u00edficos ao Smteg \n\ndurante todo protocolo experimental apresentaram diminui\u00e7\u00e3o estatisticamente significativa \n\nna carga parasit\u00e1ria presente nos camundongos imunizados. Diante disso, n\u00f3s resolvemos \n\ninvestigar qual seria a fun\u00e7\u00e3o dos anticorpos na elimina\u00e7\u00e3o do parasito.  \n\n\n\n\u00a0\n\n\u00a0\n\n144\u00a0\n\n\u00a0\n\n O papel dos anticorpos na resposta imune contra o S. mansoni pode ser regulat\u00f3rio ou \n\nefetor dependendo do isotipo de anticorpo produzido. Tem sido sugerido que os mecanismos \n\nefetores de elimina\u00e7\u00e3o do parasito em uma Infec\u00e7\u00e3o pelo S. mansoni ou no caso da imunidade \n\nprotetora induzida por vacina\u00e7\u00e3o tem como principal alvo os esquistoss\u00f4mulos. Em humanos, \n\nIgG1, IgG3 e IgE s\u00e3o anticorpos capazes de mediar a destrui\u00e7\u00e3o de esquistoss\u00f4mulos in vitro \n\nna presen\u00e7a de eosin\u00f3filos, macr\u00f3fagos e plaquetas por um mecanismo de citotoxidade \n\nmediada por anticorpo \u2013 ADCC e fixa\u00e7\u00e3o de complemento (Capron &amp; Capron, 1994; Khalife \n\net al., 1986; Joseph et al., 1983). Assim, em camundongos, ap\u00f3s a realiza\u00e7\u00e3o do ensaio de \n\ncitotoxidade em experimento in vitro utilizando esquistoss\u00f4mulos rec\u00e9m-transformados, \n\nobservamos que os anticorpos foram capazes de se ligar \u00e0 superf\u00edcie do parasito sendo \n\ncapazes de reconhecer e se ligar \u00e0s prote\u00ednas de superf\u00edcie. Al\u00e9m disso, observamos o \n\nimportante papel do complemento na elimina\u00e7\u00e3o do parasito por via cl\u00e1ssica e que a presen\u00e7a \n\nde anticorpos espec\u00edficos aumentou a capacidade do complemento em matar o \n\nesquistoss\u00f4mulo. Estudos demonstram que a ativa\u00e7\u00e3o do complemento tem papel \n\nfundamental na elimina\u00e7\u00e3o do parasito principalmente no come\u00e7o da Infec\u00e7\u00e3o (Corre-Oliveira \n\net al., 1982). Muitas c\u00e9lulas tais como eosin\u00f3filos e macr\u00f3fagos promovem a morte do \n\nparasito atrav\u00e9s do mecanismo de citotoxidade celular depende de anticorpos (ADCC) (David \n\net al., 1980; James et al., 1981). Al\u00e9m disso, em experimento in vivo por meio da \n\ntransfer\u00eancia passiva de soros de camundongos imunizados com Smteg + CFA/IFA n\u00f3s \n\nverificamos uma redu\u00e7\u00e3o significativa de 27% da carga parasit\u00e1ria de camundongos que \n\nreceberam soro contendo anticorpos anti-Smteg al\u00e9m de uma redu\u00e7\u00e3o significativa de 37% e \n\n47% no n\u00famero de ovos presos no intestino e f\u00edgado destes animais, respectivamente (Melo \n\nTT, 2014). Este trabalho corrobora com o estudo de Torben et al. (2011), o qual tamb\u00e9m \n\nobservou significativa diminui\u00e7\u00e3o da carga parasit\u00e1ria de 31-45% de camundongos receberam \n\nsoro anti-Sm-p80. \n\n Tem-se descrito na literatura alguns tipos de linf\u00f3citos com perfis de respostas \n\ndistintos. Entre eles, h\u00e1 aqueles que possuem um perfil Th1, produtores de citocinas IFN-?, \n\nIL-12 e TNF-?. H\u00e1 o tipo Th2 que s\u00e3o produtores das citocinas IL-4, IL-5, IL-10 e IL-13 \n\n(Hilleman et al., 1998). Um modelo de resist\u00eancia bastante estudado na esquistossomose \u00e9 o \n\nque utiliza cerc\u00e1ria irradiada em imuniza\u00e7\u00f5es. Uma \u00fanica exposi\u00e7\u00e3o \u00e0 cerc\u00e1ria atenuada \u00e9 \n\n\n\n\u00a0\n\n\u00a0\n\n145\u00a0\n\n\u00a0\n\ncapaz de induzir altos n\u00edveis de prote\u00e7\u00e3o em camundongos desafiados com a cerc\u00e1ria n\u00e3o \n\natenuada, e essa imunoprote\u00e7\u00e3o est\u00e1 relacionada \u00e0 produ\u00e7\u00e3o de IFN-? e \u00e0 imunidade mediada \n\npor c\u00e9lulas (Vignali et al., 1989; Wilson et al., 1996). Esses autores sugerem que a prote\u00e7\u00e3o \n\nnesse modelo est\u00e1 relacionada a um perfil de resposta imune do tipo Th1. Em humanos, a \n\nresposta do tipo Th1 tamb\u00e9m tem sido associada \u00e0 resist\u00eancia contra Infec\u00e7\u00e3o pelo S. \n\nmansoni, j\u00e1 que PBMC de indiv\u00edduos naturalmente resistentes \u00e0 Infec\u00e7\u00e3o por este parasito \n\nproduzem altos n\u00edveis de IFN-? in vitro quando estimulados com ant\u00edgenos das diferentes \n\nfases de desenvolvimento do S. mansoni (Viana et al., 1995). Para ativar esses mecanismos \n\nefetores \u00e9 importante a ativa\u00e7\u00e3o de c\u00e9lulas CD4+ secretando IFN-? e TNF-? al\u00e9m de induzir a \n\nprodu\u00e7\u00e3o de anticorpos capazes de ativar o complemento e de promover a citotoxicidade \n\ncelular dependente de anticorpo (ADCC). Dessa forma, a imunidade protetora contra a \n\nInfec\u00e7\u00e3o pelo S. mansoni em camundongos est\u00e1 relacionada com o desenvolvimento de uma \n\nresposta celular e humoral, sendo a produ\u00e7\u00e3o de IFN- ? e TNF-? importantes para a \n\nelimina\u00e7\u00e3o do parasito (Wilson et al., 1996; Jankovic et al., 1999). \n\n Em rela\u00e7\u00e3o \u00e0s respostas celulares observadas nos trabalhos aqui apresentados, na \n\nimuniza\u00e7\u00e3o de camundongos com Smteg na aus\u00eancia de adjuvante, observamos um aumento \n\nda porcentagem de c\u00e9lulas espl\u00eanicas CD4+IFN-?+ e CD4+IL-10+ com aumento \n\nestatisticamente significativo na produ\u00e7\u00e3o de citocinas IFN-? e IL-10. Al\u00e9m disso, observou-\n\nse ainda que o Smteg foi capaz de induzir c\u00e9lulas dendr\u00edticas derivadas da medula \u00f3ssea a \n\nproduzir n\u00edveis estatisticamente significativos de IL-10. Estes resultados sugerem que a IL-10 \n\nproduzida em resposta a imuniza\u00e7\u00e3o estaria envolvida na modula\u00e7\u00e3o da resposta inflamat\u00f3ria \n\ne, consequentemente,na perda da prote\u00e7\u00e3o.Na imuniza\u00e7\u00e3o utilizando como adjuvantes alum e \n\nalum+ CpG-ODN, o perfil de citocinas foi diferente entre as formula\u00e7\u00f5es, enquanto a \n\nimuniza\u00e7\u00e3o com Smteg/alum levou a um predom\u00ednio do da resposta imune do tipo Th2 com \n\nalta produ\u00e7\u00e3o de IL-4, a imuniza\u00e7\u00e3o com Smteg/alum/CpG-ODN induziu um perfil misto de \n\nresposta com significativa produ\u00e7\u00e3o de IL-4 e IFN-? . Em ambas as formula\u00e7\u00f5es observou-se \n\naumento significativo na produ\u00e7\u00e3o de TNF-? no sobrenadante de esplen\u00f3citos. A imuniza\u00e7\u00e3o \n\ncom adjuvante CpG-ODN tamb\u00e9m levou a ativa\u00e7\u00e3o de c\u00e9lulas CD4+, macr\u00f3fagos e aumento \n\nno percentual de c\u00e9lulas B. \n\n\n\n\u00a0\n\n\u00a0\n\n146\u00a0\n\n\u00a0\n\n A imuniza\u00e7\u00e3o na forma de DNA com o plasm\u00eddeo pcDNA3.1V5His.A contendo o \n\ngene SmCyp induziu um aumento significativo na produ\u00e7\u00e3o de IFN- ?  por esplen\u00f3citos e \n\ndiminui\u00e7\u00e3o significativa na produ\u00e7\u00e3o de IL-10.  \n\n Em camundongos imunizados com o gene SmCyp foi observada uma modula\u00e7\u00e3o do \n\ngranuloma, medida pela redu\u00e7\u00e3o da \u00e1rea dos mesmos.Vale ressaltar que, analisamos \n\nespecificamente um est\u00e1gio do granuloma: exsudativo-produtivo. Segundo Lenzi et al. (1998) \n\n\u00e9 de fundamental import\u00e2ncia em estudos histopatol\u00f3gicos utilizar granulomas centrados por \n\novos vi\u00e1veis e de mesma fase evolutiva, para tal sugere-se que sejam analisados granulomas \n\nexsudativo-produtivo. Infelizmente, a maioria dos trabalhos sobre modula\u00e7\u00e3o dos granulomas \n\nn\u00e3o discrimina esses aspectos topogr\u00e1ficos e os dados s\u00e3o heterog\u00eaneos, vari\u00e1veis e at\u00e9 \n\ncontradit\u00f3rios de modelo para modelo que dificultam uma an\u00e1lise integral (Lenzi et al.(1998). \n\nA regula\u00e7\u00e3o do granuloma parece seguir mecanismos diferentes conforme a fase de Infec\u00e7\u00e3o. \n\nAl\u00e9m disso, a regula\u00e7\u00e3o negativa do tamanho dos granulomas em Infec\u00e7\u00f5es agudas (oito \n\nsemanas) difere da regula\u00e7\u00e3o da fase cr\u00f4nica (Flores-Villanueva et al., 1996). Assim, para \n\numa melhor compreens\u00e3o da patog\u00eanese da doen\u00e7a \u00e9 importante sempre levar em \n\nconsidera\u00e7\u00e3o os mecanismos imunes envolvidos. \n\n Al\u00e9m do equil\u00edbrio Th1/Th2 na modula\u00e7\u00e3o de granuloma, outros mecanismos \n\nimunol\u00f3gicos poderiam ser citados como alternativa, por exemplo, a ativa\u00e7\u00e3o de macr\u00f3fagos \n\n(aaM?) (Herbert et al.., 2004), ativa\u00e7\u00e3o de c\u00e9lulas T reguladoras (Singh et al.., 2005) ou o \n\naumento da produ\u00e7\u00e3o de IL-10 (Wynn et al., 1998), tamb\u00e9m foram descritos na modula\u00e7\u00e3o \n\ngranuloma. Em nosso, estudo a IL-10 parece n\u00e3o estar envolvida nesta regula\u00e7\u00e3o uma vez que \n\nos n\u00edveis desta citocina est\u00e3o diminu\u00eddos nos camundongos imunizados.No entanto, os \n\nmecanismos imunol\u00f3gicos envolvidos nesta regula\u00e7\u00e3o precisam ser melhor investigados.  \n\n A imuniza\u00e7\u00e3o de camundongos com SmCyp na forma de DNA, como demonstrado \n\nanteriormente, n\u00e3o elicitou  prote\u00e7\u00e3o nos camundongos, mas ativou c\u00e9lulas do sistema imune \n\ninduzindo modula\u00e7\u00e3o do granuloma. Sendo assim, a SmCyp \u00e9 um bom candidato vacinal. \n\nEntretanto, a escolha da estrat\u00e9gia vacinal n\u00e3o favoreceu a indu\u00e7\u00e3o de resposta protetora. \n\nNovas formula\u00e7\u00f5es ter\u00e3o que ser avaliadas para investigar, de forma mais consistente, a \n\nhabilidade da prote\u00edna SmCyp induzir prote\u00e7\u00e3o. \n\n\n\n\u00a0\n\n\u00a0\n\n147\u00a0\n\n\u00a0\n\n As an\u00e1lises prote\u00f4micas foram extremamente importantes para a identifica\u00e7\u00e3o das \n\nprote\u00ednas do tegumento do esquistoss\u00f4mulo do S. mansoni (Smteg) respons\u00e1veis pela ativa\u00e7\u00e3o \n\ndo sistema imune, o que torna poss\u00edvel a identifica\u00e7\u00e3o de futuros candidatos vacinais. A \n\nconstante atualiza\u00e7\u00e3o das ferramentas utilizadas na prote\u00f4mica juntamente com a gen\u00f4mica e \n\nan\u00e1lise de bioinform\u00e1tica, t\u00eam ajudado no aprimoramento do conhecimento da biologia do \n\nparasito e na busca de novos alvos vacinais, terap\u00eauticos e de diagn\u00f3sticos (Fonseca et al., \n\n2012).  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n148\u00a0\n\n\u00a0\n\n6 ANEXOS \n\n6.1 Aceite CEUA  \n\n \n\n \n\n \n\n\n\n\u00a0\n\n\u00a0\n\n149\u00a0\n\n\u00a0\n\n6.2 Artigo Revis\u00e3o \u201cSchistosoma tegument protein in vaccine and Diagnosis \n\ndevelopment: an Update\u201d \n\n \n\n \n\nReview Article \nSchistosoma Tegument Proteins in Vaccine and \nDiagnosis Development: An Update \n\n \n \n \n\nCristina Toscano Fonseca,1, 2 Garde?nia Braz Figueiredo Carvalho,1 \nClarice Carvalho Alves,1 and Tatiane Teixeira de Melo1 \n\n \n1 Laborato?rio de Esquistossomose, Centro de Pesquisas Re ne?  Rachou, Fun da?c a?o Oswaldo Cru z, Avenida Augusto de Lim a 1715, \nBelo Horizonte,MG 30190-002, B ra zil \n\n2 Instituto Nacional de Ci?encias e Tecnologia em Doenc? as Tropicais (INCT-DT), Avenida Augusto de Lim a 1715, \nBelo Horizonte, MG 30190-002, Brazil \n\n \nCorrespondence should b e addressed to Cristina Toscano Fonseca, cto scan o@cpqrr.fiocruz.br \n\n \nReceived 27  July 2012; Accepted 24 September 2012 \n\n \nAcademic E dito r: And rea Teixeira-Carvalho \n\n \nCopyrig ht \u00a9 2012 Cristina Toscano Fonseca et al.  This  is an  open  access article  distributed   under  the  Creative Commons \nAttribu tion License, which p ermits unrestricted use, distribution , and  reproduction in any medium, provided the original work is \nproperly cited . \n\n \nThe d evelopment o f a vaccine against schistosomiasis and also the availability of a more sensitive diagnosis test are impo rtan t \ntools to h elp chemotherapy in contro lling disease trans mission. Bioinformatics tools, to gether with the access to parasite geno me, \npu blished recently, should help generate new kno wledge on parasite biology and search for n ew vaccines or therapeutic targets \nand antigens to b e used in the disease diagn osis. Parasite surface proteins, especially those expressed  in schistoso mula tegument, \nrepresent interesting targets to  be used  in vaccine formulations an d in the diagno sis of early infectio ns, since the tegumen t \nrepresents the interface between host and parasite and its molecules are responsible for essential fun ctions to parasite survival. In \nthis p aper we will present the advances in th e develop ment of vaccines and diagnosis tests achieved with the use of the info rmation \nfrom schistosome geno me fo cused o n p arasite tegu ment as a source for antigens. \n\n \n \n \n1. Introduction \n\n \nSchistosomiasis i s still a signifi cant publi c healt h problem  \ni n tropical countries despite t he existence of e? ective drug s \na gainst t he parasite [1]. Chemotherapy as a strategy for dis- \ne ase control has proved ine? ective in controlling transmis- \nsion [1] therefore, the development of a vaccine against th e \nd isease and also a more sen sitive diagn osis test is necessary to  \nass is t chemotherapy in control programs [1, 2]. \n\nIn  this context, t he  recent availabilit y of schistosome \ngenomes informat ion  represents  an  important  toll to  be \nused i n the discover y of new target s for vaccine and diag- \nnosis. Schistoso ma mansoni genome, published in 2009 [3] \ndescri bed 1 1.8 09 gen es  w hile Schistos om a japon icu m genome \n[4] has been described to  be composed of 13.469 genes. \nT heir assembl ies were generated by conventional capillary \nsequencing resulting in 19.022 sca? olds (S. mansoni) and \n25.048 sca? old s (S. japoni cum). More recent ly an impro ved \nversion of t he S. m an so ni genome w as published [5], uti lizing \n\na combination of traditional San ger capillary sequencing and \ndeep-coverage Illumina sequencing that refined gene pre- \ndiction resulting in a reduction in the number of p red icted  \ng en es from 11 .8 09 to 10.85 2. Illumi na-based technology was \nalso used in Sch istosom a haematobium genome sequencing, \nwhich described 1 3.073  g enes [6]. \n\nSimultaneousl y to  genome  publication,  a n  important \ntool to access a nd a nalyze parasi te genome has bee n devel- \noped, the  SchistoDB (http://www.schistodb.net /)  database \n[7]. The SchistoDB enables access to informat ion  on th e \nparasite genome even to t hose researchers not s pecial ized in \ncomputer langua ge. The current 3.0 database version pro - \nv id es access to the latest draft of S. m an son i genome sequence \nand annotation and also  to S. jap on icum  and S. haematobium \ngenome annotation. \n\nThe bioinformatics tools, together with the av ailability  to  \naccess parasi te genome, should h av e helped the kn ow ledg e of \nparasite b iolog y and the search for new vaccines, therapeu tic \ntargets, and antigens to be used in the disease diagnosis. In \n\n\n\n\u00a0\n\n\u00a0\n\n150\u00a0\n\n\u00a0\n\n \n\n \n\nt his paper we will  present the advances in the develo pment \nof vaccines and diagnosti cs tests ach ieved wi th the use of th e \ni nformation from schi stosome genome, focus will be given \nto the parasite te gument as a source for ant igens. \n\n \n2. Host-Parasite Relationship: Role for \n\nthe Parasite Tegument \n \n\nHi ghly ada pted to parasitic life, schi stosomes can live for \nyears or decades even in a hostil e environment as t he circu- \nl atory system from vertebrate host where the parasite has an \ni nti mate contact with ci rculating elements of the immun e \ns ystem [8 ]. \n\nIn  this  successful  host-parasite  rel ationship,  the  h o st \ni mmune  system plays an import ant  role in both  parasite \ndevelopment and elimination. CD4+ cells, hormones, and \nc ytokines as TN F-?, TGF-?, and IL-7 produced by the h o st, \nseem to assist the parasite devel opme nt [9\u201315]. While CD 4 + \ncell s, B cells, IFN-?, and TN F-? ha s been described to be \ni nvolved in parasite eliminat ion in t he irradiated cercariae \nv accin e model [16\u201318]. \n\nMoreover, t he hig hly  adapted relationship bet ween schis- \ntosomes and the mammalian  definit ive host al so involves \nt he e? ective mechanisms for evading the immune response \nt hat  they provoke. In this context , the parasite teg um en t \np lays  an i mportant role [19, 20]. A fter penetration, the para- \ns ite su rface undergoes a profound chan ge t hat allo ws parasite \na daptation into t he host  internal microenvironment  where \nt he parasite swi tches from its immune -se nsitive to an \ni mmune-refractory  state [21]. In  cercariae, the  surface is \nc haracterized by a single bilayer me mbrane  covered by a \ndense glicocalyx. Duri ng penetration, t he glicocaly x is lost \na nd t he me mbrane t ransforms into a double bilayer me m- \nbrane  [22].  Evading mechanisms  as  antigenic  mi micr y, \nmembra ne turnover, production of immunomodulatory \nmolecules and modulation  of surface a nti gens expression \na lso takes place i n t he parasi te surface and cont ri butes to  \nschistosome s urviv al [23, 24]. \n\nTrying to eliminate the parasite, host i mmune  syste m \nt argets t he antige ns i n parasite surface. S tudies in mice have \nshown that the development al st age most  susceptible to th e \nhost immune system at tack is the schistosomula stage. Very \nearly  after infecti on, schi stosomula are su sceptibl e to cel lula r \na nd humoral immunity, however, in the course of parasite \ndevelopment the suscepti bili ty i s rapidly lost [25, 26]. The \nresi stance to host  immune  response acqui red by parasites \nc an be in part expl ained by surface changes in de pendentl y \nof host ant ige ns adsorpt ion  [27\u201329]. In additi on,  El Ridi \na nd colleagues [30], demonst rated that l ung-stage schisto- \nsomulum protect th emselves from the host immune syste m \nby confini ng antigeni c m olecu les i n lipid-ri ch s ites of surface \nmembra ne.  In  contrast,  McLaren, in  1989 [31],  demon- \nstrated that both skin and l ung schistosomula phases are ta r- \ngets of the immune system in the radiation-at tenuated  vac - \nc ine model which trigger a n i nflamma tory reaction around \nt he larvae i nhibiting t heir m ig ratio n . \n\nSi nce schistosomula  is  the   maj or  target  of  the  h o st \ni mmune  system attack  and  its  tegument  represents  th e \ni nterface bet ween parasite and host, also performi ng vital \n\nfunctions t hat ensure parasite survival  [32], the study of i ts \nstructure and how it interacts with the host  immune system \ncan provide important  i nformation  about disease co ntrol, \nespecially to those related to the search for ne w drugs and \nvaccine developme nt. We have recentl y demonstrated  that \nthe schi stosomula tegument from S. mansoni (Smteg) i s rec- \nognized by TLR4  in dendritic cells (D C) leadi ng to DC acti- \nvation and production of proinfl ammatory cytokines as IL- \n12 and TNF-? [33]. In contrast to this i nflammator y profile, \nSm teg  also induce IL -1 0 production b y D C in a TL R (Toll li ke \nreceptors) 2, 3, 4, and 9 independent  ma nner (un p u bl ish ed  \ndata) once again  demonstrating that schis tos om ula tegu m en t \ncan both activate or modulate host i mmune system. \n \n3. The Tegument as Antigen Source for \n\nVaccine D evelopment \n \nMost of the studies that ai med to id entify  membrane protein s \nin parasite tegument were performed in adult worms [34\u2013 \n36]. Although sc histosomula is the major target  for h o st \nimmunit y, its tegume nt proteins have sti ll not been charac- \nterized, mainly due to the di? culty i n obtaining su? cient  \nquantit ies of material for such protein st udies [37]. Indeed \nprotective antigens are found in S. mansoni schistosomula \ntegument  (S mteg)  since mice immunization  with  S mteg \nformulated wi th Freu nd s\u2019  adjuvant [38] or Alum  + CPG- \nODN  (unpubli shed data) is ab le to reduce s ignificantly w o rm \nburden and egg elimination wit h the feces. The characteri- \nzation of these protective anti gens i s being performed usi ng \nimmune-proteomics analys is  and genome datab as es to iden- \ntify candi dates to be used in a vaccine formulation against \nschistosomiasis. Ot her \u201comics\u201d technologies are also being \nused to iden tify schi stosoma proteins, mainly those expressed \nin schi stosomula. In t his context, two studies, using cDNA \nmicroarrays technologies assessed t he most rel evant tran- \nscripti onal chang es in the sc histosomula devel opme nt phase. \nThese studies demonst rated that tetraspanin, Sm2 2.6 , Sm29, \nS m200 and phosphadiesterase are membrane  proteins are \nhighl y expressed during schistosomula phase [39, 40]. Fu r- \nthermore, the studi es t hat used gene silen ci ng through RNAi \ntechnique could clari fy t he importance  of some proteins, \nsuch as cathepsi ns [41, 42] and tetraspanins [43] for parasite \ndevelopment and surv iv al. The sa me me mbrane protein was \nidentified in adult  worm tegument preparations usi ng Mass \nspectrome try (MS -)-based proteomics [33, 34] together with \ngenome, transcriptome  and geneti c maps i nformation  [3, \n44\u201346]. Recently a proteomi c  analysis demonst rated  that \nS m29 and Sm200 are li nked to parasite surface me m brane \nthrough a  G PI-anchor [47] w hile the most abundant  protein \nin adult worm tegument, among the investiga ted molecules, \nare  aquapori n,  dysferli n, TSP-2, and  ATP  d ip h os p h oh y- \ndrolase [48]. Among this expressive catalogue of protein \nexpressed in the schistosome tegument, some of the m have \nbeen ev aluated  as v accine antigen in immunization pro to cols \nin mice. The Table 1 summarizes the results ob served in the se \npreclinical  tri als usi ng tegument pro tein s. \n\nS m29 was identi fied by Cardoso and coworkers usi ng in  \nsilico analysis to iden tify in S . ma ns oni transcriptome putative \nexpressed proteins localized in t he parasite tegument [4 9].\n\n\n\n\u00a0\n\n\u00a0\n\n151\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \nSm29 recombi nant form induces a Th1 profile in mice asso- \nciated with a reduction of 51% in worm burden when used \nin v accine formulati on [50]. The tegumental protein, Sm22.6 \nand its homologue in S. j aponicum (Sj 22.6), are involved in \nresistance to rei nfection in endemic areas [51, 52]. Immu- \nnizat ion of mice with recombinant  22.6 formul ated with Fre- \nund adjuvant resulted in 34.5%  reduct ion on worm b urd en  \n[53] whi le S m22.6 formulate d with alum fail ed to in d u ce \nprotection against schistosomiasis but induced a regulatory \nresponse able to modulate allergic asthma in mice [54, 55]. \n\nTetraspanins ( TSP) 1 and 2 were identi fied in a cD NA  \nlibrary from S. mansoni based on their m em b ran e-targ etin g  \nsignal [56]. Immunization  of mice wi th TS P1 recombinant \nprotein  resulted in a reduction  of 57%  in worm burden  \nand reduct ion  in the number  of eggs i n l iver (64%) and \ninte stine (65% ), T SP2 recombinant protein was less e? ective \nin reducing worm burden (34%) but had simi lar e? ects in \nreducing the number of eggs trapped in the liver (52%) and \ninte stine (69% ) [57]. The TSP-2 homologue in S. japonicum \nhas also been ev alu ated in murine i mmunizat ion h owever no \nprotection was  observed [58 ]. \n\nECL or Sm200 is a GP I-anchored protein in the S. m an - \nsoni tegument that has also been ass ociated wit h praziq u antel \ne? cacy, since anti bodies  against t his  protei n  can resto re \ndrug e? cacy in B cells depleted mice [59, 60]. Muri ne DNA \nvaccination with the gene encoding Sm200 elicited 38.1% \nprotection whil e immunizat ion of mice wi th enzymatic ally \ncleaved GP I-anchore d proteins from the S. mansoni teg u - \nment, in which Sm20 0 represent the most abundant protein \nresult  in 43% reduction  in adult  worm burden  [61, 62]. \nSm21 .7  was tested as antigen in a recombi nant va ccine [6 3 ] \nand D NA vaccine [64]. Immunization of mice with recom- \nbi nant Sm21.7 resulted in a de crease of 41%\u201370%  i n wo rm \nburden while D NA vacci nati on resulted in of 41.5%  wo rm \nburden reduction [63, 64]. \n\nThe  schistosome ant ioxidant  enzymes (Cu/Zn  super- \noxide dismutase-SOD, gl utathione-S-peroxi dase-GP X) are \n\ndevelopmenta lly regulated. The lowe st level of ge ne expres- \nsion a nd enzyme-specifi c activit y was found in the l arval  \nstag es  while the highest level of gene ex pres sion  was observed \nin  adult  worms  [65\u201368].  Thi s  suggests that  antiox ida nt  \nenzymes are important  in i mmune evasion by adult schis- \ntosome parasite s [67]. Also RNAi assays demonst rated that \nknocking down t he  antioxidants  enzymes GPX and  GS T \nresult in dra mati c decreas es in s porocys ts surv ival indicating \nthat these enzy m es are cap able of enhancing parasite survival  \nin an oxi dati ve environme nt  [69]. Mice immuniz ed  wi th \nthe antioxi dant  enzyme Cu-Zn superoxi de dismutase in a  \nDN A vaccin e s trategy  resulted i n 4 4\u2013 60 % reduct ion in worm \nburden [65]. \n \n4. Antigens to Be Used in Schistosomiasis \n\nDiagnostic Test \n \nCurrent ly, all available techniques for the d iagn osis  of schist - \nosomiasi s are  characterized  by  havi ng  some  lim itati on s, \nesp ecially when it become s necessary to detect infection in \na large number of patients wi th low parasite load [70]. One  \nof the initial  di? cu lties  in the development of a test  for th e \ndiagnosis of schi stosomia sis is the choice of an appro priate \nantigen. There are several factors t hat infl uence this choice: \neasily of producti on, high stabilit y in sample storage, immu- \nnogenicit y, sp ecificity, and ability to be incorporated to low \ncost s test platforms [7 1]. \n\nIn this context , the av ailab ility of the comple te genome \nsequences in combination with other technologies such as \nbioinformatics and proteomics, provides important  tol ls to \nseek for an ideal candidate to compose an e? cient immun- \nodiagnostic  test. With this in mind, our group have recentl y \ndesig n ed  an in silico strategy  based in t he principles of reverse \nvaccino log y, and using a rat ional criteria to mi ne can d id ates \nin parasite genome to be used in the i mmunodiagnosis of \nsch isto som iasis [72]. Six antigens were s elected based on the  \nev id en ce of g en e exp ress ion  at di? erent p hases of the parasite  \n\n\n\n\u00a0\n\n\u00a0\n\n152\u00a0\n\n\u00a0\n\n \n\n \n\n \n \n\nl ife cycle in t he defi nitive host, accessib ility  to host immun e \nsystem (exposed proteins), low si mil ari ty wi th human and \nother hel mi nthic proteins, and presence of predicted B cells \ne pitopes (Table 2) [72]. Although our i n silico analysis led to \ni dentification of six candidates, this s trateg y has not been yet \ne xperimentall y val idated. \n\nOt her groups have also used bioi nformatics analysis to  \nselect target sequence from S. jap on icum  genome to be used \nfor the dete ction of parasite DNA in blood samples. A 230- \nbp sequence from t he h igh ly repetitive retrotransposon SjR2 \nwa s identified and  it was demonst rated  that  P CR test to  \ndetect Sj R2 is highly sensitive and  specific for  d et ecti on  \nS. j aponi cum infection in the sera of infected rabbits and \npatients [73]. More recently the same group performed a \ncomparative study to determine the best target  to be used \ni n a molec ular diagnosis test for schi stosomia sis jap o nic um  \ni n 29 retrot ransposons ide ntified by bioinformati cs analysis. \nA 303-bp seque nce had the highest sens itivity  and specificit y \nfor the detect ion of S. japo nicu m D NA  in serum s am p les [74 ]. \n\nProteomics an aly sis has also been used in the i dentifica- \nt ion of candidates to t he immunodiagnosi s of schi stosomia - \nsis. Western Blot with sera from S. ja po nicum  infected rab b it \ni n a t wo-dimensi onal gel loade d wit h adult  worm prepara- \nt ion identified 10 spots that were demonstrated by LC/MS- \nM S to correspond to four di?erent proteins: SjLAP (Leucine \na minopeptidases), SjFBPA (fructose-1,6-bisphosphate al do- \nl ase), SjGST (Glutathione-S-transferase)  and  SJ22.6 [75]. \nRecombinant SjLA P a nd SjFBPA were tested in ELISA  assay \na nd presented high e? cacy for the diagnosis of S. japoni cum \ni nfection, with 96 .7 % s pecificity for both proteins and 98.1% \nor 87.8% sen sitivi ty to detect acute and chroni cally infected \ni ndividuals, resp ectively, when SjLAP was used as ant igen or \na  sens itiv ity  of 100% (acute) and 84.7% (chronic infection) \nwhen SjFBPA  was used as anti gen [ 75]. \n\n \n \n5. Other Membrane Proteins Candidates \n\nto Be Used in Vaccine Formulation and \nDiagnosis Tests \n\n \nAquaporins are small integral me mbrane proteins i nvolved \ni n the selec tive transportat ion  of water and ot her  solutes \nt hrough plasma membra nes of mammal s, plants and lower \n\norganisms [76]. T his  protein was d es cribed to be abundant in \nschistosome tegument and due to its p hysio log ical fu n ctio n  \nand abundance represent an interesting target to vaccines \nand diag nos is tests [48]. Characterization of the S. j aponicum \naquaporin-3  using bioi nformatics tools demonst rated  that \nthis 32 .9  kDa  transme mbrane protein has predicted B cel ls \nepitopes wi th the most  likely epitopes prese nt i n the N- \nterminal  portion  of the protein, located outside the mem- \nbrane [77]. Other abundant protei n in schis tos om a tegu m en t \nis dysferlin, based on analogy with homologues from o ther \norganisms, this protein see ms to be involved in me m bra ne \nrepair and/or vesicle fusi on i n tegument su rface [3 4]. \n\nATP-diphosphohydrolases are enzymes involved in ADP \nand AT P hyd ro lysis t hat has been related to host  i mmune sys- \ntem ev asio n, since thi s enzy me coul d hy droly ze the AT P pro - \nduced in response to parasite induced stress i n the e nd o the- \nlio thus modulating  the DAMP (danger associated mo le- \ncular pattern)-mediated  inflammatory  signali ng [78, 79]. \nIn schistosomes two di? ere nt protei ns have been described \nSmAT PDase 1 and SmAT PDase2 with approxi mately 63 and \n5 5 kDa [80, 81]. SmATPDase 1 is located in  t he  border \nof the te gument while SmATP Dase2 is located in internal \nstructure  of t he tegument  syncytium and can be secreted \n[81]. The immunogeni city of the syntheti c peptide (r175\u2013 \n190) from SmATPDa se2 has been demonstrated  in Balb-c \nmice, ho w ev er the protection induced by this epitope has not \nbeen evaluated [82 ]. \n\nAlt hough most te gume nt protein listed in this paper has \nbeen identified in adul t worm tegument, an in silico an al- \nysis performed  in  Sc histoDB (ht tp: //www.schisto d b.net/) \ndemonstrates that some of them are also expressed in th e \nschistosomula st age as demonstrated in F igure 1 reinforcing \ntheir potential to be used in a vaccine formulation or in th e \nearly  d iag no sis of sc histosome infection. \n \n6. Conclusion \n \nSo far t he genome, transcriptome, and proteome i nfo rma- \ntion provided many targets t o be tested in schistosomiasis \nv accine and d iagn osi s and also  new k now led ge about schisto- \nsome biology. However approximately 40% of the sc histo- \nsome genome is composed of hypothetical proteins  wit h \nunknow n funct ion that represents interesting target s to be \n\n\n\n\u00a0\n\n\u00a0\n\n153\u00a0\n\n\u00a0\n\n \n\n \n\nN\num\n\nb\ner\n\ns \nof\n\n E\nS\n\nT\n \n\n \n40 \n\n35 \n\n30 \n\n25 \n\n20 \n\n15 \n\n10 \n\n5 \n\n0 \nSm200   Sm29    TSP-2   TSP-1 Dysferlin Sm22.6 Sm21.7 \n\n[8 ] A. R. C. H arris, R. J. Russell, and A. D. Charters, \u201cA review o f \nschistosomiasis in immigrants in Western Australia, demon- \nstrating the unusual longevity of Schistosoma mansoni,\u201d Trans- \nactions o f the Roya l Society of Tropical Medicine and Hyg iene, \nvol. 78, no. 3, pp. 385\u2013388, 1984. \n\n[9 ] S. J. Davies, J. L. Grogan, R. B. Blank, K . C. Lim, R. M. Lock- \nsley, and  J. H. McKerrow, \u201cModu lation of b lo od fluke d evelop - \nment in the liver by hep atic CD4+ lympho cytes,\u201d Science, vol. \n294, no. 5545, pp. 1358\u20131361, 2001. \n\n[10] R. L. De Mendonc?a, H. Escriva? , D. Bouton, V. Laudet, an d \nR. J. Pierce, \u201cHormones and n uclear receptors in schisto so me \ndevelopment,\u201d Parasitology Today, vol. 16, no. 6, pp. 2 33\u2013240, \n2000. \n\n[11] P. Saule, E. Adriaen ssens, M. Delacre et al., \u201cEarly variatio ns \nC erca riae \nSchistosomula \n\nAdult worm \nEgg \n\nof host thyrox ine and in terleukin-7 favor Schistosoma m ansoni \ndevelopment,\u201d Journal o f Parasitology, vol. 8 8, no. 5, pp. 849\u2013 \n\n \nFig ure 1: Predicted expressio n of schistosome tegumen t proteins \nin the d i? erent parasite life stage in  the definitive h ost. schistosome \ntegument  protein  identified by pro teomics analysis of the adult \nw orm tegument w as analyzed in  SchistoDB database (http://w ww \n.sch istodb.net/). Bars rep resent the numbers of EST in each p arasite \nlife stage who se annotation  correspond  to Sm20 0, Sm2 9, TSP-2, \nTSP-1, Dysferlin, Sm22.6, o r Sm21 .7. \n\n \n\n \n \n\ntested and characterized. An increase in the kno w ledg e a bo u t \nparasi te bio log y, p ath og enesis , and host -parasite relationship \nc an be expected for the next ye ars. \n\n \nAcknow ledgments \n\n \nT his work w as supported by CN Pq, INCT-DT/CNP q, Ripag/ \nCPqRR-Fiocruz, and Papes/Fiocruz. G. B. F. Carvalho and \nC. C. Alves both received fe llowshi p from F apemig. C. T. \nFo nseca received  a fello w ship  from PQ /CN Pq . \n\n \nRefer ences \n\n \n[1] N . R. Bergquist, L. R. Leonardo, and G. F. Mitchell, \u201cVaccine- \n\nlinked  chemotherapy:  can  schisto somiasis con trol  benefit \nfrom an  integrated approach?\u201d Trends in Parasitology, vol. 2 1, \nno. 3, pp. 112\u2013117, 2005. \n\n[2] N . Berhe, G . Medhin, B. Erko et al., \u201cVariation s in helminth \nfaecal egg counts in Kato-Katz th ick s mears and  th eir implica- \ntions in  assessing infection status with Schistosoma manson i,\u201d \nActa Tropica, vol. 92, no. 3, pp. 205\u2013212, 2004. \n\n[3] M. Berriman, B. J. Haas, P. T. Loverde et al., \u201cThe genome \nof the blood fluke Schistosoma mansoni,\u201d Nature, vo l. 460, n o. \n7253, pp. 352\u2013358, 2009 . \n\n[4] Y. Z hou, H . Z heng , Y. Chen et al., \u201cThe Schistosoma japonicu m \ngenome reveals features of host-p arasite interplay,\u201d Nature, \nvol. 460, no. 7253, pp. 345\u2013351, 20 09. \n\n[5] A. V. Protasio, I. J. Tsai, A. Babbage et al., \u201cA  \nsystematically \n\nimproved  high quality genome and tran scriptome of th e \nhuman  b loo d fluke Schistosoma mansoni,\u201d  PLoS Ne glected \nTropical Diseases, vol. 6, no. 1, Article ID e1455, 2012. \n\n[6] N . D. Young, A. R. Jex, B. Li et al., \u201cWh ole-genome seq uence \nof Schistosoma haematobium,\u201d Nature Genetics, vol. 44, n o. 2, \npp. 221\u2013225, 201 2. \n\n[7] A. Zerlo tini, M. Heiges, H. Wan g et al., \u201cSchistoDB: a Sch isto- \nsoma mansoni genome reso urce,\u201d Nucleic Acids Research, vol. \n37, no. 1, pp. D579\u2013D582, 2009. \n\n855, 2002. \n[12] P. Amiri, R. M. Locksley, T. G. Parslow et al., \u201cTu mo ur necrosis \n\nfactor ? restores granulomas and  in duces parasite egg-laying \nin  sch istosome-in fected SCID mice,\u201d Nature, vol. 356, n o. \n6370, pp. 604\u2013607, 1992. \n\n[13] P. T. LoVerde, A. O sman, and A. Hinck, \u201cSchistosoma m ansoni: \nTGF-? signaling pathw ays,\u201d Experimental Parasitology,  vo l. \n117, no. 3, pp. 304\u2013317, 2007. \n\n[14] I. Wolowczuk, S. Nutten, O. Roye et al., \u201cIn fection of mice \nlacking interleukin-7 (IL-7 ) reveals an unexp ected ro le fo r IL- \n7 in the developmen t of th e parasite Schistosoma mansoni,\u201d \nInfection a nd Im munity, vol. 67, no. 8, pp. 4183\u20134190, 1999. \n\n[15] R. B. Blank, E. W. Lamb, A. S. Tocheva et al., \u201cThe common ? \nch ain cytokines interleukin (IL)-2 an d IL-7 indirectly modu - \nlate blood fluke developmen t via e? ects on CD4+  T cells,\u201d \nJournal o f Infectious Diseases, vol. 19 4, no. 1 1, pp. 1609\u20131616, \n2006. \n\n[16] D. A. A. Vignali, P. Crocker, Q. D. Bickle, S. Cobbold, H. Wald- \nmann, and M. G. Taylor, \u201cA role for CD4+  bu t not CD8 +  T \ncells in immunity to Schistosoma mansoni induced by 20 krad- \nirradiated an d Ro 11 -3128-terminated infection s,\u201d Imm u- \nnology, vol. 67, no. 4, pp. 466\u2013472, 1989. \n\n[17] D. Jankovic, T. A. Wynn, M . C. Kullberg et al., \u201cOptimal vac- \ncinatio n against Schistosoma m ansoni requires the in ductio n \nof both B cell- and IFN-?-dependent  e? ector mechanisms,\u201d \nJournal of Immunolog y, vol. 162, no. 1 , pp. 345\u2013351, 1999. \n\n[18] M. Street, P. S. Coulson, C. Sadler et al., \u201cTNF is essential for \nthe cell-mediated protective immun ity ind uced  by the radi- \nation-attenuated  schistosome vaccin e,\u201d Journal of Im muno l- \nogy, vol. 163, no. 8, pp. 4489\u20134494, 1 999. \n\n[19] F. G. C. Abath an d  R. C. Werkhauser, \u201cThe tegument  o f \nSchistosoma mansoni: functional and immun ological features,\u201d \nParasite Immunology,  vo l. 1 8, no. 1, pp. 15\u201320, 1996. \n\n[20] Z. G. H an, P. J. Brindley, S . Y.  Wang, and C. Zhu, \u201cSchistoso ma \ngen omics: new  perspectives on  sch istosome biology and host- \nparasite in teraction,\u201d Annual Review of Genomics and Huma n \nGenetics, vol. 10 , pp. 211\u2013240, 2009. \n\n[2 1] M. K. Jones, G . N. G obert, L. Zhang, P. Su nderland, and D. \nP. McManus, \u201cThe cytoskeleton and motor p roteins of hu man \nschistosomes an d their roles in  surface maintenance and host- \nparasite interactions,\u201d BioEssays, vo l. 26, no. 7, pp. 752 \u2013765, \n2004. \n\n[22] D.  J. Hockley and  D.  J. McLaren, \u201cSchistosoma mansoni: \nch anges in  the  outer  membrane  of  th e  tegument  during \ndevelopment from cercaria to adult worm,\u201d International Jour- \nnal for Parasitology, vol. 3, no. 1, pp. 13\u201320, 1973. \n\n[23] M. Salzet, A. Capron , and G. B. Stefano, \u201cMolecular crosstalk \nin host-parasite relatio nship s: Schistoso me- and  leech-host \n\n\n\n\u00a0\n\n\u00a0\n\n154\u00a0\n\n\u00a0\n\n \n\n \n\n \n \n\ninteractio ns,\u201d Parasitology Today, vo l. 16, n o. 12, pp. 536\u2013540, \n2000 . \n\n[24] R. T. D amian,  \u201cMolecu lar mimicry rev isited,\u201d Paras itology \nToday, vol. 3 , no. 9, pp. 263\u2013266, 1987. \n\n[25] S. R. Smithers, D. J. McLaren, and F. J. Rahalho-Pinto, \u201cImmu- \nnity to schistosomes: the target,\u201d American Journal of Tropical \nMedicine and Hyg iene, vol. 26, no. 6, pp. 11\u201319, 1 977. \n\n[26] F. Santo ro, P. J. Lachmann, A. Cap ron, and M. Capron, \u201cActi- \nvation  of co mplement by Schistosoma mansoni sch istosomula: \nkilling of p arasites by the alternative p athway and requirement \nof IgG for classical pathway activation ,\u201d Journal of Im mun ol- \nogy, vol. 123, no. 4 , pp. 1551\u20131557, 1979. \n\n[27] D. A. D ean, \u201cDecreased binding  of cytotoxic antibody  by \ndeveloping  Schistosoma mansoni.  Evid ence  for  a  surface \nchange independent  of host antigen adsorption  an d mem- \nbrane turnover,\u201d Journal of Parasitology, vol. 63, no. 3, pp. 418\u2013 \n426, 19 77. \n\n[28] A. Dessein, J. C. Samuelson, an d A. E. Butterwo rth, \u201cImmune \nevasion by Schistosoma m ansoni: loss of susceptibility to an ti- \nbody or complement-depen dent eosinophil attack by schisto- \nsomula cultured in medium free of macromo lecu les,\u201d Para- \nsitology, vol. 82, no. 3, pp. 357\u2013374, 1981. \n\n[29] E. L. Racoosin, S. J. Davies, and E. J. Pearce, \u201cCaveolae-like \nstructures in the surface membrane of Schistosoma manson i,\u201d \nMolecular an d Biochemical  Parasitology, vo l. 104, no. 2, pp. \n285\u2013297, 1999. \n\n[30] R. El Ridi, S. H .  Moh amed ,  and   H .  Tallima, \u201cIncubation \nof Schistosoma man so ni lung-stage schistosomula in corn o il \nexposes their surface membrane an tigenic specificities,\u201d Jour- \nnal of Parasitology, vol. 89 , no. 5, pp. 1064\u20131067, 2003. \n\n[31] D. J. McLaren, \u201cWill the real target of immunity to schistoso- \nmiasis please stan d up,\u201d Parasitology Today, vo l. 5, no. 9, pp. \n279\u2013282, 1989. \n\n[32] G . N. Gobert, M. Chai, and  D. P. McManus, \u201cBiology o f \nthe schistosome lung-stage schistosomu lu m,\u201d Parasitology, vol. \n134, no. 4, pp. 453\u2013460, 2007. \n\n[33] F. V. D ura?es, N. B. Carvalho, T. T. Melo, S. C. Oliveira, an d \nC. T. Fonseca, \u201cIL-12 and TNF-? produ ction by d endritic cells \nstimu lated w ith  Schistosoma mansoni schistosomula tegument \nis TLR4- and MyD 88-d ependent,\u201d Immunolog y Letters, vol. \n125, no. 1, pp. 72\u201377, 200 9. \n\n[34] B. W. M. Van  Balkom, R. A. Van Gestel, J. F. H. M. Brouwers et \nal., \u201cMass spectrometric analysis of the Schistosoma m ansoni \ntegu mental sub -proteo me,\u201d Journal of Proteome Research, vo l. \n4, no. 3, p p. 958\u2013966, 20 05. \n\n[35] S. Braschi, W. C. Borges, and  R. A. Wilson, \u201cProteomic analysis \nof  the  shistosome  tegument  and  its  surface membranes,\u201d \nMemorias d o Instituto Oswaldo Cruz, vol. 101 , sup plement 1, \npp. 205\u2013212, 200 6. \n\n[36] S. Braschi and R. A. Wilson, \u201cProteins exposed at th e adult \nschistosome surface revealed by b io tinylation,\u201d Molecular and \nCellular Proteomics, vol. 5, no. 2 , pp. 347\u2013356, 2006. \n\n[37] A. Loukas, S. Gaze, J. P. Mulvenna et al., \u201cVaccinomics for th e \nmajor blood feeding helminths of humans,\u201d OMICS A Journal \nof Integrative Biology, vo l. 1 5, no. 9, pp. 567\u2013577, 2 011. \n\n[38] T. Teixeira De Melo, J. Michel De Arau jo, F. Do Valle Dura?es \net al., \u201cImmunization  with new ly  transformed  Schistosoma \nma nsoni schistosomula tegument  elicits tegu ment  damage, \nreduction in egg and parasite burd en,\u201d Parasite Imm unology, \nvol. 32, n o. 11-12, pp. 749\u2013759, 20 10. \n\n[39] G. P. D illon, T. Feltwell, J. P. Skelton et al., \u201cMicro array analysis \nidentifies genes preferentially expressed in th e lun g schisto- \nsomulum of Schistosoma m ansoni,\u201d Internatio nal Journal  for \nParasitology, vol. 36, n o. 1, pp. 1\u20138, 2006. \n\n[40] G. N. Go bert, M. H. Tran, L. Moertel et al., \u201cTran scriptional \nch anges in Schistosoma mansoni during early schistosomula \ndevelopment  and  in  the  p resence  of  erythrocytes,\u201d PLoS \nNeglected Tropical Diseases, vol. 4, no. 2, article e600, 2010. \n\n[41] J. M. Correnti, P. J. Brindley, and E. J. Pearce, \u201cLong-term su p- \npressio n of cathepsin B levels by RNA interference retards \nschistosome growth,\u201d Molecular and Biochemical Parasitolog y, \nvol. 143, no. 2, pp. 209\u2013215, 2 005. \n\n[42] M. E . Morales, G. Rinaldi, G . N. Gob ert, K. J. Kines, J. F. To rt , \nan d P. J. Brindley, \u201cRNA interference of Schistosoma m ansoni \ncathepsin D, the ap ical enzyme of the hemog lo bin proteo lysis \ncascade,\u201d Molecular and Biochemical Parasitology, vol. 157, no. \n2, pp. 160\u2013168, 20 08. \n\n[43] M. H. Tran, T. C. Freitas, L. Co oper et al., \u201cSuppression of \nmRN As encoding tegu ment  tetraspanins  from  Schistosoma \nmanso ni results in  impaired  tegument turnover,\u201d PLoS pa th - \nogens, vol. 6, no. 4 , Article ID  e1000840, 2010. \n\n[44] F. Liu, S. J. Cui, W. Hu, Z. Fen g, Z. Q. Wang, and Z. G. H an, \n\u201cE xcretory/secretory pro teome  of th e  adult  developmental \nstage of hu man blood flu ke, Schistosoma japonicum,\u201d Mole cu- \nlar and Cellular Proteomics, vol. 8, n o. 6, pp. 1236\u20131251, 2009. \n\n[45] S. Verjovski-Almeid a, R. DeMarco, E. A. L. Martins et al., \n\u201cTranscriptome  analysis o f th e acoelomate human   parasite \nSchistosoma mansoni,\u201d Nature Genetics, vol. 35, no. 2, pp. 148\u2013 \n157, 2003. \n\n[46] C. D. Criscione, C. L. L. Valentim, H . H irai, P. T. L oVerde, \nan d T. J. C. Anderson, \u201cGeno mic linkage map of th e hu man  \nblood fluke Schistosoma mansoni,\u201d Genome Biology, vol. 10, no. \n6, article R71, 20 09. \n\n[47] W. Castro-Borges, A. Dowle, R. S. Curwen, J. Tho mas-O ates, \nan d R. A. Wilson, \u201cEnzymatic shav in g of the tegument su r- \nface of live schistosomes fo r proteo mic  analysis: a rational \nap proach to select vaccine candidates,\u201d PLoS Neglected Tropical \nDiseases, vol. 5, no. 3 , article e993, 2011. \n\n[48] W. Castro-Borges, D. M. Simpso n, A. D owle et al., \u201cAb un- \ndance o f tegument surface pro teins in the human blood flu ke \nSchistosoma manso ni d etermined by Qcon CAT proteomics,\u201d \nJournal of Proteomics, vol. 74, pp. 1519\u20131533, 2011. \n\n[49] F. C. Cardo so, J. M. R. Pinho, V. Azevedo, and S. C. O liveira, \n\u201cId entification  of a  new Schistosom a ma nsoni membran e- \nbound protein through bioinformatic analysis,\u201d Genetics a nd \nMolecular Research, vol. 5, n o. 4, pp. 609\u2013618, 2006. \n\n[50] F. C. Cardoso, G. C. Macedo, E. Gava et al., \u201cSchistosoma m an- \nsoni tegument p rotein Sm29 is able to induce a Th 1-type o f \nimmun e response and p rotection against parasite infection,\u201d \nPLoS Neglected Tropical Diseases, vo l. 2, no. 10, article e308, \n2008. \n\n[51] D. W. Dunne, M. Webster, P. Smith et al., \u201cTh e iso latio n o f \na 2 2 kD a band after SDS-PAGE of Schistosoma man soni adult \nworms an d its use to demonstrate the IgE  responses against \nthe antigen(s) it contains are associated w ith human resistance \nto reinfection,\u201d Parasite Immunology,  vol. 19 , no. 2, p p. 79\u201389, \n1997. \n\n[52] M. L. San tiago, J. C. R. Hafalla, J. D. Kurtis et al., \u201cIdentifica- \ntion of the Schistosoma japonicum 22.6-kDa an tigen as a major \ntarget of the human   IgE resp onse: similarit y of IgE-binding \nep itopes to allergen pep tides,\u201d International Archives of Allergy \nand Imm unology, vo l. 117, no. 2, pp. 94\u2013104, 1 998. \n\n[53] L. G. G. Pac??fico, C. T. Fon seca, L . Chiari, and S. C. O liveira, \n\u201cImmun ization  with Schistosoma mansoni 22.6 kD a antigen \ninduces partial p rotection  against experimental in fectio n in a \nrecombinan t protein form but no t as DNA  vaccine,\u201d Im m u- \nnobiology, vol. 211, no. 1 -2, pp. 97\u2013104, 2 006. \n\n\n\n\u00a0\n\n\u00a0\n\n155\u00a0\n\n\u00a0\n\n \n\n \n\n \n \n\n[54] L. G . G. Pac??fico, C. T. Fonseca, M. M. Barsante,  L. S. Card oso, \nM. I. Arau? jo, an d S. C. Oliveira, \u201cAluminum hydroxid e asso - \nciated to  Schistosoma  mansoni 22.6 kDa protein  abro gates \npartial protection against experimental infection but not alter \ninterleukin-1 0 production,\u201d  Memorias do Instituto Oswaldo \nCruz, vol. 101, supplement 1, pp. 365\u2013368, 2006. \n\n[55] L . S. Cardoso, S. C. Oliveira, A. M. Go? es et al., \u201cSchistosoma \nma nsoni antigens modulate th e allergic resp onse in a mu rine \nmodel of ovalbumin-induced airway inflammation ,\u201d Clinical \nand  Experimental Imm unology, vo l. 160, no. 2, pp. 266\u2013274 , \n2010 . \n\n[56] D. Smyth , D. P. McManus, M. J. Smout, T. Laha, W. Zhan g, \nand A. Loukas, \u201cIsolation of cDNAS encoding secreted and \ntransmembrane p roteins from Schistosoma mansoni by a signal \nsequence trap metho d,\u201d Infection and Immunity, vol. 71, no. 5, \npp. 2548\u20132554, 2003. \n\n[57] M. H. Tran , M. S. Pearson, J. M. Bethony et al., \u201cTetrasp anins \non the surface of Schistosoma m ansoni are p rotective antigens \nagainst schistosomiasis,\u201d Nature Medicine, vol. 12, n o. 7, p p. \n835\u2013840, 2006. \n\n[58] W. Zh ang, J. Li, M. D uke et al., \u201cInconsistent pro tective e? - \ncacy an d marked p olymo rphism limits the value of Schisto- \nsoma jap onicum tetraspanin -2 as a vaccine target,\u201d PLoS Neg- \nlected Tropical Diseases, vol. 5, no. 5, Article ID e1166, 2011. \n\n[59] S. Y. Sauma and M. Strand, \u201cIdentification and characteriza- \ntion of glycosylphosphatidylinositol-linked Schistosoma m an - \nsoni ad ult  worm immun ogens,\u201d  Molecular and Biochemical \nParasitology, vol. 38, n o. 2, pp. 199\u2013210, 199 0. \n\n[60] P. J. Brindley, M. Strand, A. P. Norden, and A. Sher, \u201cRole of \nhost antibody in the chemotherapeu tic action  of praziquan tel \nagainst Schistosoma mansoni: identification of target antigens,\u201d \nMolecular and Biochemical Parasitology, vol. 34 , no. 2 , pp. 9 9\u2013 \n108, 19 89. \n\n[61] E . J. M. Nascimen to, R. V. Amorim,  A. Cavalcanti et al., \n\u201cAssessment of a DNA vaccine encoding an ancho red- gly- \nco sylp hosphatidylinositol tegumental antigen comp lexed to \nprotamine  sulphate  on  immu noprotection   against mu rine \nschistosomiasis,\u201d Memorias do  Instituto Oswaldo Cru z, vol. \n102, no. 1, pp. 21\u201327, 200 7. \n\n[62] V. P. Martins, C. S. Pin heiro, B. C. P. Figueiredo et al., \u201cVac- \ncin ation with  enzy matically cleaved GPI-anchored  p roteins \nfrom schisto so ma mansoni induces protection against chal- \nlen ge in fection,\u201d Clinical and Developmental Immunology, vol. \n2012, Article ID 962538, 11 pages, 2012. \n\n[63] H. M. Ahmed  and  M. H Ro meih, \u201cProtection  against S chis- \ntosoma  man soni infection with recombinan t  schistosomula \n21.7 kDa protein,\u201d Arab Journal of Biotechnology, vol. 24, p p. \n229\u2013249, 2001. \n\n[64] H. M. Ahmed, M. H. Ro meih, and T. S. Abou -Shousha, \u201cD NA \nimmunization  with the gene encoding Sm21.7  protects mice \nagainst S. mansoni infections,\u201d American Journal of Science, vol. \n2, pp. 59\u201369, 2006. \n\n[65] K. A. Shalaby, L. Yin, A. Thaku r, L. Christen, E. G. Niles, and P. \nT. LoVerde, \u201cProtection  against Schistosoma mansoni utilizing \nDNA  vaccination  with genes encod in g Cu/Zn cytosolic super- \noxide dismutase, signal peptid e-containing superoxide dismu- \ntase and glutathione peroxidase enzymes,\u201d Vaccine, vol. 22, no . \n1, pp. 130\u2013136, 2003. \n\n[66] Z. Ho ng,  D. J. Kosman, A. Thakur,  D. Rekosh , and  P. T. \nLoVerde, \u201cIdentificatio n and purification o f a second form \nof Cu/Zn sup eroxide d ismutase from Schistosoma manson i,\u201d \nInfection and Immunity, vo l. 60 , no. 9, p p. 3641\u20133651, 1992 . \n\n[67] H. Mei and P. T. L oVerde, \u201cSchistosoma mansoni: the devel- \nopmen tal regulation an d immunolocalization of antioxid an t \n\nenzymes,\u201d Experimental Parasitology, vol. 86, no. 1, pp. 69\u201378, \n1997. \n\n[68] H. Mei, A. Thaku r, J. Schwartz, and P. T. Lo Verde, \u201cExpression \nan d  characterization  of  glutath ion e  peroxid ase activity in \nthe human   blood fluke Schistosoma m ansoni,\u201d Infection and \nImm unity, vol. 64, n o. 10, pp. 4299\u20134306, 1996. \n\n[69] M. D. M. Mou ra?o,  N. Dinguirard, G. R. Franco, and T. P. \nYoshino, \u201cRole o f the endogen ous antioxidant system in the \nprotection of Schistosoma man so ni primary sporocysts against \nexogenous oxidative stress,\u201d PLoS Neglected Tropical Disease s, \nvol. 3, no. 11, article e550, 2009. \n\n[70] J. V. Hamilton, M. Klinkert, and M. J. Doenho? , \u201cDiag nosis of \nschistosomiasis: antibody detection, with notes on  parasito- \nlogical an d antigen detection meth ods,\u201d Parasitology, vo l. 117, \npp. S41\u2013S57, 1998. \n\n[71] M. J. Do enho? , P. L. Chiodini, and J. V. Hamilton, \u201cSpecific \nan d sensitive diagnosis of schistosome infection: can it be don e \nwith antibodies?\u201d Trends in Parasitology, vol. 2 0, no. 1, p p. 3 5\u2013 \n39, 20 04. \n\n[72] G. B. F. Carvalho, R. A. d a Silva-Pereira,  L. G. G. Pac??fico, and  \nC. T. Fo nseca, \u201cIdentificatio n of Sch istosoma mansoni candi- \ndate antigen s for diagno sis of schistoso miasis,\u201d Memorias do \nInstituto Oswaldo Cru z, vol. 106, no. 7, pp. 837\u2013843, 2 011. \n\n[73] C. M. Xia, R. Rong, Z. X. Lu et al., \u201cSchistosoma japonicum: a \nPCR assay fo r the early detection and evaluation  of treatm en t \nin a rab bit mod el,\u201d Experimental  Parasitology, vol. 121, no. 2, \npp. 175\u2013179, 2009. \n\n[74] J.-J. Guo, H.-J. Zheng, J. Xu, X.-Q. Zhu, S.-Y. Wang, and C.- \nM. Xia, \u201cSensitive and specific target seq uences selected fro m \nretrotransposons of Schistosoma japonicum for the diagnosis \nof schistosomiasis,\u201d PLoS Neglected Tropical Diseases, vol. 6, n o. \n3, Article ID e1579, 2012. \n\n[75] Z. R. Zhon g, H. B. Zhou, X. Y.  Li et al., \u201cSerological pro- \nteome-oriented screen in g and application of antigens for the \ndiagn osis of Schistosomiasis japonica,\u201d Acta Tropica, vol. 116, \nno. 1, pp. 1\u20138, 2010. \n\n[76] A. S. Verkman , \u201cPhysiological importance o f aquaporin water \nch annels,\u201d Annals o f Medicine, vol. 34 , no. 3, p p. 192\u2013200, \n2002. \n\n[77] J. Song and  Q.-F. He, \u201cBioinformatics analysis of the structure \nan d linear B-cell epito pes of aqu aporin -3  from Schistosoma \njaponicum,\u201d  Asian Pacific Journal of Tropical Medicine, vol. 5, \nno. 2, pp. 107\u2013109, 2012. \n\n[78] E. G. Vasconcelos, P. S. Nascimento, M. N. L. Meirelles, S. \nVerjovski-Almeida, and S. T. Ferreira, \u201cCharacterization an d \nlocalization of an ATP-diphosphohydrolase on th e external \nsurface of the tegument of Schistosoma mansoni,\u201d Molecular \nand Biochemical Parasitology, vol. 58, no. 2, pp. 205\u2013214, 1 993. \n\n[79] R. Bhardwaj and P. J. Skelly, \u201cPurinergic signaling an d im mune \nmodulation  at the schistosome surface?\u201d Tren ds in Parasito - \nlogy, vol. 25 , no. 6, pp. 256\u2013260, 20 09. \n\n[80] R.  DeMarco,  A. T.  Kowaltowski, R.  A. Mortara,  an d  S. \nVerjovski-Almeida, \u201cMolecular characterizatio n and imm u- \nnolocalization  of Schistosoma m ansoni ATP-diph ospho hydro- \nlase,\u201d Biochemical and Biophysical Research Communications, \nvol. 307, no. 4, pp. 831\u2013838, 2 003. \n\n[81] J. Levan o-Garcia, R. A. Mortara, S. Verjovski-Almeida, an d \nR. DeMarco, \u201cCharacterization of Schistosoma m ansoni ATP- \nDase2 gene, a novel apyrase family member,\u201d Biochemical and \nBiophysical Research Communications, vol. 352, no. 2, pp. 384\u2013 \n389, 2007. \n\n[82] R. G. P. R. Mendes, M. A. N. Gu sma?o,  A. C. R. G. Maia \net al., \u201cImmuno stimulatory  property o f a synthetic pep tide \nbelon gin g to  the soluble ATP diph osphohyd rolase  isoform \n\n\n\n\u00a0\n\n\u00a0\n\n156\u00a0\n\n\u00a0\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n(SmAT PDase 2) and immunolocalisation of this p rotein  in \nthe schisto so ma manson i egg,\u201d Memorias do Instituto Oswaldo \nCruz, vol. 106, no. 7, pp. 808\u2013813, 2011. \n\n[83] M. E. Hemler, \u201cSpecific tetraspanin functions,\u201d Jou rn al of Cell \nBiology, vol. 155, no. 7, pp. 1103\u20131107, 200 1.\n\n\n\n\u00a0\n\n\u00a0\n\n157\u00a0\n\n\u00a0\n\n7 REFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n\nAbath FGC, Werkhauser RC. The tegument of Schistosoma mansoni: functional and \n\nimmunological features. Parasite Immunology, 1996; 18: 15-20. \n\nAbbas A. K., Murphy K. M., Sher A. Functional diversity of helper T lymphocytes. Nature \n\n1996;383. \n\nAebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422: 198-207. \n\nAhmad G, Torbem W, Zhang W, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine \n\nformulation induces potent protective immunity against Schistosoma mansoni. Parasite \n\nImmunol, 2009; 31 (3): 156-61. \n\nAhmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, Chavez-Suarez M, \n\nKennedy RC, Siddiqui AA. Protective and antifecundity effects of Sm-p80-based DNA \n\nvaccine formulation against Schistosoma mansoni in a nonhuman primate model.Vaccine. \n\n2009; 27(21):2830-7 \n\nAhmed HM, Romeiih MH. Protection against Schistosoma mansoni IFNection with \n\nrecombinant schistosomula 21.7 kDa protein. Arab Journal of biotechnology, 2001; 24: 229-\n\n49. \n\n Ahmed HM, Romeiih MH, Abou Shousha TS et al.. DNA immunization with encoding \n\nSm21.7 protects mice against S. mansoni IFNections. American Journal of Science, 2006; 2: \n\n59-69. \n\nAmiri P, Locksley RM, Parslow TG, Sadick M, Rector E, Ritter D, McKerrow JH. Tumour \n\nnecrosis factor alpha restores granulomas and induces parasite egg-laying in schistosome \n\nIFNected SCID mice. Nature, 1992; 356:604-7. \n\nAndre FE. Schistosomal and liver hepatopathy. Mem Inst Oswaldo Cruz, 2004; 99: 51-57. \n\n\n\n\u00a0\n\n\u00a0\n\n158\u00a0\n\n\u00a0\n\nAra\u00fajo NP, Souza SP, Passos LKJ, Simpson AJG, Dias Neto E, Pereira TR, Cerutti JRC, \n\nAlencar FEC, Dietze R, Katz N. Suscetibilidade aos agentes quimioter\u00e1picos de isolados de \n\nSchistosoma mansonioriundos de pacientes tratados com oxamniquina e praziquantel e n\u00e3o \n\ncurados. Rev Soc Bras Med Trop, 1996; 29: 467 \u2013 76. \n\nAraujo JM, Melo TT, Sena IC, Alves CC, Araujo N, Dur\u00e3es FV, Oliveira SC, Fonseca CT. \n\nSchistosoma mansoni tegument (Smteg) immunization in absence of adjuvant induce IL-10 \n\nproduction by CD4+ cells failed to protect mice against challenge IFNection. Acta Tropica, \n\n2012; 124: 140-46. \n\nAtanasiu P, Orth G; Dragonas P. Delayed specific antitumoral resistance in the hamster \n\nimmunized shortly after birth with the polyoma virus. C R Hebd Seances Acad Sci, 1962; \n\n254:2250-2. \n\nAzevedo V, Oliveira S.C. Vacinas de DNA in Bor\u00e9m, Almeida e Santos: Biotecnologia de A \n\na Z. 2003. Universidade Federal de Vi\u00e7osa, MG. \n\nBallas ZK, Rasmussen WL, Krieg AM.Induction of NK activity in murine and human cells by \n\nCpG motifs in oligoosynucleotides and bacterial DNA. J Immunol, 1996; 157 (5): 1840-45. \n\nBalloul JM, Sondermeyer P, Dreyer D, Capron M, Grzych JM, Pierce RJ, et al.. Molecular \n\ncloning of a protective antigen of schistosomes. Nature, 1987; 326(6109):149-53. \n\nBarrie JA, Grant AR, McManus DP. Role of resident liver cells in the pathogenesis of \n\nschistosomiasis. Trends in Parasitol, 2012; 28: 572-79. \n\nBaumgart M, Tompkins F, Leng J, Hesse M. Naturally occurring Cd4+Foxp3+regulatory T \n\ncells are an essential, Il-10-independet part of the immunoregulatory network in Schistosoma \n\nmansoni egg-induced IFNlammation. J Immunol, 2006; 176: 5374-87. \n\nBecker PD; Noerder M; Guzm\u00e1n CA. Genetic Immunization: Bacteria as DNA vaccine \n\ndelivery vehicle. Cap\u00edtulo 6 (71-97), 1998; In Sleator, R. e Hill, C. Patho-biotechnology: \n\nBiotechnology intelligence unit. Landes Bioscience, 216 p. \n\n\n\n\u00a0\n\n\u00a0\n\n159\u00a0\n\n\u00a0\n\nBelkaid Y, Rouse BT. Natuarl regulatory T cells in IFNectious disease. Nat Immunol, 2005; \n\n6(4):353-60. \n\nBerriman M, Hass BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, et al..The genome \n\nof the blood fluke Schistosoma mansoni. Nature, 2009; 460: 352-8. \n\nBilliau A, Matthys P. Modes of action of Freund\u2018s Adjuvant in experimental models of \n\nautoimmune disease. Journal of Leukocyte Biolgy,2001; 70: 846-860.  \n\nBird AP. CpG-rich islandas and the function of DNA methylation. Nature, 1986; 321: 209-13. \n\nBloch EH. In vivo microscopy of schistosomiasis, II-migration of Schistosoma mansoni in the \n\nlungs, liver and intestine. Am J Trop Med Hyg, 1980; 29:62-70. \n\nBloom BR. New approaches to vaccine development. Reviews of IFNectious disease, 1989; \n\n11: 460-66. \n\nBoros DL. Immunopathology of Schistosoma manson iIFNection. Clin Microbes Rev, 1989; \n\n2:250-69. \n\nBoulanger D, Reid GD, Sturrock RF, Wolowczuk I, Balloul JM, Grezel D, et al.. \n\nImmunization of mice and baboons with the recombinant Sm28GST affects both worm \n\nviability and fecundity after experimental IFNection with Schistosoma mansoni. Parasite \n\nImmunol,1991;13(5):473-90. \n\nBradford MM. A rapid and sensitive method for the quantification of microgram quantities of \n\nprotein utilizing the principle of protein-dye binding. Anal Biochemic, 1976; 72:248-254. \n\nBraschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by \n\nbiotinylation. Mol cell Proteomics, 2006; 5: 347-56. \n\nBraschi S, Borges WC, Wilson RA. Proteomic analysis of the schistosome tegument and its \n\nsurface membranes. Mem Inst Oswaldo Cruz, 2006; 101 (Suppl 1): 205-12. \n\n\n\n\u00a0\n\n\u00a0\n\n160\u00a0\n\n\u00a0\n\nBraschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, Wilson A. The tegument surface \n\nmembranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after \n\ndifferential extraction. Proteomics, 2006b; 6: (1471-82). \n\nBrindley PJ, Strand M, Norden AP, Sher A. Role of host antibody in the chemotherapeutic \n\naction of praziquantel against Schistosoma mansoni: identification of target antigens. \n\nMolecular and biochemical Parasitology, 1989; 34: 99-108. \n\nBrito CF, Oliveira SC, Street M, Riengrojpitak S, Wilson RA, Simpson A J, et al..Sm14 gene \n\nexpression in different stages of the Schistosoma mansoni life cycle and immunolocalization \n\nof the Sm14 protein within the adult worm. Braz J Med Biol Rev, 2002; 35 (3): 377-81. \n\nBroderson, JR. Uma an\u00e1lise retrospectiva das les\u00f5es associadas com o uso de Adjuvante de \n\nFreund. Laborat\u00f3rio. Anim. Sci, 1989;  39:400-405.  \n\nBrophy PM, Barrett J. Glutathione transferase in helminths. Parasitology, 1990;100 (2):345-9. \n\nBueding E, Hawkins J, Cha YN. AntiSchistosomal effect of cycloporine A. Agents Actions, \n\n1981; 4: 380-383 \n\nCant\u00fa MD, Carrilho E, Wulff NA, Palma MS. Sequ\u00eanciamento de pept\u00eddeos usando \n\nespectrometria de massas: um guia pr\u00e1tico. Quim. Nova, 2008; 31: 669-75. \n\nCapron, A. Immunity to Schistosomiasis: progress towaed vaccine. Sciencie, 1987; 238: \n\n1065-1072. \n\nCapron M, Capron A. Immunoglobulin E and effector cells in schistosomiasis. Science. 1994; \n\n264 (5167): 1876-7. \n\nCapron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite \n\ninteractions to vaccines in clinical trials. Trends Parasitol, 2005; 21(3):143-9. \n\n\n\n\u00a0\n\n\u00a0\n\n161\u00a0\n\n\u00a0\n\nCardoso FC, Pacifico RN, Mortara RA, Oliveira SC. Human antibody responses of patients \n\nliving in endemic \u00e1reas for schistosomiasis to the tegumental protein Sm29 identified through \n\ngenomic studies. Clin Exp Immunol, 2006\u00aa; 144: 382-391. \n\nCardoso FC, Oliveira SC. Caracteriza\u00e7\u00e3o molecular e imunol\u00f3gica da prote\u00edna da membrana \n\nSm29 do Schistosoma mansoni. Tese (doutorado). Universidade Federal de Minas Gerais. \n\nN\u00famero de chamada: T2764 577.1 C268c; 2006b. \n\nCardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, Melo AL, et al.. Schistosoma \n\nmansoni tegument protein Sm29 is able to induce a Th1-type of immune response and \n\nprotection against parasite IFNection. Plos Negl Trop dis, 2008; 2(10): e308. \n\nCarson DA, Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J \n\nExp Med, 1997; 186 (10): 1621-2. \n\nCarvalho AT, Martins Filho AO, Oliveira RC. A resposta imune na forma cr\u00f4nica da \n\nesquistossomose mansoni. In: Carvalho OS, Coelho PMZ, Lenzi HL, (editores). Schistosoma \n\nmansoni e esquistossomose: uma vis\u00e3o multidisciplinar. 20\u00aa ed. Rio de Janeiro: Fiocruz 2008. \n\np. 670-716. \n\nChace JH, Hooker NA, Midlestein KL, Krieg AM, Cowdery JS. Bacterial DNA-induced NK \n\ncell IFN-?  production is dependent on macrophage secretion of IL-12. Clin Immunol \n\nImmunopathol, 1997; 84 (2):185-93. \n\nCheever AW. Pipe-stem fibrosis of the liver. Trans R Soc Trop Med Hyg, 1972; 66(6): 947-8. \n\nCheever AW, Macedonia JG, Mosimann JE, Cheever EA. Kinetics of egg production and egg \n\nexcretion by Schistosoma mansoniand S. japonicum in mice IFNected with a single pair \n\nworms. Am J Trop Med Hyg, 1994; 50:281-295. \n\nCheever AW, Hoffman KF, Wynn TA. Immunopathology of schistosomiasis in mice and \n\nmen.Immunol Today, 2001; 465-6. \n\n\n\n\u00a0\n\n\u00a0\n\n162\u00a0\n\n\u00a0\n\nCheng GF, Lin JJ, Feng XG, Gu ZQ, Jin YM, Yuan CX, Zhou YC, Cai YM. Proteomic \n\nanlysis of differentially expressed proteins between the male and female worm of \n\nSchistosoma japonicum after pairing. Proteomics, 2005; 5: 511-21. \n\nChitsulo L, Engels D, Monstreor A, Savioli L. The global status of schistosomisis \n\nand is control. Acta trop, 2000; 77: 41-51. \n\nChu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act \n\nas adjuvants that switch on T helper 1 (Th1) immunity. J exp Med, 1997; 186: 1623-31. \n\nClarck TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev \n\nBiol (Basel), 2005;121:153-63. \n\nClerinx J, Van Gompel A. Schistosomiasis in travelers and migrants. Travel Med IFNect Dis,  \n\n2011; 9: 6-24. \n\nColes GC, Bruce JL, Kinoti GK, Mutahi WT, Dias EP, Katz N. Drug resistence in \n\nschistosomiasis. Trans R Soc Trop Med Hyg, 1986; 80:347-351. \n\nColley DG, Savage AM, Lewis FA. Host response induced and elicited by cercariae, \n\nschistosomula, and cercarial antigenic preparations. Am J Trop Med Hyg, 1977; 26(6): 88-95. \n\nComunica\u00e7\u00e3o/Instituto Oswaldo Cruz. Dispon\u00edvel em: \n\nhttp://www.fiocruz.br/ioc/cgi/cgilua.exe/sys/start.htm?IFNoid=1492&amp;sid=32. Acesso em \n\n20/12/2013. \n\nCorrea- Oliveira R, Mota-Sanos TA, Gazzineli G. Schisosoma mansoni: in vitro and in vivo \n\nkilling of antibody-coated schistosomula. Am J Trop Med Hyg, 1982; 31:991-998. \n\nCorrea-Oliveira R, Malaquias LC, Falc\u00e3o PL, Viana IR, Bahia-Oliveira LM, Silveira AM et \n\nal.. Cytokines as determinants of resistence and pathology in human Schistosoma mansoni \n\nIFNection. Braz J Med Biol Res, 1998; 31(1):171-7. \n\n\n\n\u00a0\n\n\u00a0\n\n163\u00a0\n\n\u00a0\n\nCorreenti, JM, Brindley, PJ, Pearce, EJ. Long- term supression of cathepsin B levels by RNA \n\ninterference retards Schistosoma growth. Mol. Biochem. Parasitol, 2005; 143: 209-215. \n\nCoura JR, Coura LC, Kalache A, et al. Esquistossomose aguda aut\u00f3ctone de foco na cidade do \n\nRio de Janeiro. Estudo de 22 casos.Rev Soc Bras Med Trop 1970;6:387-96.  \n\n \n\nCox GJ, Zamb TJ, Babiuk LA. Bovine herpesvirus 1; immune responses in mice and cattle \n\ninjected with plasmid DNA. J. Virol. 1993; 67: 5664\u20137.  \n\n \n\nCruz A, Khader SA, Torrado E, Fraga A, Pearl JE, Pedrosa J, et al. Cutting edge: IFN-gamma \n\nregulates the induction and expansion of IL-17 producing CD4T cells during mycobacterial \n\nIFNection. J Immunol, 2006; 177: 1416-20. \n\nCurwen RS, Ashton PD, Johnston DA, Wilson RA. The Schistosoma mansoni soluble \n\nproteome: a comparison across four life-cycle stages. Mol Biochem Parasitol, 2004; 138: 57-\n\n66. \n\nCurwen RS, Ashton PD, Sundaralingam S, Wilson RA. Identification of a novel proteases and \n\nimmunomodulators in the secretions of schistosome cercariae that facilitate host entry. Mol \n\nCell Proteomics, 2006; 5: 835-44. \n\nCutts L, Wilson RA. Elimination of a primary schistosome IFNection from rats coincides \n\nwith elevated IgE titres and mast cell degranulation. Parasite Immunol 1997; 19: 91-102. \n\nDa\u2019Dara AA, Skelly PJ, Walker CM, Harn DA. A DNA prime/ protein-boost vaccination \n\nregimen enhances Th2 immune responses but not protection following Schistosoma mansoni  \n\nIFNection. Parasite Immunol, 2003; 25 (8-9): 429-37. \n\nDamonneville M, Wietzerbin J, Pancre V, Joseph M, Delanoye A, Capron A, et al.. \n\nRecombinant tumor necrosis factors mediate platelet cytotoxicity to Schistosoma mansoni \n\nlarvae. J Immunol, 1988; 140(11): 3962-5. \n\n\n\n\u00a0\n\n\u00a0\n\n164\u00a0\n\n\u00a0\n\nDavid JR, Butterworth AE, Vadas MA. Mechanism of the interaction mediating killing of \n\nSchistosoma mansoni by human eosinophils. Am J Trop Med Hyg; 1980;29: 842-848. \n\nDavies SJ, Shoemaker CB, Pearce EJ. A divergent member of the transforming growth factor \n\nbeta receptor family from Schistosoma mansoni is expressed on the parasite surface \n\nmembrane. J Biol Chem, 1998; 273:11234-40. \n\nDavies SJ, Grogan JL, Blank RB, Lim KC, Locksley RM, McKerrow JH.Modulation of blood \n\nfluke development in the liver by hepatic CD4+ lymphocytes. Science, 2001; 294:1358-61. \n\nDavis AH. Schistosomiasis. In: Azizi F, Janghorbani M, Hatami H. Epidemiology and \n\nCommunity Control f disease in Warm Climate countries. Churchill Livingstone, London; \n\n1985. p. 389-412. \n\nDen JMM, Bevan MJ. Antigen presentation to CD8+T cells: cross-priming in IFNectious \n\ndiseases. Current Opinion in Immunol, 2001; 13(4): 47-441. \n\nDepartamento de IFNorm\u00e1tica do Sistema \u00danico de Sa\u00fade (DATA \n\nSUS).http://portal.saude.gov.br/portal/saude/profissional/area.cfm?id_area=1551, acesso em \n\n2013). \n\nDomingo EO, Warren KS. Pathology and pathophysiology of the small intestine in murine \n\nschistosomiasis mansoni, including a review of the literature. Gastroenterology, 1969; 56(2): \n\n231-40. \n\nDorsey CH. Ultraestruture of the Schistosoma mansonicerc\u00e1ria. Micron, 2002; 33:279323. \n\nDunne DW, Richardson BA, Jones FM, et al.. The use of mouse/human chimaeric antibodies \n\nto investigates the roles of different antibody isotypes, incluiding IgA2, in the killing of \n\nSchistosoma mansoni by eosinophils. Parasite Immunol, 1993: 15 (3):181-5. \n\nDur\u00e3es FV, Carvalho NB, Melo TT, Oliveira SC, Fonseca CT. IL-12 and TNF-a production \n\nby dendritcs cells stimulated with Schistosoma mansoni schistosomula tegument is TLR4- \n\nand MyD88-dependent. Immunol Lett, 2009; 31: 432-439. \n\n\n\n\u00a0\n\n\u00a0\n\n165\u00a0\n\n\u00a0\n\nEl Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory \n\nantigens as a vaccine candidates against schistosomiasis. Vaccine, 2009; 27: 666-73. \n\nFalc\u00e3o PL, Malaquias LCC, Martins-Filho OA, Silveira AMS, Passos M, Prata A, et al.. \n\nHuman schistosomiasis mansoni:IL-10 modulates the in vitro granuloma formation. Parasite \n\nImmunol, 1998; 20:447-454. \n\nFischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-\n\nprolyl cis-trans isomerase are probably identical proteins. Nature, 1989; 337: 476-78. \n\nFlores-Villanueva P. O. et al. Recombinant IL-10 and IL-10/Fc treatment dowregulate egg \n\nantigen-especific delayed hypersensitivity reactions and egg granuloma formation in \n\nschistosomiasis. The Journal of immunology 1996; 156:3315-3320. \n\nFonseca CT, Brito CF, Alves JB., Oliveira SC. IL-12 enhances protective immunity in mice \n\nengendered by immunization with recombinant 14 kDa Schistosoma mansonifatty acid-\n\nbinding protein trhough an IFN-? and TNF- ? dependent pathway. Vaccine, 2004; 22:503-\n\n510. \n\nFonseca CT, Carvalho FGB, Alves CC, Melo TT. Schistosoma tegument proteins n vaccine \n\nand diagnosis development: an update.  J Parasitol Res, 2012:541268. doi: \n\n10.1155/2012/541268. Epub 2012 Oct 18. \n\nGalat A. Peptidylproline cis-trans isomerases: immunophilins. Eu J Biochem, 1993; 216: 689-\n\n707. \n\nGarcia TC, Fonseca CT, Pac\u00edfico LG, Dur\u00e3es FV, Marinho FA, Penido ML, et al. Peptides \n\ncontaining T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type \n\nof immune response, reduction in liver pathology and partial protection against Schistosoma \n\nmansoni IFNection in mice. Acta Trop 2008; 106 (3): 162-67. \n\nGazzinelli G, Montesano MA, Correa-Oliveira R, Lima MS, Katz N, Rocha RS, Colley DG. \n\nImmune response in different clinical groups of schistosomiasis patients. Mem Inst Oswaldo \n\nCruz, 1987; 4:95-100. \n\n\n\n\u00a0\n\n\u00a0\n\n166\u00a0\n\n\u00a0\n\nGordon RM, Griffiths RB. Observations of means by wich the cercariae of Schistosoma \n\nmansoni penetrate mammalian skin, together with an account of certain morphological \n\nexchanges in the newly penetrate larvae. Ann Trop Med Parasitol, 1951; 45: 4577-85. \n\nGorg A, Postel W, Gunther S. The current state of two-dimensional electrophoresis with \n\nimmobilized pH gradients. Electrophoresis, 1988; 9: 531-46. \n\nGorg A, Drews O, Luck C, Weiland F, Weiss W.  2-DE with IPGs. Electrophoris, 2009; 30 \n\n(suppl 1): 122-32. \n\nGoto N; Kato H; Maeyama J, YOSHIHARA S. Studies on the toxicities of aluminium \n\nhydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine, 1993; \n\n11:914-8. \n\nGrant EP, Rock KL. MHC class I-restricted presentation of exogenous antigen by thymic \n\nantigen by thymic antigen-presenting cells in vitro and in vivo. Journal of Immunol, 1992; \n\n148 (1): 13-18. \n\nGryssels B, Mbaye A, de Vlas SJ, et al..Are poor response to praziquantel for the treatment of \n\nSchistosoma mansoni IFNections in Senegal due to resistence? An overview of the evidence. \n\nTrop Med Int Health, 2001; 6: 864-73. \n\nGryssels B, Polman K, Clerinx J, et al..Human schistosomiasis. Lancet, 2006; 368: 1106-18. \n\nGryssels B, 2012. Schistosomiasis. IFNect Dis Clin N Am, 2012; 383-97. \n\nGurunathan, S.; Wu, C.Y.; Freidag, B.L.; Seder, R.A. DNA vaccines: a key for inducing long-\n\nterm cellular immunity. Curr Opin Immunol, 2000a. 12(4):442-7. \n\nHagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA. Human IgE, IgG4 and \n\nresistence to reIFNection with Schistosoma haematobium. Nature, 1991; 349: 243-5. \n\nHagan P. ReIFNection and immunity in human schistosomiasis. Parasitol Today, 1992; 8: 12-\n\n6. \n\n\n\n\u00a0\n\n\u00a0\n\n167\u00a0\n\n\u00a0\n\nHalper MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-g \n\nproduction by stimulation of interleukin-12 and tumor necrosis factor-a. Cell Immun, 1996; \n\n167: 72-78. \n\nHan ZG, Brindley PJ, Wang SY, Zhu C. Schistosoma genomics: new perspectives on \n\nschistosome biology and host-parasite interaction. Annual Review of Genomic and Human \n\nGenetics, 2009; 10: 211-240. \n\nHandschumacher RF, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific \n\ncytosolic protein for cyclosporine A. Science, 1984; 266: 544-547 \n\nHilleman M. R. Six decades of vaccine development- a personal history. Nature Medicine \n\n1998; 4:507-514 \n\nHockley DJ. Ultraestruture of the tegument of Schistosoma mansoni. Adv Parasitol, 1973; 11: \n\n233-305. \n\nHoffmann KF, Cheever AW, Wynn TA. IL10 and the dangers of immune polarization: \n\nexcessive type 1 and type 2 cytokine responses induce distinct forms of lethal \n\nimmunopathology in murine schistosomiasis. J Immunol, 2000;164 (12): 6406-16. \n\nHogg KG, Kumkate S, Anderson S, Mountford AP. Interleukin-12 p40 secretion by cutaneous \n\nCD11+ and F4/80 cells is a major features of the innate response in mice that develop Th1- \n\nmediated protective immunity to Schistosoma mansoni. IFNect Immun. 2003 a; 71 (6): 3563-\n\n71. \n\nHongxiao H, Peng J, Hong Y, Fu Z, Xu J, Lin J, Tao J. Molecular cloning and \n\ncharacterization of a cyclophilin A homologue from Schistosoma japonicum. Parasitol Res, \n\n2012; 111: 807-817. \n\nHota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection \n\nagainst Schistosoma mansoni IFNection with a recombinant baculovirus-expressed subunit of \n\ncalpain. Vaccine, 1997; 15: 1631-40. \n\n\n\n\u00a0\n\n\u00a0\n\n168\u00a0\n\n\u00a0\n\nHotez PJ, Bundy DAP, Beegle K, Brooker S, Drake LSN, et al.. Helminth IFNections: Soil-\n\nTransmitted Helminth IFNections and Schistosomiasis, 2006, 2nded. \n\nHotez PJ, Engels D, Fenwick A, Saviolki L. \u00c1frica is desperate for praziquantel. Lancet, \n\n2010: 376: 496-8. \n\nIngolotti, M.; Kawalekar, O.; Shedlock, D.J.; Muthumani, K.; Weiner, D.B. DNA vaccines \n\nfor targeting bacterial IFNections. Expert Rev Vaccines, 2010; 9(7):747-63. \n\nIto Y. A tumor-producing factor extracted by phenol from papillomatous tissue (Shope) of \n\ncottontail rabbits. Virology, 1960 ; 12:596-601. \n\nJames SL. In vitro proliferative response to living schistosomula by T lymphocytes from mice \n\nIFNected with Schistosoma mansoni. Parasitology 1981; 83 (pt1): 147-162 \n\nJames CE, Hudson AL, Davey MW. An update on P-glycoprotein and drug resistence in \n\nSchistosoma mansoni. Trends Parasitol, 2009; 25: 538-9. \n\n114. Jankovic D, Aslund L, Oswald LP, Caspar P, Champion C, Pearce E, Coligan JE, Strand \n\nM, Sher A, James SL.  Calpain is the target antigen of a Th1 clone that transfers protective \n\nimmunity against Schistosoma mansoni. J Immunol, 1996; 157:806-14. \n\nJankovic D, Wynn TA, Kullberg MC, Caspar R, James S,  Cheever AW, et al.. Optimal \n\nvaccination against Schistosoma mansoni requires the induction of both B cell and IFN-? \n\ndependent effector mechanisms. J Immunol 1999; 162 (1): 345-351 \n\nJassim A, Hassan K, Catty D. Antibody isotype in human schistosomiasis mansoni. Parasite \n\nimmunol, 1987; 9(6):627-50. \n\nJelinek T, Nothdurf HD, Loscher T. Schistosomiasis in travelers and expatriates. J Travel \n\nMed, 1996; 13: 160-4. \n\n\n\n\u00a0\n\n\u00a0\n\n169\u00a0\n\n\u00a0\n\nJones MK, Gobert GN,  Zhang L, Sunderland P, McManus DP. The cytoskeleton and motor \n\nproteins of human schistosomes and their roles in surface maintenance and host-parasite \n\ninteractions.bioEssays, 2004, 26: 752-65. \n\nJordan P, Webbe G, Sturrock FS. Human schistosomiasis. Wallingford (CT): CAB \n\ninternational; 1993. \n\nJordan P. From Katayama to the Dakhla Oasis: the beginning of epidemiology and control of \n\nbilharzias. Acta Trop, 2000; 77: 9-40. \n\nJoseph M, Auriault C, Capron A, Vorng H, Viens P. A new function for plateles igdependent \n\nkilling of schistosomes. Nature, 1983; 303: 810-5. \n\nJuberg AD, Gon\u00e7alves T, Costa TA, de Mattos AC, Pascarelli BM, de Manso PP, Ribeiro-\n\nAlves M, Pelajo-Machado M, Peralta JM, Coelho PM, Lenzi HL. The embryonic \n\ndevelopment of Schistosoma mansoni eggs: proposal for a new staging system. Dev Genes \n\nEvol. 2009; 219(5): 219-34. \n\nKhalife J, Capron M, Grzych JM, Butterworth AE, Dunne DW, Ouma JH. Immunity in \n\nhuman schistosomiasis mansoni: regulation of protective immune mechanism by IgM \n\nblocking antibodies. J Exp Med. 1986; 142(12):4422-7. \n\nKenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal \n\ninjection of IFNluenza vaccine. N Engl J Med, 2004; 351: 2295-2301. \n\nKiang D, El Ghazalie NE, Medhat AM, Abdel-Fattah M, Karim AM, LoVerde PT. \n\nIdentification and characterization of Schistosoma mansoni p17.7, a cyclophilin. Mole Bioch  \n\nParasitol. 1996; 76 (1-2): 73-82. \n\nKim D, Know S, Rhee J, Kim KD, Park CS, Choi MJ, Suh JG, Kim DS, Lee Y, Kwon HJ. \n\nProduction of antibodies with peptide-CpG- DNA \u2013Lipossome complex without \n\ncarriers.BCM Immunol, 2011; 12:29. \n\n\n\n\u00a0\n\n\u00a0\n\n170\u00a0\n\n\u00a0\n\nKing CH, Dickman K, Tisch DJ. Regauging the cost of chronic helminthic IFNection: meta-\n\nanalysis of disability-related outcomes in endemic schistosomiasis. Lancet, 2005; 365: 1561-\n\n9. \n\nKlinman DM, Currie D, Gursel I, Verthelyl D. Use of CpG oligodeoxynucleotides as immune \n\nadjuvants. Immunol Rev,2004; 199:201-06. \n\nKnudsen GM, Medzihradszky KF, Lim KC, Hansell E, McKerrow JH. Proteomic analysis of \n\nSchistosoma mansoni cercarial secretions. Mol Cell Proteomics, 2005; 4: 1862-75. \n\nKourilov\u00e1 P, Hogg KG, Kol\u00e1rov\u00e1 L, et al. Cercarial dermatitis caused by bird Schistosomes \n\ncomprises both immediate and late phase cutaneous hypersensitivity reactions. J Immunol \n\n2004;172(6):3766-74. \n\nKrieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, \n\nKlinman DM. CpG motifs present in bacterial DNA trigger direct B cell activation. Nature, \n\n1995; 374: 546-49. \n\nKutzler, M.A. Weiner, D.B. DNA vaccines: ready for prime time? Nature Reviews Genetics, \n\n2008; 9:776\u201388. \n\nLambertucci JR, Barata CH, Rayes AAM. Unusual manifestations of acute \n\nschistosomiasis.Arq Bras Med 1996;70:445-9. \n\n \n\nLenzi LH, Kimmel E, Schechtman H, Pelajo-Machado M, Romanha WS, Pacheco RG, \n\nMariano M, Lenzi JA. Histoarchiteture of Schistosomal granuloma development and \n\ninvolution: morphogenetic and biochanical approaches. Mem Ins. Oswaldo Cruz, Rio de \n\nJaneiro.1998; 1:141-151. \n\nLevy S, Shohan T. Protein-protein interaction in the tetraspanin web. Physiology (Bethesda), \n\n2005; 20: 218-24. \n\n\n\n\u00a0\n\n\u00a0\n\n171\u00a0\n\n\u00a0\n\nLi H, Nookala S, Re F. Aluminum hydroxide adjuvants activates caspase-1 and induce IL-1B \n\nand IL-18 release. J Immunol, 2007; 178: 5271-76. \n\nLichtenbergova L, Kolbekova P, Kourilova P, et a. Antibody responses induced by \n\nTrichobilharzia regenti antigens in murine and human hosts exhibiting cercarial dermatitis. \n\nParasite Immunol, 2008;30(11-12):585-95. \n\nLipscomb MF, Masten BJ. Dendritic cells: immune regulators in health and disease. Physiol \n\nRev. 2002; (1):97-130 \n\nLoukas A, Gaze S, Mulvenna JP et al. Vaccinomics for the major blood feeding helminthes of \n\nhumans. OMICS A Journal of Integrative Biology, 2011; 9: 567-77. \n\nLubberts E, Joosten LA, Chabaud M, Van Den Bersselar L, Oppers B, Coenen-De Roo CJ, et \n\nal. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin \n\nligand and prevents bone erosin. J Clin Invest. 2000; 105: 1697-1710. \n\nMahmoud AAF. Esquistossomose e outras Infec\u00e7\u00f5es por tremat\u00f3deos. In: Braunwald E, \n\nKasper DL, Fauci AS, et al. (editores). Harrison medicina interna. 17\u00aa ed. Rio de Janeiro: \n\nMcGraw-Hill; 2009.p. 1330-5. \n\nMakrides, S. C. Strategies for achieving high-level expression of genes in Escherichia coli. \n\nMicrobiol Rev 1996, 60: 512\u2013538. \n\nMalaquias LCC, Falc\u00e3o PL, Silveira AMS, Gazzinelli G, Prata A, Coffman RL et al.. \n\nCytokine regulation of human immune response to Schistosoma mansoni: analysis of the role \n\nIL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. Scand J Immunol, \n\n1997; 121:41-50. \n\nMannervik B. The isoenzymes of glutathione transferase. Adv Enzymol Relat Areas Mol \n\nBiol, 1985; 57:357-417. \n\nMarrack P, Mckee AS, Munks MW. Towards an understanding of the adjuvant action of \n\naluminium.Nat Rev Immunol, 1996; 9: 287-93. \n\n\n\n\u00a0\n\n\u00a0\n\n172\u00a0\n\n\u00a0\n\nMartins VP, Pinheiro CS Figueiredo BCP et al. Vaccination with enzymatically cleaved GPI-\n\nanchored proteins from Schistosoma mansoni induces protection against challenge IFNection. \n\nClinical and develop immunol, 2012; 962538. \n\nMcKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can \n\nadjuvants rise to the challenge? BMC Biol, 2010; 12: 8-37. \n\nMacLaren DJ, Hockley DJ. Blood flukes have a double outher membrane. Nature.1977; \n\n269:147-149. \n\nManfras BJ, Reuter S, Wendland T, Kern P. Increased activation and oligoclonality of \n\nperipheral CD8(+) T cells in the chronic human helminth IFNection alveolar echinococcosis. \n\nIFNect Immun, 2002; 70(3):1168-74. \n\nMartins-Filho OA, Cunha-Melo JR, Lambertucci JR et al. Clinica forms of human \n\nSchistosoma mansoni IFNection are associated with differential activation of T-cell subsets \n\nand costimulatory molecules. Dig Dis Sci 1999;44:570\u20137 \n\nMcLaren DJ. Schistosoma mansoni: the parasite surface in relation to host immunity. \n\nLetchworth: Research Studies Press. 1980. \n\nMcManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev. \n\n2008; 21 (1): 225-42. \n\nMei H, Lo Verde PT. Schistosoma mansoni: the developmental regulation and \n\nimmunolocalization of antioxidant enzymes. Experimental Parasitology, 1997; 86: 69-78. \n\nMelo TT, Sena IC, Ara\u00fajo N, Fonseca CT. Antibodies are involved in the protective \n\nimmunity induced in mice by Schisosoma mansoni schistosomula tegument (Smteg) \n\nimmunization. Parasite immunology, 2014; 36: 107-111. \n\nMilan EP, Keim LS. Esquistossom\u00edase mans\u00f4nica. In: Tavares W, Marinho LAC, (editores). \n\nRotinas de diagn\u00f3stico e tratamento das doen\u00e7as Infecciosas e parasit\u00e1rias. 2\u00aa ed. S\u00e3o Paulo: \n\nAtheneu; 2007. p. 345-50. \n\n\n\n\u00a0\n\n\u00a0\n\n173\u00a0\n\n\u00a0\n\nMiller P, Wilson RA. Migration of the schistossomula of Schistosoma mansoni from skin the \n\nlungs. Parasitology, 1980; 77:281-302. \n\nMinai M, Hosaka Y, Ohta N. Historical view of schistosomiasis japonica in Japan: \n\nimplementation and evaluation of disease-control strategies in Yamanashi prefecture. \n\nParasitol Int, 2003; 52: 321-6. \n\nMir L. Gen\u00f4mica: do DNA \u00e0 transg\u00eanese. 2004; 1 ed. Rio de Janeiro. \n\nMolyneux DH, Hotez PJ, Fenwick A. \u201cRapid- impact interventions\u201d: how a policy of \n\nintegrated control for \u00c1frica`s neglected tropical diseases could benefit the poor: PLoS Med, \n\n2005; 2: e336. \n\nMontenegro SM, Miranda P, Mahanty S, Abath FG, Teixeira KM, Coutinho EM et al.. \n\nCytokine production in acute versus chronic human Schistosomiasis mansoni: the cross-\n\nregulatory role of interferon-gamma and interleukin-10 in the responses of peripheral blood \n\nmononuclear cells and splenocytes to parasite antigens. J IFNect Dis, 1999; 179(6):1502-14. \n\nMoore DL, Grove DI, Warren KS. The Schistosoma mansoniegg granuloma:quantitation of \n\ncell populations. J Pathol, 1977; 121(1): 41-50. \n\nMoser D, Tendler M, Griffiths G, Klinkert MQ. A 14-kDa Schistosoma mansonipolypeptide \n\nis homologous to a gene family of fatty acid binding proteins. Bio Chem, 1991; 266 (13): \n\n8454. \n\nMosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. \n\nImmunol, 1996; 17: 138-46. \n\nMour\u00e3o MM, Grunau C, LoVerde PT, Jones MK, Oliveira G. Recents advances in \n\nSchistosoma genomics. Parasite Immunology, 2012; 34: 151-62. \n\nMukai T, Nagaki M, Imose M, Kimura K, Stake S, Takai S et al. Prevention of hepatic \n\nfibrosis in nonobese diabetic mice: a critical role for interfereon-gamma. Liver Int. 2006; 26: \n\n1006-14. \n\n\n\n\u00a0\n\n\u00a0\n\n174\u00a0\n\n\u00a0\n\nNabel GJ. Designing tomorrow's vaccines.N Engl J Med, 2013 7;368(6):551-60. \n\nNascimento EJ, Amorim RV, Cavalcante A et al. Assessment of a DNA vaccine encoding an \n\nanchored-glycosylphosphatidyllinositol tegumental antigen complexed to protamine sulphate \n\non immunoprotection against murine schistosomiasis.Mem Insti, Oswaldo Cruz, 2007; 102 \n\n(1): 21-27. \n\nNesvizhskii AI. A survey of computational methods and error rate estimation procedure for \n\npeptide and protein identification in shotgun proteomics. Journal of proteomics, 2010; 2092-\n\n2123. \n\nNeuhoff V, Arold N, Taube D, Ehrhardt W. Improved staining of proteins in polyacrylamide \n\ngels including isoelectric focusing gels with clear background at nanogram sensitivity using \n\nCoomassie Brilliant Blue G-250 and R-250.Electrophoresis. 1988; 9(6):255-62. \n\nO`Farrell PH. High resolution two-dimension electrophoresis of proteins. J. Biol. Chem, \n\n1975; 250: 4007-21. \n\nPac\u00edfico LG, Fonseca CT, Chiari L, Oliveira SC. Immunization wirh Schistosoma mansoni \n\n22.6 kDa antigen induces partial protection against IFNection in a recombinant protein form \n\nbut not as DNA vaccine. Immunobiology, 2006; 211 (1-2): 97-104. \n\nPalatnick-de-Souza LB. Vaccine for leishmania for coming 25 years. 2008; Vaccine 26: 1709-\n\n24. \n\nPancre V, Monte D, Delanoye A, Capron A, Auriault C. Interleukin-6 is the main mediator of \n\nthe interaction between monocytes and platelets in the killing of Schistosoma mansoni. Eur \n\nCytokine Netw, 1990; 1(1):15-9. \n\nPearce EJ, MacDonald AS.The immunobiology of schistosomiasis.Nat Rev Immunol, 2002; \n\n2: 499-511. \n\nPellegrino J, Siqueira AF. T\u00e9cnica de perfus\u00e3o para colheita de Schistosoma mansoni em \n\ncobaias experimentalmente IFNestadas. Rev Bras Malariol Doen\u00e7as Trop, 1956; 8:589-597. \n\n\n\n\u00a0\n\n\u00a0\n\n175\u00a0\n\n\u00a0\n\nPerez-Sanchez R, Ramajo-Hernadez A, Ramajo-Hernandez A, Siles-Lucas M, Ramajo-Martin \n\nV, Oleaga A. A proteomic approach to the identification of tegumental proteins of male e \n\nfemale Schistosoma bovis worm. Proteomic, 2006; 6 (suppl 1): 226-36. \n\nPhillips SM, Lammie PJ. Immunopathology of granuloma formation and fibrosis in \n\nschistosomiasis. Parasitol Today, 1986; 2(11):296-302. \n\nPorchet E, McNair A, Caron A, Kusnierz JP, Zemzoumi K, Capron A. Tissue expression of \n\nthe Schistosoma mansoni28 kDa glutathione S-transferase. Parasitology, 1994; 109 ( Pt \n\n5):565-72. \n\nRamalho-Pinto FJ, Gazzinelli G, Howells RE, Mota-Santos TA, Figueiredo EA, Pelegrino. \n\nSchistosoma mansoni: defined system for stepwise transformation of cercariae to \n\nschistossomule in vitro. Exp Parasitol, 1974; 36 (3):360-72. \n\nRaz E, Tighe H, Sato Y, Dudler J\u00c1, Romam M, Swain SL, Spiegelberg HL, Carson DA. \n\nPreferential induction of a Th1 immune response and inhibition of specific IgE antibody \n\nformation by plasmid DNA immunization. Proc Natl Acad Aci, 1996; 93: 5141-45. \n\nReed  SG, Bertholet S, Coler RN, Friede M. New horizonts for vaccine development. Trends \n\nImmunol, 2009; 30 (1): 23-32. \n\nRemain RM, Thompson RW, Feng CG, Hari D, Knight R, Cheever AW et al..Interleukin 5 \n\n(IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. IFNect.Immun, \n\n2006; 74 (3):1471-9. \n\nReynolds SR, Shoemaker CB, Harn DA. T and B cell epitope mapping of Sm23 an integral \n\nmembrane protein of Schistosoma mansoni. J Immunol, 1992; 149 (12):3995-4001. \n\nRibeiro F, Vieira CS, Fernandes A, Araujo N, Katz N. The effects ofimmunization with \n\nrecombinant Sm14 (rSm14) in reducing worm burden and mortality of mice IFNected with \n\nSchistosoma mansoni. Rev Soc Bras Med Trop, 2002; 35(1):11-7. \n\n\n\n\u00a0\n\n\u00a0\n\n176\u00a0\n\n\u00a0\n\nRimaniol AC, Gras G, Verdier F, Capel F, Grigoriev VB, Porcheray F, Sauzeat E, Fournier \n\nJG, Clayette P, Siegrist CA, Dormont D. Aluminum hydroxide adjuvant induces macrophages \n\ndifferentiation towards a specialized antigen-presenting cell type. Vaccine, 2004; 22: 3127-35. \n\nRock KL, Gamble S, Rothstein L. Gramm C, Benacerraf B. Dissociation of B2-microglobulin \n\nleads to the accumulation of substantial pool of inactive class I MHC heavy chains on the cell \n\nsurface. Cell, 1991; 64 (4): 611-620. \n\nRock KL, Fleischacker C, Gamble S. Peptide-primming of cytolytic T cell immunity in vivo \n\nusing B2-microglobulin as an adjuvant. Journal of Immunology, 1993: 150 (4): 1244-52. \n\nRollinson D, Simpsom AJ. The biology of Schistosomes- from genes to latrines, Harcourt \n\nBrace Jovanovich, London 1987. \n\nRomeih MH, Hassan HM, Shousha TS, Saber MA. Immunization against Egyptian \n\nSchistosoma mansoni IFNection by multivalent DNA vaccine. Acta Biochimica et Biophysica \n\nSinica, 2008; 40 (4): 327-38. \n\nRoss AG, Bartley PB, Sleigh AC, et al..Schistosomiasis. N Engl J Med, 2002; 346: 1212-20. \n\nRoss AG, Vickers D, Olds GR, et al..Immunopathology of schistosomiasis. Immunol Cell \n\nBiol, 2007; 85: 148-54. \n\nRush BR; Flaminio M.J. Immunomodulation in horses. Vet Clin North Am Equine Pract. \n\n2000;16: 183-97. \n\nRutitzky LI, Hernadez HJ, Stadecker MJ. Th1- polarizing immunization with egg antigens \n\ncorrelates with severe exacerbation of immunopathology and death in Schistosome IFNection. \n\nProc Nat Acad Sci USA, 2001; 98: 13243-13248. \n\nRutitzky LI, Lopes JR, Stadecker MJ. Severe CD4 T Cell-Mediated Immunopathology in \n\nMurine Schistosomiasis Is Dependent on IL-12p40 and Correlates with High Levels of IL-17. \n\nJournal Immunol, 2005; 175: 3920-26. \n\n\n\n\u00a0\n\n\u00a0\n\n177\u00a0\n\n\u00a0\n\nSadler CH, Rutitzky LI, Stadecker MJ, Wilson RA. IL10 is crucial for the transition from \n\nacute to chronic disease state during IFNection of mice with Schistosoma mansoni. Eur J \n\nImmunol, 2003; 15 (4): 880-8. \n\nSakagucchi S, Ono M, Setoguchi R, Yagi H, Hori H, Fehervari Z et al. Foxp3Cd25CD4 \n\nnatural regulatory T cells in dominant self-tolerance and autoimmune disease.Immunol Rev, \n\n2006; 212:8-27. \n\nSato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, \n\nRaz E. Immunostimulatory DNA sequences necessary for effective intradermal gene \n\nimmunization. Science, 1996; 273: 352-54. \n\nSauma SY, Strand M. Identification and characterization of glycosylphosphatidylinositol-\n\nlinked Schistosoma mansoni adult worm immunogens. Molecular and Biochemical \n\nParasitology, 1990; 38: 199-210. \n\nSegatori L, Murphy L, Arredondo S, Kadokura H, Gilbert H, Beckwith J, Georgiou \n\nG.Conserved role of the linker alpha-helix of the bacterial disulfide isomerase DsbC in the \n\navoidance of misoxidation by DsbB.J Biol Chem. 2006 Feb 24; 281(8):4911-9. Epub 2005 \n\nNov 9. \n\nShalaby KA, Yin L, Thakur A, Christen L, Niles EG, LoVerde PT. Protection against \n\nSchistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic \n\nsuperoxide dismutase, signal peptide-containing superoxide dismutase and glutathione \n\nperoxidase enzymes. Vaccine, 2003; 22: 130-136. \n\nSkelly PJ, Shoemaker CB. Induction cues for tegument formation during the transformation \n\nof Schistosome mansoni cerc\u00e1rie. Int J Parasitol, 2000; 30: 625-631. \n\nSiddiqui AA, Zhou Y, Podesta RB, Karez SR, Tognon CE, Strejan GH, Dekaban GA, Clarke \n\nMW. Characterization of Ca (2+)-dependent neutral protease (calpain) from human blood \n\nflukes, Schistosoma mansoni. Biochim Biophys. Acta, 1993; 1181: 37-44. \n\n\n\n\u00a0\n\n\u00a0\n\n178\u00a0\n\n\u00a0\n\nSiddiqui AA, Phillips T, Charest RB, Podesta ML, Quilin JR, Pinkston JR, Hoyd JD, Pompa \n\nJ, Villalovos RM, Paz M. Enhancement of Sm-p80 (large subuninit of calpain) induced \n\nprotective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and \n\ninterleukin-12 in a DNA vaccine formulation. Vaccine, 2003; 21: 2882-89.  \n\nSiddiqui AA, Schistosomiasis vaccines. Human Vaccines, 2011, 7:11, 1192-1197. \n\nSilva JR, Neves RH, Gomes DC. Filogenia, co-evolu\u00e7\u00e3o, aspectos morfol\u00f3gicos e biol\u00f3gicos \n\ndas diferentes fases do desenvolvimento do Schistosoma mansoni. In: Carvalho, OS (Org.); \n\nCoelho, PMZ (Org.); Lenzi, HL (Org.). Schistosoma mansonie esquistossomose: uma vis\u00e3o \n\nmultidisciplinar. Rio de Janeiro: Ed. Fiocruz, 2008. P. 43-84. Capa dura, 26 cm. ISBN 978-\n\n857541-150-6. \n\nSilva-Teixeira DN, Doughty BL, Goes AM. Human schistosomiasis: modulation of in  vitro \n\ngranulomatous hypersensitivity and lymphocyte proliferative response by macrophages \n\nundergoing differentiation. Scand J immunol, 1996; 44:522-9. \n\nSingh M; O'hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 1999;17:1075-8. \n\nSingh KP, Gerard HC, Hudson AP, Reddy TR, Boros DL. Retroviral Foxp3 gene transfer \n\nameliorates liver granuloma pathology in Schistosoma mansoni IFNected mice. Immunology, \n\n2005; 114: 410-417. \n\nSmythies LE, Betts C, Coulson OS, Dowling MA, Wilson RA. Kinetics and mechanism of \n\neffector focus formation in the lungs of mice vaccined with cercariae of Schistosoma \n\nmansoni. Parasite Immunol, 1996; 18: 359-69.  \n\nSouza FPC, Vitorino RR, Costa AP, Faria FC, Santana LA, Gomes AP. Esquistossomose \n\nmans\u00f4nica: aspectos gerais, imunologia, patog\u00canise e hist\u00f3ria natural. Rev Bras Med, 2011; \n\n9(4): 300-7. \n\nSparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H. Bacterial \n\nDNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of \n\nmurine dendritic cells. Eur. J. Immunol, 1998; 28: 2045-54. \n\n\n\n\u00a0\n\n\u00a0\n\n179\u00a0\n\n\u00a0\n\nSpreacifico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between \n\nNLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol, 2010; 40: \n\n638-42. \n\nStacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J. \n\nImmunol, 1996; 157: 2116-22. \n\nStadecker MJ, asahi H, Finger E, Hernandez HJ, Rutitzky LI, Sun J. The immunobiology of \n\nTh1 polarization in high-pathology schistosomiasis. Immunol Rev. 2004; 201: 168-79. \n\nStanworth DR, Smith AK. Inhibition of reagin mediated PCA reactions in baboons by the \n\nhuman IgG4 subclass. Clin Allerg, 1973; 3:37-41. \n\nSteinmann P, Keiser J, Bos J, Tanner M, Utzinger J. Schistosomiasis and water resources \n\ndevelopment: systematic review, meta-analysis, and estimates of people at risk. Lancet IFNect \n\nDis 2006; 6 (7): 411-25. \n\nStirewalt MA, Cousin CE, Dorsey CH. Schistosoma mansoni stimulus and transformation of \n\ncercariae into schistossomules. Exp. Parasitol, 1983; 56: 358-68. \n\nSutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin \n\nJ, Coyle AJ, Gal\u00e1n JE, Askenase PW, Flavell RA. Critical role for NALP3/CIAS1/Cryopyrin \n\nin innate and adaptative immunity through its regulation of caspase-1. Immunity, 2006; 24: \n\n317-27 \n\nSwartz JR. Advances in Escherichia coli production of therapeutic proteins. Curr Opin \n\nBiotechnol. 2001 Apr;12(2):195-201. \n\nTang, D.C.; DeVit, M.; Johnston, S.A.  Genetic immunization is a simple method for  \n\neliciting an immune response. Nature , 1992; 356: 152\u2013154. \n\n\n\n\u00a0\n\n\u00a0\n\n180\u00a0\n\n\u00a0\n\nTaylor JJ, Mohrs M, Pearce EJ. Regulatory T cell response develop in parallel to th responses \n\nand control the magnitude and phenotype of the Th effector population. J Immunol, 2006; \n\n176: 5839-47. \n\nTeixeira- Carvalho A, Martins Filho OA, Peruhype-Magalh\u00e3es V, Silveira-Lemos D, \n\nMalaquias LCC, Alves Oliveira LF, Silveira MASet al.. Cytokine, chemokine receptors \n\nCD4+CD25HIGH+ T-cells and clinical forms of human schistosomiasis.Acta Trop, 2008; \n\n108:139-149. \n\nTeixeira de Melo T, Araujo JM, Do Valle Dur\u00e3es F, Caliari MV, Oliveira SC, Coelho PM, \n\nFonseca CT. Immunization with newly transformed Schistosoma mansoni schistosomula \n\ntegument elicits tegument damage, reduction in egg and parasite burden. Parasite Immunol, \n\n2010; 32 (11-12): 749-59. \n\nTeixeira de Melo T, Araujo JM, Campos de Sena I, Carvalho Alves C, Ara\u00fajo N, Toscano \n\nFonseca C. Evaluation of the protective immune response induced in mice by immunization \n\nwith Schistosoma mansoni schistosomula tegument (Smteg) in association with CpG-ODN. \n\nMicrobes and IFNection, 2012; 15 (2013): 28-36. \n\nTendler M, Brito CA, Vilar MM, Serra- Freire N, Diogo CM, Almeida MS, et al.. \n\nSchistosoma mansonifatty acid-binding protein, Sm14, is the potential basis of a dual-purpose \n\nanti-helminth vaccine. Proc Natl Acad Sci, 1996;93 (1): 269-73. \n\nTorben W, Ahmad G, Zhang W, Siddiqui AA. Role of antibodies in Sm-p80-mediated \n\nprotection against Schistosoma mansoni challenge IFNection in murine and nonhuman \n\nprimate models. Vaccine, 2011; 29: 2262-2271. \n\nTran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al..Tetraspanins on \n\nthe sufarce of Schistosoma mansoni are proctetive antigens against schistosomiasis. Nat Med, \n\n2006; 12 (7): 835-40. \n\n\n\n\u00a0\n\n\u00a0\n\n181\u00a0\n\n\u00a0\n\nTran MH, Tori CF, Leanne C, Gaze S, Gatton M, Jons M, Lovas E, Pearce EJ, Loukas A. \n\nSuppression of mRNAs encoding tegument tetraspanins from Schistosoma mansoni results in \n\nimpaired tegument turnover. Plos pathogens, 2010; 6(4): e1000840 \n\nUlmer, J.B.; Donnelly, J.J.; Parker, S.E.; Rhodes, G.H.; Felgner, P.L.; Dwarki, V.J.; \n\nGromkowski, S.H.; Deck, R.R.; DeWitt, C.M.; Friedman, A. Heterologous protection against \n\ninfluenza by injection of DNA encoding a viral protein. Science, 1993; Mar 19;259(5102), \n\n1745\u20131749. \n\nValadares E, Coelho PMZ, Pelegrino J, Sampaio IBM. Schistosoma mansoni: compara\u00e7\u00e3o da \n\noviposi\u00e7\u00e3o entre as cepas LE (Belo Horizonte), SP (S\u00e3o Paulo) e ST (Lib\u00e9ria) em \n\ncamundongos. Rev Inst Med Trop S\u00e3o Paulo, 1981; 23: 1-5. \n\nVan Balkom BW, Van Gestel RA, Brouwers JF, Krijgsveld J, Tielens AG, Heck AJ, Van \n\nHellemond JJ. Mass spectrometric analysis of the Schistosoma mansoni tegumental sub-\n\nproteome. J. Proteome Res, 2005; 4: 958-66. \n\nVan Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends \n\nImmunol, 2006; 27: 49-59. \n\nVan Hellemond JJ, Van Balkon BW, Tielens AG. Schistosome biology and proteomics: \n\nprogress and challenges. Exp Parasitol. 2007; 117 (3):267-74. \n\nVaughan EE, DeGiulio JV, Dean DA.Intracellular trafficking of plasmids for gene therapy: \n\nmechanisms of cytoplasmic movement and nuclear import.Curr Gene Ther, 2006 \n\nDec;6(6):671-81. \n\nVicogne J, Cailliau K, Evans RJ. Molecular properties of ATP-gated P2x receptor ion \n\nchannels.Trends Pharmacol Sci, 2004; 25:487-93. \n\nViana IR, Correa-Oliveira R, Carvalho Odos, Massara CL, Colosimo E, Colley DG et al. \n\nComparison of antibody isotype response to Schistosoma mansoni antigens by IFNected and \n\nputative resistant individuals living in a endemic area. Parasite Immunol 1995; 17 (6):297-\n\n304. \n\n\n\n\u00a0\n\n\u00a0\n\n182\u00a0\n\n\u00a0\n\nVignali DA,  Crocker P,  Bickle QD,  Cobbold S,  Waldmann H,  Taylor MG. A role for \n\nCD4+ but not CD8+ T cells in immunity to Schistosoma mansoni induced by 20 krad-\n\nirradiated and Ro 11-3128-terminated IFNections. Immunology 1989; 67 (4): 466-72. \n\nVon Lichtenberg F. Studies on granuloma formation. III. Antigen sequestration and \n\ndestruction in the schistosome pseudotubercle. Am J Pathol, 1964; 45: 75-93. \n\nXiang, Z.Q.; Spitalnik, S.; Tran, M.; Wunner, W.H.; Cheng, J.; Ertl, H.C. Vaccination with a \n\nplasmid vector carrying the rabies virus glycoprotein gene induces protective immunity \n\nagainst rabies virus. Virology, 1994; 199:132-40. \n\nXu CB, Verwaerde C, Grzych JM, Fontaine J, Capron A. A monoclonal antibody blocking \n\nthe Schistosoma mansoni28-kDa glutathione S-transferase activity reduces female worm \n\nfecundity and egg viability. Eur J Immunol, 1991; 21(8):1801-7. \n\nXu, Z.L.; Mizuguchi, H.; Ishii-Watabe, A.; Uchida, E.; Mayumi, T.; Hayakawa, T. Strength \n\nevaluation of transcriptional regulatory elements for transgene expression by adenovirus \n\nvector. J Control Release, 2002; 81:155-63. \n\nZhou Y, Zhang H, Sun XJ, Zheng D, Liang YJ, Luo J, Wang Y, Zhang ZS. Murine CD8(+)T \n\ncell cytotoxicity against schistosomula induced by inoculation of Schistosomal 22.6/26GST \n\ncoupled Sepharose 4B beads. Vaccine, 2012; 30(14):2440-7 \n\nWack A, Rappuoli R. Vaccinology at the bebinning of the 21st centure. Current Opinion in \n\nImmunology, 2005; 17:411-418. \n\nWalsh CT, Zygdowsky LD, McKeon F. Cyclosporin A, the cyclophilin class signal \n\ntransduction. J Immunol Chem 1992; 267: 13115-118. \n\nWang, B.; Ugen, K.E.; Srikantan, V.; Agadjanyan, M.G.; Dang, K.; Refaeli, Y.; Sato, A.I.; \n\nBoyer, J.; Williams, W.V.; Weiner, D.B. Gene inoculation generates immune responses \n\nagainst human immuNODeficiency virus type 1. Proc Natl Acad Sci USA, 1993; 90:4156-60. \n\n\n\n\u00a0\n\n\u00a0\n\n183\u00a0\n\n\u00a0\n\nWarren KS. Regulation of the prevalence and intensity of schistosomiasis in man: \n\nimmunology or ecology? J IFNec Dis, 1973; 127(5):595-609. \n\nWilliams, J.A.; Carnes, A.E.; Hodgson, C.P. Plasmid DNA Vaccine vector design: impact on \n\nefficacy, safety and upstream production. Biotechnol Adv., 2009; 27(4): 353\u2013370. \n\nWilson RA, Barnes PE. The tegument of Schistosoma mansoni: observation on the formation, \n\nstructure and composition of cytoplasmatic inclusions in relation to tegument function. \n\nParasitology, 1974; 68: 239-58. \n\nWilson RA, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. \n\nImmunopathology of schistosomiasis. Immunol Cell Biol, 2007; 85(2):148-54. \n\nWilson RA, Coulson PS, Betis C, Dowking MA, Smythies LE. Impaired immunity and \n\naltered pulmonary response in mice with a disrupted interferon-? receptor gene exposed to the \n\nirradiated Schistosoma mansoni vaccine. Immunology 1996; 87 (2): 275-282. \n\nWilson RA, Langermans JA, Van Dam GJ, Vervenne RA, Hall SL, Borges WC, et \n\nal.Elimination of Schistosoma mansoniadult worms by rhesus macaques: basis for therapeutic \n\nvaccine? Plos Megl Trop Dis, 2008 2:e290. \n\nWynn TA, Cheever AW. Cytokine regulation of granuloma formation in schistosomiasis. \n\nCurr Opin Immunol 1995; 7 (4): 505-511. \n\nWolowczuk I, Nutten S, Roye O, Delacre M, capron M, Murray RM, trottein F, Auriault C. \n\nIFNection of mice lacking interleukin-7 (IL-7) reveals an unexpected role for IL-7 in the \n\ndevelopment of the parasite Schistosoma mansoni. IFNect Immun. 1989; 67:4183-4190. \n\nWorld Health Organization. Proceedings of the second Global Vaccine Research \n\nF\u00f3rum.Montreux, Switzerland, Geneve: 2001. \n\nWorld Health Organization. Guidelines on clinical evaluation of vaccines: regulatory \n\nexpectations. Geneve: WHO, 2002. \n\n\n\n\u00a0\n\n\u00a0\n\n184\u00a0\n\n\u00a0\n\nWorld Health Organization. Guidelines on clinical evaluation of vaccines: regulatory \n\nexpectations. Geneve: WHO, 2013. \n\nhttp://www.who.int/mediacentre/factsheets/fs115/en/index.html, Acesso em 01 de mar\u00e7o de \n\n2013. \n\nYamamoto S, Yamamoto T, Schimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga. DNA \n\nfrom bacteria, but not from vertebrates, induces interferon, activates natural killers cells and \n\ninhibits tumor growth. Microbiomol Immunol, 1992; 36: 983-97. \n\nYang DC, Jackson DC, Zeng Q, McManus DP. Multiepitope schistosome vaccine candidates \n\ntested for protective immunogenicity in mice. Vaccine, 2000; 19 (1): 103-13."}]}}}